9-16-05

DAC \$

SEP 1 4 2005

SEP 1 4 2005

THE TRANSPORT OF THE PROPERTY OF T

Atty. Dkt. No. 355492-1300 Patent No. 5,667,767

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

officant: GREFF, et al.

Title:

COMPOSITIONS FOR USE IN

EMBOLIZING BLOOD VESSELS

Patent No.:

5,667,767

Issue Date:

9/16/1997

Serial No.:

08/507,863

Filing Date:

7/27/1995

CERTIFICATE OF EXPRESS MAILING
I hereby certify that this correspondence is being deposited with the United States Postal Service's "Express Mail Post Office To Addressee" service under 37 C.F.R. § 1.10 on the date indicated below and is addressed to: Mail Stop Patent Ext., Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

EV 643 730 754 US September 14, 2005
(Express Mail Label Number) (Date of Deposit)

Laura DiStefano
(Printed Name)
(Signature)

APPLICATION FOR EXTENSION OF PATENT TERM TRANSMITTAL

Mail Stop Patent Ext. Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450 RECEIVED

SEP 2 1 2005

OFFICE OF PETITIONS

Sir:

Transmitted herewith for filing is an Application for Extension of Patent Term under 35 U.S.C. § 1.56 and accompanying papers.

Enclosed are:

- [X] Application for Extension of Patent Term under 35 U.S.C. § 156 and Appendix A-E referenced therein (33 pgs.);
- [X] Two additional copies of the Application (for a total of 3 copies);
- [X] Check No. 1334 in the amount of \$1,120.00;
- [X] Return Receipt Postcard.

09/20/2005 MAHMED1 00000013 5667767

01 FC:1457

1120.00 OP

Atty. Dkt. No. 355492-1300 Patent No. 5,667,767

[X] The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 C.F.R. §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 50-0872. Should no proper payment be enclosed herewith, as by a check being in the wrong amount, unsigned, post-dated, otherwise improper or informal or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 50-0872.

Please direct all correspondence to the undersigned attorney or agent at the address indicated below.

Respectfully submitted,

Date September 14,2005

FOLEY & LARDNER LLP 1530 Page Mill Road Palo Alto, California 94304-1125

Telephone:

ď

(650) 251-1104

Facsimile:

(650) 856-3710

Lorna L. Tanner

Attorney for Applicant Registration No. 50,782



N THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

GREFF, et al.

Title:

COMPOSITIONS FOR USE IN

EMBOLIZING BLOOD VESSELS

Patent No.:

5,667,767

Issue Date:

9/16/1997

Ser. No.:

08/507,863

Filing Date:

7/27/1995

| CERTIFICATE OF EXPRESS MAILING I hereby certify that this correspondence is being deposited with the United States Postal Service's "Express Mail Post Office To Addressee" service under 37 C.F.R. § 1.10 on the date indicated below and is addressed to: Mail Stop Patent Ext., Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450. |
|--|
| EV 643 730 754 US September 14, 2005 (Express Mail Label Number) (Date of Deposit) |
| Laura DiStefano (Printed Name) |
| (Signature) |

APPLICATION FOR EXTENSION OF PATENT TERM UNDER 35 U.S.C. § 156

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

MAIL STOP PATENT EXT.

Sir:

Applicant, Micro Therapeutics, Inc., a corporation of the State of Delaware, represents that it is the assignee of the entire interest in and to letters patent of the United States

No. 5,667,767 granted to Richard J. Greff, et al. on September 16, 1997 for Compositions for USE IN EMBOLIZING BLOOD VESSELS, by virtue of an assignment in favor of

Micro Therapeutics, Inc. recorded on September 26, 1995 at Reel 7699 and Frame 0014.

Applicant submits this Application for extension of the patent term for U.S. Patent 5,667,767 by providing the following information, as required by 35 U.S.C. § 156

and 37 C.F.R. § 1.710 et seq. For the convenience of the U.S. Patent & Trademark Office, the information in this application will be organized corresponding to 37 C.F.R. § 1.740.

1. The approved product is identified as Onyx® Liquid Embolic System (LES). The device is a kit indicated for presurgical embolization of brain arteriovenous malformations.

Onyx® LES consists of a 1.5 mL vial of the Onyx® composition, a 1.5 mL vial of dimethylsulfoxide (DMSO), and three 1 mL Onyx® delivery syringes.

The composition included in the kit is referred to herein as Onyx®. The injected composition is a non-adhesive liquid embolic agent comprised of ethylene vinyl alcohol (EVOH) copolymer dissolved in DMSO, and suspended micronized tantalum. The EVOH copolymer contains approximately 48 mole percent of ethylene and 52 mole percent of vinyl alcohol. Onyx® may be one of two compositions as follows, namely Onyx® 18 and Onyx® 34:

- a. Onyx® 18: 3.2 weight percent EVOH; 38.6 weight percent of tantalum; 58.2 weight percent of DMSO. Onyx® 18 has a nominal viscosity of 18 centistokes at 40°C.
- b. Onyx® 34: 4.2 weight percent EVOH; 38.2 weight percent of tantalum; 57.6 weight percent of DMSO. Onyx® 34 has a nominal viscosity of 33 centistokes at 40°C.
- 2. Onyx® LES was subject to regulatory review under Section 515 of the Federal Food, Drug, and Cosmetic Act.
- 3. Onyx® LES received permission for commercial marketing under Section 515 of the Federal Food, Drug, and Cosmetic Act on July 21, 2005.

Atty. Dkt. No. 355492-1300

4. Onyx® Liquid Embolic System (LES) contains the Onyx® composition as described above in item 1 above. This composition for use in embolizing blood vessels has not been previously approved for commercial marketing under Section 515 of the Federal Food, Drug, and Cosmetic Act.

- 5. This Application for extension of patent term is being submitted within the sixty day period permitted for submission pursuant to 37 C.F.R. § 1.720(f); said period will expire on September 19, 2005.
 - 6. The patent for which patent term extension is sought is U.S. Patent 5,667,767.

Inventors: Richard J. Greff, et al.

Patent No.: 5,667,767

Issued: September 16, 1997

Expiration Date: July 27, 2015 based on a filing date of July 27, 1995.

- 7. A complete copy of U.S. Patent 5,667,767 is attached hereto as Appendix A.
- 8. There has been no disclaimer, certificate of correction, or reexamination certificate issued in regard to U.S. Patent 5,667,767. The first maintenance fee was paid on March 16, 2001 for which a receipt is attached hereto as Appendix B. The second maintenance fee was paid on January 3, 2005 for which a receipt is attached hereto as Appendix C.
- 9. U.S. Patent 5,667,767 claims the approved product in the following applicable claims:

SVCA_17331.1 3

Claim 1 recites the approved product. Specifically, claim 1 recites the Onyx® composition comprising three components. All of the weight percents recited in this claim are based on the total weight of the composition.

One component of the composition is the ethylene vinyl alcohol copolymer. This copolymer is present in an amount from about 2.5 to about 8.0 weight percent of an ethylene vinyl alcohol copolymer. The amount of ethylene vinyl alcohol copolymer present in Onyx® is 3.2 (Onyx® 18) or 4.2 (Onyx® 34) weight percent and thus the amount of the polymer in the approved product falls within the claimed range.

Another component of the composition of claim 1 is a water insoluble contrast agent. The contrast agent may be tantalum, tantalum oxide and barium sulfate and is present in the amount of from about 10 to about 40 weight percent. The amount of tantalum in the approved product is 38.6 (Onyx® 18) and 38.2 (Onyx® 34) weight percent and thus falls within the claimed range.

Still another component of the composition of claim 1 is a biocompatible solvent which is present in an amount of from about 52 to about 87.5 weight percent. Turning to the specification, the biocompatible solvent can be DMSO as illustrated in column 5, line 13. The amount of DMSO in the approved product is 58.2 (Onyx® 18) and 57.6 (Onyx® 34) weight percent and thus falls within the claimed range.

Claim 2 recites the ethylene vinyl alcohol copolymer of claim 1, wherein the copolymer is from about 25 to about 60 mole percent of ethylene and from about 40 to about 75 mole percent

SVCA_17331.1 4

of vinyl alcohol in the Onyx® composition. Thus, the product described above is claimed in claim 2.

Claim 3 recites the biocompatible solvent of claim 1, wherein the solvent is DMSO.

Thus, the product described above is claimed in claim 3.

Claim 4 recites the contrast agent of claim 1, wherein the contrast agent is tantalum.

Thus, the product described above is claimed in claim 4.

Claim 7 covers the method of using the approved product. Specifically, claim 7 recites a method of embolizing a blood vessel by injecting an embolizing composition into the blood vessel under such conditions wherein a precipitate is formed which embolizes the blood vessel. The composition recites the following components: 2.5 to about 8.0 weight percent of an ethylene vinyl alcohol copolymer embolizing agent; from about 10 to about 40 weight percent of a water insoluble contrast agent selected from the group consisting of tantalum, tantalum oxide and barium sulfate; and from about 52 to about 87.5 weight percent of a biocompatible solvent. All of the weight percents are based upon the total weight of the composition. As detailed above, this composition employed in the method of claim 7 recites the composition in the approved product.

The composition acts to embolize the blood vessel by forming a precipitate in the blood vessel in the following manner. The copolymer is soluble in DMSO and insoluble in blood and the DMSO is miscible in blood. Therefore, when the composition is injected into the blood vessel, the DMSO dissipates into the blood and the copolymer forms a precipitate thereby embolizing the blood vessel.

Claim 8 recites the copolymer of claim 7, wherein the copolymer is from about 25 to about 60 mole percent of ethylene and from about 40 to about 75 mole percent of vinyl alcohol in the Onyx® composition. Thus, the method of using the product described above is claimed in claim 8.

Claim 9 recites the biocompatible solvent of claim 7, wherein the solvent is DMSO.

Thus, the method of using the product described above is claimed in claim 9.

Claim 10 recites the contrast agent, wherein the contrast agent is tantalum. Thus, the method of using the product described above is claimed in claim 10.

Claim 13 recites that the composition is injected into the blood vessel at a rate of about 0.05 to 0.3 cc/minute. According to the product labeling of the approved product, the composition should be injected at a rate of no more than 0.3 milliliters/minute (cc/minute). Thus, the method of using the product described above is claimed in claim 13.

SVCA_17331.1

- 10. The relevant dates and information pursuant to 35 U.S.C. § 156(g) are as follows:
 - (A) December 14, 2000 Effective date of IDE G000296.
 - (B) March 12, 2003 PMA P030004 initially submitted to FDA.
 - (C) July 21, 2005 PMA P030004 approved by FDA.

11. A detailed description of significant activities undertaken by applicant during the applicant regulatory review period is appended hereto as Appendix D and E, and incorporated herein by reference.

Appendix D is the chronology of IDE G000296. Appendix E is the chronology of PMA P030004. Both chronologies are organized in the same manner. Specifically, the communications to the FDA are listed on the left-hand side of the paper and the FDA responses are listed on the right-hand side of the paper.

12. In the opinion of the applicant, the patent is eligible for the requested extension.

Statement of Eligibility of the Patent for Extension

Section 156(a) provides, in relevant part, that the term of a patent which claims a product, a method of using a product, or a method of manufacturing a product shall be extended if the requirements (1)-(5) are satisfied.

(1) [T]he term of the patent has not expired before an application for extension is submitted.

The term of U.S. Patent 5,667,767 is currently set to expire on July 27, 2015. This application has been submitted before the expiration of the patent term. Accordingly, this requirement is satisfied.

(2) [T]he term of the patent has never been extended.

The term of U.S. Patent 5,667,767 has never been extended. Accordingly, this requirement is satisfied.

(3) [T]he application for extension is submitted by the owner of record of the patent or its agent in accordance with 35 U.S.C. § 156(d).

This application is submitted by an agent of the owner of record, Micro Therapeutics, Inc. This application is submitted in accordance with 35 U.S.C. § 156(d) in that it is submitted within the sixty day period beginning on the date that the approved product received permission for commercial marketing and use and contains the information required by 35 U.S.C. § 156(d). Accordingly, this requirement is satisfied.

(4) [T]he product has been submitted to a regulatory review period before its commercial marketing or use.

The approved product was subject to regulatory review under Section 515 of the Federal Food, Drug, and Cosmetic Act by filing IDE G000296 on November 10, 2000 and PMA P030004 on March 12, 2003. Accordingly, this requirement is satisfied.

(5) [T]he permission for the commercial marketing or use of the product after such regulatory review period is the first permitted commercial marketing or use of the product under the provision of law under which such regulatory review period occurred.

The permission for the commercial marketing and use of the Onyx® LES for use in presurgical embolization of brain arteriovenous malformations granted in July 21, 2005, after regulatory review under Section 515 is the first permitted commercial marketing or use of the product in the United States. Accordingly, this requirement is satisfied.

As noted above, all of the requirements of 35 U.S.C. § 156(a) have been satisfied and thus, this patent is eligible for an extension.

Statement as to the Length of Extension Claimed

The term of U.S. Patent 5,667,767 should be extended <u>1,271 days</u>, or until <u>January 18, 2018</u> (including the additional day due to the leap year). This term of extension was determined on the following basis:

As set forth in 35 U.S.C. § 156 (g)(3)(B), the regulatory review period equals the sum of the following periods (i) and (ii):

(i) the period beginning on the date a clinical investigation on humans involving the device was begun and ending on the date an application was initially submitted with respect to the device under section 515, and

SVCA_17331.1

(ii) the period beginning on the date an application was initially submitted with respect to the device under section 515 and ending on the date such application was approved under such Act or the period beginning on the date a notice of completion of a product development protocol was initially submitted under section 515(f)(5) and ending on the date the protocol was declared completed under section 515(f)(6).

The regulatory review period started on December 14, 2000, the day that IDE G000296 became effective. An application was initially submitted with respect to the device under section 515 on March 12, 2003. The number of days from December 14, 2000 to March 12, 2003 was 818 days. The application was approved under such Act was July 21, 2005. The number of days from March 12, 2003 to July 21, 2005 was 862 days (including the additional day due to the leap year). Thus, the regulatory review period was 4 years and 219 days (1,680 days, including the additional day due to the leap year).

In accordance with 35 U.S.C. § 156(c), the term of a patent eligible for extension shall be extended by the time equal to the regulatory review period for the approved product which occurred after the date the patent issued. U.S. Patent 5,667,767 issued on September 16, 1997. The regulatory review period began on December 14, 2000. Thus, there were no days of regulatory review prior to the issuance of the patent.

Section 156 (c) also sets forth the following exceptions (1)-(3) which may operate to shorten the length of the review period used to calculate the patent term extension:

(1) each period is reduced by any period during which the application did not act with due diligence.

SVCA_17331.1 11

In the opinion of the Applicant, there has been no lack of due diligence during the period of regulatory review calculated above. Accordingly, no reduction in the review period is required by this provision.

(2) each period includes only one-half of the number of days in phase (i).

One-half the number of days in phase (i) equals one-half of 818 days (the number of days from December 14, 2000 to March 12, 2003) or 409 days. Adding this number to the number of days in phase (ii) (862 days) results in a review period of 1,271 days.

(3) if the period remaining in the patent term after the date of approval of the approved product was added to the regulatory review period as revised under paragraphs (1) and (2) above exceeds fourteen years, the period of extension shall be reduced so that the sum of both periods does not exceed fourteen years.

On the date of approval of the product, 10 years and 6 days remained in the term of U.S. Patent 5,667,767. Adding this period to the review period calculated above yields a period of less than fourteen years. This provision, therefore, does not operate to shorten the period of extension to which U.S. Patent 5,667,767 is entitled.

Section 156(g)(6) limits the period of patent term extension to a maximum of five years from the original date of the patent. The original expiration date of U.S. Patent 5,667,767 is July 27, 2015. The maximum extension allowed by this provision would extend the term to July 27, 2020. Extension of the patent term by the number of days calculated above would not extend the patent beyond July 27, 2020. Accordingly, this provision does not limit the patent term extension available.

In sum, U.S. Patent 5,667,767 is entitled to an extension of patent term until

January 18, 2018 or 1,271 days.

13. Applicant acknowledges the duty to disclose to the Director of the United States

Patent and Trademark Office and the Secretary of Health and Human Services or the Secretary of

Agriculture any information which is material to the determination of entitlement to the

extension sought.

14. The fee of \$1,120.00 (37 CFR § 1.20(j)) is enclosed herewith.

15. Inquiries and correspondence relating to this Application for Patent Term

Extension should be directed to:

Lorna L. Tanner
Foley & Lardner LLP
1530 Page Mill Road
Pala Alta CA 04204 1126

Palo Alto, CA 94304-1125 Tel: 650-856-3700

Fax: 650-856-3710

16. This application is accompanied by two additional copies of the application (for a

total of three copies).

17. The undersigned, a duly authorized agent of Micro Therapeutics, Inc., hereby

declares:

(1). that she is a patent attorney authorized to practice before the United States

Patent and Trademark Office and has general authority from Applicant for the purpose of

SVCA_17331.1

13

transacting all matters reasonably related to obtaining an extension of patent term for U.S. Patent No. 5,667,767;

- (2).that she has reviewed and understands the content of this application being submitted pursuant to 35 U.S.C. § 156;
- (3). that she believes the patent is subject to extension pursuant to 37 C.F.R. § 1.710;
- that she believes an extension of the length claimed is justified under (4). 35 U.S.C. § 156 and the applicable regulations; and
- that she believes the patent for which the extension is being sought meets **(5)**. the conditions for extension of the term of a patent as set forth in 37 C.F.R. § 1.720.

Respectfully submitted,

September 14,2005

FOLEY & LARDNER LLP 1530 Page Mill Road Palo Alto, California 94304-1125 Telephone: (650) 251-1104

Facsimile:

(650) 856-3710

Lorna L. Tanner

Attorney for Applicant

Registration No. 50,782

By Horner Dances

APPENDIX A



US005667767A

United States Patent [19]

Greff et al.

[11] Patent Number:

5,667,767

[45] Date of Patent:

Sep. 16, 1997

[54] COMPOSITIONS FOR USE IN EMBOLIZING BLOOD VESSELS

[75] Inventors: Richard J. Greff, Yorba Linda;

Michael L. Jones. Capistrano Beach; Scott Evans, Santa Ana, all of Calif.

[73] Assignce: Micro Therapeutics, Inc., San

Clemente, Calif.

[21] Appl. No.: 507,863

[22] Filed: Jul. 27, 1995

); 604/52; 604/53; 604/56; 604/70

[56] References Cited

U.S. PATENT DOCUMENTS

| 4,079,124 | 3/1978 | Winchell 424/4 |
|--------------|---------|-------------------------|
| 4,631,188 | 12/1986 | Stoy et al 424/81 |
| 4,795,741 | 1/1989 | Leshchiner et al 514/21 |
| 4,938,763 | 7/1990 | Dunn et al 604/891.1 |
| 5,202,352 | 4/1993 | Okada et al 514/475 |
| 5,443,454 | 8/1995 | Tanabe et al 604/264 |
| B1 4,938,763 | 7/1995 | Dunn et al 604/891.1 |

FOREIGN PATENT DOCUMENTS

5-57014 · 3/1993 Japan . 5-253283 10/1993 Japan .

6-107549 4/1994 Japan .

OTHER PUBLICATIONS

Toxicology, Amdur et al., Editors, Toxic Effects of Metals. 4th Edition, pp. 661-664, Pergamon Press, New York, New York.

Guglielmi, et al., Electrothrombosis of Saccular Aneurysms via Endovascular Approach, J. Neurosurg., 75:8–14 (1991). Kinugasa, et al., Early Treatment of Subarachnoid Hemorrhage After Preventing Rerupture of an Aneurysm, J. Neurosurg., 83:34–41 (1995).

Kinugasa, et al., Prophylatic Thrombosis to Prevent New Bleeding and to Delay Aneurysm Surgery, Neurosurgery, 36(4):661-667 (1995).

Kinugasa, et al., Direct Thrombosis of a Pseudoaneurysm after Obliteration of a Carotid-Cavernous Fistula with Cellulose Acetate Polymer: Technical Case Report, Neurosurgery, 35(4):755-760 (1994).

Kinugasa, et al., Direct Thrombosis of Aneurysms with Cellulose Acetate Polymer, Part II: Preliminary Clinical Experience, J. Neurosurg., 77:501-507 (1992).

Mandai, et al., Direct Thrombosis of Aneurysms with Cellulose Acetate Polymer, Part 1: Results on Thrombosis in Experimental Aneurysms, J. Neurosurg., 77:497-500 (1992).

Miyatake, et al., Cobb's Syndrome and its Treatment with Embolization, J. Neurosurg., 72:497-499 (1990).

Sadato, et al., Experimental Study and Clinical Use of Poly(vinyl acetate) Emulsion as Liquid Embolisation Material, Neuroradiology, 36:634-641 (1994).

Sugiu, et al., Direct Thrombosis of Experimental Aneurysms with Cellulose Acetate Polymer (CAP): Technical Aspects, Angiographic Follow Up, and Histological Study. J. Neurosurg., 83:531-538 (1995).

Taki, et al., A New Liquid Material for Embolization of Arteriovenous Malformatoins, Am. J. Neuroradiology, 11:163-168 (1990).

Taki, et al., Selection and Combination of Various Endovascular Techniques in the Treatment of Giant Aneurysms, J. Neurosurg., 77:37-42 (1992).

Terada, et al.. Embolization of Arteriovenous Malformations with Peripheral Aneurysms using Ethylene Vinyl Alcohol Copolymer, J. Neurosurg., 75:655-660 (1991).

Yamashita, et al. Characteristics of Ethylene Vinyl Alcohol Copolymer (EVAL) Mixtures, Am. J. Neuroradiology. 15:1103-1105 (1994).

Medical Tribune, "Possibility and Limit of Intravascular Surgery", Taki, Oct. 26, 1989, pp. 46-47.

Primary Examiner—Patrick Niland Attorney, Agent, or Firm—Burns, Doane, Swecker & Mathis, L.L.P.

[57] ABSTRACT

Disclosed are compositions suitable for use in embolizing blood vessels which compositions comprise an ethylene vinyl alcohol copolymer, a biocompatible solvent and a water insoluble contrasting agent selected from the group consisting of tantalum, tantalum oxide and barium sulfate. Also disclosed are methods for embolizing a blood vessel using the compositions described herein.

15 Claims, No Drawings

COMPOSITIONS FOR USE IN EMBOLIZING BLOOD VESSELS

BACKGROUND OF THE INVENTION

Field of the Invention

This invention is directed to compositions suitable for use in embolizing blood vessels. In particular, this invention is directed to embolizing compositions comprising an ethylene vinyl alcohol copolymer, a biocompatible solvent and a water insoluble contrasting agent. The compositions of this invention find particular utility in embolizing blood vessels in, for example, the treatment of aneurysms and in ablating diseased tissues.

References

The following publications are cited in this application as superscript numbers: 1 Casarett and Doull's Toxicology, Amdur et al., Editors, Pergamon Press, New York, pp. 20 661-664 (1975) Taki, et al., "A New Liquid Material for Embolization of Arteriovenous Malformations", American Society of Neuroradiology, 11: 163-168 (1990) ³Terada, et al., 'Embolization of Arteriovenous Malformations with Peripheral Aneurysms Using Ethylene Vinyl Alcohol 25 Copolymer", J. Neurosurg., 75: 655-660 (1991)

All of the above references are herein incorporated by reference in their entirety to the same extent as if each individual reference was specifically and individually indicated to be incorporated herein by reference in its entirety. 30

State of the Art

It is desirable in many clinical situations to embolize blood vessels to prevent/control bleeding (e.g., organ bleeding, gastrointestinal bleeding, vascular bleeding, bleeding associated with an aneurysm) or to ablate diseased tissue (e.g., tumors, etc.). Embolization of blood vessels has heretofore employed polymer compositions and particulates, e.g., silicone, metallic coils, sclerosing materials and the like. Polymeric materials employed in the polymeric compositions include those which polymerize in situ at the vascular site (e.g., cyanoacrylates) and those wherein a preformed polymer in situ precipitates from a carrier solution at the vascular site.

The in situ polymerization of cyanoacrylates delivered via a catheter causes complications due to premature polymerization and/or adhesion of the polymer to the catheter. Accordingly, there has been recent focus on incorporating preformed polymeric materials into embolization compositions. Ideally, such compositions should be easy to deliver (e.g., low viscosity) and should cause rapid embolization in the intended vascular site. Additionally, these compositions should be sterile, stable, biocompatible and radiopaque. This embolizing composition into the vascular site and to confirm its presence after the procedure is complete.

Current embolizing compositions employing preformed polymers typically fail to meet one or more of the requirements of ideal embolizing compositions and a compromise 60 must be made in selecting the embolizing agents relative to the given clinical case. At times, embolization of the blood vessel, although called for by the clinical condition of the subject, is not performed due to difficulties in selecting an

Failure of such embolizing compositions to meet these ideal requirements often arises from the particular combi-

nation of embolizing and contrast agents used in the embolizing composition. Specifically, the biocompatible embolizing agent should produce a well defined coherent plug/ solid upon contact with blood and the contrast agent should be encapsulated in the formed solid in order to permit adequate definition of the location of embolism formation. While certain compositions comprising an embolizing agent, a contrast agent and a biocompatible solvent such as dimethylsulfoxide (DMSO) have heretofore been disclosed, the choice of embolizing agent in combination with contrast agent is critical to successful use in embolizing conditions. For example, the selected embolizing agent must be biocompatible, capable of rapid precipitation to form a solid, space-filling material and compatible with the selected con-15 trast agent. Additionally, the resulting solid material must be sufficiently coherent so as to minimize fragmentation which results in smaller solid materials being incorporated within the circulation system. As is apparent, the presence of solid materials in the circulation system can lead to embolization of blood vessels at undesired locations. In the extreme, unintended embolization of essential blood vessels can lead to subject death.

The choice of contrast agent relative to the embolizing agent is particularly critical and contrast agents heretofore employed for gastrointestinal tract applications and intravascular injections are not always suitable for use in embolizing blood vessels. For example, while bismuth trioxide is a well known contrast agent, recent evidence indicates that exposure to this agent can lead to progressive mental confusion, irregular myoclonic jerks, a distinctive pattern of disordered gait, and a variable degree of dysarthria which was fatal to subjects who continued its use1. Contrast agents which interfere with or retard solid/plug formation for a particular embolizing agent are also not desirable. Moreover, the contrast agent should be water insoluble and must be encapsulated into the resulting precipitate otherwise adverse medical problems can arise. Complications arising from the use of a water insoluble contrast agents which are not encapsulated into the formed precipitate include particles of contrast agent migrating through the circulation system causing embolization of unintended blood vessels. Complications arising from the use of water soluble contrast agents include dissolution of these agents into the blood upon injection into the vascular site leading to potential systemic side effects in the treated subject. Additionally, the use of water soluble contrast agents limits the clinician's ability to continuously monitor the injection of the embolizing agent into the blood vessel because, upon contact with the blood, the contrast agent is dissolved and removed from the site of injection. As still a further complication, the contrast agent selected must not alter the physical properties of the solution, e.g. viscosity, in such a manner as to render the composition unsuitable for vascular use.

In view of the above, whether an embolizing agent and last property is necessary in order to monitor injection of the 55 contrast agent will be suitable in combination to embolize a blood vessel is very empirical and substitution of one embolizing agent for another or one contrast agent with another often leads to deleterious results. This problem is not particularly surprising because ultimately a successful combination of embolizing agent and contrast agent requires compatibility between these components in producing the requisite coherent precipitate having the contrast agent encapsulated therein as well as maintaining the requisite properties for vascular use. When, for example, one contrast embolizing composition suitable for use in the given case. 65 agent is replaced by another contrast agent, the chemical and physical properties of each contrast agent will dictate whether it is compatible with the selected embolizing agent. 3

Accordingly, it is not unexpected that contrast agents having different chemical and/or physical properties will result in changes in the overall properties of the embolizing composition.

This invention is directed to our discovery of a novel 5 injectable liquid embolizing composition comprising an ethylene vinyl alcohol copolymer dissolved in a biocompatible solvent and a water insoluble contrast agent selected from either tantalum, tantalum oxide, or barium sulfate. Surprisingly, this embolizing composition is easily delivered $\ ^{10}$ to the vascular site and rapidly forms a coherent solid material which readily encapsulates the contrast agent.

Heretofore, Taki. et al.2 disclose an example of an embolizing composition containing an ethylene vinyl alcohol copolymer (67 mole percent ethylene and 33 mole percent 15 vinyl alcohol) and a water soluble contrast agent (metrizamide) in DMSO. An apparently similar composition was also disclosed by Terada, et al.3 However, the water soluble contrast agents disclosed in these references significantly limit the suitability of these compositions for use in 20 embolizing blood vessels. Moreover, as above, the apriori substitution of a water insoluble contrast agents for metrizamide is inherently problematic because it is unpredictable what affect the different chemical and/or physical properties of the water insoluble contrast agent as compared to the soluble contrast agent will have on the ultimate properties of the resulting compositions.

SUMMARY OF THE INVENTION

As above, this invention is directed to our discovery of a novel injectable liquid embolizing composition comprising an ethylene vinyl alcohol copolymer dissolved in dimethylsulfoxide or other suitable biocompatible solvent and a water insoluble contrast agent selected from tantalum, tan- 35 talum oxide, or barium sulfate.

Accordingly, in one of its composition aspects, this invention is directed to a composition composition comprising:

- (a) from about 2.5 to about 8 weight percent of an ethylene vinyl alcohol copolymer embolizing agent;
- (b) from about 10 to about 40 weight percent of a water insoluble contrast agent selected from the group consisting of tantalum, tantalum oxide and barium sulfate;
- biocompatible solvent

wherein the weight percent of each of the components is based on the total weight of the complete composition.

In one of its method aspects, this invention is directed to a method for embolizing a blood vessel by injecting into said 50 blood vessel a sufficient amount of an embolizing composition comprising:

- (a) from about 2.5 to about 8 weight percent of an ethylene vinyl alcohol copolymer embolizing agent;
- (b) from about 10 to about 40 weight percent of a water insoluble contrast agent selected from the group consisting of tantalum, tantalum oxide and barium sulfate;
- (c) from about 52 to about 87.5 weight percent of a biocompatible solvent

wherein the weight percent of each of the components is based on the total weight of the complete composition

under conditions wherein a precipitate is formed which embolizes the blood vessel.

In a preferred embodiment, the molecular weight of the 63 ethylene vinyl alcohol copolymer composition is selected such that a solution of 6 weight percent of the ethylene vinyl

alcohol composition, 35 weight percent of a tantalum contrast agent in DMSO has a viscosity equal to or less than 60 centipoise at 20° C. and more preferably 40 centipoise or less at 20° C. In another preferred embodiment, the ethylene vinyl alcohol copolymer composition comprises from about 25 to about 60 mole percent of ethylene and from about 40 to about 75 mole percent of vinyl alcohol.

Preferably, the biocompatible solvent is dimethylsulfox-

DETAILED DESCRIPTION OF THE INVENTION

This invention is directed to specific embolizing compositions comprising a specific embolizing agent, specific contrast agents and a biocompatible solvent.

Prior to discussing this invention in further detail, the following terms will first be defined:

The term "embolizing" as used in conjunction with "embolizing compositions" and "embolizing agents" refers to a process wherein a material is injected into a blood vessel which thereafter fills or plugs the blood vessel and/or encourages clot formation so that blood flow through the vessel ceases. The embolization of the blood vessel is important in preventing/controlling bleeding (e.g., organ bleeding, gastrointestinal bleeding, vascular bleeding, bleeding associated with an aneurysm) or to ablate diseased tissue (e.g., tumors, etc.) by cutting off its blood supply.

The term "ethylene vinyl alcohol copolymers" refers to copolymers comprising residues of both ethylene and vinyl alcohol monomers. Small amounts (e.g., less than 5 mole percent) of additional monomers can be included in the polymer structure or grafted thereon provided such additional monomers do not alter the embolizing properties of the composition. Such additional monomers include, by way of example only, malcic anhydride, styrene, propylene, acrylic acid, vinyl acetate and the like.

Ethylene vinyl alcohol copolymers used herein are either commercially available or can be prepared by art recognized 40 procedures. Preferably, the ethylene vinyl alcohol copolymer composition is selected such that a solution of 6 weight percent of the ethylene vinyl alcohol copolymer, 35 weight percent of a tantalum contrast agent in DMSO has a viscosity equal to or less than 60 centipoise at 20° C. As is (c) from about 52 to about 87.5 weight percent of a 45 apparent to one skilled in the art, with all other factors being equal, copolymers having a lower molecular weight will impart a lower viscosity to the composition as compared to higher molecular weight copolymers. Accordingly, adjustment of the viscosity of the composition as necessary for catheter delivery can be readily achieved by mere adjustment of the molecular weight of the copolymer composition.

> As is also apparent, the ratio of ethylene to vinyl alcohol in the copolymer affects the overall hydrophobicity/ hydrophilicity of the composition which, in turn, affects the relative water solubility/insolubility of the composition as well as the rate of precipitation of the copolymer in an aqueous solution (e.g., blood). In a particularly preferred embodiment, the copolymers employed herein comprise a mole percent of ethylene of from about 25 to about 60 and a mole percent of vinyl alcohol of from about 40 to about 75. These compositions provide for requisite precipitation rates suitable for use in embolizing blood vessels.

> The term "contrast agent" refers to a radiopaque material capable of being monitored during injection into a mammalian subject by, for example, radiography. The term "water insoluble contrast agent" refers to contrast agents which are essentially insoluble in water (i.e., having a water solubility

of less than 0.01 mg/ml at 20° C.). The water insoluble contrast agents included within the scope of this invention are tantalum, tantalum oxide and barium sulfate, each of which is commercially available in the proper form for in vivo use including a particle size of about 10 µm or less. Other contrast agents suitable for use herein include gold

The term "biocompatible solvent" refers to an organic material liquid at least at body temperature of the mammal in which the ethylene vinyl alcohol copolymer is soluble 10 and, in the amounts used, is substantially non-toxic. Suitable biocompatible solvents include, by way of example, dimethylsulfoxide, analogues/homologues of dimethylsulfoxide, and the like. Preferably, the biocompatible solvent is dimethylsulfoxide.

The term "encapsulation" as used relative to the contrast agent being encapsulated in the precipitate is not meant to infer any physical entrapment of the contrast agent within the precipitate much as a capsule encapsulates a medicament. Rather, this term is used to mean that the contrast 20 agent and copolymer form an integral coherent precipitate which does not separate into a copolymer component and a contrast agent component.

Compositions

The compositions of this invention are prepared by conventional methods whereby each of the components is added and the resulting composition mixed together until the overall composition is substantially homogeneous. copolymer are added to the biocompatible solvent to achieve the effective concentration for the complete embolizing composition. Preferably, the embolizing composition will comprise from about 2.5 to about 8 weight percent of the ethylene vinyl alcohol copolymer composition based on the total weight of the embolizing composition and more preferably from about 4 to about 5.2 weight percent. If necessary, gentle heating and stirring can be used to effect dissolution of the copolymer into the biocompatible solvent, 40 e.g., 12 hours at 50° C.

Sufficient amounts of the contrast agent are then added to the biocompatible solvent to achieve the effective concentration for the complete embolizing composition. Preferably, the embolizing composition will comprise from about 10 to about 40 weight percent of the contrast agent and more preferably from about 20 to about 40 weight percent and even more preferably 35 weight percent. Insofar as the contrast agent is not soluble in the biocompatible solvent. stirring is employed to effect homogeneity of the resulting suspension. In order to enhance formation of the suspension, the particle size of the contrast agent is preferably maintained at about 10 µm or less and more preferably at from about 1 to about 5 μm (e.g., an average size of about 2 μm).

The particular order of addition of components to the 55 biocompatible solvent is not critical and stirring of the resulting suspension is conducted as necessary to achieve homogeneity of the composition. Preferably, mixing/stirring of the composition is conducted under an anhydrous atmosphere at ambient pressure. The resulting composition is heat sterilized and then stored preferably in scaled amber bottles or vials until needed.

Methods

The compositions described above are then employed in methods for embolizing mammalian blood vessels.

Specifically, a sufficient amount of this composition is introduced into the selected blood vessel by conventional means (e.g., injection or catheter delivery under fluoroscopy) so that upon precipitation of the ethylene vinyl alcohol copolymer, the blood vessel is embolized. The particular amount of embolizing composition employed is dictated by the total volume of the vasculature to be embolized, the concentration of copolymer in the composition, the rate of precipitation (solids formation) of the copolymer, etc. Such factors are well within the skill of the art. The rate of precipitation can be controlled by changing the overall hydrophobicity/hydrophilicity of the copolymer with faster precipitation rates being achieved by a more hydrophobic copolymer composition which, in turn, 15 can be achieved by increasing the ethylene content of the copolymer composition.

One particularly preferred method for delivering the embolizing compositions of this invention to the selected vascular site is via a small diameter medical catheter. The particular catheter employed is not critical provided that polymeric catheter components are compatible with the embolizing composition (i.e., the catheter components will not readily degrade in the embolizing composition). In this regard, it is preferred to use polyethylene in the catheter components because of its inertness in the presence of the embolizing composition described herein. Other materials compatible with the embolizing compositions can be readily determined by the skilled artisan and include, for example, Specifically, sufficient amounts of the ethylene vinyl alcohol 30 other polyolefins, fluoropolymers (e.g., Teflon™), silicone.

> When delivered by catheter, the injection rate dictates, in part, the form of the precipitate at the vascular site. Specifically, low injection rates of approximately 0.05 to 0.3 cc/minute will provide for a precipitate in the form of a kernel or nodule which is particularly beneficial for site specific embolization because the precipitate forms primarily at the point of injection. Contrarily, high injection rates of about 0.1 to 0.5 or more cc/several seconds (e.g., up to ten seconds) will provide for a filament like mass projecting down stream from the catheter tip which is particularly beneficial for providing the embolizing agent deep into the vascular tree. Such procedures are suitable for embolizing tumor masses, organs and arteriovenous malformations (AVM).

> When introduced into the vascular site, the biocompatible solvent diffuses rapidly into the blood and a solid precipitate forms which precipitate is the ethylene vinyl alcohol copolymer with the contrast agent encapsulated therein. Without being limited to any theory, it is believed that initially, a soft gel to spongy solid precipitate forms upon contact with the blood which precipitate is open and fibrous in structure. This precipitate then restricts blood flow, entrapping red cells thereby causing clot embolization of the blood vessel.

Utility

The compositions described herein are useful in embolizing mammalian blood vessels which, in turn, can be used to prevent/control bleeding (e.g., organ bleeding, gastrointestinal bleeding, vascular bleeding, bleeding associated with an aneurysm) or to ablate diseased tissue (e.g., tumors, etc.). Accordingly, these compositions find use in human and other mammalian subjects requiring emboliza-65 tion of blood vessels.

Additionally, these compositions provide an appropriate vehicle for the delivery of a medicament to the vascular site.

7

Specifically, a suitable medicament, e.g., a chemotherapeutic agent, growth factor agents, anti-inflammatory agents, anti-spasmatic agents, etc. which are compatible with the embolizing composition can be included in this composition in therapeutic levels and delivered directly to the vascular site.

The following examples are set forth to illustrate the claimed invention and are not to be construed as a limitation thereof

EXAMPLES

Unless otherwise stated, all temperatures are in degrees Celsius. Also, in these examples, unless otherwise defined 15 below, the abbreviations employed have their generally accepted meaning:

cc=cubic centimeter

DMSO=dimethylsulfoxide

EVOH=ethylene vinyl alcohol copolymer
gm=gram
mL=milliliters
mm=millimeter
psi=pounds per square inch

Example 1

The purpose of this example is to demonstrate the suitability of ethylene vinyl alcohol copolymer compositions in DMSO as embolizing agents. The tests were conducted by addition of the copolymer solution into saline and determining the precipitation parameters. Rapid formation of a coherent precipitation evidences suitability of the copolymer composition as an embolizing agent.

Specifically, five ethylene vinyl alcohol copolymer resins were employed of varying concentrations—27, 32, 38, 44 and 48 mole percent ethylene (available from EVAL Company of America, Lisle, Ill., USA) having a viscosity grade as defined by a melt index of about 4–15 (gm/10 minutes) at 210° C. The resin appears as clean, translucent cylindrical particles about 1×2 mm. Samples were prepared at 5.2% concentration in DMSO (obtained from Aldrich Chemical Company, Milwaukee, Wis., USA as M8180-2, 99+% purity). Dissolution was complete within 24 hours at 52° C.

Approximately 0.1 to 0.5 mL of each solution was added 50 by needle/syringe to a normal saline solution at 37° C. or at room temperature. All five samples immediately generated a white mass or string of polymer upon contact with saline. As the ethylene content in the sample increased, the resulting precipitate was whiter, tougher and more dense. The two 55 lowest ethylene content resins appeared to yield a weaker, more gelatinous mass, which nevertheless were suitable for use as embolizing agents.

Accordingly, these results indicate that EVOH copolymers are suitable embolizing agents.

Flow rates were assessed for each of these samples at 10 psi and 37° C. over 3 minutes using a 3 French Infusion catheter (available from Micro Therapeutics, Inc., Aliso Viejo, Calif., USA) in order to assess suitability for catheter 65 delivery of these compositions to the vascular site. The results of this analysis are set forth in Table I below:

8

TABLE I

| | Ethylene Content in EVOH Copolymer | Flow Rate |
|---------------|---------------------------------------|----------------------------|
| 5 — | 27% | |
| | 32% | 0.22 cc/min 0.25 cc/min |
| | 38% 44% | 0.20 cc/min |
| | 48% | 0.25 cc/min 0.30 cc/min |
| o | | |

The above results indicate that these compositions possess flow rates suitable for catheter delivery to the vascular site. These results also suggest that preferable results are achieved using a more hydrophobic EVOH composition (e.g., about 48 mole % ethylene content) at a concentration of about 2.5 to about 8.0 weight percent.

Example 2

The purpose of this example is to illustrate that not all polymers are suitable as embolizing agents. Specifically, in this example, the EVOH copolymers described above were replaced with polyurethane (DOW PELLETHANE 2363-80A. Dow Chemical Company, Midland, Mich., USA), polymethylmethacrylate (available from Rohm & Haas, Philadelphia, Pa., USA), polycarbonate (MOBAY MAKROLON 2558-1112, Mobay Chemical Company, Bayer Inc., Pittsburgh, Pa., USA), two different cellulose diacetates [Cellulose Acetate NF CA 320-S (-32% acetyl content) and Cellulose Acetate NF CA 398-10 (-39.8 acetyl content) both available from FMC Corp., Pharmaceutical Division, Philadelphia, Pa., USA)] and cellulose triacetate (Cellulose Acetate NF CA 435-75S (-43.5% acetyl content)—FMC Corp., Pharmaceutical Division, Philadelphia, Pa., USA).

The results of this analysis indicated that polyurethane samples were slow to dissolve in DMSO at 52° C, and, upon cooling to room temperature, formed a high viscosity solution/gel unsuitable for injection. In the case of the polymethylmethacrylate, the polymer dissolved in DMSO but the precipitate formed upon addition to saline was unsuitable for use as an embolizing agent because it lacked cohesiveness and easily fragmented. In the case of the polycarbonate, the polymer failed to dissolve in DMSO at 52° C. over 3 days. The cellulose triacetate sample provided too high a viscosity for effective delivery via a catheter at a concentration sufficient to effectively embolize a blood vessel and reduction of the concentration to less than 2.5 weight percent resulted in precipitate formation which was unsuitable for vascular embolization. Only the cellulose diacetates provided suitability for vascular embolization in a manner similar to EVOH and the use of such polymers as embolizing agents is described in further detail in U.S. patent application Ser. No. 08/508,248 filed concurrently herewith as Attorney Docket No. 018413-003 entitled "CELLULOSE DIACETATE COMPOSITIONS FOR USE IN EMBOLIZING BLOOD VESSELS" which application is incorporated herein by reference in its entirety.

Example 3

The purpose of this example is to compare in vitro results achieved by incorporating a water soluble contrast agent and a water insoluble contrast agent of this invention into an embolizing composition containing EVOH in DMSO. Specifically, in this example, an EVOH composition (44 mole percent ethylene) was dissolved into DMSO to provide for an 6.8 weight percent concentration of the copolymer in

Q

DMSO. To this solution was added either tantalum (10 weight percent, available from Leico Industries, New York, N.Y., USA, 99.95% purity, less than 43 µm in size) as a water insoluble contrast agent or metrizamide (38.5 weight percent, available from Aldrich Chemical Company, Milwaukee, Wis., USA) as a water soluble contrast agent. Because these results are in vitro results, the tantalum particle size is not important and the larger particles size is not expected to affect these results.

In the tantalum composition, tantalum settling can result 10 from prolonged standing. Sonification may help but thorough mixing prior to use is required.

Approximately 0.2 mL of the each composition was then added by syringe/needle to a saline solution at 37° C. and the characteristics of the resulting precipitate examined. In the case of the tantalum sample, a precipitate immediately formed which was characterized by firm spongy filaments and nodules. The metrizamide sample on the other hand did not form a well defined solid mass as the metrizamide rapidly diffused away.

Example 4

The purpose of this example is to illustrate that certain embolizing agent/contrast agent combinations provide for physical properties which makes injection of the combination into vascular sites significantly more difficult. Specifically, in this example, a composition comprising 6.8 weight percent of EVOH (44 mole percent ethylene) in DMSO was prepared. The viscosity of this composition was approximately 60 centipoise at 20° C. Upon addition of 38.5 weight percent of metrizamide to this composition, the viscosity increased significantly to approximately 145 centipoise at 20° C.

Contrarily, the addition of 35 weight percent of tantalum or barium sulfate to a similar EVOH/DMSO composition did not materially alter the viscosity of the composition.

The above results indicate that the use of tantalum as the contrast agent provides for compositions with significantly lower viscosity than those employing metrizamide. In turn, such lower viscosities render the compositions easier to deliver either by injection or by catheter to the vascular site thereby proportionally reducing the likelihood of vascular injury.

Example 5

The purpose of this example is to illustrate an in vivo application of the embolizing composition of this invention.

In this example, a 50 pound male hound was prepared for blood vessel embolization using an embolic composition 50 trast agent is tantalum. comprising 5.8 weight percent EVOH polymer (containing 48 weight percent ethylene), 20 weight percent tantalum in DMSO was loaded into a syringe. Embolization of the left kidney proceeded by placement of a 3F micro catheter into the kidney through a 5F AngioDynamics Headhunter catheter. The catheter was advanced into the renal artery, flushed with contrast agent to identify the location and then flushed with DMSO, followed by 0.3 cc of the EVOH composition described above, followed yet by more DMSO within the catheter. The EVOH composition was quickly injected into 60 the renal artery. After delivery of about 0.2 cc of EVOH composition, the upper pole of the kidney was blocked. Delivery of the remaining EVOH composition resulted in the entire kidney being embolized.

The above results indicate that the compositions of this 65 malformations (AVM). invention are suitable for in vivo embolization of blood vessels in mammalian subjects.

10

From the foregoing description, various modifications and changes in the composition and method will occur to those skilled in the art. All such modifications coming within the scope of the appended claims are intended to be included therein.

What is claimed is:

- 1. A composition comprising:
- (a) from about 2.5 to about 8.0 weight percent of an ethylene vinyl alcohol copolymer;
- (b) from about 10 to about 40 weight percent of a water insoluble contrast agent selected from the group consisting of tantalum, tantalum oxide and barium sulfate;
- (c) from about 52 to about 87.5 weight percent of a biocompatible solvent
- wherein the weight percent of each of the components is based on the total weight of the complete composition.
- 2. The composition according to claim 1 wherein said ethylene vinyl alcohol copolymer comprises from about 25 to about 60 mole percent of ethylene and from about 40 to about 75 mole percent of vinyl alcohol.
- 3. The composition according to claim 2 wherein said biocompatible solvent is DMSO.
- 4. The composition according to claim 3 wherein said contrast agent is tantalum.
- The composition according to claim 3 wherein said contrast agent is tantalum oxide.
- 6. The composition according to claim 3 wherein said contrast agent is barium sulfate.
- 7. A method for embolizing a blood vessel by injecting into said blood vessel a sufficient amount of an embolizing composition comprising:
 - (a) from about 2.5 to about 8.0 weight percent of an ethylene vinyl alcohol copolymer embolizing agent;
 - (b) from about 10 to about 40 weight percent of a water insoluble contrast agent selected from the group consisting of tantalum, tantalum oxide and barium sulfate;
 - (c) from about 52 to about 87.5 weight percent of a biocompatible solvent
- wherein the weight percent of each of the components is based on the total weight of the complete composition under conditions wherein a precipitate is formed which embolizes the blood vessel.
- 8. The method according to claim 7 wherein said ethylene vinyl alcohol copolymer comprises from about 25 to about 60 mole percent of ethylene and from about 40 to about 75 mole percent of vinyl alcohol.
 - 9. The method according to claim 8 wherein said biocompatible solvent is DMSO.
 - 10. The method according to claim 9 wherein said contrast agent is tantalum.
 - 11. The method according to claim 9 wherein said contrast agent is tantalum oxide.
 - 12. The method according to claim 9 wherein said contrast agent is barium sulfate.
 - 13. The method according to claim 7 wherein the embolizing composition is injected into the blood vessel at a rate of about 0.05 to 0.3 cc/minute.
 - 14. The method according to claim 7 wherein the embolizing composition is injected into the blood vessel at a rate of at least 0.6 cc/minute.
 - 15. The method according to claim 14 wherein the injection rate of at least 0.6 cc/minute is employed to form a filament like mass projecting down stream from the catheter tip for embolizing tumor masses, organs and arteriovenous malformations (AVM).

* * * * *

APPENDIX B

UNITED STATES PATENT AND TRADEMARK OFFICE



Commissioner for Patents United States Patent and Trademark Office P.O. Box 1450 Alexandria, VA 22313-1450 www.uspto.gov

Customer Num: 25188

DENNEMEYER & CO. 6990 COLUMBIA GATEWAY DRIVE SUITE 360 COLUMBIA MD 21046

MAINTENANCE FEE STATEMENT

The data shown below is from the records of the U.S. Patent and Trademark Office. If the maintenance fee and any necessary surcharge have been timely paid for the patent listed below, the notation "PAID" will appear in the "STAT" column.

If the statement of small entity status is defective the reason will be indicated below in the "Small Entity" status column. THE STATEMENT OF SMALL ENTITY STATUS WILL BE ENTERED UPON RECEIPT OF ACCEPTABLE CORRECTION.

| PATENT NUMBER | FEE AMT | SUR CHARGE | U.S. APPLICATION NUMBER | ISSUE DATE | APPL. FILING DATE | PAYMENT YEAR | SMALL ENTITY? | STAT | ATTY DKT NUMBER | |
|------------------|----------|---------------|-------------------------|---------------|-------------------------|-----------------|---------------|------|--------------------|--|
| 5,667,767 | \$425.00 | \$0.00 | 08/507,863 | 09/16/97 | 07/27/95 | 04 | NO | PAID | 018413-002 | |

Direct any questions about this notice to:
Mail Stop M Correspondence
Director of the U.S. Patent and Trademark Office
P.O. Box 1450
Alexandria, VA 22313-1450

Computer Patent Annuities Limited Partnership

PO Box 778, Jersey JE1 1BL Channel Islands Phone: +44 (0) 1534 888711

Fax: +44 (0) 1534 888747 E-Mail: cpa@cpajersey.com Web Site: www.cpajersey.com

Our Ref:

Your Ref:

Date:

2298130/0FRCPT

06 APR 2001

Burns Doane, Swecker & Mathis

Send all USA Receipts to client. ALL OTHERS STORE

> BURNS, DOANE, MAY 1 4 21

SWECKER & MATHIS, L

Dear Sirs

OFFICIAL RECEIPT / RENEWAL CERTIFICATE

Country Name:

U.S.A.

Type Name:

Small Entity

Patent No.:

5667767

Base date:

16 SEP 1997

Proprietor:

GREFF, RICHARD J.

Client case code:

P12746US0

Reference:

018413-002

Client no.:

0857763

Annuity:

Renewal date:

16 MAR 2001

We enclose official confirmation of payment of the annuity indicated above: this document should be kept in a safe place in case proof of payment is required at any time. If you would like such receipts stored by us in future, rather than sent to you, please let us know by signing and returning this letter: as storage of receipts here is more efficient for us as well as you, this can result in a reduction in charge for future renewals on your account.

Yours faithfully

Computer Patent Annuities Limited Partnership

APPENDIX C

UNITED STATES PATENT AND TRADEMARK OFFICE



Commissioner for Patents United States Patent and Trademark Office P.O. Box 1450 Alexandria, VA 22313-1450 www.uspto.gov

Customer Num: 25188

DENNEMEYER & CO. 6990 COLUMBIA GATEWAY DRIVE SUITE 360 COLUMBIA MD 21046

MAINTENANCE FEE STATEMENT

The data shown below is from the records of the U.S. Patent and Trademark Office. If the maintenance fee and any necessary surcharge have been timely paid for the patent listed below, the notation "PAID" will appear in the "STAT" column.

If the statement of small entity status is defective the reason will be indicated below in the "Small Entity" status column. THE STATEMENT OF SMALL ENTITY STATUS WILL BE ENTERED UPON RECEIPT OF ACCEPTABLE CORRECTION.

| 5,667,767 | \$2,300.00 | \$0.00 | 08/507,863 | 09/16/97 | 07/27/95 | 08 | NO | PAID | 018413-002 | |
|------------------|------------|---------------|----------------------------|-------------------------|-------------------------|-----------------|------------------|------|--------------------|--|
| PATENT NUMBER | FEE AMT | SUR CHARGE | U.S. APPLICATION NUMBER | PATENT ISSUE DATE | APPL. FILING DATE | PAYMENT YEAR | SMALL ENTITY? | STAT | ATTY DKT NUMBER | |

Direct any questions about this notice to:
Mail Stop M Correspondence
Director of the U.S. Patent and Trademark Office
P.O. Box 1450
Alexandria, VA 22313-1450

Dennemeyer Patent Renewal Service

Receipts listing dated 23-Mar-2005

for client 2908 division cost centre 055

Foley & Lardner Silicon Valley

Micro Therapeutics, Inc.

Please find attached hereto the official receipt(s) proving the payment of the annuity/working on the following case(s)

| Patent Number | Patentee | Your Reference | Due Date | Tax | Payment Ty |
|---------------|--------------------------|----------------|------------|-----|------------|
| US 5667767 | Micro Therapeutics, Inc. | 355492-1300 | 16/03/2005 | ~ | Taxes C |

APPENDIX D

Onyx® Liquid Embolic System (LES)

Chronology for Investigational Device Exemption (IDE) G000296

| Contact Date 11-10-00 01-24-01 | + |
|----------------------------------|---|
| Supp Supp Supp Supp | Supplement S001 Supplement S001 - Amendment |
| Supplement S002 Supplement | 2 2 |
| Supp | pplement S003 |
| | Supplement S004 Notification S005 |
| | Supplement S006 |

Onyx® Liquid Embolic System (LES)

Chronology for IDE G000296

| Contact Record Solia No Response PDA Response 3-15-02 FDA Response 12-06-02 FDA Response 12-06-02 FDA Response Solia 12-06-02 FDA Response Additional Patient Soli6 Continued Access 06-19-03 FDA Response O2-20-04 FDA Response 3-5 year Follow-up | Supplement Site Expansion Request to expand the number of sites. Annual Report Annual Report Prist Annual Report submitted. Supplement Supplement DMSO Stability Submitted regarding FDA's Sol13 Supplement Supplement Patient Count Submitted regarding FDA's Sol13 Supplement Patient Count Sol4 Final Report PMA Application Submission for IDE Final Report Submission Continued Access protocol and plan changes, including protocol and plan changes, including pending PMA approval (protocol and Sol-9-03) Submission Syear Follow-up Pending PMA approval (protocol and D2-20-04) Submission Syear Follow-up Pending PMA approval (protocol and D2-20-04) Submission Side Expansion Sid | Supplement Site Expansion Request to expand the number of sites. 02-06-02 FDA Response Site Expansion Soll Supplement DMSO aging/stability submitted regarding FDA's submitted regarding FDA's sounditional approval letter dated 12-07-01. Supplement Patient Count Request to increase number of Studies Soll Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission Supplement of Supplement for 3-5 year follow-up protocol and plan changes, including informed consent) Supplement Site Expansion PDA's Site Expansion Site Expansion Site Expansion PDA's Soll Soll Soll Soll Soll Soll Soll Sol | Supplement Site Expansion Request to expand the number of sites. 02-06-02 FDA Response Site Expansion Supplement Patient Count Supplement Studies Supplement DMSO Stability studies Supplement Studies Submitted regarding FDA's sonditional approval letter dated 12- Supplement Submitted regarding FDA's Submission Continued Access PMA Application Submission Final Report PMA Application Submission Final Report Submission | Supplement Site Expansion Request to expand the number of sites. Annual Report Annual Report First Annual Report submitted. Supplement Supplement DMSO Stability Submitted regarding FDA's S013 Supplement Patient Count Request to increase number of S014 Final Report PMA Application Submission for IDE Final Report. Submission Continued Access Continued access after pivotal study, protocol and plan tandalum in Onyx. Submission Supplement Supplement for 3-5 year follow-up pending PMA approval (protocol and plan approval pending PMA approval pending PMA approval (protocol and plan S016 Submission Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and plan S016 Submission | Supplement Site Expansion Request to expand the number of sites. 02-06-02 FDA Response Site Expansion S011 Annual Report Annual Report First Annual Report submitted. No Response Supplement DMSO Stability Studies Supplement Studies Supplement Patient Count S013 Supplement Patient Count Request to increase number of 12-06-02 FDA Response Studies S013 Supplement Patient Count Request to increase number of 12-06-02 FDA Response Studies S014 Supplement Patient Count Patients. S014 PDA Response Potocol and plan changes, including increased tantalum in Onyx. Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and informers) Supplement PDA Response Continued Access protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informers) Submission Submission Submission Graphore Supplement for 3-5 year follow-up pending PMA approval (protocol and plan changes) | Supplement Site Expansion Request to expand the number of sites. 02-06-02 FDA Response Site Expansion S011 Annual Report Annual Report First Annual Report submitted. No Response Submited Suddies Submitted regarding FDA's S013 Supplement Patient Count Request to increase number of 12-06-02 FDA Response Stability Studies S014 Supplement Patient Count Request to increase number of 12-06-02 FDA Response Studies S014 Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and information pending PMA approval pending PMA approval protocol and plan changes, including increased tantalum in Onyx. Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and information pending PMA approval (protocol and pending PMA approval (pending PMA | Supplement Site Expansion Request to expand the number of sites. 02-06-02 FDA Response Site Expansion S011 Annual Report Annual Report First Annual Report submitted. No Response Supplement Studies Submitted regarding FDA's submitted regarding FDA's submitted regarding FDA's submitted regarding FDA's sonditional approval letter dated 12- 07-01. Supplement Patient Count Request to increase number of Sudies Supplement Patients. Patient Count patients. Supplement Patient Count Request to increase number of 12-06-02 FDA Response Submission Submission Final Report PMA Application Submission for IDE Final Report Submission For IDE Final Report Submission Submission Submission Submission Submission Submission Submission Submission Supplement for 3-5 year follow-up protocol and plan changes, including informed access after pivotal study, protocol and plan changes, including informed access after pivotal study, protocol and plan changes, including informed access after pivotal study, protocol and plan changes, including informed access after pivotal study, protocol and plan changes, including informed access after pivotal study, protocol and plan changes, including informed access after pivotal study, protocol and plan changes, including informed access after pivotal study, protocol and plan changes, including informed access after pivotal study, protocol and plan changes, including informed access after pivotal study, protocol and plan changes, including informed access after pivotal study, protocol and plan changes, including informed access after pivotal study, protocol and plan changes, including informed access after pivotal study, protocol and plan changes, including informed access after pivotal study, protocol and plan changes, including informed access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. | Supplement Site Expansion Request to expand the number of sites. 02-06-02 FDA Response Site Expansion S011 Annual Report Annual Report First Annual Report submitted. No Response Submitted regarding FDA's S013 Supplement DMSO Stability Studies Submitted regarding FDA's S013 Supplement Patient Count Request to increase number of 12-06-02 FDA Response Studies S014 Supplement Patient Count Request to increase number of 12-06-02 FDA Response Additional Patient S014 Final Report PMA Application Submission for 1DE Final Report S016 Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and informated pending PMA approval (protocol and increased). | Supplement Site Expansion Request to expand the number of sites. 02-06-02 FDA Response Site Expansion S011 Annual Report Annual Report First Annual Report submitted. No Response Supplement DMSO Stability Studies Supplement Patient Count S013 Studies Conditional approval letter dated 12-07-01. Supplement Patient Count Request to increase number of 12-06-02 FDA Response Studies S013 Submission Continued Access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and informed pending PMA approval (protocol and plan changes). | Supplement Site Expansion Request to expand the number of sites. 02-06-02 FDA Response Site Expansion S011 Annual Report Annual Report First Annual Report submitted. No Response Submited Suddies Submitted regarding FDA's S013 Supplement Patient Count Request to increase number of 12-06-02 FDA Response Stability Studies S014 Supplement Patient Count Request to increase number of 12-06-02 FDA Response Studies S014 Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and information pending PMA approval pending PMA approval protocol and plan changes, including increased tantalum in Onyx. Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and information pending PMA approval (protocol and pending PMA approval (pending PMA | Supplement Site Expansion Request to expand the number of sites. 02-06-02 FDA Response Site Expansion S011 Annual Report Annual Report First Annual Report submitted. No Response Supplement DMSO Stability studies submitted regarding FDA's S013 Supplement Patient Count Request to increase number of S014 Final Report PMA Application Submission for IDE Final Report Submission Submission Submission Submission Submission Submission Submission Supplement for 3-5 year Follow-up Englement for 3-5 year Follow-up Supplement for 3-5 year follow-up Informed consent). | Supplement Site Expansion Request to expand the number of sites. 02-06-02 FDA Response Site Expansion S011 Annual Report Annual Report First Annual Report submitted. No Response Submitted regarding FDA's S013 Supplement DMSO Stability Studies Submitted regarding FDA's S013 Supplement Patient Count Request to increase number of 12-06-02 FDA Response Studies S014 Supplement Patient Count Request to increase number of 12-06-02 FDA Response Additional Patient S014 Final Report PMA Application Submission for 1DE Final Report S016 Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and informated pending PMA approval (protocol and increased). | Supplement Site Expansion Request to expand the number of sites. 02-06-02 FDA Response Site Expansion S011 Supplement DMSO Stability Studies Supplement Studies Supplement DMSO Stability studies Supplement Studies Submitted regarding FDA's S013 Studies Submitted regarding FDA's S013 Submission Continued Access PMA Application Submission Final Report PMA Application Submission Final Report Submission Submi | Supplement Site Expansion Request to expand the number of sites. 02-06-02 FDA Response Site Expansion S011 Annual Report Annual Report First Annual Report submitted. No Response Supplement DMSO Stability studies submitted regarding FDA's S013 Supplement Patient Count Request to increase number of S014 Final Report PMA Application Submission for IDE Final Report Submission Continued Access Protocol and plan changes, including Increased tantalum in Onlyx. Supplement PDA Response PDA Response Potocol and plan changes, including Increased tantalum in Onlyx. Submission Supplement Solutional Potocol and Potocol and plan changes, including Increased tantalum in Onlyx. Supplement PDA Response PDA Response Potocol and plan changes, including Increased tantalum in Onlyx. Supplement PDA Response PDA Response PDA Response Potocol and plan changes, including Increased tantalum in Onlyx. Supplement PDA Response PDA Respo | Supplement Site Expansion Request to expand the number of sites. 02-06-02 FDA Response Site Expansion Supplement Patient Count Supplement Studies Supplement DMSO Stability studies Supplement Studies Submitted regarding FDA's sonditional approval letter dated 12- Supplement Submitted regarding FDA's Submission Continued Access PMA Application Submission Final Report PMA Application Submission Final Report Submission | Supplement Site Expansion Request to expand the number of sites. 02-06-02 FDA Response Site Expansion S011 Supplement DMSO Stability Studies Supplement Studies Supplement DMSO Stability studies Supplement Studies Submitted regarding FDA's S013 Studies Submitted regarding FDA's S013 Submission Continued Access PMA Application Submission Final Report PMA Application Submission Final Report Submission Submi | Supplement Site Expansion Request to expand the number of sites. 02-06-02 FDA Response Site Expansion S011 Supplement DMSO Stability Studies Supplement Studies Supplement DMSO Stability studies Supplement Studies Submitted regarding FDA's S013 Studies Submitted regarding FDA's S013 Submission Continued Access PMA Application Submission Final Report PMA Application Submission Final Report Submission Submi | Supplement Site Expansion Request to expand the number of sites. 02-06-02 FDA Response Site Expansion S011 Supplement Annual Report First Annual Report submitted. No Response Submitted Report Studies Submitted regarding FDA's conditional approval letter dated 12- S013 Supplement Patient Count Request to increase number of S014 Final Report PMA Application Submission for IDE Final Report Submission Continued Access Protocol and plan changes, including Increased tantalum in Onlyx. Submission Submission S-5 year Follow-up Supplement for a 5-5 year follow-up Submission Informed consent). | Supplement Site Expansion Request to expand the number of sites. 02-06-02 FDA Response Site Expansion S011 Supplement DMSO Stability Studies Supplement Studies Supplement DMSO Stability studies Supplement Studies Submitted regarding FDA's S013 Studies Submitted regarding FDA's S013 Submission Continued Access PMA Application Submission Final Report PMA Application Submission Final Report Submission Submi | Supplement Site Expansion Request to expand the number of sites. Supplement Supplement Site Expansion Request to expand the number of sites. Annual Report Annual Report First Annual Report submitted. No Response Sol11 Supplement DMSO Stability Studies Submitted regarding FDA's Sol13 Supplement Patient Count Request to increase number of Sol14 Final Report PMA Application Submission for IDE Final Report Enal Report Submission Submission Submission Submission For IDE Final Report PMA Application Submission For IDE Final Report Enrollment For Sol14 Submission Submission Submission for IDE Final Report Enrollment For Sol14 Submission Submission Submission for IDE Final Report Enrollment For Sol14 Submission Submission Submission For IDE Final Report Enrollment For Sol14 Submission Submission Submission For IDE Final Report Enrollment For Sol14 Submission Submission Submission For IDE Final Report Enrollment For Sol14 Submission Submission Submission For IDE Final Report Follow-up pending PMA approval (protocol and plan changes, including informed consent). Final Report PMA Approval (protocol and plan changes, including informed consent). | Supplement Site Expansion Request to expand the number of sites. 02-06-02 FDA Response Site Expansion Supplement Patient Count Supplement Studies Supplement DMSO Stability studies Supplement Studies Submitted regarding FDA's sonditional approval letter dated 12- Supplement Submitted regarding FDA's Submission Continued Access PMA Application Submission Final Report PMA Application Submission Final Report Submission | Supplement Site Expansion Request to expand the number of sites. Supplement Supplement Site Expansion Request to expand the number of sites. Annual Report Annual Report First Annual Report submitted. No Response Sol11 Supplement DMSO Stability Studies Submitted regarding FDA's Sol13 Supplement Patient Count Request to increase number of Sol14 Final Report PMA Application Submission for IDE Final Report Enal Report Submission Submission Submission Follow-up England (protocol and plan changes, including informed consent). Submission Submission Submission Occident Solidow-up Submission Submissi | Supplement Site Expansion Request to expand the number of sites. 02-06-02 FDA Response Site Expansion Supplement Patient Count Supplement Studies Supplement DMSO Stability studies Supplement Studies Submitted regarding FDA's sonditional approval letter dated 12- Supplement Submitted regarding FDA's Submission Continued Access PMA Application Submission Final Report PMA Application Submission Final Report Submission | Supplement Site Expansion Request to expand the number of sites. Supplement Supplement Site Expansion Request to expand the number of sites. Annual Report Annual Report First Annual Report submitted. No Response Sol11 Supplement DMSO Stability Studies Submitted regarding FDA's Sol13 Supplement Patient Count Request to increase number of Sol14 Final Report PMA Application Submission for IDE Final Report Enal Report Submission Submission Submission Submission For IDE Final Report PMA Application Submission For IDE Final Report Enrollment For Sol14 Submission Submission Submission for IDE Final Report Enrollment For Sol14 Submission Submission Submission for IDE Final Report Enrollment For Sol14 Submission Submission Submission For IDE Final Report Enrollment For Sol14 Submission Submission Submission For IDE Final Report Enrollment For Sol14 Submission Submission Submission For IDE Final Report Enrollment For Sol14 Submission Submission Submission For IDE Final Report Follow-up pending PMA approval (protocol and plan changes, including informed consent). Final Report PMA Approval (protocol and plan changes, including informed consent). | Supplement Site Expansion Request to expand the number of sites. Supplement Supplement Site Expansion Request to expand the number of sites. Annual Report Annual Report First Annual Report submitted. No Response Sol11 Supplement DMSO Stability Studies Submitted regarding FDA's Sol13 Supplement Patient Count Request to increase number of Sol14 Final Report PMA Application Submission for IDE Final Report Enal Report Submission Submission Submission Submission For IDE Final Report PMA Application Submission For IDE Final Report Enrollment For Sol14 Submission Submission Submission for IDE Final Report Enrollment For Sol14 Submission Submission Submission for IDE Final Report Enrollment For Sol14 Submission Submission Submission For IDE Final Report Enrollment For Sol14 Submission Submission Submission For IDE Final Report Enrollment For Sol14 Submission Submission Submission For IDE Final Report Enrollment For Sol14 Submission Submission Submission For IDE Final Report Follow-up pending PMA approval (protocol and plan changes, including informed consent). Final Report PMA Approval (protocol and plan changes, including informed consent). | Supplement Site Expansion Request to expand the number of sites. Supplement Supplement Site Expansion Request to expand the number of sites. Annual Report Annual Report First Annual Report submitted. No Response Sol11 Supplement DMSO Stability studies submitted regarding FDA's Sol13 Supplement Patient Count Request to increase number of Sol14 Final Report PMA Application Submission for IDE Final Report Enal Report Submission Continued Access Protocol and plan charges, including including protocol and plan charges, including pending PMA approval (protocol and plan charges, including informed consent). Submission Submission Submission PDA Response PDA Response PDA Response Pool Response PDA Re | Supplement Site Expansion Request to expand the number of sites. Supplement Supplement Site Expansion Request to expand the number of sites. Annual Report Annual Report First Annual Report submitted. No Response Sol11 Supplement DMSO Stability studies submitted regarding FDA's Sol13 Supplement DMSO againg/stability studies submitted regarding FDA's Sol13 Supplement Patient Count Request to increase number of 12-06-02 Final Report PMA Application Submission for IDE Final Report Enrollment Sol16 Final Report PMA Application Submission for IDE Final Report PMA approval fortoxol and plan charges, including increase datantalum in Omyx. Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protoxol and plan consent). Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protoxol and plan consent). | Supplement Site Expansion Request to expand the number of sites. Supplement Supplement Site Expansion Request to expand the number of sites. Annual Report Annual Report First Annual Report submitted. No Response Sol11 Supplement DMSO Stability studies submitted regarding FDA's Sol13 Supplement DMSO againg/stability studies submitted regarding FDA's Sol13 Supplement Patient Count Request to increase number of 12-06-02 Final Report PMA Application Submission for IDE Final Report Enrollment Sol16 Final Report PMA Application Submission for IDE Final Report PMA approval fortoxol and plan charges, including increase datantalum in Omyx. Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protoxol and plan consent). Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protoxol and plan consent). | Supplement Site Expansion Request to expand the number of sites. Supplement Supplement Site Expansion Request to expand the number of sites. Annual Report Annual Report First Annual Report submitted. No Response Sol11 Supplement DMSO Stability studies submitted regarding FDA's Sol13 Supplement DMSO againg/stability studies submitted regarding FDA's Sol13 Supplement Patient Count Request to increase number of 12-06-02 Final Report PMA Application Submission for IDE Final Report Enrollment Sol16 Final Report PMA Application Submission for IDE Final Report PMA approval fortoxol and plan charges, including increase datantalum in Omyx. Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protoxol and plan consent). Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protoxol and plan consent). |
|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|
| Supplement Site Expansion Request to expand the number of sites. Annual Report Annual Report First Annual Report submitted. Supplement DMSO Stability Submitted regarding FDA's solid submit | Supplement Site Expansion Request to expand the number of sites. Supplement Site Expansion Request to expand the number of sites. Supplement Supplement DMSO Stability DMSO aging/stability studies submitted regarding FDA's conditional approval letter dated 12- S011 Supplement Supplement Patient Count Request to increase number of 12-406-02 FDA Response Studies S014 Final Report PMA Application Submission for IDE Final Report. Submission Continued Access protocol and plan changes, including increased fanatalum in Onyx. Submission S- year Follow-up pending PMA approval (protocol and D2-20-04 FDA Response S-5 year Follow-up pending PMA approval (protocol and D2-20-04 FDA Response S-5 year Follow-up pending PMA approval (protocol and D2-20-04 FDA Response S-5 year Follow-up pending PMA approval (protocol and D2-20-04 FDA Response S-5 year Follow-up pending PMA approval (protocol and D2-20-04 FDA Response S-5 year Follow-up pending PMA approval (protocol and D2-20-04 FDA Response S-5 year Follow-up pending PMA approval (protocol and D2-20-04 FDA Response S-5 year Follow-up pending PMA approval (protocol and D2-20-04 FDA Response S-5 year Follow-up pending PMA approval (protocol and D2-20-04 FDA Response S-5 year Follow-up pending PMA approval (protocol and D2-20-04 FDA Response S-5 year Follow-up pending PMA approval (protocol and D2-20-04 FDA Response S-5 year Follow-up pending PMA approval (protocol and D2-20-04 FDA Response S-5 year Follow-up pending PMA approval (protocol and D2-20-04 FDA Response S-5 year Follow-up PMA approval (protocol and D2-20-04 FDA Response S-5 year Follow-up PMA approval (protocol and D2-20-04 FDA Response S-5 year Follow-up PMA approval (protocol and D2-20-04 FDA Response S-5 year Follow-up PMA approval (protocol and D2-20-04 FDA Response S-5 year Follow-up PMA Approval (protocol and D2-20-04 FDA Response S-5 year Follow-up PMA Approval (protocol and D2-20-04 FDA Response S-5 year Follow-up PMA Approval (protocol and D4-20-20-20-20-20-20-20-20-20-20-20-20-20- | Supplement Site Expansion Request to expand the number of sites. Supplement Site Expansion Request to expand the number of sites. Supplement Soll First Annual Report Stability Supplement Studies Submitted regarding FDA's conditional approval letter dated 12-soll Soll Supplement Patient Count Patients. Supplement Supplement Patient Count Patients. Supplement Politication Submission for IDE Final Report IDE Final Report Submission Submission Submission Submission Submission Submission Submission Supplement for 3-5 year follow-up protocol and plan changes, including informed access after pivotal study, protocol and plan changes, including informed access after pivotal study. Submission Supplement for 3-5 year follow-up protocol and plan changes, including informed access after pivotal study. Submission Supplement for 3-5 year follow-up protocol and plan changes, including informed access after pivotal study. Supplement Studies Solid Stability Studies Solid Expansion Submission Submi | Supplement Site Expansion Request to expand the number of sites. Supplement Soll First Annual Report submitted. Annual Report Annual Report First Annual Report submitted. Supplement DMSO Stability Studies submitted regarding FIDA's Soll3 Supplement Patient Count Request to increase number of Submission Submission Final Report Submission for IDE Final Report Bubmission for IDE Final Report Submission Final Report Submission Final Report Submission Final Report PMA Application Submission for IDE Final Report Submission Submission Submission Final Report PMA approval (protocol and plan changes, including Informed consent). Submission Submission Submission Final Report Submission Sub | Supplement Site Expansion Request to expand the number of sites. Annual Report Annual Report First Annual Report submitted. Supplement Studies Submitted regarding FDA's Sol13 Supplement Patient Count Request to increase number of 12-06-02 FDA Response Studies submitted regarding FDA's Sol13 Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and plan changes). FDA Response Continued Access pending PMA approval (protocol and plan onlyx. | Supplement Site Expansion Request to expand the number of sites. Annual Report Annual Report First Annual Report submitted. Supplement Studies Supplement Studies Submitted regarding FDA's conditional approval letter dated 12- Supplement Studies Submission Continued Access Protocol and plan changes, including increased tantalum in Onyx. Submission Supplement First Annual Report Studies Submission Submission Submission Submission Submission Supplement for 3-5 year follow-up protocol and informed consent). Contact Record Contact Request to expand the number of sites. 02-46-02 FDA Response Stability Soll Stability Supplement for Submission Submission Submission for IDE Final Report Submission Su | Supplement Site Expansion Request to expand the number of sites. Annual Report Annual Report First Annual Report submitted. Supplement Studies Supplement Studies Supplement Patient Count Studies Supplement Studies Supplement Studies Supplement Patient Count Request to increase number of Studies Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission Supplement Follow-up Ponding PMA approval (protocol and informed consent). Contact Record Contact Record Stite Expansion Stability Studies Stability Studies Stability Studies Stability Studies Stability Studies Stability Stabi | Supplement Site Expansion Request to expand the number of sites. Supplement Site Expansion Request to expand the number of sites. Supplement Solid Expansion Request to expand the number of sites. Supplement Solid Expansion Request to expand the number of sites. Supplement Sudies Submitted regarding FDA's submitted regarding FDA's submitted regarding FDA's conditional approval letter dated 12- Solid Solid Stability patients. Supplement Patient Count Request to increase number of Solid Solid Stability patients. Supplement Patient Count Request to increase number of Solid Solid Stability patients. Supplement Potent Count Potents of I2-06-02 FDA Response Solid Enrollment Enrollment in Continued access after pivotal study, protocol and plan changes, including increased tandalum in Onyx. Submission 3-5 year Follow-up Supplement for 3-5 year follow-up informed access of the protocol and plan changes, including increased tandalum in Conyx. Submission Solid FDA Response Solid FDA Respon | Supplement Site Expansion Request to expand the number of sites. 02-06-02 FDA Response Site Expansion Soll Supplement DMSO Stability DMSO aging/stability studies sonditional approval letter dated 12- 07-01. Supplement Supplement Patient Count Sold PMA Application Submission Continued Access Communed access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission Supplement Follow-up Ponding PMA approval (protocol and informed consent). Contact Record Contact Record Site Expansion Site Expansion Site Expansion Site Expansion Site Expansion Soll Stability Studies Soll Soll Stability Studies Soll Soll Stability Soll Soll Stability Soll Soll Soll Stability Soll Soll Soll Soll Soll Soll Soll Sol | Supplement Site Expansion Request to expand the number of sites. Supplement Site Expansion Request to expand the number of sites. Supplement Soll First Annual Report Submitted. Supplement DMSO Stability Studies Submitted regarding FDA's conditional approval letter dated 12- conditional approval letter dated 12- Soll Supplement Sold PMA Application Submission Continued Access Continued access after privotal study, protocol and plan changes, including increased tantalum in Onyx. Submission Supplement for 3-5 year follow-up protocol and informed consent). Contact Record Contact Record Site Expansion Soll Expansion Site Expansion Site Expansion Site Expansion PMA Application Studies Soll Soll Soll Studies Soll Soll Soll Soll Soll Soll Soll Sol | Supplement Site Expansion Request to expand the number of sites. Annual Report Annual Report First Annual Report submitted. Supplement Studies Supplement Studies Supplement Patient Count Studies Supplement Studies Supplement Studies Supplement Patient Count Request to increase number of Studies Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission Supplement Follow-up Ponding PMA approval (protocol and informed consent). Contact Record Contact Record Stite Expansion Stability Studies Stability Studies Stability Studies Stability Studies Stability Studies Stability Stabi | Supplement Site Expansion Request to expand the number of sites. Supplement Solic Expansion Request to expand the number of sites. Annual Report Annual Report First Annual Report submitted. No Response Solic Expansion DMSO stability Submitted regarding FDA's sonditional approval letter dated 12-07-01. Supplement Patient Count Request to increase number of 12-46-02 FDA Response Studies submitted regarding FDA's patients. Supplement Polication Submission for IDE Final Report Solid FDA Response PDA Response Enrollment in Continued Access protocol and plan changes, including increased tantalum in Conyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Supplement Site Expansion Request to expand the number of sites. 02-06-02 FDA Response Site Expansion Soll Supplement DMSO Stability DMSO aging/stability studies sonditional approval letter dated 12- 07-01. Supplement Supplement Patient Count Sold PMA Application Submission Continued Access Communed access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission Supplement Follow-up Ponding PMA approval (protocol and informed consent). Contact Record Contact Record Site Expansion Site Expansion Site Expansion Site Expansion Site Expansion Soll Stability Studies Soll Soll Stability Studies Soll Soll Stability Soll Soll Stability Soll Soll Soll Stability Soll Soll Soll Soll Soll Soll Soll Sol | Supplement Site Expansion Request to expand the number of sites. Supplement Solite Expansion Request to expand the number of sites. Annual Report Annual Report First Annual Report submitted. Supplement DMSO Stability Studies submitted regarding FDA's Solid Studmitted regarding FDA's submitted regarding FDA's Solid Submitted regarding FDA's Solid Patient Count Request to increase number of Solid Patients. Supplement Patient Count Request to increase number of Solid Solid Submission Submission for IDE Final Report PMA Application Submission for IDE Final Report Solid Submission FDA Response PMA Approval (protocol and plan changes, including Increased tantalum in Onlyx. Submission Solid Solid Submission | Supplement Site Expansion Request to expand the number of sites. Supplement DMSO Stability Submitted regarding FDA's submitted regarding FDA Response SUBMITTED Final Report Submission Continued Access after privotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Supplement Site Expansion Request to expand the number of sites. Supplement Soll First Annual Report submitted. Annual Report Annual Report First Annual Report submitted. Supplement DMSO Stability Studies submitted regarding FIDA's Soll3 Supplement Patient Count Request to increase number of Submission Submission Final Report Submission for IDE Final Report Bubmission for IDE Final Report Submission Final Report Submission Final Report Submission Final Report PMA Application Submission for IDE Final Report Submission Submission Submission Final Report PMA approval (protocol and plan changes, including Informed consent). Submission Submission Submission Final Report Submission Sub | Supplement Site Expansion Request to expand the number of sites. Supplement Solite Expansion Request to expand the number of sites. Annual Report Annual Report First Annual Report submitted. Supplement DMSO Stability Studies submitted regarding FDA's Solid Studmitted regarding FDA's submitted regarding FDA's Solid Submitted regarding FDA's Solid Patient Count Request to increase number of Solid Patients. Supplement Patient Count Request to increase number of Solid Solid Submission Submission for IDE Final Report PMA Application Submission for IDE Final Report Solid Submission FDA Response PMA Approval (protocol and plan changes, including Increased tantalum in Onlyx. Submission Solid Solid Submission | Supplement Site Expansion Request to expand the number of sites. Supplement Solite Expansion Request to expand the number of sites. Annual Report Annual Report First Annual Report submitted. Supplement DMSO Stability Studies submitted regarding FDA's Solid Studmitted regarding FDA's submitted regarding FDA's Solid Submitted regarding FDA's Solid Patient Count Request to increase number of Solid Patients. Supplement Patient Count Request to increase number of Solid Solid Submission Submission for IDE Final Report PMA Application Submission for IDE Final Report Solid Submission FDA Response PMA Approval (protocol and plan changes, including Increased tantalum in Onlyx. Submission Solid Solid Submission | Supplement Site Expansion Request to expand the number of sites. Supplement DMSO Stability Submitted regarding FDA's submitted regarding FDA Response Submitted Request to increase number of studies submitted 12-d6-d2 FDA Response Enrollment S014 FDA Response PDA Response protocol and plan changes, including increased tandalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and plan changes, including informed consent). | Supplement Site Expansion Request to expand the number of sites. Supplement Solite Expansion Request to expand the number of sites. Annual Report Annual Report First Annual Report submitted. Supplement DMSO Stability Studies submitted regarding FDA's Solid Studmitted regarding FDA's submitted regarding FDA's Solid Submitted regarding FDA's Solid Patient Count Request to increase number of Solid Patients. Supplement Patient Count Request to increase number of Solid Solid Submission Submission for IDE Final Report PMA Application Submission for IDE Final Report Solid Submission FDA Response PMA Approval (protocol and plan changes, including Increased tantalum in Onlyx. Submission Solid Solid Submission | Supplement Site Expansion Request to expand the number of sites O2-06-02 FDA Response Site Expansion S011 Supplement Annual Report First Annual Report submitted. No Response Submitted regarding FDA's Solides Submitted Request to increase number of 12-06-02 FDA Response Additional Patient Solides Final Report PMA Application Submission for IDE Final Report Solides PMA Application Submission For IDE Final Report Submission FDA Response Protocol and plan charges, including Increased tantalum in Onyx. Submission Submission Submission Submission FDA Response PDA Response PDA Response PDA Response PDA Response Submission Submission Submission Submission Submission Submission FDA Response PDA Response PDA Response PDA Response PDA Response Submission Submissi | Supplement Site Expansion Request to expand the number of sites. Supplement Soll First Annual Report submitted. Annual Report Annual Report First Annual Report submitted. Supplement DMSO Stability Studies submitted regarding FIDA's Soll3 Supplement Patient Count Request to increase number of Submission Submission Final Report Submission for IDE Final Report Bubmission for IDE Final Report Submission Final Report Submission Final Report Submission Final Report PMA Application Submission for IDE Final Report Submission Submission Submission Final Report PMA approval (protocol and plan changes, including Informed consent). Submission Submission Submission Final Report Submission Sub | Supplement Site Expansion Request to expand the number of sites O2-06-02 FDA Response Site Expansion S011 Supplement Annual Report First Annual Report submitted. No Response Supplement Supplement DMSO stability studies submitted regarding FDA's conditional approval letter dated 12- Supplement S013 Supplement Patient Count Request to increase number of 12-06-02 FDA Response Submitted Submitted regarding FDA's S013 Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onlyx. Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and plan changes, including informed consent). Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and plan changes, including informed consent). | Supplement Site Expansion Request to expand the number of sites. Supplement Soll First Annual Report submitted. Annual Report Annual Report First Annual Report submitted. Supplement DMSO Stability Studies submitted regarding FIDA's Soll3 Supplement Patient Count Request to increase number of Submission Submission Final Report Submission for IDE Final Report Bubmission for IDE Final Report Submission Final Report Submission Final Report Submission Final Report PMA Application Submission for IDE Final Report Submission Submission Submission Final Report PMA approval (protocol and plan changes, including Informed consent). Submission Submission Submission Final Report Submission Sub | Supplement Site Expansion Request to expand the number of sites O2-06-02 FDA Response Site Expansion S011 Supplement Annual Report First Annual Report submitted. No Response Submitted regarding FDA's Solides Submitted Request to increase number of 12-06-02 FDA Response Additional Patient Solides Final Report PMA Application Submission for IDE Final Report Solides PMA Application Submission For IDE Final Report Submission FDA Response Protocol and plan charges, including Increased tantalum in Onyx. Submission Submission Submission Submission FDA Response PDA Response PDA Response PDA Response PDA Response Submission Submission Submission Submission Submission Submission FDA Response PDA Response PDA Response PDA Response PDA Response Submission Submissi | Supplement Site Expansion Request to expand the number of sites O2-06-02 FDA Response Site Expansion S011 Supplement Annual Report First Annual Report submitted. No Response Submitted regarding FDA's Solides Submitted Request to increase number of 12-06-02 FDA Response Additional Patient Solides Final Report PMA Application Submission for IDE Final Report Solides PMA Application Submission For IDE Final Report Submission FDA Response Protocol and plan charges, including Increased tantalum in Onyx. Submission Submission Submission Submission FDA Response PDA Response PDA Response PDA Response PDA Response Submission Submission Submission Submission Submission Submission FDA Response PDA Response PDA Response PDA Response PDA Response Submission Submissi | Supplement Site Expansion Request to expand the number of sites O2-06-02 FDA Response Site Expansion S011 Supplement Annual Report First Annual Report submitted. No Response Supplement Studies Supplement Submitted regarding FDA's Conditional approval letter dated 12-S014 Supplement Patient Count Request to increase number of S14 PDA Response Solidies Solidients. Patients. Patients Patients S014 Final Report PMA Application Submission for IDE Final Report Encollment protocol and plan changes, including increased tantalum in Omyx. Submission Submission Submission Submission of 3-5 year follow-up pending PMA approval (protocol and plan changes). PDA Response | Supplement Site Expansion Request to expand the number of sites 02-06-02 FDA Response Site Expansion S011 Supplement Annual Report First Annual Report submitted. No Response Submitted regarding FDA's Supplement Studies Conditional approval letter dated 12-Supplement S014 Final Report PMA Application Submission for IDE Final Report Increase number of Final Report Follow-up pending PMA approval (protocol and plan changes, including informed consent). Submission Submission Submission of Submission of Submission Particular Supplement for 3-5 year follow-up pending PMA approval (protocol and plan changes, including informed consent). | Supplement Site Expansion Request to expand the number of sites 02-06-02 FDA Response Site Expansion S011 Supplement Annual Report First Annual Report submitted. No Response Submitted regarding FDA's Supplement Studies Conditional approval letter dated 12-Supplement S014 Final Report PMA Application Submission for IDE Final Report Increase number of Final Report Follow-up pending PMA approval (protocol and plan changes, including informed consent). Submission Submission Submission of Submission of Submission Particular Supplement for 3-5 year follow-up pending PMA approval (protocol and plan changes, including informed consent). | Supplement Site Expansion Request to expand the number of sites 02-06-02 FDA Response Site Expansion S011 Supplement Annual Report First Annual Report submitted. No Response Submitted regarding FDA's Supplement Studies Conditional approval letter dated 12-Supplement S014 Final Report PMA Application Submission for IDE Final Report Increase number of Final Report Follow-up pending PMA approval (protocol and plan changes, including informed consent). Submission Submission Submission of Submission of Submission Particular Supplement for 3-5 year follow-up pending PMA approval (protocol and plan changes, including informed consent). |
| Supplement Site Expansion Request to expand the number of sites. 02-06-02 FDA Response Site Expansion S011 Annual Report Annual Report First Annual Report submitted. No Response Supplement DMSO Stability Studies submitted regarding FDA's Supplement Studies Supplement Patient Count Patients. Supplement Patient Count Request to increase number of 12-06-02 FDA Response Studies S014 Final Report PMA Application Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increase d tartatum in Onlyx. Submission 3-5 year Follow-up Supplement for 3-5 year follow-up pendical and Continued access after pivotal and O2-20-04 FDA Response Syear Follow-up | Supplement Site Expansion Request to expand the number of sites. 02-06-02 FDA Response Site Expansion S011 Annual Report Annual Report First Annual Report submitted. No Response Supplement Studies Submitted regarding FDA's conditional approval letter dated 12- S014 Supplement Patient Count Patients. Request to increase number of Sudies Submission Continued Access protocol and plan changes, including provided study, protocol and plan changes, including provided access after pivotal study, protocol and plan changes, including pending PMA approval (protocol and Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and Submission Su | Supplement Site Expansion Request to expand the number of sites. 02-06-02 FDA Response Site Expansion S011 Annual Report Annual Report First Annual Report submitted. No Response S011 Supplement DMSO Stability Studies submitted regarding FDA's conditional approval letter dated 12-07-01. Supplement Patient Count Request to increase number of S014 Final Report PMA Application Submission for IDE Final Report Final Report PMA Application Submission Continued Access Protocol and plan changes, including increased tantalum in Onyx. Submission Supplement for 3-5 year follow-up protocol and plan changes, including informed consent) Supplement PDA Response Supplement for 3-5 year follow-up protocol and plan changes, including informed access after pivotal study, protocol and plan changes, including informed consent) Supplement PDA Response Supplement for 3-5 year follow-up protocol and plan changes, including informed access after pivotal study, protocol and plan changes, including informed access after pivotal study. Supplement PDA Response Supplement for 3-5 year follow-up protocol and plan changes, including informed access after pivotal study. | Supplement Site Expansion Request to expand the number of sites. Annual Report Annual Report DMSO Stability Studies Supplement DMSO Stability Studies Submitted regarding FDA's Supplement Patient Count Request to increase number of S014 Submission Continued Access Trial Report PMA Application Submission Final Report Submission Submission Submission Submission Submission Supplement for 3-5 year follow-up Supplement (Annual Report Polar Supplement (Annual Report PMA Approval (protocol and plan changes, including informed consent). Submission Sub | Supplement Site Expansion Request to expand the number of sites. 02-06-02 FDA Response Site Expansion S011 Annual Report Annual Report First Annual Report submitted. No Response S011 Supplement DMSO Stability Studies Submitted regarding FDA's conditional approval letter dated 12- 07-01. Supplement Studies Supplement Patient Count Patients. Supplement Patient Count Patients. Supplement Sudients. Supplement PMA Application Submission Continued Access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and plan changes) increased tantalum of the pending PMA approval (protocol and plan changes) increased tantalum of the pending PMA approval (protocol and plan changes) increased tantalum of the pending PMA approval (protocol and plan changes) increased tantalum of the pending PMA approval (protocol and plan changes) increased tantalum of the pending PMA approval (protocol and plan changes) increased tantalum of the pending PMA approval (protocol and plan changes) including the pending PMA approval (protocol and plan changes) including the pending PMA approval (protocol and plan changes) including the pending PMA approval (protocol and plan changes) including the pending PMA approval (protocol and plan changes) including the pending PMA approval (protocol and plan changes) including the pending PMA approval (protocol and plan changes) including the pending PMA approval (protocol and plan changes) including the pending PMA approval (protocol and plan changes) including the pending PMA approval (protocol and plan changes) including the pending PMA approval (protocol and plan changes) including the pending PMA approval (protocol and plan changes) including the pending PMA approval (protocol and plan changes) including the pending PMA approval (protocol and plan changes) including the pending PMA approval (protocol and plan changes) including the pending PMA approval (protocol and plan changes) inc | Supplement Site Expansion Request to expand the number of sites. 02-06-02 FDA Response Site Expansion S011 Annual Report Annual Report First Annual Report submitted. No Response S011 Supplement DMSO Stability DMSO aging/stability studies submitted regarding FDA's conditional approval letter dated 12-07-01. Supplement Patient Count Request to increase number of S014 Final Report PMA Application Submission for IDE Final Report Final Report PMA Application Submission Continued Access Protocol and plan changes, including increased tantalum in Onyx. Submission Supplement for 3-5 year follow-up protocol and informed consent). Supplement FDA Response Stability Studies S013 Submission Supplement for 3-5 year follow-up protocol and informed consent). | Supplement Site Expansion Request to expand the number of sites. 02-06-02 FDA Response Site Expansion S011 Annual Report Annual Report First Annual Report submitted. No Response S011 Supplement DMSO Stability Conditional approval letter dated 12- S013 Supplement Patient Count Request to increase number of S014 Supplement Patient Count Patients. Patients. Patients. Patients. S014 Final Report PMA Application Submission for IDE Final Report. Submission Continued Access Protocol and plan changes, including increased tantalum in Onyx. Submission Supplement for 3-5 year follow-up protocol and informed consent). Supplement for 3-5 year follow-up informed consent). | Supplement Site Expansion Request to expand the number of sites. 02-06-02 FDA Response Site Expansion S011 Annual Report Annual Report First Annual Report submitted. No Response S011 Supplement DMSO Stability Studies submitted regarding FDA's conditional approval letter dated 12-07-01. Supplement Patient Count Request to increase number of S014 Final Report PMA Application Submission for IDE Final Report Submission Continued Access Protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up Supplement for 3-5 year follow-up informed access after pivotal and piper for of the protocol and piper for of the protocol and piper for of supplement for 3-5 year follow-up protocol and piper for of the protocol and piper for of the protocol and piper for of the protocol and piper for of of the protocol and piper for o | Supplement Site Expansion Request to expand the number of sites. 02-06-02 FDA Response Site Expansion S011 Annual Report Annual Report First Annual Report submitted. No Response S011 Supplement DMSO Stability DMSO aging/stability studies submitted regarding FDA's S013 Supplement Patient Count Request to increase number of S014 Supplement Patient Count Patients. Patients. Supplement Patients. Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission Supplement for 3-5 year follow-up profoso and plan changes, including informed consent). Supplement for 3-5 year follow-up profoso and plan changes, including informed consent). | Supplement Site Expansion Request to expand the number of sites. 02-06-02 FDA Response Site Expansion S011 Annual Report Annual Report First Annual Report submitted. No Response S011 Supplement DMSO Stability Conditional approval letter dated 12-07-01. Supplement Patient Count Request to increase number of S014 Final Report PMA Application Submission for IDE Final Report Final Report PMA Application Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission Supplement for 3-5 year follow-up proformed pMA approval (protocol and informed consent). | Supplement Site Expansion Request to expand the number of sites. 02-06-02 FDA Response Site Expansion S011 Annual Report Annual Report First Annual Report submitted. No Response S011 Supplement DMSO Stability Conditional approval letter dated 12- S013 Supplement Patient Count Request to increase number of S014 Supplement Patient Count Patients. Patients. Patients. Patients. S014 Final Report PMA Application Submission for IDE Final Report. Submission Continued Access Protocol and plan changes, including increased tantalum in Onyx. Submission Supplement for 3-5 year follow-up protocol and informed consent). Supplement for 3-5 year follow-up informed consent). | Supplement Site Expansion Request to expand the number of sites. 02-06-02 FDA Response Site Expansion S011 Annual Report Annual Report First Annual Report submitted. No Response S011 Supplement DMSO Stability DMSO aging/stability studies submitted regarding FDA's sonditional approval letter dated 12- S013 Supplement Patient Count Request to increase number of S014 Final Report PMA Application Submission for IDE Final Report Submission Continued Access Protocol and plan changes, including increased tantalum in Onyx. Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). | Supplement Site Expansion Request to expand the number of sites. 02-06-02 FDA Response Site Expansion S011 Annual Report Annual Report First Annual Report submitted. No Response S011 Supplement DMSO Stability DMSO aging/stability studies submitted regarding FDA's S013 Supplement Patient Count Request to increase number of S014 Supplement Patient Count Patients. Patients. Supplement Patients. Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission Supplement for 3-5 year follow-up profoso and plan changes, including informed consent). Supplement for 3-5 year follow-up profoso and plan changes, including informed consent). | Supplement Site Expansion Request to expand the number of sites. Annual Report Annual Report Prist Annual Report submitted. Supplement DMSO Stability Studies submitted regarding FDA's sonditional approval letter dated 12- S014 Supplement Patient Count Request to increase number of S014 Supplement Patient Count Request to increase number of patients. Supplement Phient Count Request to increase number of S014 Submission Continued Access Octainued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and plan changes, including informed consent). | Supplement Site Expansion Request to expand the number of sites. 02-06-02 FDA Response Site Expansion S011 Annual Report Annual Report First Annual Report submitted. No Response S011 Supplement DMSO Stability DMSO aging/stability studies submitted regarding FDA's sonditional approval letter dated 12- S013 Supplement Patient Count Request to increase number of S014 Final Report PMA Application Submission for IDE Final Report Submission Continued Access protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA apply Supplement for 3-5 year follow-up informed consent). | Supplement Site Expansion Request to expand the number of sites. Annual Report Annual Report DMSO Stability Studies Supplement DMSO Stability Studies Submitted regarding FDA's Supplement Patient Count Request to increase number of S014 Submission Continued Access Trial Report PMA Application Submission Final Report Submission Submission Submission Submission Submission Supplement for 3-5 year follow-up Supplement (Annual Report Polar Supplement (Annual Report PMA Approval (protocol and plan changes, including informed consent). Submission Sub | Supplement Site Expansion Request to expand the number of sites. Annual Report Annual Report Prist Annual Report submitted. Supplement DMSO Stability Studies submitted regarding FDA's sonditional approval letter dated 12- S014 Supplement Patient Count Request to increase number of S014 Supplement Patient Count Request to increase number of patients. Supplement Phient Count Request to increase number of S014 Submission Continued Access Octainued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and plan changes, including informed consent). | Supplement Site Expansion Request to expand the number of sites. Annual Report Annual Report Prist Annual Report submitted. Supplement DMSO Stability Studies submitted regarding FDA's sonditional approval letter dated 12- S014 Supplement Patient Count Request to increase number of S014 Supplement Patient Count Request to increase number of patients. Supplement Phient Count Request to increase number of S014 Submission Continued Access Octainued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and plan changes, including informed consent). | Supplement Site Expansion Request to expand the number of sites. Annual Report Annual Report DMSO Stability DMSO aging/stability studies sounditional approval letter dated 12- S014 Supplement Sold Report Patient Count Request to increase number of S014 Supplement Patient Count Patients. Supplement Patient Count Request to increase number of S014 Final Report PMA Application Submission for IDE Final Report PMA Application Submission for IDE Final Report PMA Application Submission for IDE Final Report PMA approval (protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up Supplement for 3-5 year follow-up pending PMA approval (protocol and plan changes, including informed consent). | Supplement Site Expansion Request to expand the number of sites. Annual Report Annual Report Prist Annual Report submitted. Supplement DMSO Stability Studies submitted regarding FDA's sonditional approval letter dated 12- S014 Supplement Patient Count Request to increase number of S014 Supplement Patient Count Request to increase number of patients. Supplement Phient Count Request to increase number of S014 Submission Continued Access Octainued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and plan changes, including informed consent). | Supplement Site Expansion Request to expand the number of sites. Annual Report Annual Report DMSO aging/stability studies submitted regarding FDA's regarding FDA | Supplement Site Expansion Request to expand the number of sites. Annual Report Annual Report DMSO Stability Studies Supplement DMSO Stability Studies Submitted regarding FDA's Supplement Patient Count Request to increase number of S014 Submission Continued Access Trial Report PMA Application Submission Final Report Submission Submission Submission Submission Submission Supplement for 3-5 year follow-up Supplement (Annual Report Polar Supplement (Annual Report PMA Approval (protocol and plan changes, including informed consent). Submission Sub | Supplement Site Expansion Request to expand the number of sites. Annual Report Annual Report DMSO Stability Studies Supplement Studies Supplement Patient Count Request to increase number of Studies Submission Continued Access PMA Application Submission Continued Access Continued access after pivotal study, protocol and plan changes, including Informed consent). Submission Submission Syear Follow-up Submission of Syear Follow-up Ending PMA approval (protocol and pinomed consent). | Supplement Site Expansion Request to expand the number of sites. Annual Report Annual Report DMSO Stability Studies Supplement DMSO Stability Studies Submitted regarding FDA's Supplement Patient Count Request to increase number of S014 Submission Continued Access Trial Report PMA Application Submission Final Report Submission Submission Submission Submission Submission Supplement for 3-5 year follow-up Supplement (Annual Report Polar Supplement (Annual Report PMA Approval (protocol and plan changes, including informed consent). Submission Sub | Supplement Site Expansion Request to expand the number of sites. Annual Report Annual Report DMSO aging/stability studies submitted regarding FDA's regarding FDA | Supplement Site Expansion Request to expand the number of sites. Annual Report Annual Report DMSO aging/stability studies submitted regarding FDA's regarding FDA | Supplement Site Expansion Request to expand the number of sites. Annual Report Annual Report DMSO aging/stability studies submitted regarding FDA's submitted FDA Response FDA Response Submitted FDA Response PDA Response POIOtomal Patient Submitted regarding FDA's pear follow-up pending PMA approval (protocol and plan changes, including informed consent). | Supplement Site Expansion Request to expand the number of sites. Annual Report Annual Report DMSO aging/stability studies submitted regarding FDA's | Supplement Site Expansion Request to expand the number of sites. Annual Report Annual Report DMSO aging/stability studies submitted regarding FDA's | Supplement Site Expansion Request to expand the number of sites. Annual Report Annual Report DMSO aging/stability studies submitted regarding FDA's |
| Supplement Site Expansion Request to expand the number of sites. Supplement Site Expansion Request to expand the number of sites. Annual Report Annual Report Stability DMSO aging/stability studies submitted regarding FDA's submitted regarding FDA's submitted regarding FDA's submitted regarding FDA's Sol13 Supplement Patient Count Request to increase number of Sol4 Final Report PMA Application Submission for IDE Final Report Submission Submission Submission Submission Submission Submission Submission Supplement Request to increase after pivotal study, increase of and plan changes, including increase of an annual Report Submission Submissi | Supplement Site Expansion Request to expand the number of sites. Supplement Solli Site Expansion Request to expand the number of sites. Annual Report Annual Report First Annual Report submitted. No Response Solli | Supplement Site Expansion Request to expand the number of sites. 02-46-92 FDA Response Site Expansion S011 Annual Report Annual Report First Annual Report submitted. No Response Supplement DMSO Stability Studies Sol13 Supplement DMSO Stability DMSO aging/stability studies Sol13 Supplement Patient Count Request to increase number of S014 Final Report PMA Application Submission for IDE Final Report Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and informed access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and informed access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and plan changes, including informed access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. | Supplement Site Expansion Request to expand the number of sites. Supplement Site Expansion Request to expand the number of sites. Annual Report Annual Report submitted. Supplement Sudies Submitted regarding FDA's sonditional approval letter dated 12- Supplement Fatient Count Submission for IDE Final Report PMA Application Submission for IDE Final Report Submission for IDE Final Report FDA Response PMA Application Submission for IDE Final Report Submission FDA Response Pool of Submission Fool of the FDA Response Pool of Submission FDA Response Pool of Submission FDA Response Pool of Submission | Supplement Site Expansion Request to expand the number of sites. Supplement Studies Sol11 Supplement DMSO Stability Studies Sol13 Supplement DMSO Stability Studies Sol13 Supplement DMSO Stability Studies Sol13 Supplement Patient Count Request to increase number of Studies Sol14 Final Report PMA Application Submission for IDE Final Report Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and percent pending PMA approval (protocol and pending PMA approval (pen | Supplement Site Expansion Request to expand the number of sites. 02-06-02 FDA Response Site Expansion S011 Annual Report Annual Report First Annual Report submitted. No Response Supplement DMSO aging/stability studies submitted regarding FDA's S013 Supplement Patient Count Request to increase number of S014 Supplement Patient Count Patients. Patients. Patients. PhA Application Submission for IDE Final Report S016 Final Report PMA Application Submission for IDE Final Report S016 Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission Supplement for 3-5 year follow-up protocol and informed consent). PDA Response S-5 year follow-up protocol and informed consent). | Supplement Site Expansion Request to expand the number of sites. 02-06-02 FDA Response Site Expansion S011 Annual Report Annual Report First Annual Report submitted. No Response Supplement DMSO Stability Suddies Submitted regarding FDA's submitted regarding FDA's submitted regarding FDA's S013 Supplement Patient Count Request to increase number of S014 Supplement Patient Count Request to increase number of S014 Final Report PMA Application Submission for IDE Final Report Submission Continued Access Protocol and plan changes, including Increased tantalum in Onyx. Submission Supplement for 3-5 year follow-up protocol and protocol and informed consent). Supplement Site Expansion Site Expansion Solic Expans | Supplement Site Expansion Request to expand the number of sites. 02-46-92 FDA Response Site Expansion S011 Annual Report Annual Report First Annual Report submitted. No Response Supplement DMSO Stability Studies Submitted regarding FDA's Response Submitted regarding FDA's Submitted regarding FDA's Subm | Supplement Site Expansion Request to expand the number of sites. 02-06-02 FDA Response Site Expansion S011 Annual Report Annual Report First Annual Report submitted. No Response Supplement DMSO aging/stability studies submitted regarding FDA's submitt | Supplement Site Expansion Request to expand the number of sites. 02-06-02 FDA Response Site Expansion S011 Annual Report Annual Report First Annual Report submitted. No Response Supplement DMSO Stability Studies Sounditional approval letter dated 12- O7-01. Supplement Supplement Patient Count Request to increase number of S014 PTMA Application Submission Final Report PMA Application Submission for IDE Final Report. Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). Supplement Site Expansion Site Expansion Solic Expansion Solic Expansion Site Expansion Solic Exp | Supplement Site Expansion Request to expand the number of sites. 02-06-02 FDA Response Site Expansion S011 Annual Report Annual Report First Annual Report submitted. No Response Supplement DMSO Stability Suddies Submitted regarding FDA's submitted regarding FDA's submitted regarding FDA's S013 Supplement Patient Count Request to increase number of S014 Supplement Patient Count Request to increase number of S014 Final Report PMA Application Submission for IDE Final Report Submission Continued Access Protocol and plan changes, including Increased tantalum in Onyx. Submission Supplement for 3-5 year follow-up protocol and protocol and informed consent). Supplement Site Expansion Site Expansion Solic Expans | Supplement Site Expansion Request to expand the number of sites. 02-06-02 FDA Response Site Expansion S011 Annual Report Annual Report First Annual Report submitted. No Response Supplement DMSO Stability Studies Submitted regarding FDA's submitted regarding FDA's S013 Supplement Patient Count Request to increase number of S014 Supplement Patient Count Request to increase number of S014 Final Report PMA Application Submission for IDE Final Report Submission Continued Access protocol and plan changes, including increased tantalum in Onyx. Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and pinformed consent). Submission Signature Signature Submission Su | Supplement Site Expansion Request to expand the number of sites. 02-06-02 FDA Response Site Expansion S011 Annual Report Annual Report First Annual Report submitted. No Response Supplement DMSO aging/stability studies submitted regarding FDA's submitt | Supplement Site Expansion Request to expand the number of sites. Supplement Site Expansion Request to expand the number of sites. Annual Report Annual Report Submitted. Supplement Sudies Submitted regarding FDA's submitted FDA Response Enrollment Submitted Report Submission Continued Access protocol and plan changes, including increased tantalum in Onyx. Submission S-year Follow-up Supplement for 3-5 year follow-up predning PMA approval (protocol and plan changes, including informed consent). | Supplement Site Expansion Request to expand the number of sites. 02-06-02 FDA Response Site Expansion S011 Sol1 Annual Report Annual Report First Annual Report submitted. No Response Submitted regarding FDA's S013 Supplement Patient Count Request to increase number of S014 Final Report PMA Application Submission for IDE Final Report Submission Continued Access of the protocol and plan changes, including increased tantalum in Onyx. Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and plan changes, including informed consent). | Supplement Site Expansion Request to expand the number of sites. Supplement Site Expansion Request to expand the number of sites. Annual Report Annual Report submitted. Supplement Sudies Submitted regarding FDA's sonditional approval letter dated 12- Supplement Fatient Count Submission for IDE Final Report PMA Application Submission for IDE Final Report Submission for IDE Final Report FDA Response PMA Application Submission for IDE Final Report Submission FDA Response Pool of Submission Fool of the FDA Response Pool of Submission FDA Response Pool of Submission FDA Response Pool of Submission | Supplement Site Expansion Request to expand the number of sites. Supplement Site Expansion Request to expand the number of sites. Annual Report Annual Report Submitted. Supplement Sudies Submitted regarding FDA's submitted FDA Response Enrollment Submitted Report Submission Continued Access protocol and plan changes, including increased tantalum in Onyx. Submission S-year Follow-up Supplement for 3-5 year follow-up predning PMA approval (protocol and plan changes, including informed consent). | Supplement Site Expansion Request to expand the number of sites. Supplement Site Expansion Request to expand the number of sites. Annual Report Annual Report Submitted. Supplement Sudies Submitted regarding FDA's submitted FDA Response Enrollment Submitted Report Submission Continued Access protocol and plan changes, including increased tantalum in Onyx. Submission S-year Follow-up Supplement for 3-5 year follow-up predning PMA approval (protocol and plan changes, including informed consent). | Supplement Site Expansion Request to expand the number of sites. 02-06-02 FDA Response Site Expansion S011 Solil Site Expansion Request to expand the number of sites. 02-06-02 FDA Response S011 Annual Report Annual Report submitted. No Response Submitted regarding FDA's submitted regarding FDA's submitted regarding FDA's sonditional approval letter dated 12-07-01. Supplement Patient Count Request to increase number of S014 Final Report PMA Application Submission for IDE Final Report Submission Continued Access or protocol and plan changes, including increased tantalum in Onyx. Submission S-5 year Follow-up Supplement for 3-5 year follow-up pending PMA approval (protocol and plan changes, including informed consent). | Supplement Site Expansion Request to expand the number of sites. Supplement Site Expansion Request to expand the number of sites. Annual Report Annual Report Submitted. Supplement Sudies Submitted regarding FDA's submitted FDA Response Enrollment Submitted Report Submission Continued Access protocol and plan changes, including increased tantalum in Onyx. Submission S-year Follow-up Supplement for 3-5 year follow-up predning PMA approval (protocol and plan changes, including informed consent). | Supplement Site Expansion Request to expand the number of sites. 02-06-02 FDA Response Site Expansion S011 Annual Report Annual Report submitted. No Response Submitted Patient Count Submitted regarding FDA's S013 Supplement Supplement Patient Count Submitted regarding FDA's S014 Final Report PMA Application Submission for IDE Final Report Informed access after pivotal study, protocol and plan changes, including informed consent). Submission Submission Submission Supplement for 3-5 year Follow-up Pending PMA approval (protocol and informed consent). | Supplement Site Expansion Request to expand the number of sites. Supplement Site Expansion Request to expand the number of sites. Annual Report Annual Report submitted. Supplement Sudies Submitted regarding FDA's sonditional approval letter dated 12- Supplement Fatient Count Submission for IDE Final Report PMA Application Submission for IDE Final Report Submission for IDE Final Report FDA Response PMA Application Submission for IDE Final Report Submission FDA Response Pool of Submission Fool of the FDA Response Pool of Submission FDA Response Pool of Submission FDA Response Pool of Submission | Supplement Site Expansion Request to expand the number of sites. Supplement Site Expansion Request to expand the number of sites. Annual Report Annual Report Submitted. Supplement Sudies Submitted regarding FDA's Submitted | Supplement Site Expansion Request to expand the number of sites. Supplement Site Expansion Request to expand the number of sites. Annual Report Annual Report submitted. Supplement Sudies Submitted regarding FDA's sonditional approval letter dated 12- Supplement Fatient Count Submission for IDE Final Report PMA Application Submission for IDE Final Report Submission for IDE Final Report FDA Response PMA Application Submission for IDE Final Report Submission FDA Response Pool of Submission Fool of the FDA Response Pool of Submission FDA Response Pool of Submission FDA Response Pool of Submission | Supplement Site Expansion Request to expand the number of sites. 02-06-02 FDA Response Site Expansion S011 Annual Report Annual Report submitted. No Response Submitted Patient Count Submitted regarding FDA's S013 Supplement Supplement Patient Count Submitted regarding FDA's S014 Final Report PMA Application Submission for IDE Final Report Informed access after pivotal study, protocol and plan changes, including informed consent). Submission Submission Submission Supplement for 3-5 year Follow-up Pending PMA approval (protocol and informed consent). | Supplement Site Expansion Request to expand the number of sites. 02-06-02 FDA Response Site Expansion S011 Annual Report Annual Report submitted. No Response Submitted Patient Count Submitted regarding FDA's S013 Supplement Supplement Patient Count Submitted regarding FDA's S014 Final Report PMA Application Submission for IDE Final Report Informed access after pivotal study, protocol and plan changes, including informed consent). Submission Submission Submission Supplement for 3-5 year Follow-up Pending PMA approval (protocol and informed consent). | Supplement Site Expansion Request to expand the number of sites. 02-06-02 FDA Response Site Expansion S011 Annual Report Annual Report submitted. No Response Submitted Priest Annual Report submitted regarding FDA's S013 Supplement Supplement Submitted regarding FDA's S013 Supplement Patient Count Request to increase number of S014 Final Report PMA Application Submission for IDE Final Report Submission Continued Access after privotal study, increased tandatum in Onyx. Submission Supplement for 3-5 year Follow-up Pending PMA approval (protocol and pinformed consent). Submission Size Expansion Request to expand the number of sites. No Response Site Expansion Site Expansion DMSO Stability Solidies Solid | Supplement Site Expansion Request to expand the number of sites. 02-06-02 FDA Response Site Expansion S011 Annual Report Annual Report First Annual Report submitted. No Response Submitted regarding FDA's Submitted regarding FDA's Sol13 Supplement Supplement Patient Count Submitted regarding FDA's Sol13 Supplement Patient Count Request to increase number of Submission Continued Access Trial Report Submission Final Report Submission Final Report Submission For IDE Final Report Submission Submission Submission Submission Submission Submission Submission Supplement for 3-5 year follow-up Pending PMA approval (protocol and pinformed consent). Supplement Site Expansion Site Expansion Site Expansion Site Expansion Sol11 Submission DMSO Stability Submitted regarding FDA's Sol13 Submission Site Expansion Site Expansion Sol11 FDA Response DMSO Stability Studies Sol13 Submission Site Expansion Site Expansion Sol11 DMSO Stability Sol12-0-2 FDA Response Additional Patient Sol16 Enrollment Sol14 FDA Response Continued Access protocol and pinformed consent). | Supplement Site Expansion Request to expand the number of sites. 02-06-02 FDA Response Site Expansion S011 Annual Report Annual Report First Annual Report submitted. No Response Submitted regarding FDA's Submitted regarding FDA's Sol13 Supplement Supplement Patient Count Submitted regarding FDA's Sol13 Supplement Patient Count Request to increase number of Submission Continued Access Trial Report Submission Final Report Submission Final Report Submission For IDE Final Report Submission Submission Submission Submission Submission Submission Submission Supplement for 3-5 year follow-up Pending PMA approval (protocol and pinformed consent). Supplement Site Expansion Site Expansion Site Expansion Site Expansion Sol11 Submission DMSO Stability Submitted regarding FDA's Sol13 Submission Site Expansion Site Expansion Sol11 FDA Response DMSO Stability Studies Sol13 Submission Site Expansion Site Expansion Sol11 DMSO Stability Sol12-0-2 FDA Response Additional Patient Sol16 Enrollment Sol14 FDA Response Continued Access protocol and pinformed consent). | Supplement Site Expansion Request to expand the number of sites. 02-06-02 FDA Response Site Expansion S011 Annual Report Annual Report First Annual Report submitted. No Response Submitted regarding FDA's Submitted regarding FDA's Sol13 Supplement Supplement Patient Count Submitted regarding FDA's Sol13 Supplement Patient Count Request to increase number of Submission Continued Access Trial Report Submission Final Report Submission Final Report Submission For IDE Final Report Submission Submission Submission Submission Submission Submission Submission Supplement for 3-5 year follow-up Pending PMA approval (protocol and pinformed consent). Supplement Site Expansion Site Expansion Site Expansion Site Expansion Sol11 Submission DMSO Stability Submitted regarding FDA's Sol13 Submission Site Expansion Site Expansion Sol11 FDA Response DMSO Stability Studies Sol13 Submission Site Expansion Site Expansion Sol11 DMSO Stability Sol12-0-2 FDA Response Additional Patient Sol16 Enrollment Sol14 FDA Response Continued Access protocol and pinformed consent). |
| Supplement Site Expansion Request to expand the number of sites. 02-06-02 FDA Response Site Expansion S011 Annual Report Annual Report First Annual Report submitted. No Response S011 Supplement DMSO Stability Studies submitted regarding FDA's conditional approval letter dated 12- 07-01. Supplement Sudies S013 Supplement Patient Count Request to increase number of S014 Final Report PMA Application Submission for IDE Final Report. Submission Submission Submission Supplement for 3-5 year follow-up pending between the pending lement for 3-5 year follow-up | Supplement Site Expansion Request to expand the number of sites. 02-06-02 FDA Response Site Expansion S011 Annual Report Annual Report First Annual Report submitted. No Response Supplement DMSO Stability Studies Sounditional approval letter dated 12-07-01. Supplement Supplement Patient Count Request to increase number of Supplement S014 Final Report PMA Application Submission Continued Access Continued access after pivotal study, increase fundalum in Conyx. Submission Supplement Final Report Supplement for 3-5 year follow-up pending PMA approval (protocol and pendin | Supplement Site Expansion Request to expand the number of sites. 02-06-02 FDA Response Site Expansion S011 Annual Report Annual Report First Annual Report submitted. No Response Supplement DMSO Stability Studies Submitted regarding FDA's S013 Supplement Patient Count Request to increase number of S014 Final Report PMA Application Submission for IDE Final Report Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent) Supplement Site Expansion Site Expansion Site Expansion No Response Sol11 Final Report PDA Response Sol21 FDA Response Continued Access protocol and plan changes, including increased tantalum in Onyx. Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent) Supplement Site Expansion Site Expansion Site Expansion Site Expansion DMSO Stability Studies Sol13 FDA Response Continued Access protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up protocol and plan changes, including increased tantalum in Conyx. | Supplement Site Expansion Request to expand the number of sites. 02-06-02 FDA Response Site Expansion Sol11 Supplement DMSO Stability DMSO aging/stability studies submitted regarding FDA's Sol13 Supplement DMSO Stability DMSO aging/stability studies submitted regarding FDA's sonditional approval letter dated 12- 07-01. Supplement Patient Count Request to increase number of Sol14 Final Report PMA Application Submission for IDE Final Report Submission Continued Access protocol and plan changes, including increased tandalum in Onyx. Submission 3-5 year Follow-up Suphement for 3-5 year follow-up pending PMA approval (protocol and plan changes, including informed consent). | Supplement Site Expansion Request to expand the number of sites. 02-06-02 FDA Response Site Expansion S011 Annual Report Annual Report First Annual Report submitted. No Response Supplement DMSO Stability Studies conditional approval letter dated 12-07-01. Supplement Patient Count Request to increase number of S014 PMA Application Submission Final Report PMA Application Submission for IDE Final Report PMA Application Submission for IDE Final Report PMA Application Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and Pacess FDA Response PAResponse PRAResponse PAResponse PAResponse PRAResponse PAResponse | Supplement Site Expansion Request to expand the number of sites. 02-06-02 FDA Response Site Expansion S011 Annual Report Annual Report First Annual Report submitted. No Response Supplement Studies Submitted regarding FDA 's conditional approval letter dated 12-07-01. Supplement Patient Count Request to increase number of S014 Final Report PMA Application Submission for IDE Final Report Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission Submission Supplement for 3-5 year follow-up profosool and plan changes, including informed consent). Supplement PDA Response Continued Access for pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission Supplement for 3-5 year follow-up profosool and plan changes, including informed consent). | Supplement Site Expansion Request to expand the number of sites. 02-06-02 FDA Response Site Expansion S011 Annual Report Annual Report First Annual Report submitted. No Response Supplement Sudies Submitted regarding FDA's S013 Supplement Patient Count Request to increase number of S014 Final Report PMA Application Submission for IDE Final Report Submission Continued Access protocol and plan changes, including increased tantalum in Onyx. Submission Submission Supplement for 3-5 year follow-up proformed Managers informed Consent), Supplement for 3-5 year follow-up proformed Managers informed Consent), Supplement for 3-5 year follow-up proformed Managers informed Consent), Supplement for 3-5 year follow-up proformed Managers informed Consent), Supplement for 3-5 year follow-up proformed Managers informed Consent), Supplement for 3-5 year follow-up proformed Managers informed Consent), Supplement for 3-5 year follow-up proformed Managers informed Consent), Supplement for 3-5 year follow-up proformed Managers informed Consent), Supplement for 3-5 year follow-up proformed Managers informed Consent), Supplement for 3-5 year follow-up proformed Managers informed Consent), Supplement for 3-5 year follow-up proformed Managers informed Consent), Supplement for 3-5 year follow-up proformed Managers informed Consent), Supplement for 3-5 year follow-up proformed Consent for 3-5 year follow-up proformed Cons | Supplement Site Expansion Request to expand the number of sites. 02-06-02 FDA Response Site Expansion S011 Annual Report Annual Report First Annual Report submitted. No Response Submitted regarding FDA is submitted regarding FDA is conditional approval letter dated 12-07-01. Supplement Supplement Patient Count Request to increase number of submitted regarding FDA is submitted increase number of patients. Supplement Patient Count Request to increase number of submitted regarding FDA is studies submitted regarding FDA is submission Submission Submission for IDE Final Report. Final Report PMA Application Submission for IDE Final Report. Submission Submission Submission for IDE Final Report. Final Report PMA Approval (protocol and in Onyx. Submission Submission Submission Submission for IDE Final Report. Final Report PMA Approval (protocol and in Onyx. Submission Submission Submission Submission for IDE Final Report. Final Report PMA Approval (protocol and in Onyx. Submission Submission Submission Submission for IDE Final Report. Final Report PMA Approval (protocol and in Onyx. Submission Su | Supplement Site Expansion Request to expand the number of sites. 02-06-02 FDA Response Site Expansion S011 Annual Report Annual Report First Annual Report submitted. No Response Supplement Studies Submitted regarding FDA's submitted regarding FDA's S013 Supplement Patient Count Request to increase number of S014 Final Report PMA Application Submission for IDE Final Report Submission Continued Access protocol and plan changes, including increased tantalum in Onyx. Submission Submission Supplement for 3-5 year follow-up profong PMA approval (protocol and pinformed consent). Site Expansion Site Expansion Site Expansion PAN Response Site Expansion PAN Response Site Expansion PAN Response Sol Submission Submission Submission First Annual Report Stability Supplement for 3-5 year follow-up protocol and pinformed sonsent). | Supplement Site Expansion Request to expand the number of sites. 02-06-02 FDA Response Site Expansion S011 Annual Report Annual Report First Annual Report submitted. No Response Supplement DMSO Stability Studies Submitted regarding FDA's S013 Supplement Patient Count Request to increase number of S014 Final Report PMA Application Submission for IDE Final Report Final Report Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). Supplement PDA Response Continued Access Informed Consent). Supplement PDA Response Continued Access Submission Supplement for 3-5 year follow-up protocol and informed consent). | Supplement Site Expansion Request to expand the number of sites. 02-06-02 FDA Response Site Expansion S011 Annual Report Annual Report First Annual Report submitted. No Response Supplement Sudies Submitted regarding FDA's S013 Supplement Patient Count Request to increase number of S014 Final Report PMA Application Submission for IDE Final Report Submission Continued Access protocol and plan changes, including increased tantalum in Onyx. Submission Submission Supplement for 3-5 year follow-up proformed Managers informed Consent), Supplement for 3-5 year follow-up proformed Managers informed Consent), Supplement for 3-5 year follow-up proformed Managers informed Consent), Supplement for 3-5 year follow-up proformed Managers informed Consent), Supplement for 3-5 year follow-up proformed Managers informed Consent), Supplement for 3-5 year follow-up proformed Managers informed Consent), Supplement for 3-5 year follow-up proformed Managers informed Consent), Supplement for 3-5 year follow-up proformed Managers informed Consent), Supplement for 3-5 year follow-up proformed Managers informed Consent), Supplement for 3-5 year follow-up proformed Managers informed Consent), Supplement for 3-5 year follow-up proformed Managers informed Consent), Supplement for 3-5 year follow-up proformed Managers informed Consent), Supplement for 3-5 year follow-up proformed Consent for 3-5 year follow-up proformed Cons | Supplement Site Expansion Request to expand the number of sites. 02-06-02 FDA Response Site Expansion S011 Annual Report Annual Report First Annual Report submitted. No Response Submitted regarding FDA's S013 Supplement Sudies Submitted regarding FDA's S013 Supplement Patient Count Request to increase number of S014 Final Report PMA Application Submission for IDE Final Report Submission Continued Access protocol and plan changes, including increased tantalum in Onyx. Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and plan changes, including informed consent). Submission Site Expansion PMA Response Site Expansion Site Expansion PMA Response PDA Response Enrollment Patient PMA Response PMA Response PMA Response PDA Response PMA Response PDA Res | Supplement Site Expansion Request to expand the number of sites. 02-06-02 FDA Response Site Expansion S011 Annual Report Annual Report First Annual Report submitted. No Response Supplement Studies Submitted regarding FDA's submitted regarding FDA's S013 Supplement Patient Count Request to increase number of S014 Final Report PMA Application Submission for IDE Final Report Submission Continued Access protocol and plan changes, including increased tantalum in Onyx. Submission Submission Supplement for 3-5 year follow-up profong PMA approval (protocol and pinformed consent). Site Expansion Site Expansion Site Expansion PAN Response Site Expansion PAN Response Site Expansion PAN Response Sol Submission Submission Submission First Annual Report Stability Supplement for 3-5 year follow-up protocol and pinformed sonsent). | Supplement Site Expansion Request to expand the number of sites. 02-06-02 FDA Response Site Expansion Sol11 Supplement DMSO Stability Submitted Report submitted. No Response Submitted regarding FDA's Sol13 Supplement DMSO Stability Studies Submitted regarding FDA's Sol13 Supplement Patient Count Request to increase number of Sol14 Final Report PMA Application Submission for IDE Final Report Submission Continued Access Protocol and plan changes, including increased tandalum in Onyx. Submission Submission Syear Follow-up Supplement for 3-5 year follow-up Informed consent). | Supplement Site Expansion Request to expand the number of sites. 02-06-02 FDA Response Site Expansion S011 Supplement DMSO Stability DMSO aging/stability studies submitted Patient Count S013 Supplement Patient Count Request to increase number of S014 Final Report PMA Application Submission for IDE Final Report Submission Continued Access protocol and plan changes, including increased tantalum in Onyx. Submission Supplement of Supplement of Supplement of Supplement of PMA Approval (protocol and plan changes, including informed consent). Submission Sear Follow-up Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). | Supplement Site Expansion Request to expand the number of sites. 02-06-02 FDA Response Site Expansion Sol11 Supplement DMSO Stability DMSO aging/stability studies submitted regarding FDA's Sol13 Supplement DMSO Stability DMSO aging/stability studies submitted regarding FDA's sonditional approval letter dated 12- 07-01. Supplement Patient Count Request to increase number of Sol14 Final Report PMA Application Submission for IDE Final Report Submission Continued Access protocol and plan changes, including increased tandalum in Onyx. Submission 3-5 year Follow-up Suphement for 3-5 year follow-up pending PMA approval (protocol and plan changes, including informed consent). | Supplement Site Expansion Request to expand the number of sites. 02-06-02 FDA Response Site Expansion Sol11 Supplement DMSO Stability Submitted Report submitted. No Response Submitted regarding FDA's Sol13 Supplement DMSO Stability Studies Submitted regarding FDA's Sol13 Supplement Patient Count Request to increase number of Sol14 Final Report PMA Application Submission for IDE Final Report Submission Continued Access Protocol and plan changes, including increased tandalum in Onyx. Submission Submission Syear Follow-up Supplement for 3-5 year follow-up Informed consent). | Supplement Site Expansion Request to expand the number of sites. 02-06-02 FDA Response Site Expansion Sol11 Supplement DMSO Stability Submitted Report submitted. No Response Submitted regarding FDA's Sol13 Supplement DMSO Stability Studies Submitted regarding FDA's Sol13 Supplement Patient Count Request to increase number of Sol14 Final Report PMA Application Submission for IDE Final Report Submission Continued Access Protocol and plan changes, including increased tandalum in Onyx. Submission Submission Syear Follow-up Supplement for 3-5 year follow-up Informed consent). | Supplement Site Expansion Request to expand the number of sites. 02-06-02 FDA Response Site Expansion S011 Annual Report Annual Report First Annual Report submitted. No Response Supplement Sudies Submitted regarding FDA's conditional approval letter dated 12- S014 Supplement Supplement Patient Count Request to increase number of S014 Final Report PMA Application Submission for IDE Final Report Submission Continued Access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and plan changes, including informed consent). | Supplement Site Expansion Request to expand the number of sites. 02-06-02 FDA Response Site Expansion Sol11 Supplement DMSO Stability Submitted Report submitted. No Response Submitted regarding FDA's Sol13 Supplement DMSO Stability Studies Submitted regarding FDA's Sol13 Supplement Patient Count Request to increase number of Sol14 Final Report PMA Application Submission for IDE Final Report Submission Continued Access Protocol and plan changes, including increased tandalum in Onyx. Submission Submission Syear Follow-up Supplement for 3-5 year follow-up Informed consent). | Supplement Site Expansion Request to expand the number of sites. 02-06-02 FDA Response Site Expansion Sol11 Annual Report Annual Report First Annual Report submitted. No Response Submitted regarding FDA's Submitted regarding FDA's submitted regarding FDA's Sol13 Supplement Supplement Patient Count Submitted in Request to increase number of Submission Continued Access after privotal study, increased tanalam in Onyx. Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). | Supplement Site Expansion Request to expand the number of sites. 02-06-02 FDA Response Site Expansion Sol11 Supplement DMSO Stability DMSO aging/stability studies submitted regarding FDA's Sol13 Supplement DMSO Stability DMSO aging/stability studies submitted regarding FDA's sonditional approval letter dated 12- 07-01. Supplement Patient Count Request to increase number of Sol14 Final Report PMA Application Submission for IDE Final Report Submission Continued Access protocol and plan changes, including increased tandalum in Onyx. Submission 3-5 year Follow-up Suphement for 3-5 year follow-up pending PMA approval (protocol and plan changes, including informed consent). | Supplement Site Expansion Request to expand the number of sites. 02-06-02 FDA Response Site Expansion Sol11 Annual Report Annual Report First Annual Report submitted. No Response Submitted regarding FDA's Sol13 Supplement DMSO Stability Studies Submitted regarding FDA's Sol13 Supplement Supplement Patient Count Sol14 Final Report PMA Application Submission for IDE Final Report Final Report Submission Continued Access Increase and plan changes, including protocol and plan changes, including Informed consent). Submission Syear Follow-up Pending PMA approval (protocol and informed consent). | Supplement Site Expansion Request to expand the number of sites. 02-06-02 FDA Response Site Expansion Sol11 Supplement DMSO Stability DMSO aging/stability studies submitted regarding FDA's Sol13 Supplement DMSO Stability DMSO aging/stability studies submitted regarding FDA's sonditional approval letter dated 12- 07-01. Supplement Patient Count Request to increase number of Sol14 Final Report PMA Application Submission for IDE Final Report Submission Continued Access protocol and plan changes, including increased tandalum in Onyx. Submission 3-5 year Follow-up Suphement for 3-5 year follow-up pending PMA approval (protocol and plan changes, including informed consent). | Supplement Site Expansion Request to expand the number of sites. 02-06-02 FDA Response Site Expansion Sol11 Annual Report Annual Report First Annual Report submitted. No Response Submitted regarding FDA's Submitted regarding FDA's submitted regarding FDA's Sol13 Supplement Supplement Patient Count Submitted in Request to increase number of Submission Continued Access after privotal study, increased tanalam in Onyx. Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). | Supplement Site Expansion Request to expand the number of sites. 02-06-02 FDA Response Site Expansion Sol11 Annual Report Annual Report First Annual Report submitted. No Response Submitted regarding FDA's Submitted regarding FDA's submitted regarding FDA's Sol13 Supplement Supplement Patient Count Submitted in Request to increase number of Submission Continued Access after privotal study, increased tanalam in Onyx. Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). | Supplement Site Expansion Request to expand the number of sites. 02-06-02 FDA Response Site Expansion S011 Annual Report Annual Report prist Annual Report submitted. No Response S011 Supplement Supplement Sudies S013 Supplement Patient Count Submitted regarding FDA's submitted regarding FDA's submitted regarding FDA's sonditional approval letter dated 12-S014 Supplement Patient Count S014 Final Report PMA Application Submission for IDE Final Report Submission Continued Access after privotal study, protocol and plan changes, including process dataplam in Onyx. Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and plan changes, including informed consent). | Supplement Site Expansion Request to expand the number of sites. 02-06-02 FDA Response Site Expansion S011 Annual Report Annual Report Prist Annual Report submitted. No Response S011 Supplement Supplement Sudies S013 Supplement Patient Count Submitted regarding FDA's S013 Supplement Patient Count S07-01. Final Report PMA Application Submission for IDE Final Report Submission Continued Access after pivotal study, produced and plan changes, including increase tantalum in Onyx. Submission Supplement of 3-5 year follow-up pending PMA approval (protocol and plan changes, including informed consent). Submission Syear Follow-up pending PMA approval (protocol and plan changes, including informed consent). | Supplement Site Expansion Request to expand the number of sites. 02-06-02 FDA Response Site Expansion S011 Annual Report Annual Report Prist Annual Report submitted. No Response S011 Supplement Supplement Sudies S013 Supplement Patient Count Submitted regarding FDA's S013 Supplement Patient Count S07-01. Final Report PMA Application Submission for IDE Final Report Submission Continued Access after pivotal study, produced and plan changes, including increase tantalum in Onyx. Submission Supplement of 3-5 year follow-up pending PMA approval (protocol and plan changes, including informed consent). Submission Syear Follow-up pending PMA approval (protocol and plan changes, including informed consent). | Supplement Site Expansion Request to expand the number of sites. 02-06-02 FDA Response Site Expansion S011 Annual Report Annual Report Prist Annual Report submitted. No Response S011 Supplement Supplement Sudies S013 Supplement Patient Count Submitted regarding FDA's S013 Supplement Patient Count S07-01. Final Report PMA Application Submission for IDE Final Report Submission Continued Access after pivotal study, produced and plan changes, including increase tantalum in Onyx. Submission Supplement of 3-5 year follow-up pending PMA approval (protocol and plan changes, including informed consent). Submission Syear Follow-up pending PMA approval (protocol and plan changes, including informed consent). |
| Supplement Site Expansion Request to expand the number of sites. Supplement Supplement DMSO Stability Studies Sol13 Supplement DMSO Stability Studies Sol13 Supplement DMSO Stability Studies Sol13 Supplement Patient Count Patient Sol4 Supplement Sol14 Final Report PMA Application Submission Submission 3-5 year Follow-up Pending PMA approval frontocol and Submission Supplement for 3-5 year follow-up Supplement for 3-5 year follow-up Pending PMA approval frontocol and Submission Submission Supplement for 3-5 year follow-up Supplement follow-up Supplement for 3-5 year follow- | Supplement Site Expansion Request to expand the number of sites. Supplement Supplement DMSO Stability Studies Submitted Expansion Supplement Patient Count Sol Phase Sol Phase Sol Stability Studies Sol Phase Protocol and Plan changes, including Increased tunalum in Onyx. Submission Submission Supplement for 3-5 year follow-up pending Phase | Supplement Site Expansion Request to expand the number of sites. Supplement Supplement DMSO Stability DMSO aging/stability studies soll3 Supplement Suddies Submitted regarding FDA's conditional approval letter dated 12- 97-01. Supplement Supplement Patient Count Submission Continued Access protocol and plan changes, including informed DMSO agring PMA approval broadent protocol and informed DMSO stability studies submitted. No Response Soll3 S15-02 FDA Response DMSO Stability studies Soll3 S15-02 FDA Response Soll3 Submission PMA Application Submission for IDE Final Report Solf-02 FDA Response Enrollment Solf-03 FDA Response DMSO Stability studies Soll3 Submission Submission Submission for IDE Final Report PMA Approval plan changes, including increased tantalum in Onyx. Submission Submission Submission PMA approval (protocol and informed access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission Submission Submission PMA approval (protocol and informed access after pivotal study, protocol and study, protocol and study approval (protocol and study). | Supplement Site Expansion Request to expand the number of sites. Annual Report Annual Report First Annual Report submitted. Supplement Supplement Sudies Submitted regarding FDA's SO13 Supplement Patient Count Request to increase number of Supplement SO14 Final Report PMA Application Submission for IDE Final Report Submission Continued Access Protocol and plan changes, including protocol and plan changes, including informed consent). Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Supplement Site Expansion Request to expand the number of sites. Supplement Supplement DMSO Stability DMSO aging/stability studies submitted regarding FDA's Sol13 Supplement Patient Count Request to increase number of Studies Sol14 Supplement PA Application Submission for IDE Final Report Submission Continued Access Continued access after privotal study, perotocol and plan changes, including increase follow-up pending PMA approval (protocol and plan changes, including pending PMA approval (protocol and pending PMA approval (protocol | Supplement Site Expansion Request to expand the number of sites. Supplement Supplement DMSO Stability Sulpilement Sudies Supplement Sudies Supplement Patient Count Sudies Supplement Supplement Supplement Submitted regarding FDA's Supplement Patient Count Request to increase number of Supplement Supplement Patient Supplement Patient Submission Continued Access protocol and plan changes, including increased tantalum in Onyx. Submission Submission Supplement for 3-5 year follow-up pending PMA approval protocol and protoc | Supplement Site Expansion Request to expand the number of sites. Supplement Supplement DMSO Stability Supplement Supplement DMSO Stability Supplement Sudies Supplement Suddies Supplement Patient Count Request to increase number of 12-07-01. Supplement Supplement Patient Count Request to increase number of 12-06-02 FDA Response Submitted regarding FDA's Supplement Patient Count Request to increase number of 12-06-02 FDA Response Submitted regarding FDA's Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tuntalum in Onyx. Submission Syear Follow-up Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). Submission Syear Follow-up Supplement for 3-5 year follow-up informed consent). | Supplement Site Expansion Request to expand the number of sites. Supplement Supplement DMSO Stability DMSO aging/stability studies soll3 Supplement DMSO Stability DMSO aging/stability studies soll3 Supplement Patient Count Request to increase number of Supplement Soll4 Final Report PMA Application Submission Continued Access protocol and plan changes, including increased tantalum in Onyx. Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and protocol an | Supplement Site Expansion Request to expand the number of sites. Supplement Supplement DMSO Stability Supplement Supplement DMSO Stability Supplement Supplement Patient Count Sudies Supplement Supplement Patient Count Patients. Supplement Supplement Patient Count Submission Final Report Informed access after pivotal study, protocol and plan changes, including increased tuntalum in Onyx. Submission Submission Supplement for 3-5 year follow-up pending PMA approval protocol and informed consent). Supplement PAA Response Supplement for 3-5 year follow-up pending PMA approval for Onyx. Submission Submission Submission Submission Submission PMA approval for Supplement for 3-5 year follow-up pending PMA approval for Onserol. Submission Sub | Supplement Site Expansion Request to expand the number of sites. Supplement Supplement DMSO Stability Sulpilement Sudies Supplement Suddies Supplement Patient Count Sudies Supplement Supplement Sol13 Supplement Patient Count Request to increase number of Submission Continued Access protocol and plan changes, including increased tantalum in Onyx. Submission Submission Submission PMA approval pending PMA approval pending PMA approval pending PMA approval for onsent). Supplement Patient Count Request to increase number of Submission for IDE Final Report Submission Submission Submission Final Report PMA approval pending PMA approval for Joyac FDA Response Enrollment Patient Submission | Supplement Site Expansion Request to expand the number of sites. Supplement Supplement DMSO Stability Supplement Supplement DMSO Stability Supplement Sudies Supplement Suddies Supplement Patient Count Request to increase number of 12-07-01. Supplement Supplement Patient Count Request to increase number of 12-06-02 FDA Response Submitted regarding FDA's Supplement Patient Count Request to increase number of 12-06-02 FDA Response Submitted regarding FDA's Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tuntalum in Onyx. Submission Syear Follow-up Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). Submission Syear Follow-up Supplement for 3-5 year follow-up informed consent). | Supplement Site Expansion Request to expand the number of sites. Annual Report Annual Report First Annual Report submitted. Supplement DMSO Stability Submitted regarding FDA's sonditional approval letter dated 12- S014 Final Report PMA Application Submission for IDE Final Report Final Report Submission Continued Access protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA apply Supplement for 3-5 year follow-up pending PMA apply Supplement for 3-5 year follow-up informed consent). | Supplement Site Expansion Request to expand the number of sites. Supplement Supplement DMSO Stability Supplement Supplement DMSO Stability Supplement Supplement Patient Count Sudies Supplement Supplement Patient Count Patients. Supplement Supplement Patient Count Submission Final Report Informed access after pivotal study, protocol and plan changes, including increased tuntalum in Onyx. Submission Submission Supplement for 3-5 year follow-up pending PMA approval protocol and informed consent). Supplement PAA Response Supplement for 3-5 year follow-up pending PMA approval for Onyx. Submission Submission Submission Submission Submission PMA approval for Supplement for 3-5 year follow-up pending PMA approval for Onserol. Submission Sub | Supplement Site Expansion Request to expand the number of sites. Annual Report Annual Report First Annual Report submitted. Supplement Supplement DMSO Stability Submitted regarding FDA's S013 Supplement Patient Count Request to increase number of S014 Final Report PMA Application Submission for IDE Final Report Submission Continued Access Protocol and plan changes, including increased tandalum in Onyx. Submission 3-5 year Follow-up Supplement for 3-5 year follow-up pending PMA approval (protocol and pinomed consent). | Supplement Site Expansion Request to expand the number of sites. Annual Report Annual Report First Annual Report submitted. Supplement Supplement DMSO Stability Submitted regarding FDA's submitted regarding FDA's submitted regarding FDA's submitted regarding FDA's SO13 Supplement Patient Count Supplement Patient Count SO14 Final Report PMA Application Submission for IDE Final Report Submission Continued Access Protocol and plan changes, including increased tantalum in Onyx. Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and pinformed consent). | Supplement Site Expansion Request to expand the number of sites. Annual Report Annual Report First Annual Report submitted. Supplement Supplement Sudies Submitted regarding FDA's SO13 Supplement Patient Count Request to increase number of Supplement SO14 Final Report PMA Application Submission for IDE Final Report Submission Continued Access Protocol and plan changes, including protocol and plan changes, including informed consent). Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Supplement Site Expansion Request to expand the number of sites. Annual Report Annual Report First Annual Report submitted. Supplement Supplement DMSO Stability Submitted regarding FDA's S013 Supplement Patient Count Request to increase number of S014 Final Report PMA Application Submission for IDE Final Report Submission Continued Access Protocol and plan changes, including increased tandalum in Onyx. Submission 3-5 year Follow-up Supplement for 3-5 year follow-up pending PMA approval (protocol and pinomed consent). | Supplement Site Expansion Request to expand the number of sites. Annual Report Annual Report First Annual Report submitted. Supplement Supplement DMSO Stability Submitted regarding FDA's S013 Supplement Patient Count Request to increase number of S014 Final Report PMA Application Submission for IDE Final Report Submission Continued Access Protocol and plan changes, including increased tandalum in Onyx. Submission 3-5 year Follow-up Supplement for 3-5 year follow-up pending PMA approval (protocol and pinomed consent). | Supplement Site Expansion Request to expand the number of sites. Annual Report Annual Report First Annual Report submitted. Supplement Supplement DMSO Stability Submitted regarding FDA's submitted regarding FDA's submitted regarding FDA's submitted regarding FDA's SO13 Supplement Patient Count Supplement Request to increase number of Sold PMA Application Submission Final Report PMA Application Submission for IDE Final Report PMA Application Submission for IDE Final Report PMA Approval (protocol and plan changes, including micreased tandalum in Onyx. Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and plan changes, including informed consent). | Supplement Site Expansion Request to expand the number of sites. Annual Report Annual Report First Annual Report submitted. Supplement Supplement DMSO Stability Submitted regarding FDA's S013 Supplement Patient Count Request to increase number of S014 Final Report PMA Application Submission for IDE Final Report Submission Continued Access Protocol and plan changes, including increased tandalum in Onyx. Submission 3-5 year Follow-up Supplement for 3-5 year follow-up pending PMA approval (protocol and pinomed consent). | Supplement Stite Expansion Request to expand the number of sites. Annual Report Annual Report First Annual Report submitted. Supplement Supplement Submitted regarding FDA's submitted regarding FDA's submitted regarding FDA's solidies so | Supplement Site Expansion Request to expand the number of sites. Annual Report Annual Report First Annual Report submitted. Supplement Supplement Sudies Submitted regarding FDA's SO13 Supplement Patient Count Request to increase number of Supplement SO14 Final Report PMA Application Submission for IDE Final Report Submission Continued Access Protocol and plan changes, including protocol and plan changes, including informed consent). Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Supplement Site Expansion Request to expand the number of sites. Annual Report Annual Report First Annual Report submitted. Supplement Supplement DMSO Stability Submitted regarding FDA's S013 Supplement Patient Count Request to increase number of S014 Final Report PMA Application Submission for IDE Final Report protocol and plan changes, including informed consent). Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). | Supplement Site Expansion Request to expand the number of sites. Annual Report Annual Report First Annual Report submitted. Supplement Supplement Sudies Submitted regarding FDA's SO13 Supplement Patient Count Request to increase number of Supplement SO14 Final Report PMA Application Submission for IDE Final Report Submission Continued Access Protocol and plan changes, including protocol and plan changes, including informed consent). Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Supplement Stite Expansion Request to expand the number of sites. Annual Report Annual Report First Annual Report submitted. Supplement Supplement Submitted regarding FDA's submitted regarding FDA's submitted regarding FDA's solidies so | Supplement Stite Expansion Request to expand the number of sites. Annual Report Annual Report First Annual Report submitted. Supplement Supplement Submitted regarding FDA's submitted regarding FDA's submitted regarding FDA's solidies so | Supplement Site Expansion Request to expand the number of sites. Supplement Solitability Sudies Submitted. Supplement Supplement Sudies Submitted regarding FDA's Solia Solia Submitted regarding FDA's Solia Soli | Supplement Site Expansion Request to expand the number of sites. Annual Report Annual Report First Annual Report submitted. Supplement Supplement Studies Supplement Submitted regarding FDA's submitted regarding FDA's sonditional approval letter dated 12- S014 Supplement Patient Count Request to increase number of 12-06-02 FDA Response Studies submitted access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission Supplement Follow-up pending PMA approval (protocol and plan changes, increased tantalum informed consent). Submission S-5 year Follow-up pending PMA approval (protocol and plan changes). | Supplement Site Expansion Request to expand the number of sites. Annual Report Annual Report First Annual Report submitted. Supplement Supplement Studies Supplement Submitted regarding FDA's submitted regarding FDA's sonditional approval letter dated 12- S014 Supplement Patient Count Request to increase number of 12-06-02 FDA Response Studies submitted access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission Supplement Follow-up pending PMA approval (protocol and plan changes, increased tantalum informed consent). Submission S-5 year Follow-up pending PMA approval (protocol and plan changes). | Supplement Site Expansion Request to expand the number of sites. Annual Report Annual Report First Annual Report submitted. Supplement Supplement Studies Supplement Submitted regarding FDA's submitted regarding FDA's sonditional approval letter dated 12- S014 Supplement Patient Count Request to increase number of 12-06-02 FDA Response Studies submitted access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission Supplement Follow-up pending PMA approval (protocol and plan changes, increased tantalum informed consent). Submission S-5 year Follow-up pending PMA approval (protocol and plan changes). |
| Supplement Site Expansion Request to expand the number of sites. 02-06-02 FDA Response S011 Annual Report Annual Report First Annual Report submitted. No Response Supplement DMSO Stability Suddies Supplement Supplement Patient Count S013 Studies Supplement S014 Final Report PMA Application Submission To TDE Final Report Submission Submission Supplement Final Report Submission Submission Supplement Soliability Submission Supplement Final Report Submission Submission Submission Supplement Final Report Supplement Soliability Submission Submission Submission Submission Submission Submission Supplement Final Report Supplement Final Report Supplement Final Report Submission Submission Supplement For 3-5 year Follow-up Supplement For 3-5 year Follow-up Supplement Final Report Submission Supplement For 3-5 year Follow-up Supplement For 3-5 year Follo | Supplement Site Expansion Request to expand the number of sites. 02-06-02 FDA Response Site Expansion S011 Annual Report Annual Report First Annual Report submitted. No Response Supplement DMSO Stability Submitted regarding FDA's submitted regarding FDA's conditional approval letter dated 12-07-01. Supplement Supplement Patient Count Request to increase number of S014 FDA Response PMA Application Submission for IDE Final Report Submission Submission Submission Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and PDA Response Supplement S013 PDA Response Supplement S015 PDA Response Supplement for 3-5 year follow-up pending PMA approval (protocol and Submission S15 year follow-up pending PMA approval (protocol and S15 year follow-up pending PMA approval year follow-up year follow-u | Supplement Site Expansion Request to expand the number of sites. 02-06-02 FDA Response Site Expansion S011 Annual Report Annual Report First Annual Report submitted. No Response Supplement Studies Sol13 Studies Submitted regarding FDA's conditional approval letter dated 12-07-01. Supplement Supplement Patient Count Request to increase number of S014 FDA Response PMA Application Submission Final Report PMA Application Submission for IDE Final Report PMA Application Submission For IDE Final Report Submission Submission Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and informed access after pivotal study, produced and plan changes, including increased tantalum in Onyx. Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and informed access after pivotal study, produced and plan changes, including increased tantalum in Onyx. Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and informed access after pivotal study, produced access after pivotal study, produced and plan changes, including increased tantalum in Onyx. Submission Submission Supplement for 3-5 year follow-up patient submitted. No Response Soll Submission Submis | Supplement Site Expansion Request to expand the number of sites. 02-06-02 FDA Response Site Expansion S011 Annual Report Annual Report First Annual Report submitted. No Response Supplement Studies Sol Sol Studies Sol Studies Sol Sol Studies Sol Studies Sol Sol Studies Sol Sol Studies Sol Sol Studies Sol | Supplement Site Expansion Request to expand the number of sites. 02-06-02 FDA Response Site Expansion S011 Annual Report Annual Report First Annual Report submitted. No Response S011 Supplement Studies Sol13 Supplement Patient Count Request to increase number of Supplement S014 Final Report PMA Application Submission Final Report Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased translum in Onlyx. Submission Submission Supplement for 3-5 year Follow-up pending PMA approval (protocol and proval (protocol and proval (protocol and pending PMA approval (protocol and pending P | Supplement Site Expansion Request to expand the number of sites. 02-06-02 FDA Response Site Expansion S011 Annual Report Annual Report First Annual Report submitted. No Response S011 Supplement Studies Submitted regarding FDA's conditional approval letter dated 12-07-01. Supplement Supplement Patient Count Request to increase number of S014 Final Report PMA Application Submission for IDE Final Report Submission Continued Access protocol and plan changes, including increased tuntalum in Onyx. Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and informed onsent). Supplement PAT Application Submission for IDE Final Report Supplement for 3-5 year follow-up pending PMA approval (protocol and informed onsent). Submission Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and informed onsent). | Supplement Site Expansion Request to expand the number of sites. 02-06-02 FDA Response Site Expansion S011 Annual Report Annual Report First Annual Report submitted. No Response Supplement Studies Submitted regarding FDA's conditional approval letter dated 12-07-01. Supplement Supplement Patient Count S014 Patient Count S014 Patient Sold Pha Application Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission Submission S-5 year Follow-up Supplement for 3-5 year follow-up Ending PMA approval (protocol and informed consent). Submission Site Expansion Request to expand the number of sites. 02-06-02 FDA Response S011 Soldies S013 Soldies S013 Submission Studies Soldies | Supplement Site Expansion Request to expand the number of sites. 02-06-02 FDA Response Site Expansion S011 Annual Report Annual Report First Annual Report submitted. No Response Supplement Studies Sol13 Supplement Supplement Patient Count Request to increase number of Supplement S014 Final Report PMA Application Submission Final Report Submission Continued Access protocol and plan changes, including increased tantalum in Onyx. Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and processor) Supplement PA Response Supplement for 3-5 year follow-up pending PMA approval (protocol and processor) Supplement PA Response Supplement for 3-5 year follow-up pending PMA approval (protocol and processor) Supplement PA Response Supplement for 3-5 year follow-up pending PMA approval (protocol and processor) Supplement PA Response Supplement for 3-5 year follow-up pending PMA approval (protocol and processor) Supplement PA Response Supplement for 3-5 year follow-up pending PMA approval (protocol and processor) Supplement PA Response Supplement for 3-5 year follow-up pending PMA approval (protocol and processor) | Supplement Site Expansion Request to expand the number of sites. 02-06-02 FDA Response Site Expansion S011 Annual Report Annual Report First Annual Report submitted. No Response Supplement Studies S013 Studies Submitted regarding FDA's conditional approval letter dated 12-07-01. Supplement Supplement Patient Count Request to increase number of S014 FDA Response PAA Application Submission Continued Access PAA Application Submission Final Report PAA Application Submission Submission Submission Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and plan changes, including informed onsent). Submission Stability Studies Sol13 Sol13 Sol13 Studies Sol13 Sol13 Submission Subm | Supplement Site Expansion Request to expand the number of sites. 02-06-02 FDA Response Site Expansion S011 Annual Report Annual Report First Annual Report submitted. No Response Supplement Studies Sol13 Studies Submitted regarding FDA's conditional approval letter dated 12- 07-01. Supplement Supplement Patient Count Request to increase number of S014 PMA Application Submission Final Report PMA Application Submission for IDE Final Report PMA Application Submission Final Report Submission Continued Access Protocol and plan changes, including increased tantalum in Onyx. Submission S-5 year Follow-up Employed (protocol and informed access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission S-5 year Follow-up Employed (protocol and informed access after pivotal study, protocol and pivotal stud | Supplement Site Expansion Request to expand the number of sites. 02-06-02 FDA Response Site Expansion S011 Annual Report Annual Report First Annual Report submitted. No Response Supplement Studies Submitted regarding FDA's conditional approval letter dated 12-07-01. Supplement Supplement Patient Count S014 Patient Count S014 Patient Sold Pha Application Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission Submission S-5 year Follow-up Supplement for 3-5 year follow-up Ending PMA approval (protocol and informed consent). Submission Site Expansion Request to expand the number of sites. 02-06-02 FDA Response S011 Soldies S013 Soldies S013 Submission Studies Soldies | Supplement Site Expansion Request to expand the number of sites. 02-06-02 FDA Response Site Expansion S011 Annual Report Annual Report First Annual Report submitted. No Response Supplement Studies Submitted regarding FDA's conditional approval letter dated 12- 07-01. Supplement Supplement Patient Count S014 PA Application Submission Continued Access Protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Supplement Site Expansion Request to expand the number of sites. 02-06-02 FDA Response Site Expansion S011 Annual Report Annual Report First Annual Report submitted. No Response Supplement Studies S013 Studies Submitted regarding FDA's conditional approval letter dated 12-07-01. Supplement Supplement Patient Count Request to increase number of S014 FDA Response PAA Application Submission Continued Access PAA Application Submission Final Report PAA Application Submission Submission Submission Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and plan changes, including informed onsent). Submission Stability Studies Sol13 Sol13 Sol13 Studies Sol13 Sol13 Submission Subm | Supplement Site Expansion Request to expand the number of sites. 02-06-02 FDA Response Site Expansion S011 Annual Report Annual Report First Annual Report submitted. No Response Supplement Studies Submitted regarding FDA's conditional approval letter dated 12-S014 Supplement Sold Patient Count Patients. Request to increase number of S07-01. Submission Submission Continued Access Continued access after pivotal study, protocol and plan changes, including informed consent). Supplement informed consent). Submission Submission Syear Follow-up pending PMA approval (protocol and informed consent). | Supplement Site Expansion Request to expand the number of sites. 02-06-02 FDA Response Site Expansion S011 Annual Report Annual Report First Annual Report submitted. No Response Supplement Studies Submitted regarding FDA's conditional approval letter dated 12- 07-01. Supplement Sold Report Patient Count Sold Request to increase number of Final Report PMA Application Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Supplement Site Expansion Request to expand the number of sites. 02-06-02 FDA Response Site Expansion S011 Annual Report Annual Report First Annual Report submitted. No Response Supplement Studies Sol Sol Studies Sol Studies Sol Sol Studies Sol Studies Sol Sol Studies Sol Sol Studies Sol Sol Studies Sol | Supplement Site Expansion Request to expand the number of sites. 02-06-02 FDA Response Site Expansion S011 Annual Report Annual Report First Annual Report submitted. No Response Supplement Studies Submitted regarding FDA's conditional approval letter dated 12-S014 Supplement Sold Patient Count Patients. Request to increase number of S07-01. Submission Submission Continued Access Continued access after pivotal study, protocol and plan changes, including informed consent). Supplement informed consent). Submission Submission Syear Follow-up pending PMA approval (protocol and informed consent). | Supplement Site Expansion Request to expand the number of sites. 02-06-02 FDA Response Site Expansion S011 Annual Report Annual Report First Annual Report submitted. No Response Supplement Studies Submitted regarding FDA's conditional approval letter dated 12-S014 Supplement Sold Patient Count Patients. Request to increase number of S07-01. Submission Submission Continued Access Continued access after pivotal study, protocol and plan changes, including informed consent). Supplement informed consent). Submission Submission Syear Follow-up pending PMA approval (protocol and informed consent). | Supplement Site Expansion Request to expand the number of sites. 02-06-02 FDA Response Site Expansion S011 Annual Report Annual Report First Annual Report submitted. No Response Supplement Studies Submitted regarding FDA's conditional approval letter dated 12- 07-01. Supplement Sold Report Patient Count Patients. Request to increase number of Sold FDA Response PDA Response Sold Soldients. Sold PMA Application Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onlyx. Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). Submission Site Expansion Request to expand the number of sites. 02-06-02 FDA Response Solli Solli Studies Solli Sol | Supplement Site Expansion Request to expand the number of sites. 02-06-02 FDA Response Site Expansion S011 Annual Report Annual Report First Annual Report submitted. No Response Supplement Studies Submitted regarding FDA's conditional approval letter dated 12-S014 Supplement Sold Patient Count Patients. Request to increase number of S07-01. Submission Submission Continued Access Continued access after pivotal study, protocol and plan changes, including informed consent). Supplement informed consent). Submission Submission Syear Follow-up pending PMA approval (protocol and informed consent). | Supplement Site Expansion Request to expand the number of sites. 02-06-02 FDA Response Site Expansion S011 Annual Report Annual Report First Annual Report submitted. No Response Supplement Studies submitted regarding FDA's Supplement Studies conditional approval letter dated 12-07-01. Supplement Supplement Patient Count Request to increase number of Supplement S014 Final Report PMA Application Submission for IDE Final Report Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and plan changes, including increase fundalum in Onyx. Submission S-5 year Follow-up pending PMA approval (protocol and informed consent). | Supplement Site Expansion Request to expand the number of sites. 02-06-02 FDA Response Site Expansion S011 Annual Report Annual Report First Annual Report submitted. No Response Supplement Studies Sol Sol Studies Sol Studies Sol Sol Studies Sol Studies Sol Sol Studies Sol Sol Studies Sol Sol Studies Sol | Supplement Site Expansion Request to expand the number of sites. 02-06-02 FDA Response Site Expansion S011 Annual Report Annual Report First Annual Report submitted. No Response Supplement Studies Submitted regarding FDA's Supplement Studies Supplement Sold Patient Count Patients. Supplement Sold Patient Count Patients. Sold Patients. Sold Patients. Sold Patients. Sold Response PMA Application Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). Submission Sold PA Response Continued Access Patients Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). | Supplement Site Expansion Request to expand the number of sites. 02-06-02 FDA Response Site Expansion S011 Annual Report Annual Report First Annual Report submitted. No Response Supplement Studies Sol Sol Studies Sol Studies Sol Sol Studies Sol Studies Sol Sol Studies Sol Sol Studies Sol Sol Studies Sol | Supplement Site Expansion Request to expand the number of sites. 02-06-02 FDA Response Site Expansion S011 Annual Report Annual Report First Annual Report submitted. No Response Supplement Studies submitted regarding FDA's Supplement Studies conditional approval letter dated 12-07-01. Supplement Supplement Patient Count Request to increase number of Supplement S014 Final Report PMA Application Submission for IDE Final Report Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and plan changes, including increase fundalum in Onyx. Submission S-5 year Follow-up pending PMA approval (protocol and informed consent). | Supplement Site Expansion Request to expand the number of sites. 02-06-02 FDA Response Site Expansion S011 Annual Report Annual Report First Annual Report submitted. No Response Supplement Studies submitted regarding FDA's Supplement Studies conditional approval letter dated 12-07-01. Supplement Supplement Patient Count Request to increase number of Supplement S014 Final Report PMA Application Submission for IDE Final Report Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and plan changes, including increase fundalum in Onyx. Submission S-5 year Follow-up pending PMA approval (protocol and informed consent). | Supplement Site Expansion Request to expand the number of sites. 02-06-02 FDA Response Site Expansion S011 Annual Report Annual Report First Annual Report submitted. No Response Supplement Studies Submitted regarding FDA's conditional approval letter dated 12-S014 Supplement Soldies Submitted regarding FDA's Soldies Submitted regarding FDA's Soldies Sold | Supplement Site Expansion Request to expand the number of sites. 02-06-02 FDA Response Site Expansion S011 Annual Report Annual Report First Annual Report submitted. No Response Supplement Studies Submitted regarding FDA's conditional approval letter dated 12-S014 Supplement Soldies Submitted regarding FDA's Soldies Submitted regarding FDA's Soldies Sold | Supplement Site Expansion Request to expand the number of sites. 02-06-02 FDA Response Site Expansion S011 Annual Report Annual Report First Annual Report submitted. No Response Supplement Studies Submitted regarding FDA's conditional approval letter dated 12-S014 Supplement Soldies Submitted regarding FDA's Soldies Submitted regarding FDA's Soldies Sold | Supplement Site Expansion Request to expand the number of sites. 02-06-02 FDA Response Site Expansion S011 Annual Report Annual Report First Annual Report submitted. No Response Supplement Studies Submitted regarding FDA's conditional approval letter dated 12-S014 Supplement Soldies Submitted regarding FDA's Soldies Submitted regarding FDA's Soldies Sold |
| Supplement Site Expansion Request to expand the number of sites. 02-06-02 FDA Response S011 Annual Report Annual Report Prist Annual Report submitted. No Response Supplement Studies Submitted regarding FDA's conditional approval letter dated 12-07-01. Supplement Supplement Patient Count Sol14 Final Report PMA Application Submission of IDE Final Report Submission Submission Submission Submission Submission Supplement Final Report Supplement Supplement Submission Submission Supplement Supplement Supplement Supplement Supplement Supplement Submission Submission Submission Submission Submission Supplement Supplement Final Report Supplement Su | Supplement Site Expansion Request to expand the number of sites. 02-06-02 FDA Response S011 Annual Report Annual Report First Annual Report submitted. No Response Supplement Sudices Supplement Sudices Supplement Sudices Submitted regarding FDA's conditional approval letter dated 12- 07-01. Supplement Patient Count Patients. Supplement Submission Continued Access PMA Application Submission Final Report PMA Application Submission Final Report PMA Application Submission Final Report Supplement for 3-5 year follow-up pending PMA approval (protocol and protocol and pending PMA approval (protocol and pending PMA approval pending | Supplement Site Expansion Request to expand the number of sites. Annual Report Annual Report First Annual Report submitted. Supplement Studies Submitted regarding FDA's S013 Supplement Patient Count Request to increase number of S07-01. Supplement S014 Final Report PMA Application Submission for IDE Final Report Final Report PMA Application Submission Submission Continued Access Protocol and plan changes, including increased tantalum in Onyx. Submission S-5 year Follow-up Supplement for 3-5 year follow-up pending PMA approval (protocol and informed Docesni) Submission Site Expansion Request to expand the number of sites. O2-06-02 FDA Response Additional Patient S016 FDA Response Continued Access PDA Response PDA Response PDA Response Supplement for 3-5 year follow-up pending PMA approval (protocol and informed DA approval informed DA approval informed DA approval informed DA approval (protocol and informed DA approval in | Supplement Site Expansion Request to expand the number of sites. Sol11 Annual Report Annual Report Prist Annual Report submitted. Supplement Studies Sol13 Supplement DMSO Stability Studies submitted regarding FDA's conditional approval letter dated 12- Sol13 Supplement Sol4 Final Report PMA Application Submission Continued Access PMA Approval for 1DE Final Report Submission Submission Submission Supplement Final Report Submission Submission Supplement Final Report Submission Supplement for 3-5 year Follow-up pending PMA approval (protocol and proval (protocol and proval (protocol and pending PMA approval (protocol and pending PMA a | Supplement Site Expansion Request to expand the number of sites. 02-06-02 FDA Response Site Expansion S011 Annual Report Annual Report First Annual Report submitted. No Response Supplement DMSO Stability Submitted regarding FDA's conditional approval letter dated 12-07-01. Supplement Patient Count Request to increase number of S014 PMA Application Submission Final Report PMA Application Submission Final Report Submission Continued Access Protocol and plan changes, including increased tantalum in Omyx. Submission S-5 year Follow-up pending PMA approval (protocol and S02-20-04 FDA Response Software Follow-up pending PMA approval (protocol and S02-20-04 FDA Response Software Follow-up pending PMA approval (protocol and S02-20-04 FDA Response S03-5 year Follow-up PMA approval (protocol and S02-20-04 FDA Response S03-5 year Follow-up PMA approval (protocol and S02-20-04 FDA Response S03-5 year Follow-up PMA approval (protocol and S02-20-04 FDA Response S03-5 year Follow-up PMA approval (protocol and S02-20-04 FDA Response S03-5 year Follow-up PMA approval (protocol and S02-20-04 FDA Response S03-5 year Follow-up PMA approval (protocol and S02-20-04 FDA Response S03-5 year Follow-up PMA approval (protocol and S02-20-04 FDA Response S03-5 year Follow-up PMA approval (protocol and S02-20-04 FDA Response S03-5 year Follow-up PMA approval (protocol and S02-20-04 FDA Response S03-5 year Follow-up PMA approval (protocol and S02-20-04 FDA Response S03-5 year Follow-up PMA approval (protocol and S02-20-04 FDA Response S03-5 year Follow-up PMA approval (protocol and S02-20-04 FDA Response S03-5 year Follow-up PMA approval (protocol and S02-20-04 FDA Response S03-5 year Follow-up PMA approval (protocol and S02-20-04 FDA Response S03-5 year Follow-up PMA approval (protocol and S02-20-04 FDA Response S03-5 year Follow-up PMA approval (protocol and S02-20-04 FDA Response S03-15 year FOllow-up FDA Response S03-15 year FDA Respons | Supplement Site Expansion Request to expand the number of sites. Annual Report Annual Report First Annual Report submitted. Supplement Studies Submitted regarding FDA's S013 Supplement Sold Supplement Patient Count Patients. Request to increase number of 12-06-02 FDA Response Sol13 Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). Submission Sire Expansion Request to expand the number of sites. 02-06-02 FDA Response Additional Patient S014 Final Report PMA Application Submission for IDE Final Report S016 Submission Submission Submission PMA approval (protocol and informed consent). Submission Sire Expansion S011 | Supplement Site Expansion Request to expand the number of sites. Annual Report Annual Report Prist Annual Report submitted. Supplement Studies Submitted regarding FDA's SO13 Supplement Sold Supplement Patient Count Request to increase number of patients. Supplement Sold Final Report PMA Application Submission for IDE Final Report PMA Application Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantatum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Submission Site Expansion Solic E | Supplement Site Expansion Request to expand the number of sites. Annual Report Annual Report First Annual Report submitted. Supplement Studies Submitted regarding FDA's Submitted regarding FDA's Supplement Sol13 Supplement Patient Count Patients. Supplement Sol4 Final Report PMA Application Submission for IDE Final Report protocol and plan changes, including increased tantalum in Onyx. Submission Submission 3-5 year Follow-up Engling PMA approval (protocol and processor) Supplement PAResponse Submission Submission for IDE Final Report PMA Approval (protocol and processor) Submission Submiss | Supplement Site Expansion Request to expand the number of sites. Annual Report Annual Report Prist Annual Report submitted. Supplement Studies Submitted regarding FDA's SO13 Supplement Patient Count Patients. Supplement Sold Final Report PMA Application Submission for IDE Final Report PMA Application Submission Continued Access Protocol and plan changes, including increased tantatum in Onyx. Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). Submission Sie Expansion Request to expand the number of sites. No Response Sol11 PDA Response Additional Patient Sol6 Enrollment Sol6 Enrollment PDA Response Continued Access protocol and plan changes, including informed onesent). Submission S-5 year Follow-up Supplement for 3-5 year follow-up informed consent). | Supplement Site Expansion Request to expand the number of sites. Annual Report Annual Report First Annual Report submitted. Supplement Studies Submitted regarding FDA's S013 Supplement Soldies Conditional approval letter dated 12- S014 Supplement Patient Count Patients. Supplement Patient Count Patients. Supplement Patient Count Potenties. Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tuntalum in Onyx. Submission Syear Follow-up Employer Supplement for 3-5 year follow-up informed consent). Submission Submission Submission Submission Onesento. Submission Syear Follow-up Employer Supplement for 3-5 year follow-up informed consent). | Supplement Site Expansion Request to expand the number of sites. Annual Report Annual Report Prist Annual Report submitted. Supplement Studies Submitted regarding FDA's SO13 Supplement Sold Supplement Patient Count Request to increase number of patients. Supplement Sold Final Report PMA Application Submission for IDE Final Report PMA Application Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantatum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Submission Site Expansion Solic E | Supplement Site Expansion Request to expand the number of sites. Annual Report Annual Report First Annual Report submitted. Annual Report DMSO Stability Studies submitted regarding FDA's Sol13 Supplement Studies Conditional approval letter dated 12- Sol14 Supplement Patient Count Request to increase number of 12-06-02 FDA Response Submitted Sol14 Final Report PMA Application Submission for IDE Final Report Submission Continued access after pivotal study, protocol and plan changes, including increased tartalum in Onlyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Submission Site Expansion Selection Sol11 No Response DMSO Stability Studies Sol13 Sol13 Sol14 FDA Response Continued Access Gontinued access after pivotal study, protocol and plan changes, including increased tartalum in Onlyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Supplement Site Expansion Request to expand the number of sites. Annual Report Annual Report Prist Annual Report submitted. Supplement Studies Submitted regarding FDA's SO13 Supplement Patient Count Patients. Supplement Sold Final Report PMA Application Submission for IDE Final Report PMA Application Submission Continued Access Protocol and plan changes, including increased tantatum in Onyx. Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). Submission Sie Expansion Request to expand the number of sites. No Response Sol11 PDA Response Additional Patient Sol6 Enrollment Sol6 Enrollment PDA Response Continued Access protocol and plan changes, including informed onesent). Submission S-5 year Follow-up Supplement for 3-5 year follow-up informed consent). | Supplement Site Expansion Request to expand the number of sites. Annual Report Annual Report Prist Annual Report submitted. Supplement Studies Sol13 Supplement DMSO Stability Studies submitted regarding FDA's conditional approval letter dated 12- Sol14 Supplement Sol4 Final Report PMA Application Submission Continued Access Pools of PMA Application Submission Submission Submission Submission Supplement for 3-5 year Follow-up pending PMA approval (protocol and proval (protocol and proval (protocol and pending PMA approval (protoco | Supplement Site Expansion Request to expand the number of sites. Annual Report Annual Report Prist Annual Report submitted. Supplement Studies Submitted regarding FDA's SO13 Supplement Patient Count Request to increase number of So14 Final Report PMA Application Submission for IDE Final Report Submission Continued Access after pivotal study, protocol and plan changes, including increased tantalum in Onlyx. Submission Submission Supplement of 3-5 year follow-up pending PMA approval (protocol and informed consent). Submission Site Expansion Request to expand the number of sites. O2-06-02 FDA Response DMSO Stability Studies So13 FDA Response Continued Access Protocol and plan changes, including informed consent). | Supplement Site Expansion Request to expand the number of sites. Sol11 Annual Report Annual Report Prist Annual Report submitted. Supplement Studies Sol13 Supplement DMSO Stability Studies submitted regarding FDA's conditional approval letter dated 12- Sol13 Supplement Sol4 Final Report PMA Application Submission Continued Access PMA Approval for 1DE Final Report Submission Submission Submission Supplement Final Report Submission Submission Supplement Final Report Submission Supplement for 3-5 year Follow-up pending PMA approval (protocol and proval (protocol and proval (protocol and pending PMA approval (protocol and pending PMA a | Supplement Site Expansion Request to expand the number of sites. Annual Report Annual Report Prist Annual Report submitted. Supplement Studies Sol13 Supplement DMSO Stability Studies submitted regarding FDA's conditional approval letter dated 12- Sol14 Supplement Sol4 Final Report PMA Application Submission Continued Access Pools of PMA Application Submission Submission Submission Submission Supplement for 3-5 year Follow-up pending PMA approval (protocol and proval (protocol and proval (protocol and pending PMA approval (protoco | Supplement Site Expansion Request to expand the number of sites. Annual Report Annual Report Prist Annual Report submitted. Supplement Studies Sol13 Supplement DMSO Stability Studies submitted regarding FDA's conditional approval letter dated 12- Sol14 Supplement Sol4 Final Report PMA Application Submission Continued Access Pools of PMA Application Submission Submission Submission Submission Supplement for 3-5 year Follow-up pending PMA approval (protocol and proval (protocol and proval (protocol and pending PMA approval (protoco | Supplement Site Expansion Request to expand the number of sites. Annual Report Annual Report Prist Annual Report submitted. Supplement Studies Submitted regarding FDA's SO13 Supplement Patient Count Request to increase number of So14 Final Report PMA Application Submission for IDE Final Report Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onlyx. Submission S-5 year Follow-up pending PMA approval (protocol and protocol and pinformed consent). Submission Site Expansion Request to expand the number of sites. O2-06-02 FDA Response DMSO Stability Studies So13 SUBJECTION SUBJECTION SUBMISSION SUBJECTION | Supplement Site Expansion Request to expand the number of sites. Annual Report Annual Report Prist Annual Report submitted. Supplement Studies Sol13 Supplement DMSO Stability Studies submitted regarding FDA's conditional approval letter dated 12- Sol14 Supplement Sol4 Final Report PMA Application Submission Continued Access Pools of PMA Application Submission Submission Submission Submission Supplement for 3-5 year Follow-up pending PMA approval (protocol and proval (protocol and proval (protocol and pending PMA approval (protoco | Supplement Site Expansion Request to expand the number of sites. Supplement Sol11 Annual Report Annual Report Stability Studies Sol13 Supplement DMSO Stability Studies Sol13 Supplement Patient Count Patients. Supplement Sol4 Final Report PMA Application Submission Continued Access PMA Approval (protocol and Informed consent). Submission Submission Submission Supplement for 3-5 year follow-up Pending PMA approval (protocol and Informed consent). | Supplement Site Expansion Request to expand the number of sites. Sol11 Annual Report Annual Report Prist Annual Report submitted. Supplement Studies Sol13 Supplement DMSO Stability Studies submitted regarding FDA's conditional approval letter dated 12- Sol13 Supplement Sol4 Final Report PMA Application Submission Continued Access PMA Approval for 1DE Final Report Submission Submission Submission Supplement Final Report Submission Submission Supplement Final Report Submission Supplement for 3-5 year Follow-up pending PMA approval (protocol and proval (protocol and proval (protocol and pending PMA approval (protocol and pending PMA a | Supplement Site Expansion Request to expand the number of sites. Supplement Site Expansion Request to expand the number of sites. Annual Report Annual Report Stability Studies Submitted Report submitted. Supplement DMSO Stability Studies Submitted regarding FDA's Supplement Request to increase number of Supplement Sol14 Final Report PMA Application Submission for IDE Final Report Submission Continued Access Protocol and plan changes, including increased tantalum in Onyx. Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). Submission Site Expansion Set Expansion Sol11 No Response DMSO Stability Studies Sol13 Supplement Studies Sol13 Submission Submission for IDE Final Report Sol6-02 FDA Response Continued Access protocol and plan changes, including increase datalum in Onyx. Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). | Supplement Site Expansion Request to expand the number of sites. Sol11 Annual Report Annual Report Prist Annual Report submitted. Supplement Studies Sol13 Supplement DMSO Stability Studies submitted regarding FDA's conditional approval letter dated 12- Sol13 Supplement Sol4 Final Report PMA Application Submission Continued Access PMA Approval for 1DE Final Report Submission Submission Submission Supplement Final Report Submission Submission Supplement Final Report Submission Supplement for 3-5 year Follow-up pending PMA approval (protocol and proval (protocol and proval (protocol and pending PMA approval (protocol and pending PMA a | Supplement Site Expansion Request to expand the number of sites. Supplement Sol11 Annual Report Annual Report Stability Studies Sol13 Supplement DMSO Stability Studies Sol13 Supplement Patient Count Patients. Supplement Sol4 Final Report PMA Application Submission Continued Access PMA Approval (protocol and Informed consent). Submission Submission Submission Supplement for 3-5 year follow-up Pending PMA approval (protocol and Informed consent). | Supplement Site Expansion Request to expand the number of sites. Supplement Sol11 Annual Report Annual Report Stability Studies Sol13 Supplement DMSO Stability Studies Sol13 Supplement Patient Count Patients. Supplement Sol4 Final Report PMA Application Submission Continued Access PMA Approval (protocol and Informed consent). Submission Submission Submission Supplement for 3-5 year follow-up Pending PMA approval (protocol and Informed consent). | Supplement Site Expansion Request to expand the number of sites. Sol11 Annual Report Annual Report DMSO stability studies submitted. Supplement Studies Sol13 Supplement Patient Count Patients. Supplement Sol14 Final Report PMA Application Submission Continued Access after pivotal study, pending PMA approval (protocol and Informed consent). Submission Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). | Supplement Site Expansion Request to expand the number of sites. Annual Report Annual Report DMSO stability Studies S013 Supplement DMSO Stability Studies Sol13 Supplement Patient Count Patients. Supplement Sol14 Final Report PMA Application Submission Continued Access after pivotal study, pending PMA approval (protocol and protocol and informed consent). Submission Submission Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). | Supplement Site Expansion Request to expand the number of sites. Annual Report Annual Report DMSO stability Studies S013 Supplement DMSO Stability Studies Sol13 Supplement Patient Count Patients. Supplement Sol14 Final Report PMA Application Submission Continued Access after pivotal study, pending PMA approval (protocol and protocol and informed consent). Submission Submission Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). | Supplement Site Expansion Request to expand the number of sites. Annual Report Annual Report DMSO stability Studies S013 Supplement DMSO Stability Studies Sol13 Supplement Patient Count Patients. Supplement Sol14 Final Report PMA Application Submission Continued Access after pivotal study, pending PMA approval (protocol and protocol and informed consent). Submission Submission Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). |
| Supplement Site Expansion Request to expand the number of sites. 02-06-02 FDA Response Site Expansion S011 Annual Report Annual Report First Annual Report submitted. No Response Supplement DMSO Stability Submitted regarding FDA's conditional approval letter dated 12-07-01. Supplement Supplement Patient Count Patients. Sold PMA Application Submission of rIDE Final Report PMA Application Submission of protocol and plan changes, including increase databalum in Onlyx. Submission Supplement Supplement for 3-5 year Follow-up periding DMA amongsyla (frectored and plan changes). | Supplement Site Expansion Request to expand the number of sites. 02-06-02 FDA Response Site Expansion S011 Supplement Annual Report First Annual Report submitted. No Response Supplement Studies Sol13 Submitted regarding FDA's conditional approval letter dated 12-07-01. Supplement Patient Count Patients. Supplement Patient Count Patients. Submission Continued Access PMA Application Submission Continued Access Protocol and plan changes, including Increase fluid protocol and plan changes, including Increase fluid protocol and plan changes, including Increase fluid pending PMA approval (protocol and O2-20-04 FDA Response Supplement for 3-5 year follow-up pending PMA approval (protocol and O2-20-04 FDA Response Supplement Supplement for 3-5 year follow-up pending PMA approval (protocol and D2-20-04 FDA Response Supplement Suppl | Supplement Site Expansion Request to expand the number of sites. 8011 Soll Soll Soll Supplement Annual Report First Annual Report submitted. No Response Supplement DMSO Stability Studies submitted regarding FDA's Soll Supplement Patient Count Soll Request to increase number of Soll Soll Submission Continued Access Final Report PMA Application Submission Submission Submission Submission Submission Solf Supplement for 3-5 year follow-up pending PMA Approval (protocol and plan changes, including informed access after pivotal study, protocol and plan changes, including informed access after pivotal study. Supplement for 3-5 year follow-up pending PMA approval (protocol and informed access after pivotal study. Submission Solf PDA Response Solf Solf Solf Solf Solf Solf Solf Solf | Supplement Site Expansion Request to expand the number of sites. 02-06-02 FDA Response Site Expansion S011 Annual Report Annual Report First Annual Report submitted. No Response Supplement DMSO Stability Studies Sol13 Supplement Studies Submitted regarding FDA's Conditional approval letter dated 12- 07-01. Supplement Supplement Patient Count patients. Sol14 PMA Application Submission Continued Access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and pinformed consent). Site Expansion Solt Expansion Request to expand the number of sol13 Sol11 Sol11 Final Report PDA Response Additional Patient Sol14 Sol16 PDA Response Enrollment Sol16 Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). | Supplement Site Expansion Request to expand the number of sites. 02-06-02 FDA Response Site Expansion S011 Annual Report Annual Report First Annual Report submitted. No Response Supplement DMSO stability studies submitted regarding FDA's submitted regarding FDA's submitted regarding FDA's S013 Supplement Patient Count Request to increase number of Supplement S014 Final Report PMA Application Submission for IDE Final Report S016 Submission Continued Access Protocol and plan changes, including increased tantalum in Onyx. Submission S-5 year Follow-up pending PMA approval (protocol and Submission Onyx. Submission Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and Submission S | Supplement Site Expansion Request to expand the number of sites. 02-06-02 FDA Response Site Expansion S011 Annual Report Annual Report First Annual Report submitted. No Response Supplement DMSO Stability Studies Submitted regarding FDA's Conditional approval letter dated 12-S013 S013 Submitted regarding FDA's S014 Supplement Patient Count Request to increase number of Supplement S014 Final Report PMA Application Submission for IDE Final Report Submission Continued Access Conditional plan changes, including increased tantatum in Onyx. Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and plan changes, including informed consent). Submission Site Expansion Solities. 02-06-02 FDA Response Submission Site Expansion Submitted. No Response Submission Site Expansion Solities. | Supplement Site Expansion Request to expand the number of sites. 02-06-02 FDA Response Site Expansion S011 Annual Report Annual Report First Annual Report submitted. No Response Submitted Expansion Submitted regarding FDA's conditional approval letter dated 12- S013 Supplement Supplement Studies Submitted regarding FDA's Solidional approval letter dated 12- S014 Final Report PMA Application Submission for IDE Final Report. Final Report Submission Submission Submission Submission Submission Submission Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). Submission Site Expansion Solidies Solid | Supplement Site Expansion Request to expand the number of sites. 8011 Solit Expansion Solit Ex | Supplement Site Expansion Request to expand the number of sites. 02-06-02 FDA Response Site Expansion S011 Annual Report Annual Report First Annual Report submitted. No Response Supplement DMSO Stability Studies Submitted regarding FDA's Conditional approval letter dated 12-S013 S013 Submitted regarding FDA's S014 PATENTAL Patient S014 Final Report PMA Application Submission Continued Access Conditional approval letter dated 12-Submission Submission Submission Submission Submission Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and plan changes, including informed consent). Submission Site Expansion Site Expansion Solitites. O2-06-02 FDA Response Studies Submission Site Expansion No Response Submit Submit Submission Site Expansion Submitted. No Response Submit S | Supplement Site Expansion Request to expand the number of sites. 02-06-02 FDA Response Site Expansion S011 Annual Report Annual Report First Annual Report submitted. No Response S011 Supplement DMSO Stability Studies submitted regarding FDA's conditional approval letter dated 12- 07-01. Supplement S014 Final Report PMA Application Submission Continued Access Conditional Approval patients. Submission Submission Submission Submission Submission Submission Submission Submission Submission Supplement for 3-5 year follow-up pending PMA approval protocol and plan changes, including informed access after pivotal study, protocol and plan changes, including informed access after pivotal study, protocol and plan changes, including informed access after pivotal study, protocol and plan changes, including informed access after pivotal study, protocol and plan changes, including informed access after pivotal study, protocol and plan changes, including plan submission Submis | Supplement Site Expansion Request to expand the number of sites. 02-06-02 FDA Response Site Expansion S011 Annual Report Annual Report First Annual Report submitted. No Response Submitted Expansion Submitted regarding FDA's conditional approval letter dated 12- S013 Supplement Supplement Studies Submitted regarding FDA's Solidional approval letter dated 12- S014 Final Report PMA Application Submission for IDE Final Report. Final Report Submission Submission Submission Submission Submission Submission Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). Submission Site Expansion Solidies Solid | Supplement Site Expansion Request to expand the number of sites. 02-06-02 FDA Response Site Expansion S011 Annual Report Annual Report First Annual Report submitted. No Response Supplement DMSO Stability Studies Submitted regarding FDA's Conditional approval letter dated 12-S014 Supplement Patient Count Patients. Supplement Sold Request to increase number of Submission Supplement Increase d tantalum in Onlyx. Submission Supplement Site Expansion Request to expand the number of Sites. 02-06-02 FDA Response Submission Submission for IDE Final Report. Solf Submission Submission Submission Submission Submission Submission Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and protocol and proval pending PMA approval (protocol and pinformed consent). | Supplement Site Expansion Request to expand the number of sites. 02-06-02 FDA Response Site Expansion S011 Annual Report Annual Report First Annual Report submitted. No Response Supplement DMSO Stability Studies Submitted regarding FDA's Conditional approval letter dated 12-S013 S013 Submitted regarding FDA's S014 PATENTAL Patient S014 Final Report PMA Application Submission Continued Access Conditional approval letter dated 12-Submission Submission Submission Submission Submission Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and plan changes, including informed consent). Submission Site Expansion Site Expansion Solitites. O2-06-02 FDA Response Studies Submission Site Expansion No Response Submit Submit Submission Site Expansion Submitted. No Response Submit S | Supplement Site Expansion Request to expand the number of sites. 02-06-02 FDA Response Site Expansion S011 Annual Report Annual Report First Annual Report submitted. No Response Supplement DMSO Stability Studies Sol13 Supplement Studies Sol13 Supplement Patient Count Patients. Supplement Sol14 Patient Count Patients. Sol14 PMA Application Submission Continued Access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission Supplement Supplement for 3-5 year follow-up pending PMA approval (protocol and protocol and pinformed consent). Site Expansion Sol1 Sol1 Sol1 Sol1 Sol1 Sol1 Sol1 Sol1 | Supplement Site Expansion Request to expand the number of sites. 02-06-02 FDA Response Site Expansion S011 Annual Report Annual Report First Annual Report submitted. No Response Supplement DMSO Stability Studies Submitted regarding FDA's conditional approval letter dated 12- S013 Supplement Patient Count Patients. Supplement Solid PMA Application Submission Final Report PMA Application Submission Submission Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and protocol and proval pending PMA approval (protocol and protocol and pinformed consent). Supplement Patient Count PMA Application Submission for IDE Final Report Submission Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and pinformed consent). | Supplement Site Expansion Request to expand the number of sites. 02-06-02 FDA Response Site Expansion S011 Annual Report Annual Report First Annual Report submitted. No Response Supplement DMSO Stability Studies Sol13 Supplement Studies Submitted regarding FDA's Conditional approval letter dated 12- 07-01. Supplement Supplement Patient Count patients. Sol14 PMA Application Submission Continued Access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). Supplement PA Site Expansion Solic Expansion Site Expansion Solic Expansion No Response Solic Expansion PDA Response Solic Expansion Solic Ex | Supplement Site Expansion Request to expand the number of sites. 02-06-02 FDA Response Site Expansion S011 Annual Report Annual Report First Annual Report submitted. No Response Supplement DMSO Stability Studies Sol13 Supplement Studies Sol13 Supplement Patient Count Patients. Supplement Sol14 Patient Count Patients. Sol14 PMA Application Submission Continued Access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission Supplement Supplement for 3-5 year follow-up pending PMA approval (protocol and protocol and pinformed consent). Site Expansion Sol1 Sol1 Sol1 Sol1 Sol1 Sol1 Sol1 Sol1 | Supplement Site Expansion Request to expand the number of sites. 02-06-02 FDA Response Site Expansion S011 Annual Report Annual Report First Annual Report submitted. No Response Supplement DMSO Stability Studies Sol13 Supplement Studies Sol13 Supplement Patient Count Patients. Supplement Sol14 Patient Count Patients. Sol14 PMA Application Submission Continued Access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission Supplement Supplement for 3-5 year follow-up pending PMA approval (protocol and protocol and pinformed consent). Site Expansion Sol1 Sol1 Sol1 Sol1 Sol1 Sol1 Sol1 Sol1 | Supplement Site Expansion Request to expand the number of sites. 02-06-02 FDA Response Site Expansion S011 Annual Report Annual Report First Annual Report submitted. No Response Supplement DMSO Stability Studies Submitted regarding FDA's conditional approval letter dated 12- S013 Supplement Patient Count Patients. Request to increase number of patients. Supplement Supplement PMA Application Submission for IDE Final Report. Final Report PMA Application Submission Submission Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and proval (protocol and proval pending PMA approval (protocol and pending PMA approval (protocol and pending PMA eproval (proto | Supplement Site Expansion Request to expand the number of sites. 02-06-02 FDA Response Site Expansion S011 Annual Report Annual Report First Annual Report submitted. No Response Supplement DMSO Stability Studies Sol13 Supplement Studies Sol13 Supplement Patient Count Patients. Supplement Sol14 Patient Count Patients. Sol14 PMA Application Submission Continued Access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission Supplement Supplement for 3-5 year follow-up pending PMA approval (protocol and protocol and pinformed consent). Site Expansion Sol1 Sol1 Sol1 Sol1 Sol1 Sol1 Sol1 Sol1 | Supplement Site Expansion Request to expand the number of sites. 02-06-02 FDA Response Site Expansion S011 Annual Report Annual Report First Annual Report submitted. No Response Supplement DMSO Stability Studies Submitted regarding FDA's conditional approval letter dated 12- 07-01. Supplement Supplement Patient Count Patients. Supplement Philadelphia Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onys. Submission Submission Supplement for 3-5 year follow-up Pending PMA approval (protocol and informed consent). Supplement PDM Response Supplement for 3-5 year follow-up Pending PMA approval (protocol and informed consent). | Supplement Site Expansion Request to expand the number of sites. 02-06-02 FDA Response Site Expansion S011 Annual Report Annual Report First Annual Report submitted. No Response Supplement DMSO Stability Studies Sol13 Supplement Studies Submitted regarding FDA's Conditional approval letter dated 12- 07-01. Supplement Supplement Patient Count patients. Sol14 PMA Application Submission Continued Access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). Supplement PA Site Expansion Solic Expansion Site Expansion Solic Expansion No Response Solic Expansion PDA Response Solic Expansion Solic Ex | Supplement Site Expansion Request to expand the number of sites. 02-06-02 FDA Response Site Expansion S011 Annual Report Annual Report First Annual Report submitted. No Response Supplement DMSO Stability Studies Submitted regarding FDA's conditional approval letter dated 12- 07-01. Supplement Supplement Patient Count Patients. Supplement Philadelphication Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onys. Submission Supplement Counted Access Continued access after pivotal study, pending PMA approval (protocol and plan pending PMA approval (protocol and informed consent). Supplement PDA Response Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). | Supplement Site Expansion Request to expand the number of sites. 02-06-02 FDA Response Site Expansion S011 Annual Report Annual Report First Annual Report submitted. No Response Supplement DMSO Stability Studies Sol13 Supplement Studies Submitted regarding FDA's Conditional approval letter dated 12- 07-01. Supplement Supplement Patient Count patients. Sol14 PMA Application Submission Continued Access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). Supplement PA Site Expansion Solic Expansion Site Expansion Solic Expansion No Response Solic Expansion PDA Response Solic Expansion Solic Ex | Supplement Site Expansion Request to expand the number of sites. 02-06-02 FDA Response Site Expansion S011 Annual Report Annual Report First Annual Report submitted. No Response Supplement DMSO Stability Studies Submitted regarding FDA's conditional approval letter dated 12- 07-01. Supplement Supplement Patient Count Patients. Supplement Philadelphia Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onys. Submission Submission Supplement for 3-5 year follow-up Pending PMA approval (protocol and informed consent). Supplement PDM Response Supplement for 3-5 year follow-up Pending PMA approval (protocol and informed consent). | Supplement Site Expansion Request to expand the number of sites. 02-06-02 FDA Response Site Expansion S011 Annual Report Annual Report First Annual Report submitted. No Response Supplement DMSO Stability Studies Submitted regarding FDA's conditional approval letter dated 12- 07-01. Supplement Supplement Patient Count Patients. Supplement Philadelphia Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onys. Submission Submission Supplement for 3-5 year follow-up Pending PMA approval (protocol and informed consent). Supplement PDM Response Supplement for 3-5 year follow-up Pending PMA approval (protocol and informed consent). | Supplement Site Expansion Request to expand the number of sites. 02-06-02 FDA Response Site Expansion S011 Annual Report Annual Report First Annual Report submitted. No Response Supplement DMSO Stability Studies Sounditional approval letter dated 12- 07-01. Supplement Patient Count Request to increase number of Supplement Supplement Submitted regarding FDA's Sounditional approval letter dated 12- S014 Final Report PMA Application Submission for IDE Final Report Submission Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and protocol and informed consent). Supplement PA Approval (protocol and informed consent). | Supplement Site Expansion Request to expand the number of sites. 02-06-02 FDA Response Site Expansion S011 Supplement DMSO Stability Studies submitted. No Response Supplement Studies S013 Submitted regarding FDA's conditional approval letter dated 12-07-01. Supplement Patient Count Request to increase number of Supplement Submitted regarding FDA's S013 S013 Submitted regarding FDA's S013 S013 Submitted Request to increase number of 12-06-02 FDA Response S013 Submitted Final Report Submitted regarding FDA's S016 FDA Response Submitted Report Submitted regarding FDA's pear follow-up pending PMA approval (protocol and informed consent). Submitsion 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Supplement Site Expansion Request to expand the number of sites. 02-06-02 FDA Response Site Expansion S011 Supplement DMSO Stability Studies submitted. No Response Supplement Studies S013 Submitted regarding FDA's conditional approval letter dated 12-07-01. Supplement Patient Count Request to increase number of Supplement Submitted regarding FDA's S013 S013 Submitted regarding FDA's S013 S013 Submitted Request to increase number of 12-06-02 FDA Response S013 Submitted Final Report Submitted regarding FDA's S016 FDA Response Submitted Report Submitted regarding FDA's pear follow-up pending PMA approval (protocol and informed consent). Submitsion 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Supplement Site Expansion Request to expand the number of sites. 02-06-02 FDA Response Site Expansion S011 Supplement DMSO Stability Studies submitted. No Response Supplement Studies S013 Submitted regarding FDA's conditional approval letter dated 12-07-01. Supplement Patient Count Request to increase number of Supplement Submitted regarding FDA's S013 S013 Submitted regarding FDA's S013 S013 Submitted Request to increase number of 12-06-02 FDA Response S013 Submitted Final Report Submitted regarding FDA's S016 FDA Response Submitted Report Submitted regarding FDA's pear follow-up pending PMA approval (protocol and informed consent). Submitsion 3-5 year Follow-up pending PMA approval (protocol and informed consent). |
| Supplement Site Expansion Request to expand the number of sites. 02-06-02 FDA Response S011 Annual Report Annual Report First Annual Report submitted. No Response Supplement Studies Submitted regarding FDA's submitted regarding FDA's submitted regarding FDA's Supplement Supplement Patient Count Patients. Supplement Supplement Patient Count Patients. Supplement Supplement Patient Count Patients. Supplement Submission Continued Access Polocol and plan changes, including increased tandlum in Onyx. Submission 3-5 year Follow-up Supplement for 3-5 year follow-up Continued Access PDA Response Submission O2-20-04 FDA Response Suprince Access Submission Submission Submission Submission O2-20-04 FDA Response Submission O2-20-04 FDA Response Ontinued Access Submission O2-20-04 FDA Response O2-20-04 PDA Response O2-20-04 FDA Response O2-20-04 FDA Response O2-20-04 PDA Respo | Supplement Site Expansion Request to expand the number of sites. Annual Report Annual Report First Annual Report submitted. Supplement Studies Submitted regarding FDA's submitted regarding FDA's Supplement Supplement Patient Count Patients. Supplement Supplement Patient Count Patients. Supplement Politication Submission Continued Access PMA Application Submission Submission Submission PMA Application Submission Submission PMA Application Submission Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and plan changes, including pending PMA approval (protocol and plan changes) pending P | Supplement Site Expansion Request to expand the number of sites. Annual Report Annual Report First Annual Report submitted. Supplement Studies Submitted regarding FDA's submitted regarding FDA's submitted regarding FDA's conditional approval letter dated 12-07-01. Supplement Supplement Patient Count S014 Patients. Request to increase number of 12-06-02 FDA Response Submitted regarding FDA's sudies submitted regarding FDA's S013 Submission Submission for IDE Final Report PMA Application Submission for IDE Final Report Submission Submission Submission Submission Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and informed access after pivotal study, protocol and plan changes, including informed access after pivotal study, protocol and plan changes, including pMA approval (protocol and informed access after pivotal study, protocol and plan changes, including pMA approval (protocol and informed access after pivotal study, protocol and plan changes, including pMA approval (protocol and informed access after pivotal study, protocol and informed access after pivotal study, protocol and informed access after pivotal study, informed access after pivotal study, protocol and informed access after pivotal study, informed access after pivotal study, protocol and informed access after pivotal study, including including informed access after pivotal study, including includin | Supplement Site Expansion Request to expand the number of sites. Annual Report Annual Report First Annual Report submitted. Supplement DMSO Stability Studies submitted regarding FDA's Sol13 Supplement Patient Count Studies Supplement Sol14 Final Report PMA Application Submission Continued Access Continued access after pivotal study, increased tantalum in Onyx. Submission Submission Supplement Supplement for 3-5 year follow-up pending PMA approval (protocol and plan changes), increased tantalum in Onyx. Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and plan changes), including informed consent). | Supplement Site Expansion Request to expand the number of sites. Annual Report Annual Report First Annual Report submitted. Supplement Studies Submitted regarding FDA's sounditional approval letter dated 12-07-01. Supplement Supplement Patient Count Submitted regarding FDA's sounditional approval letter dated 12-07-01. Supplement Patient Count Request to increase number of studies Submitted regarding FDA's sounditional approval letter dated 12-05-02 FDA Response Submitted regarding FDA's Sudies Submitted regarding FDA's Submitte | Supplement Site Expansion Request to expand the number of sites. Annual Report Annual Report First Annual Report submitted. Supplement Supplement DMSO Stability Studies Submitted regarding FDA's conditional approval letter dated 12-07-01. Supplement Patient Count Sudies Submission Continued Access protocol and plan changes, including increased tantalum in Omyx. Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). Supplement PA Response Submission Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). Submission Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). | Supplement Site Expansion Request to expand the number of sites. Supplement Site Expansion Request to expand the number of sites. Annual Report Annual Report First Annual Report submitted. Supplement Supplement DMSO Stability studies submitted regarding FDA's conditional approval letter dated 12-07-01. Supplement Patient Count Request to increase number of patients. Supplement Phient Count Soldmitssion for IDE Final Report PMA Application Submission Submission Submission Submission Submission Submission Supplement for 3-5 year follow-up pending PMA Approval (protocol and plan changes, including informed access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission Supplement for 3-5 year follow-up pending PMA Approval (protocol and informed consent). | Supplement Site Expansion Request to expand the number of sites. Supplement Soll Submitted Report Submitted. Annual Report Annual Report First Annual Report submitted. Supplement Sudies Submitted regarding FDA's conditional approval letter dated 12-07-01. Supplement Supplement Patient Count Soll4 Patients. Supplement Patient Count Request to increase number of Soll4 PMA Application Submission of IDE Final Report. Final Report PMA Application Submission for IDE Final Report. Submission Continued Access Protocol and plan changes, including increased tantalum in Onyx. Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and plan changes, including phan approval (protocol and plan changes, including phan approval (protocol and plan changes). Submission Submission Submission Submission of IDE Final Report PDA Response PDA Response Pollow-up pending PMA approval (protocol and plan changes). | Supplement Site Expansion Request to expand the number of sites. Supplement Site Expansion Request to expand the number of sites. Annual Report Annual Report First Annual Report submitted. Supplement Supplement DMSO Stability Studies submitted regarding FDA's conditional approval letter dated 12-07-01. Supplement Patient Count Request to increase number of patients. Supplement Phication Submission of IDE Final Report IDE Final Report Submission Submission Submission Submission Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and plan changes, including informed access after pivotal study, protocol and plan changes, including increased tantalum in Omyx. Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). | Supplement Site Expansion Request to expand the number of sites. Annual Report Annual Report First Annual Report submitted. Supplement Supplement DMSO Stability studies submitted regarding FDA's conditional approval letter dated 12-07-01. Supplement Supplement Patient Count S014 Patients. Final Report PMA Application Submission for IDE Final Report Final Report Submission Continued Access Protocol and plan changes, including increased tantalum in Onyx. Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and plan changes, including protocol and | Supplement Site Expansion Request to expand the number of sites. Supplement Site Expansion Request to expand the number of sites. Annual Report Annual Report First Annual Report submitted. Supplement Supplement DMSO Stability studies submitted regarding FDA's conditional approval letter dated 12-07-01. Supplement Patient Count Request to increase number of patients. Supplement Phient Count Soldmitssion for IDE Final Report PMA Application Submission Submission Submission Submission Submission Submission Supplement for 3-5 year follow-up pending PMA Approval (protocol and plan changes, including informed access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission Supplement for 3-5 year follow-up pending PMA Approval (protocol and informed consent). | Supplement Site Expansion Request to expand the number of sites. Annual Report Annual Report First Annual Report submitted. Supplement Supplement DMSO Stability Submitted regarding FDA's conditional approval letter dated 12-07-01. Supplement Supplement Patient Count Submission Submission Continued Access Increase number of Final Report Submission Supplement Potocol and plan changes, including increased tantalum in Onyx. Submission Submission Submission Submission of DE Final Report Submission Subm | Supplement Site Expansion Request to expand the number of sites. Supplement Site Expansion Request to expand the number of sites. Annual Report Annual Report First Annual Report submitted. Supplement Supplement DMSO Stability Studies submitted regarding FDA's conditional approval letter dated 12-07-01. Supplement Patient Count Request to increase number of patients. Supplement Phication Submission of IDE Final Report IDE Final Report Submission Submission Submission Submission Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and plan changes, including informed access after pivotal study, protocol and plan changes, including increased tantalum in Omyx. Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). | Supplement Site Expansion Request to expand the number of sites. Annual Report Annual Report First Annual Report submitted. Supplement Studies Submitted regarding FDA's conditional approval letter dated 12- 07-01. Supplement Patient Count Submission Continued Access Continued access after pivotal study, increased tantalum in Onyx. Submission Submission Supplement Supplement for 3-5 year follow-up pending PMA approval (protocol and pinormed consent). Supplement PA Expansion Submission Request to increase number of 12-06-02 FDA Response Submission Submission Submission Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and pinormed consent). | Supplement Site Expansion Request to expand the number of sites. Annual Report Annual Report First Annual Report submitted. Supplement Supplement DMSO Stability Suddies Sol13 Supplement DMSO Stability Submitted regarding FDA's conditional approval letter dated 12-07-01. Supplement Patient Count Request to increase number of S014 Final Report PMA Application Submission for IDE Final Report Submission Submission Submission Submission Submission Supplement Potocol and plan changes, including increased tantalum in Onyx. Submission Supplement Solpelement for 3-5 year follow-up pending PMA approval (protocol and informed consent). Submission Site Expansion Request to expand the number of submitted. No Response PDA Response Sol13 Submission Site Expansion Sol11 No Response DMSO Stability Studies Sol13 FDA Response Additional Patient Sol16 FDA Response Continued Access PDA Response Continued Access Including Informed Consent). Submission | Supplement Site Expansion Request to expand the number of sites. Annual Report Annual Report First Annual Report submitted. Supplement DMSO Stability Studies submitted regarding FDA's Sol13 Supplement Patient Count Studies Supplement Sol14 Final Report PMA Application Submission Continued Access Continued access after pivotal study, increased tantalum in Onyx. Submission Submission Supplement Supplement for 3-5 year follow-up pending PMA approval (protocol and plan changes), increased tantalum in Onyx. Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and plan changes), including informed consent). | Supplement Site Expansion Request to expand the number of sites. Annual Report Annual Report First Annual Report submitted. Supplement Studies Submitted regarding FDA's conditional approval letter dated 12- 07-01. Supplement Patient Count Submission Continued Access Continued access after pivotal study, increased tantalum in Onyx. Submission Submission Supplement Supplement for 3-5 year follow-up pending PMA approval (protocol and pinormed consent). Supplement PA Expansion Submission Request to increase number of 12-06-02 FDA Response Submission Submission Submission Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and pinormed consent). | Supplement Site Expansion Request to expand the number of sites. Annual Report Annual Report First Annual Report submitted. Supplement Studies Submitted regarding FDA's conditional approval letter dated 12- 07-01. Supplement Patient Count Submission Continued Access Continued access after pivotal study, increased tantalum in Onyx. Submission Submission Supplement Supplement for 3-5 year follow-up pending PMA approval (protocol and pinormed consent). Supplement PA Expansion Submission Request to increase number of 12-06-02 FDA Response Submission Submission Submission Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and pinormed consent). | Supplement Site Expansion Request to expand the number of sites. 02-06-02 FDA Response S011 Annual Report Annual Report First Annual Report submitted. No Response Supplement DMSO Stability Studies submitted regarding FDA's submitted regarding FDA's submitted regarding FDA's S013 Supplement Patient Count Request to increase number of Supplement S014 Final Report PMA Application Submission for IDE Final Report Submission Continued Access PMA Application Increased tantalum in Onlyx. Submission Supplement of 3-5 year Follow-up pending PMA approval (protocol and informed consent). Supplement Site Expansion Site Expansion of Expansion Submission Request to expand the number of soll-15-02 FDA Response Studies Studies Submission Submission for IDE Final Report Soll-6-02 FDA Response Continued Access Increased tantalum in Onlyx. Submission S-5 year Follow-up pending PMA approval (protocol and informed consent). | Supplement Site Expansion Request to expand the number of sites. Annual Report Annual Report First Annual Report submitted. Supplement Studies Submitted regarding FDA's conditional approval letter dated 12- 07-01. Supplement Patient Count Submission Continued Access Continued access after pivotal study, increased tantalum in Onyx. Submission Submission Supplement Supplement for 3-5 year follow-up pending PMA approval (protocol and pinormed consent). Supplement PA Expansion Submission Request to increase number of 12-06-02 FDA Response Submission Submission Submission Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and pinormed consent). | Supplement Site Expansion Request to expand the number of sites. Annual Report Annual Report First Annual Report submitted. Supplement DMSO Stability Studies submitted regarding FDA's Submitted regarding FDA's conditional approval letter dated 12-07-01. Supplement Supplement Patient Count Request to increase number of Studies Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased datalum in Onyx. Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). Supplement PA Annual Report Site Expansion Site Expansion Solid Patient Solid Stability Studies Solid PA Response Solid Enrollment Solid Submission Submission for IDE Final Report PMA approval (protocol and informed consent). | Supplement Site Expansion Request to expand the number of sites. Annual Report Annual Report First Annual Report submitted. Supplement DMSO Stability Studies submitted regarding FDA's Sol13 Supplement Patient Count Studies Supplement Sol14 Final Report PMA Application Submission Continued Access Continued access after pivotal study, increased tantalum in Onyx. Submission Submission Supplement Supplement for 3-5 year follow-up pending PMA approval (protocol and plan changes), increased tantalum in Onyx. Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and plan changes), including informed consent). | Supplement Site Expansion Request to expand the number of sites. Annual Report Annual Report First Annual Report submitted. Supplement DMSO Stability Studies submitted regarding FDA's Submitted regarding FDA's Conditional approval letter dated 12-07-01. Supplement Supplement Patient Count Request to increase number of Submission PMA Application Submission for IDE Final Report PMA Application Submission Final Report Submission Submission Submission Submission Submission Supplement of 3-5 year follow-up pending PMA approval (protocol and protocol and informed consent). Supplement Patient Count Request to increase number of 12-06-02 FDA Response Subditional Patient S014 Final Report PMA Application Submission for IDE Final Report Patient Goding PMA approval (protocol and linformed consent). Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). | Supplement Site Expansion Request to expand the number of sites. Annual Report Annual Report First Annual Report submitted. Supplement DMSO Stability Studies submitted regarding FDA's Sol13 Supplement Patient Count Studies Supplement Sol14 Final Report PMA Application Submission Continued Access Continued access after pivotal study, increased tantalum in Onyx. Submission Submission Supplement Supplement for 3-5 year follow-up pending PMA approval (protocol and plan changes), increased tantalum in Onyx. Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and plan changes), including informed consent). | Supplement Site Expansion Request to expand the number of sites. Annual Report Annual Report First Annual Report submitted. Supplement DMSO Stability Studies submitted regarding FDA's Submitted regarding FDA's conditional approval letter dated 12-07-01. Supplement Supplement Patient Count Request to increase number of Studies Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased datalum in Onyx. Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). Supplement PA Annual Report Site Expansion Site Expansion Solid Patient Solid Stability Studies Solid PA Response Solid Enrollment Solid Submission Submission for IDE Final Report PMA approval (protocol and informed consent). | Supplement Site Expansion Request to expand the number of sites. Annual Report Annual Report First Annual Report submitted. Supplement DMSO Stability Studies submitted regarding FDA's Submitted regarding FDA's conditional approval letter dated 12-07-01. Supplement Supplement Patient Count Request to increase number of Studies Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased datalum in Onyx. Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). Supplement PA Annual Report Site Expansion Site Expansion Solid Patient Solid Stability Studies Solid PA Response Solid Enrollment Solid Submission Submission for IDE Final Report PMA approval (protocol and informed consent). | Supplement Site Expansion Request to expand the number of sites. Annual Report Annual Report First Annual Report submitted. Supplement Supplement DMSO Stability Suddies submitted regarding FDA's Soll3 Supplement Patient Count Request to increase number of Soll4 Final Report PMA Application Submission for IDE Final Report Submission Submission Submission Submission Submission Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and Informed consent). Supplement Site Expansion Request to expand the number of soll Annual Report Submission Submission First Annual Report Submission First Annual Report Submission for IDE Final Report Submission Submission Submission Submission Final Report Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). Submission Site Expansion Soll Expansion Submission for IDE Final Report Soll FDA Response Continued Access PMA approval (protocol and informed consent). | Supplement Site Expansion Request to expand the number of sites. Annual Report Annual Report First Annual Report submitted. Supplement DMSO Stability Suddies submitted regarding FDA's Sol13 Supplement Patient Count Submitted regarding FDA's Sol14 Supplement Patient Count Request to increase number of Sol14 Final Report PMA Application Submission for IDE Final Report Submission Submission Submission Submission Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). Supplement Site Expansion Request to expand the number of sol14 First Annual Report Submitted. No Response Sol13 S-15-02 FDA Response Sol13 Submission Submission for IDE Final Report Sol16 Enrollment Sol16 Enrollment Sol16 FDA Response Continued Access after privotal study, protocol and informed consent). Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). | Supplement Site Expansion Request to expand the number of sites. Annual Report Annual Report First Annual Report submitted. Supplement DMSO Stability Suddies submitted regarding FDA's Sol13 Supplement Patient Count Submitted regarding FDA's Sol14 Supplement Patient Count Request to increase number of Sol14 Final Report PMA Application Submission for IDE Final Report Submission Submission Submission Submission Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). Supplement Site Expansion Request to expand the number of sol14 First Annual Report Submitted. No Response Sol13 S-15-02 FDA Response Sol13 Submission Submission for IDE Final Report Sol16 Enrollment Sol16 Enrollment Sol16 FDA Response Continued Access after privotal study, protocol and informed consent). Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). | Supplement Site Expansion Request to expand the number of sites. Annual Report Annual Report First Annual Report submitted. Supplement DMSO Stability Suddies submitted regarding FDA's Sol13 Supplement Patient Count Submitted regarding FDA's Sol14 Supplement Patient Count Request to increase number of Sol14 Final Report PMA Application Submission for IDE Final Report Submission Submission Submission Submission Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). Supplement Site Expansion Request to expand the number of sol14 First Annual Report Submitted. No Response Sol13 S-15-02 FDA Response Sol13 Submission Submission for IDE Final Report Sol16 Enrollment Sol16 Enrollment Sol16 FDA Response Continued Access after privotal study, protocol and informed consent). Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). |
| Supplement Site Expansion Request to expand the number of sites. 02-06-02 FDA Response Site Expansion S011 Annual Report Annual Report First Annual Report submitted. No Response Supplement Studies Supplement Studies Submitted regarding FDA's submitted regarding FDA's S013 Supplement Supplement Patient Count Patients. Request to increase number of S014 Final Report PMA Application Submission for IDE Final Report Submission Continued Access Protocol and plan changes, including increased tantalum in Onyx. Submission Submission Supplement for 3-5 year follow-up Continued Access Supplement for 3-5 year follow-up Continued Supplement for 3-5 year follow-up Continued Submission Submissio | Supplement Site Expansion Request to expand the number of sites. 02-06-02 FDA Response Site Expansion S011 Annual Report Annual Report First Annual Report submitted. No Response S011 Supplement Studies S013 DMSO aging/stability studies submitted regarding FDA's sonditional approval letter dated 12-07-01. Supplement Supplement Patient Count Request to increase number of S014 FDA Response PMA Application Submission for IDE Final Report PMA Application Submission for IDE Final Report PMA Application Submission for IDE Final Report PMA Application Submission Final Report Submission Continued access after privotal study, protocol and plan changes, including increased tandalum in Onyx. Submission S-5 year Follow-up pending PMA approval (protocol and D-20-04 FDA Response S-5 year Follow-up pending PMA approval (protocol and D-20-04 FDA Response S-5 year Follow-up pending PMA approval (protocol and D-20-04 FDA Response S-5 year Follow-up pending PMA approval (protocol and D-20-04 FDA Response S-5 year Follow-up pending PMA approval (protocol and D-20-04 FDA Response S-5 year Follow-up pending PMA approval (protocol and D-20-04 FDA Response S-5 year Follow-up pending PMA approval (protocol and D-20-04 FDA Response S-5 year Follow-up pending PMA approval (protocol and D-20-04 FDA Response S-5 year Follow-up pending PMA approval (protocol and D-20-04 FDA Response S-5 year Follow-up pending PMA approval (protocol and D-20-04 FDA Response S-5 year Follow-up pending PMA approval (protocol and D-20-04 FDA Response S-5 year Follow-up pending PMA approval (protocol and D-20-04 FDA Response S-5 year Follow-up pending PMA approval (protocol and D-20-04 FDA Response S-15-02 FD | Supplement Site Expansion Request to expand the number of sites. 02-06-02 FDA Response Site Expansion S011 Annual Report Annual Report First Annual Report submitted. No Response Supplement DMSO Stability Suddies Sol13 Studies Sol13 Studies Sol13 Studies Sol13 Studies Sol14 Patient Count Request to increase number of S014 Patient Sol4 PhMA Application Submission Continued Access Protocol and plan changes, including increased tantalum in Onyx. Submission Submission S-5 year Follow-up pending PMA Approval (protocol and plan changes, including phan chang | Supplement Site Expansion Request to expand the number of sites. 02-06-02 FDA Response S011 Annual Report Annual Report First Annual Report submitted. No Response Supplement DMSO Stability Submitted regarding FDA's conditional approval letter dated 12- 07-01. Supplement Supplement Patient Count S014 Request to increase number of Einal Report PMA Application Submission of IDE Final Report PMA Application Submission for IDE Final Report Einal Report Submission Submission Submission Supplement for 3-5 year Follow-up Pending PMA approval (protocol and Informed consent). Submission Site Expansion Request to expand the number of sites. 02-06-02 FDA Response Studies Submission Studies Submission for IDE Final Report Submission Submission for IDE Final Report Submission Submission Submission for IDE Final Report Increased danglum in Onlyx. Submission Submission Submission Submission for Syear Follow-up Pending PMA approval (protocol and Informed consent). | Supplement Site Expansion Request to expand the number of sites. 02-06-02 FDA Response S011 Annual Report Annual Report First Annual Report submitted. No Response Supplement DMSO Stability Submitted regarding FDA's conditional approval letter dated 12-07-01. Supplement Patient Count Request to increase number of S014 PMA Application Submission Final Report PMA Application Submission Final Report PMA Application Submission for IDE Final Report PMA Application Submission Final Report PMA Application Submission Final Report Submission S-5 year Follow-up pending PMA approval (protocol and plan changes, including increased tantalum in Onyx. Submission S-5 year Follow-up Supplement for 3-5 year follow-up pending PMA approval (protocol and plan changes). | Supplement Site Expansion Request to expand the number of sites. 02-06-02 FDA Response Site Expansion S011 Annual Report Annual Report First Annual Report submitted. No Response Supplement DMSO Stability Studies S013 Supplement DMSO Stability Studies Submitted regarding FDA's conditional approval letter dated 12- 07-01. Supplement S014 Final Report PMA Application Submission for IDE Final Report Submission Submission Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). Submission Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). Submission Site Expansion Request to expand the number of sites. 02-06-02 FDA Response Submission Submission Submission for IDE Final Report Submission Subm | Supplement Site Expansion Request to expand the number of sites. 02-06-02 FDA Response Site Expansion S011 Annual Report Annual Report First Annual Report submitted. No Response Supplement DMSO Stability studies submitted regarding FDA's conditional approval letter dated 12- 07-01. Supplement Supplement Patient Count S014 Patients. Request to increase number of patients. Supplement PMA Application Submission for IDE Final Report 12-06-02 FDA Response Submission Submission Submission Submission Submission Submission Submission Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). Submission Site Expansion Request to expand the number of soll-02 FDA Response Submission Stability Studies Submission Submi | Supplement Site Expansion Request to expand the number of sites. 02-06-02 FDA Response Site Expansion S011 Annual Report Annual Report First Annual Report submitted. No Response Supplement DMSO Stability Studies submitted regarding FDA's conditional approval letter dated 12-07-01. Supplement Supplement Patient Count S014 Patient Count S014 Patients. Request to increase number of S014 PMA Application Submission of IDE Final Report Submission Submission Submission Submission Continued Access Protocol and plan changes, including increased tantalum in Onyx. Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and plan changes, including photocol and phot | Supplement Site Expansion Request to expand the number of sites. 02-06-02 FDA Response Site Expansion S011 Annual Report Annual Report First Annual Report submitted. No Response Supplement DMSO Stability studies submitted regarding FDA's sudmitted regarding FDA's conditional approval letter dated 12- 07-01. Supplement Supplement Patient Count S014 Patients. Request to increase number of patients. Supplement PMA Application Submission for IDE Final Report Submission Submission Submission Submission Submission Supplement for 3-5 year follow-up pending PMA Approval (protocol and plan changes, including increased tantalum in Onyx. Submission Supplement Site Expansion Request to expand the number of soll Response Site Expansion Submission Site Expansion Submission Site Expansion Submitted Report Studies Soll3 Submission Submi | Supplement Site Expansion Request to expand the number of sites. 02-06-02 FDA Response Site Expansion S011 Annual Report Annual Report First Annual Report submitted. No Response Supplement DMSO Stability Sudies Sol13 Sudies Sol13 Studies Submitted regarding FDA's conditional approval letter dated 12- 07-01. Supplement Patient Count Patients. Request to increase number of S014 PMA Application Submission Continued Access protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and plan changes, including protocol and plan chang | Supplement Site Expansion Request to expand the number of sites. 02-06-02 FDA Response Site Expansion S011 Annual Report Annual Report First Annual Report submitted. No Response Supplement DMSO Stability studies submitted regarding FDA's conditional approval letter dated 12- 07-01. Supplement Supplement Patient Count S014 Patients. Request to increase number of patients. Supplement PMA Application Submission for IDE Final Report 12-06-02 FDA Response Submission Submission Submission Submission Submission Submission Submission Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). Submission Site Expansion Request to expand the number of soll-02 FDA Response Submission Stability Studies Submission Submi | Supplement Site Expansion Request to expand the number of sites. 02-06-02 FDA Response Sol11 Annual Report Annual Report First Annual Report submitted. No Response Sol11 Supplement DMSO Stability studies submitted regarding FDA's conditional approval letter dated 12- 07-01. Supplement Sol13 Supplement Patient Count Request to increase number of patients. Supplement Sol14 Final Report PMA Application Submission for IDE Final Report Sol16 Submission Continued Access Continued access after privotal study, protocol and plan changes, including increased tantalum in Onyx. Submission Supplement Sol16 Submission Supplement Sol16 Submission Submission Goulding increased tantalum in Conyx. Submission Supplement Sol16 Submission Supplement Sol16 Submission Submission Goulding increased tantalum in Conyx. Submission Submission Goulding informed consent). | Supplement Site Expansion Request to expand the number of sites. 02-06-02 FDA Response Site Expansion S011 Annual Report Annual Report First Annual Report submitted. No Response Supplement DMSO Stability studies submitted regarding FDA's sudmitted regarding FDA's conditional approval letter dated 12- 07-01. Supplement Supplement Patient Count S014 Patients. Request to increase number of patients. Supplement PMA Application Submission for IDE Final Report Submission Submission Submission Submission Submission Supplement for 3-5 year follow-up pending PMA Approval (protocol and plan changes, including increased tantalum in Onyx. Submission Supplement Site Expansion Request to expand the number of soll Response Site Expansion Submission Site Expansion Submission Site Expansion Submitted Report Studies Soll3 Submission Submi | Supplement Site Expansion Request to expand the number of sites. 02-06-02 FDA Response Sol11 Annual Report Annual Report First Annual Report submitted. No Response Supplement DMSO Stability Suddies Sol13 Supplement DMSO Stability Studies Submitted regarding FDA's submitted regarding FDA's submitted regarding FDA's Sol13 Supplement Patient Count Request to increase number of Sol14 Final Report PMA Application Submission for IDE Final Report Submission Submission Submission Submission Final Report Submission Submission Submission Supplement for 3-5 year Follow-up pending PMA approval (protocol and plan changes, including Informed consent). Submission Sol74 Supplement Patient Count Patient Sol75 Submission Submission Submission for IDE Final Report Submission Submiss | Supplement Site Expansion Request to expand the number of sites. 02-06-02 FDA Response Sol11 Annual Report Annual Report First Annual Report submitted. No Response Sol11 Supplement DMSO Stability Studies submitted regarding FDA's sounditional approval letter dated 12-07-01. Supplement Sol14 Supplement Patient Count Request to increase number of patients. Supplement Sol15 Submission Continued Access Continued access after privotal study, protocol and plan changes, including increased tantalum in Onyx. Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and plan changes, including informed consent). | Supplement Site Expansion Request to expand the number of sites. 02-06-02 FDA Response S011 Annual Report Annual Report First Annual Report submitted. No Response Supplement DMSO Stability Submitted regarding FDA's conditional approval letter dated 12- 07-01. Supplement Supplement Patient Count S014 Request to increase number of Einal Report PMA Application Submission of IDE Final Report PMA Application Submission for IDE Final Report Einal Report Submission Submission Submission Supplement for 3-5 year Follow-up Pending PMA approval (protocol and Informed consent). Submission Site Expansion Request to expand the number of sites. 02-06-02 FDA Response Studies Submission Studies Submission for IDE Final Report Submission Submission for IDE Final Report Submission Submission Submission for IDE Final Report Increased danglum in Onlyx. Submission Submission Submission Submission for Syear Follow-up Pending PMA approval (protocol and Informed consent). | Supplement Site Expansion Request to expand the number of sites. 02-06-02 FDA Response Sol11 Annual Report Annual Report First Annual Report submitted. No Response Supplement DMSO Stability Suddies Sol13 Supplement DMSO Stability Studies Submitted regarding FDA's submitted regarding FDA's submitted regarding FDA's Sol13 Supplement Patient Count Request to increase number of Sol14 Final Report PMA Application Submission for IDE Final Report Submission Submission Submission Submission Final Report Submission Submission Submission Supplement for 3-5 year Follow-up pending PMA approval (protocol and plan changes, including Informed consent). Submission Sol74 Supplement Patient Count Patient Sol75 Submission Submission Submission for IDE Final Report Submission Submiss | Supplement Site Expansion Request to expand the number of sites. 02-06-02 FDA Response Sol11 Annual Report Annual Report First Annual Report submitted. No Response Supplement DMSO Stability Suddies Sol13 Supplement DMSO Stability Studies Submitted regarding FDA's submitted regarding FDA's submitted regarding FDA's Sol13 Supplement Patient Count Request to increase number of Sol14 Final Report PMA Application Submission for IDE Final Report Submission Submission Submission Submission Final Report Submission Submission Submission Supplement for 3-5 year Follow-up pending PMA approval (protocol and plan changes, including Informed consent). Submission Sol74 Supplement Patient Count Patient Sol75 Submission Submission Submission for IDE Final Report Submission Submiss | Supplement Site Expansion Request to expand the number of sites. 02-06-02 FDA Response Sol11 Annual Report Annual Report First Annual Report submitted. No Response Sol11 Supplement DMSO Stability Studies submitted regarding FDA's submitted regarding FDA's submitted regarding FDA's submitted regarding FDA's sounditional approval letter dated 12- 07-01. Supplement Sol14 Supplement Patient Count Request to increase number of 12-06-02 FDA Response Studies Sol14 Final Report PMA Application Submission for IDE Final Report Submission Submission Submission of IDE Final Report PMA approval protocol and plan changes, including increased tantalum in Omyx. Submission Supplement for 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Supplement Site Expansion Request to expand the number of sites. 02-06-02 FDA Response Sol11 Annual Report Annual Report First Annual Report submitted. No Response Supplement DMSO Stability Suddies Sol13 Supplement DMSO Stability Studies Submitted regarding FDA's submitted regarding FDA's submitted regarding FDA's Sol13 Supplement Patient Count Request to increase number of Sol14 Final Report PMA Application Submission for IDE Final Report Submission Submission Submission Submission Final Report Submission Submission Submission Supplement for 3-5 year Follow-up pending PMA approval (protocol and plan changes, including Informed consent). Submission Sol74 Supplement Patient Count Patient Sol75 Submission Submission Submission for IDE Final Report Submission Submiss | Supplement Site Expansion Request to expand the number of sites. 02-06-02 FDA Response S011 Annual Report Annual Report First Annual Report submitted. No Response Supplement DMSO Stability Submitted regarding FDA's conditional approval letter dated 12- 07-01. Supplement Supplement Patient Count Sol14 Final Report PMA Application Submission of IDE Final Report. Submission Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Supplement Final Report PMA approval (protocol and informed consent). | Supplement Site Expansion Request to expand the number of sites. 02-06-02 FDA Response S011 Annual Report Annual Report First Annual Report submitted. No Response Supplement DMSO Stability Submitted regarding FDA's conditional approval letter dated 12- 07-01. Supplement Supplement Patient Count S014 Request to increase number of Einal Report PMA Application Submission of IDE Final Report PMA Application Submission for IDE Final Report Einal Report Submission Submission Submission Supplement for 3-5 year Follow-up Pending PMA approval (protocol and Informed consent). Submission Site Expansion Request to expand the number of sites. 02-06-02 FDA Response Studies Submission Studies Submission for IDE Final Report Submission Submission for IDE Final Report Submission Submission Submission for IDE Final Report Increased danglum in Onlyx. Submission Submission Submission Submission for Syear Follow-up pending PMA approval (protocol and Informed consent). | Supplement Site Expansion Request to expand the number of sites. 02-06-02 FDA Response S011 Annual Report Annual Report First Annual Report submitted. No Response Supplement DMSO Stability Submitted regarding FDA's conditional approval letter dated 12- 07-01. Supplement Supplement Patient Count S014 Patients. Continued Access after pivotal study, protocol and plan changes, including increased tantalum in Onlyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Supplement Site Expansion Request to expand the number of sites. 02-06-02 FDA Response S011 Annual Report Annual Report First Annual Report submitted. No Response Supplement DMSO Stability Submitted regarding FDA's conditional approval letter dated 12- 07-01. Supplement Supplement Patient Count S014 Request to increase number of Einal Report PMA Application Submission of IDE Final Report PMA Application Submission for IDE Final Report Einal Report Submission Submission Submission Supplement for 3-5 year Follow-up Pending PMA approval (protocol and Informed consent). Submission Site Expansion Request to expand the number of sites. 02-06-02 FDA Response Studies Submission Studies Submission for IDE Final Report Submission Submission for IDE Final Report Submission Submission Submission for IDE Final Report Increased danglum in Onlyx. Submission Submission Submission Submission for Syear Follow-up pending PMA approval (protocol and Informed consent). | Supplement Site Expansion Request to expand the number of sites. 02-06-02 FDA Response S011 Annual Report Annual Report First Annual Report submitted. No Response Supplement DMSO Stability Submitted regarding FDA's conditional approval letter dated 12- 07-01. Supplement Supplement Patient Count Sol14 Final Report PMA Application Submission of IDE Final Report. Submission Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Supplement Final Report PMA approval (protocol and informed consent). | Supplement Site Expansion Request to expand the number of sites. 02-06-02 FDA Response S011 Annual Report Annual Report First Annual Report submitted. No Response Supplement DMSO Stability Submitted regarding FDA's conditional approval letter dated 12- 07-01. Supplement Supplement Patient Count Sol14 Final Report PMA Application Submission of IDE Final Report. Submission Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Supplement Final Report PMA approval (protocol and informed consent). | Supplement Site Expansion Request to expand the number of sites. 02-06-02 FDA Response S011 Annual Report Annual Report First Annual Report submitted. No Response Supplement DMSO Stability Submitted regarding FDA's conditional approval letter dated 12- 07-01. Supplement Supplement Patient Count Patients. Submission Continued Access after pivotal study, increase datablum fornys, including informed consent). Submission Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Supplement Site Expansion Request to expand the number of sites. 02-06-02 FDA Response Sol11 Annual Report Annual Report First Annual Report submitted. No Response Supplement DMSO Stability Studies Sol13 Supplement DMSO Stability Submitted regarding FDA's submitted regarding FDA's submitted regarding FDA's Sol13 Supplement Patient Count Patients. 3-15-02 FDA Response Sol13 Supplement Patient Count Sol14 Final Report PMA Application Submission for IDE Final Report. Submission Continued Access Pmotocol and plan changes, including increased tantalum in Onnyx. Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). Submission Sol Stability Studies Sol13 Sol Stability Sol13 Sol Stability Sol13 Sol A Response Sol13 Sol Stability Sol13 Sol A Response Sol Stability Studies Sol13 Sol A Response Continued Access Including Informact Count Including Sol Stability Sol Stab | Supplement Site Expansion Request to expand the number of sites. 02-06-02 FDA Response Sol11 Annual Report Annual Report First Annual Report submitted. No Response Supplement DMSO Stability Studies Sol13 Supplement DMSO Stability Submitted regarding FDA's submitted regarding FDA's submitted regarding FDA's Sol13 Supplement Patient Count Patients. 3-15-02 FDA Response Sol13 Supplement Patient Count Sol14 Final Report PMA Application Submission for IDE Final Report. Submission Continued Access Pmotocol and plan changes, including increased tantalum in Onnyx. Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). Submission Sol Stability Studies Sol13 Sol Stability Sol13 Sol Stability Sol13 Sol A Response Sol13 Sol Stability Sol13 Sol A Response Sol Stability Studies Sol13 Sol A Response Continued Access Including Informact Count Including Sol Stability Sol Stab | Supplement Site Expansion Request to expand the number of sites. 02-06-02 FDA Response Sol11 Annual Report Annual Report First Annual Report submitted. No Response Supplement DMSO Stability Studies Sol13 Supplement DMSO Stability Submitted regarding FDA's submitted regarding FDA's submitted regarding FDA's Sol13 Supplement Patient Count Patients. 3-15-02 FDA Response Sol13 Supplement Patient Count Sol14 Final Report PMA Application Submission for IDE Final Report. Submission Continued Access Pmotocol and plan changes, including increased tantalum in Onnyx. Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). Submission Sol Stability Studies Sol13 Sol Stability Sol13 Sol Stability Sol13 Sol A Response Sol13 Sol Stability Sol13 Sol A Response Sol Stability Studies Sol13 Sol A Response Continued Access Including Informact Count Including Sol Stability Sol Stab |
| Annual Report Annual Report First Annual Report submitted. Supplement Studies conditional approval letter dated 12- Supplement Supplement Patient Count Sol14 Supplement Patient Count Request to increase number of Sol14 Final Report PMA Application Submission Final Report Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onlyx. Submission 3-5 year Follow-up Supplement for 3-5 year follow-up Submission 3-5 year Follow-up Submission Sol14 Submission Submission Submission Graces Submission Submi | Annual Report Annual Report First Annual Report submitted. No Response Supplement Submitted regarding FDA's conditional approval letter dated 12- | Annual Report Annual Report First Annual Report submitted. No Response Supplement Studies Sol13 DMSO stability studies submitted regarding FDA's conditional approval letter dated 12- Supplement Sol4 Patient Count Patients. Request to increase number of Sol13 Submission Continued Access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and protocol | Annual Report Annual Report First Annual Report submitted. Supplement Supplement DMSO Stability Studies submitted regarding FDA's conditional approval letter dated 12- 07-01. Supplement Patient Count patients. Supplement Patient Count patients. Supplement Polication Submission for IDE Final Report. Final Report PMA Application Submission for IDE Final Report. Submission Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). | Annual Report Annual Report First Annual Report submitted. No Response Supplement Supplement Studies Sol13 Supplement Patient Count Sol4 Final Report PMA Application Submission Continued Access protocol and plan changes, including increased tantalum in Onyx. Submission Submission Supplement Supplement for 3-5 year Follow-up pending PMA approval (protocol and protocol and prot | Annual Report Annual Report First Annual Report submitted. No Response Supplement DMSO Stability DMSO aging/stability studies submitted regarding FDA's conditional approval letter dated 12- 07-01. Supplement Patient Count Submission of rIDE Final Report PMA Application Submission of patients. Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission Supplement for 3-5 year follow-up pending PMA Approval (protocol and informed consent). | Annual Report Annual Report First Annual Report submitted. Supplement DMSO Stability studies submitted regarding FDA's conditional approval letter dated 12- 07-01. Supplement Supplement Patient Count patients. Supplement Patient Count Patients. Supplement Patient Count Patients. Supplement Sol14 PMA Application Submission for IDE Final Report. Final Report PMA Application Submission for IDE Final Report. Submission Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). Submission Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). | Annual Report Annual Report First Annual Report submitted. Supplement Sudies Submitted regarding FDA's conditional approval letter dated 12- 07-01. Supplement Sudies Submission Continued Access PMA Application Submission Submission 3-5 year Follow-up Enternations of Supplement for 3-5 year follow-up profession Supplement of Supplement Supplement of Supplement of Supplement for 3-5 year follow-up profession Supplement Supplement for 3-5 year follow-up profession Sup | Annual Report Annual Report First Annual Report submitted. No Response Supplement DMSO Stability DMSO aging/stability studies submitted regarding FDA's conditional approval letter dated 12- 07-01. Supplement Patient Count Patients. Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission Supplement to 3-5 year follow-up pending PMA approval (protocol and informed consent). | Annual Report Annual Report First Annual Report submitted. Supplement Sudies Submitted regarding FDA's conditional approval letter dated 12- Supplement Sol13 Supplement Patient Count Request to increase number of Sudies Sol13 Supplement Patient Count Request to increase number of Patients. Supplement Patient Count Patients. Supplement Patient Count Patients. Supplement Poliourup patients. Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increase tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and protocol | Annual Report Annual Report First Annual Report submitted. Supplement DMSO Stability studies submitted regarding FDA's conditional approval letter dated 12- 07-01. Supplement Supplement Patient Count patients. Supplement Patient Count Patients. Supplement Patient Count Patients. Supplement Sol14 PMA Application Submission for IDE Final Report. Final Report PMA Application Submission for IDE Final Report. Submission Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). Submission Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). | Annual Report Annual Report First Annual Report submitted. Supplement Supplement Sudies Submitted regarding FDA's conditional approval letter dated 12- 07-01. Supplement Supplement Patient Count patients. Supplement Patient Count patients. Supplement Sol14 PMA Application Submission for IDE Final Report. Final Report PMA Application Submission for IDE Final Report. Submission Submission Submission Submission Submission Supplement for 3-5 year Follow-up pending PMA approval (protocol and plan changes, including increased tanalum in Omyx. Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). | Annual Report Annual Report First Annual Report submitted. No Response Supplement DMSO Stability DMSO aging/stability studies submitted regarding FDA's conditional approval letter dated 12- 07-01. Supplement Patient Count Patients. Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission Supplement to 3-5 year follow-up pending PMA approval (protocol and informed consent). | Annual Report Annual Report First Annual Report submitted. Supplement Supplement DMSO Stability Studies submitted regarding FDA's conditional approval letter dated 12- 07-01. Supplement Patient Count patients. Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Annual Report Annual Report First Annual Report submitted. Supplement DMSO Stability studies submitted regarding FDA's conditional approval letter dated 12- 07-01. Supplement Supplement Patient Count patients. Submission Submission of IDE Final Report. Submission Submission Submission for IDE Final Report. Submission Submission Submission Submission for IDE Final Report. Submission Sub | Annual Report Annual Report First Annual Report submitted. Supplement Supplement DMSO Stability Studies submitted regarding FDA's conditional approval letter dated 12- 07-01. Supplement Patient Count patients. Supplement Patient Count patients. Supplement Polication Submission for IDE Final Report. Final Report PMA Application Submission for IDE Final Report. Submission Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). | Annual Report Annual Report First Annual Report submitted. Supplement Supplement DMSO Stability Studies submitted regarding FDA's conditional approval letter dated 12- 07-01. Supplement Patient Count patients. Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Annual Report Annual Report First Annual Report submitted. Supplement Supplement DMSO Stability Studies submitted regarding FDA's conditional approval letter dated 12- 07-01. Supplement Patient Count patients. Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Annual Report Annual Report First Annual Report submitted. No Response Supplement DMSO Stability Studies submitted regarding FDA's conditional approval letter dated 12- 07-01. Supplement Supplement Patient Count patients. Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tanalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Annual Report Annual Report First Annual Report submitted. Supplement Supplement DMSO Stability Studies submitted regarding FDA's conditional approval letter dated 12- 07-01. Supplement Patient Count patients. Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Annual Report Annual Report First Annual Report submitted. Supplement Supplement Sudices Sol13 Supplement Patient Count Patients. Supplement Patient Count Patients. Supplement Submission Continued Access PMA Application Submission of IDE Final Report Epinal Report PMA Approval (protocol and informed consent). Submission Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Submission Submission Submission Submission PMA approval (protocol and informed consent). Submission Sub | Annual Report Annual Report First Annual Report submitted. Supplement Supplement DMSO Stability Studies submitted regarding FDA's conditional approval letter dated 12- 07-01. Supplement Patient Count patients. Supplement Patient Count patients. Supplement Polication Submission for IDE Final Report. Final Report PMA Application Submission for IDE Final Report. Submission Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). | Annual Report Annual Report First Annual Report submitted. Supplement Supplement Sudices Sol13 Supplement Patient Count Patients. Supplement Patient Count Patients. Supplement Submission Continued Access PMA Application Submission of IDE Final Report Pmal Report Pma | Annual Report Annual Report First Annual Report submitted. Supplement Supplement DMSO Stability Studies submitted regarding FDA's conditional approval letter dated 12- 07-01. Supplement Patient Count patients. Supplement Patient Count patients. Supplement Polication Submission for IDE Final Report. Final Report PMA Application Submission for IDE Final Report. Submission Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). | Annual Report Annual Report First Annual Report submitted. Supplement Supplement Sudices Sol13 Supplement Patient Count Patients. Supplement Patient Count Patients. Supplement Submission Continued Access PMA Application Submission of IDE Final Report Epinal Report PMA Approval (protocol and informed consent). Submission Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Submission Submission Submission Submission PMA approval (protocol and informed consent). Submission Sub | Annual Report Annual Report First Annual Report submitted. Supplement Supplement Sudices Sol13 Supplement Patient Count Patients. Supplement Patient Count Patients. Supplement Submission Continued Access PMA Application Submission of IDE Final Report Epinal Report PMA Approval (protocol and informed consent). Submission Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Submission Submission Submission Submission PMA approval (protocol and informed consent). Submission Sub | Annual Report Annual Report First Annual Report submitted. No Response Supplement Supplement Sudices Sol13 DMSO stability Studies Conditional approval letter dated 12-Supplement Patient Count patients. Supplement Patient Count Patients. Submission Continued Access PMA Application Submission of IDE Final Report PMA Approval (protocol and informed consent). Supplement for 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Annual Report Annual Report First Annual Report submitted. No Response Supplement DMSO Stability studies conditional approval letter dated 12- 07-01. Supplement Patient Count Patients. Submission Continued Access PMA Application Submission Occidental Protocol and informed consent). Supplement of DMSO Stability studies solutions approval letter dated 12- 07-01. Submission Submission Continued Access PMA Application Submission of IDE Final Report PMA approval (protocol and informed consent). Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). | Annual Report Annual Report First Annual Report submitted. No Response Supplement DMSO Stability studies conditional approval letter dated 12- 07-01. Supplement Patient Count Patients. Submission Continued Access PMA Application Submission Occidental Protocol and informed consent). Supplement of DMSO Stability studies solutions approval letter dated 12- 07-01. Submission Submission Continued Access PMA Application Submission of IDE Final Report PMA approval (protocol and informed consent). Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). | Annual Report Annual Report First Annual Report submitted. No Response Supplement DMSO Stability studies conditional approval letter dated 12- 07-01. Supplement Patient Count Patients. Submission Continued Access PMA Application Submission Occidental Protocol and informed consent). Supplement of DMSO Stability studies solutions approval letter dated 12- 07-01. Submission Submission Continued Access PMA Application Submission of IDE Final Report PMA approval (protocol and informed consent). Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). |
| Supplement Studies Supplement Studies Supplement Sudies Supplement Sudies Supplement Sol Studies Submitted regarding FDA's Submitted FDA Response Continued Access protocol and plan changes, including increased tandalum in Comyx. Submitted regarding FDA's Submitted Incorporated FDA Response Submitted FDA Response Submitted Access Submitted FDA Response Submitted Access Submitted FDA Response Submitted. Submitted Report FDA Response Submitted FDA Response Submitte | Supplement Studies Supplement Studies Supplement Supplement Sol Patient Sol Patient Sol Patient Sol Patient Patient Patient Patient Patient Sol Patien | Supplement Studies DMSO Stability DMSO aging/stability studies submitted regarding FDA's submitted. No Response DMSO Stability Stability studies 3-15-02 FDA Response Enrollment Sol13 Submitted regarding FDA's submitted regar | Supplement Studies DMSO Stability DMSO aging/stability studies Supplement Studies Supplement Studies Submitted regarding FDA's | Supplement Supplement Supplement Solia Patient Count Final Report Patient Solia Physician Protocol and plan changes, including pending PMA approval (protocol and pending PMA approval (protocol approval approval a | Supplement Studies DMSO Stability DMSO aging/stability studies Supplement Studies Submitted regarding FDA's Sol13 Submitted regarding FDA's Sol13 Submitted regarding FDA's Submitted regarding FDA's Sol13 Submitted regarding FDA's submitted regarding FD | Supplement Studies DMSO Stability DMSO aging/stability studies Supplement Studies Submitted regarding FDA's Submitted regarding FDA's pear follow-up pending PMA approval (protocol and linformed consent). Submitted regarding FDA's pare follow-up Supplement for 3-5 year follow-up Supplement for 3-5 year follow-up Supplement for 3-5 year follow-up Submitted regarding FDA's pare follow-up Supplement for 3-5 year follow-up Supple | Supplement Studies DMSO Stability DMSO aging/stability studies submitted. No Response Studies Sol13 DMSO Stability Studies Submitted regarding FDA's submitted regarding FDA's Supplement Patient Count Patients. Supplement Supplement Supplement Sol14 PMA Application Submission for IDE Final Report. Final Report PMA Application Submission for IDE Final Report. Submission Submission Supplement for 3-5 year follow-up protogool and plan changes, including increased tantalum in Onyx. Submission Supplement for 3-5 year follow-up protogool and plan changes, including informed concent) Supplement Sol16 PDA Response Continued Access Informed concent (protogool and plan changes). PDA Response Supplement for 3-5 year follow-up protogool and plan changes including informed concent). | Supplement Studies DMSO Stability DMSO aging/stability studies S013 DMSO Stability Studies Submitted regarding FDA's submi | Supplement Studies DMSO Stability DMSO aging/stability studies submitted regarding FDA's submitt | Supplement Studies DMSO Stability DMSO aging/stability studies Supplement Studies Submitted regarding FDA's Submitted regarding FDA's pear follow-up pending PMA approval (protocol and linformed consent). Submitted regarding FDA's pare follow-up Supplement for 3-5 year follow-up Supplement for 3-5 year follow-up Supplement for 3-5 year follow-up Submitted regarding FDA's pare follow-up Supplement for 3-5 year follow-up Supple | Supplement Studies DMSO Stability DMSO aging/stability studies Supplement Studies Supplement Studies Submitted regarding FDA's Submitted regarding FDA's regarding FDA's Submitted regarding FDA's regarding FDA | Supplement Studies DMSO Stability DMSO aging/stability studies S013 DMSO Stability Studies Submitted regarding FDA's submi | Supplement Studies DMSO Stability DMSO aging/stability studies Supplement Studies Supplement Studies Submitted regarding FDA's Submitted regarding FDA's regar | Supplement Studies DMSO Stability DMSO aging/stability studies Supplement Studies Supplement Studies Submitted regarding FDA's Submitted regarding FDA's page Follow-up Panding FMA approval (protocol and plan changes, including informed consent). Submitted regarding FDA's Submitted regarding FDA's page Follow-up Panding FMA approval (protocol and plan changes, including informed consent). | Supplement Studies DMSO Stability DMSO aging/stability studies Supplement Studies Supplement Studies Submitted regarding FDA's | Supplement Studies DMSO Stability DMSO aging/stability studies Supplement Studies Supplement Studies Submitted regarding FDA's Submitted regarding FDA's regar | Supplement Studies DMSO Stability DMSO aging/stability studies Supplement Studies Supplement Studies Submitted regarding FDA's Submitted regarding FDA's regar | Supplement Studies DMSO Stability DMSO aging/stability studies Supplement Studies Supplement Studies Submitted regarding FDA's Submitted regarding FDA's regarding | Supplement Studies DMSO Stability DMSO aging/stability studies Supplement Studies Supplement Studies Submitted regarding FDA's Submitted regarding FDA's regar | Soli Supplement Annual Report First Annual Report submitted. No Response Supplement Studies Solia DMSO Stability Studies Solia Submitted regarding FDA's Solia Submitted regarding FDA's Solia Supplement Patient Count Solia Supplement Patient Count Solia Patients. PMA Application Submission Continued Access after pivotal study, protocol and pending PMA approval (protocol and informed consent). Solia PDA Response Solia PDA Response PDA PDA Response PDA Response PDA Response PDA Response PDA | Supplement Studies DMSO Stability DMSO aging/stability studies Supplement Studies Supplement Studies Submitted regarding FDA's | Supplement Studies DMSO Stability DMSO aging/stability studies Supplement Studies Supplement Studies Supplement Submitted regarding FDA's Submitted regarding FDA's Supplement Patient Count Request to increase number of 12-06-02 FDA Response Sudies Supplement Supplement PMA Application Submission Submission Continued Access Continued access after pivotal study, protocol and pending PMA approval (protocol and informed consent). Supplement for 3-5 year Follow-up pending PMA approval (protocol and informed consent). Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). Supplement | Supplement Studies DMSO Stability DMSO aging/stability studies Supplement Studies Supplement Studies Submitted regarding FDA's | Soli Supplement Annual Report First Annual Report submitted. No Response Supplement Studies Solia DMSO Stability Studies Solia Submitted regarding FDA's Solia Submitted regarding FDA's Solia Supplement Patient Count Solia Supplement Patient Count Solia Patients. PMA Application Submission Continued Access after pivotal study, protocol and pending PMA approval (protocol and informed consent). Solia PDA Response Solia PDA Response PDA PDA Response PDA Response PDA Response PDA Response PDA | Soli Supplement Annual Report First Annual Report submitted. No Response Supplement Studies Solia DMSO Stability Studies Solia Submitted regarding FDA's Solia Submitted regarding FDA's Solia Supplement Patient Count Solia Supplement Patient Count Solia Patients. PMA Application Submission Continued Access after pivotal study, protocol and pending PMA approval (protocol and informed consent). Solia PDA Response Solia PDA Response PDA PDA Response PDA Response PDA Response PDA Response PDA | Supplement DMSO Stability Studies Submitted regarding FDA's Southinted Request to increase number of Supplement Patient South Report PMA Application Submission for IDE Final Report Southinted access after pivotal study, Increased tantalum in Conyx. Submission Syear Follow-up Supplement for 3-5 year follow-up pending PMA approval (protocol and plan changes, including informed consent). | Supplement Studies Supplement DMSO stability Studies Submitted regarding FDA's Sol13 Sudies Submitted regarding FDA's Sol13 Supplement Supplement Patient Count Supplement Supplement Supplement Patient Count Sol14 PMA Application Submission Continued Access PMA Application Submission Submission Submission Submission Submission Submission Submission Supplement of Supplement for 3-5 year follow-up pending PMA approval (protocol and plan changes, including informed consent). | Supplement Studies Supplement DMSO stability Studies Submitted regarding FDA's Sol13 Sudies Submitted regarding FDA's Sol13 Supplement Supplement Patient Count Supplement Supplement Supplement Patient Count Sol14 PMA Application Submission Continued Access PMA Application Submission Submission Submission Submission Submission Submission Submission Supplement of Supplement for 3-5 year follow-up pending PMA approval (protocol and plan changes, including informed consent). | Supplement Studies Supplement DMSO stability Studies Submitted regarding FDA's Soulis Supplement Supplement Patient Count Supplement Supplement Supplement Supplement Supplement Supplement Supplement Patient Count Submission Continued Access Continued Access Including Increase after pivotal study, protocol and plan changes, including informed consent). Submission Supplement Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). |
| Annual Report Annual Report First Annual Report submitted. No Response Supplement Studies Sol13 Supplement Patient Count Studies Sol14 Supplement Patient Count Sol14 Supplement Patient Count Request to increase number of patients. Supplement Sol14 Submission Continued Access protocol and plan changes, including increased tantalum in Onlyx. Submission Supplement for 3-5 year follow-up Supplement for 3-5 year follow-up Patient for 3-5 year follow-up Supplement for 3-5 year follow-up Supplement for 3-5 year follow-up Patient Final Report Submission Submission Submission Supplement for 3-5 year follow-up Su | Annual Report Annual Report First Annual Report submitted. Supplement Supplement Studies Sol13 Supplement Patient Count Sol14 Patient Count Sol14 Final Report PMA Application Submission for IDE Final Report PMA Application Submission Submission Submission Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and possible) Submission Submission Submission Submission of Submission Submissi | Annual Report Annual Report First Annual Report submitted. No Response Supplement Studies Supplement Studies Supplement Studies Supplement Patient Count Request to increase number of Supplement Sold Supplement PMA Application Submission for IDE Final Report Final Report PMA Application Submission for IDE Final Report Submission Submission Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and plan changes, including increased tantalum in Omyx. Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and plan changes) PDA Response Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and plan changes) PDA Response Supplement for 3-5 year follow-up pending PMA approval (protocol and plan changes) PDA Response Supplement for 3-5 year follow-up pending PMA approval (protocol and plan changes) PDA Response Supplement for 3-5 year follow-up pending PMA approval (protocol and plan changes) PDA Response Supplement for 3-5 year follow-up pending PMA approval (protocol and plan changes) PDA Response Supplement for 3-5 year follow-up pending PMA approval (protocol and plan changes) PDA Response Supplement for 3-5 year follow-up pending PMA approval (protocol and plan changes) PDA Response Supplement for 3-5 year follow-up pending PMA approval (protocol and plan changes) PDA Response Supplement for 3-5 year follow-up pending PMA approval (protocol and plan changes) PDA Response Supplement for 3-5 year follow-up pending PMA approval (protocol and plan changes) PDA Response Supplement for 3-5 year follow-up pending PMA approval (protocol and plan changes) PDA Response Supplement for 3-5 year follow-up PDA Response Supplement | Annual Report Annual Report First Annual Report submitted. No Response Supplement DMSO Stability Sol13 Submitted regarding FDA's submitted regarding FDA's Supplement Patient Count Request to increase number of Sol14 Final Report PMA Application Submission for IDE Final Report Submission Continued Access Protocol and plan changes, including increased tandalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and plan changes) including informed consent). | Annual Report Annual Report First Annual Report submitted. Supplement Supplement Studies Sol13 Supplement Patient Count Sol4 Final Report PMA Application Submission Continued Access after privotal study increased tantalum in Onyx. Submission Submiss | Annual Report Annual Report First Annual Report submitted. Supplement Supplement Studies Submitted Patient Count Submitted regarding FDA's submitted regarding FDA Response PDA Response P | Annual Report Annual Report First Annual Report submitted. No Response Supplement DMSO Stability Sol13 Supplement DMSO Stability studies Submitted regarding FDA's submitted regarding FDA's Supplement Patient Count Request to increase number of Supplement PMA Application Submission Final Report PMA Application Submission Continued Access Potocool and plan changes, including increased tantalum in Onlyx. Submission | Annual Report Annual Report First Annual Report submitted. No Response Supplement Studies Supplement Studies Supplement Studies Supplement Patient Count Patients. Supplement Supplement Submitted regarding FDA's conditional approval letter dated 12-07-01. Supplement PhA Application Submission for IDE Final Report PhA Response PhA Application Submission for IDE Final Report PhA Application Submission for IDE Final Report PhA Application Submission Submission Submission Submission Submission Supplement for 3-5 year follow-up pending PhA approval (protocol and phanchanges, including increased tantalum in Onyx. Submission Submission Supplement for 3-5 year follow-up pending PhA approval (protocol and phanchanges) including information supplement for 3-5 year follow-up pending PhA approval (protocol and phanchanges) increased tantalum in Onyx. | Annual Report Annual Report First Annual Report submitted. Supplement Supplement DMSO Stability Studies Sol13 Supplement DMSO Stability DMSO aging/stability studies submitted regarding FDA's sonditional approval letter dated 12-07-01. Supplement Patient Count Request to increase number of Supplement PMA Application Submission Final Report PMA Application Submission for IDE Final Report PMA Application Submission for IDE Final Report PMA Application Submission Submis | Annual Report Annual Report First Annual Report submitted. Supplement Sudies Supplement Studies Sol13 Supplement Patient Count Submitted regarding FDA's conditional approval letter dated 12-07-01. Supplement Patient Count Request to increase number of Supplement Sol14 Final Report PMA Application Submission for IDE Final Report PMA approval for potations after pivotal study, protocol and plan changes, including increased tantalum in Omyx. Submission 3-5 year Follow-up pending PMA approval (protocol and plan changes) pending PMA approval (protocol and plan pending PMA approval pending PMA approval (protocol and plan pending PMA approval pe | Annual Report Annual Report First Annual Report submitted. No Response Supplement DMSO Stability Sol13 Supplement DMSO Stability studies Submitted regarding FDA's submitted regarding FDA's Supplement Patient Count Request to increase number of Supplement PMA Application Submission Final Report PMA Application Submission Continued Access Potocool and plan changes, including increased tantalum in Onlyx. Submission | Annual Report Annual Report First Annual Report submitted. No Response Supplement DMSO Stability Sol13 Submitted regarding FDA's sol13 Supplement Patient Count Request to increase number of sol14 Supplement Patient Count Request to increase number of patients. Supplement PMA Application Submission for IDE Final Report Sol13 Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Supplement PDA Response Continued Access PDA Response Sol16 Enrollment Sol16 FDA Response Continued Access PDA Response Sol16 FDA Respons | Annual Report Annual Report First Annual Report submitted. Supplement Supplement DMSO Stability Studies Sol13 Supplement DMSO Stability DMSO aging/stability studies submitted regarding FDA's sonditional approval letter dated 12-07-01. Supplement Patient Count Request to increase number of Supplement PMA Application Submission Final Report PMA Application Submission for IDE Final Report PMA Application Submission for IDE Final Report PMA Application Submission Submis | Annual Report Annual Report First Annual Report submitted. No Response Supplement DMSO Stability Sol13 Submitted regarding FDA's submitted regarding FDA's Supplement Patient Count Request to increase number of Sol4 Final Report PMA Application Submission for IDE Final Report Submission Continued Access Protocol and plan changes, including increase tantalum informed consent). Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Annual Report Annual Report First Annual Report submitted. No Response Supplement DMSO Stability Sol13 Submitted regarding FDA's sol13 Supplement Patient Count Request to increase number of sol14 Final Report PMA Application Submission for IDE Final Report. Final Report PMA Application Submission for IDE Final Report. Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in nonyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Annual Report Annual Report First Annual Report submitted. No Response Supplement DMSO Stability Sol13 Submitted regarding FDA's submitted regarding FDA's Supplement Patient Count Request to increase number of Sol14 Final Report PMA Application Submission for IDE Final Report Submission Submission Continued Access protocol and plan changes, including increased tantalum in Onyx. Submission Submission Submission Submission 3-5 year Follow-up pending PMA approval (protocol and plan changes). Informed consent). | Annual Report Annual Report First Annual Report submitted. No Response Supplement DMSO Stability Sol13 Submitted regarding FDA's submitted regarding FDA's Supplement Patient Count Request to increase number of Sol4 Final Report PMA Application Submission for IDE Final Report Submission Continued Access Protocol and plan changes, including increase tantalum informed consent). Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Annual Report Annual Report First Annual Report submitted. No Response Supplement DMSO Stability Sol13 Submitted regarding FDA's submitted regarding FDA's Supplement Patient Count Request to increase number of Sol4 Final Report PMA Application Submission for IDE Final Report Submission Continued Access Protocol and plan changes, including increase tantalum informed consent). Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Annual Report Annual Report First Annual Report submitted. No Response Supplement DMSO Stability Sol13 Submitted regarding FDA's submitted regarding FDA's submitted regarding FDA's Supplement Patient Count Request to increase number of Sol14 Final Report PMA Application Submission for IDE Final Report. Submission Continued Access Protocol and plan changes, including increased tantalum in Onlyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Submission Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Annual Report Annual Report First Annual Report submitted. No Response Supplement DMSO Stability Sol13 Submitted regarding FDA's submitted regarding FDA's Supplement Patient Count Request to increase number of Sol4 Final Report PMA Application Submission for IDE Final Report Submission Continued Access Protocol and plan changes, including increase tantalum informed consent). Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Annual Report Annual Report First Annual Report submitted. Supplement Sudies Submitted regarding FDA's sounditional approval letter dated 12-Supplement Sol14 Supplement Patient Count Request to increase number of Sol14 Final Report PMA Application Submission for IDE Final Report PMA Application Submission Final Report PMA Application Submission Final Report PMA Approval for 3-5 year follow-up pending PMA approval (protocol and informed consent). Submission Sol14 Submission Submission Submission Onyx Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). | Annual Report Annual Report First Annual Report submitted. No Response Supplement DMSO Stability Sol13 Submitted regarding FDA's submitted regarding FDA's Supplement Patient Count Request to increase number of Sol14 Final Report PMA Application Submission for IDE Final Report Submission Submission Continued Access protocol and plan changes, including increased tantalum in Onyx. Submission Submission Submission Submission 3-5 year Follow-up pending PMA approval (protocol and plan changes). Informed consent). | Annual Report Annual Report First Annual Report submitted. Supplement Sudies Submitted regarding FDA's sounditional approval letter dated 12-Supplement Submitted regarding FDA's sounditional approval letter dated 12-Supplement Patient Count Request to increase number of Supplement Submission Final Report PMA Application Submission for IDE Final Report PMA Application Submission for IDE Final Report PMA Application Submission for IDE Final Report PMA approval for 3-5 year follow-up pending PMA approval (protocol and plan changes, including informed consent). Submission 3-5 year Follow-up pending PMA approval (protocol and plan changes). | Annual Report Annual Report First Annual Report submitted. No Response Supplement DMSO Stability Sol13 Submitted regarding FDA's submitted regarding FDA's Supplement Patient Count Request to increase number of Sol14 Final Report PMA Application Submission for IDE Final Report Submission Submission Continued Access protocol and plan changes, including increased tantalum in Onyx. Submission Submission Submission Submission 3-5 year Follow-up pending PMA approval (protocol and plan changes). Informed consent). | Annual Report Annual Report First Annual Report submitted. Supplement Sudies Submitted regarding FDA's sounditional approval letter dated 12-Supplement Sol14 Supplement Patient Count Request to increase number of Sol14 Final Report PMA Application Submission for IDE Final Report PMA Application Submission Final Report PMA Application Submission Final Report PMA Approval for 3-5 year follow-up pending PMA approval (protocol and informed consent). Submission Sol14 Submission Submission Submission Onyx Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). | Annual Report Annual Report First Annual Report submitted. Supplement Sudies Submitted regarding FDA's sounditional approval letter dated 12-Supplement Sol14 Supplement Patient Count Request to increase number of Sol14 Final Report PMA Application Submission for IDE Final Report PMA Application Submission Final Report PMA Application Submission Final Report PMA Approval for 3-5 year follow-up pending PMA approval (protocol and informed consent). Submission Sol14 Submission Submission Submission Onyx Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). | Annual Report Annual Report First Annual Report submitted. Supplement Sudies Submitted regarding FDA's submitted regarding FDA's submitted regarding FDA's submitted regarding FDA's sonditional approval letter dated 12- S013 Supplement Patient Count Request to increase number of S014 Final Report PMA Application Submission for IDE Final Report Final Report PMA Application Submission Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). | Annual Report Annual Report First Annual Report submitted. Supplement Sudies Submitted regarding FDA's submitted regarding FDA's sonditional approval letter dated 12- S013 Supplement Supplement Patient Count Request to increase number of S014 Final Report PMA Application Submission for IDE Final Report Final Report PMA Application Submission Continued Access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). | Annual Report Annual Report First Annual Report submitted. Supplement Sudies Submitted regarding FDA's submitted regarding FDA's sonditional approval letter dated 12- S013 Supplement Supplement Patient Count Request to increase number of S014 Final Report PMA Application Submission for IDE Final Report Final Report PMA Application Submission Continued Access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). | Annual Report Annual Report First Annual Report submitted. Supplement Sudies Submitted regarding FDA's submitted regarding FDA's sonditional approval letter dated 12- S013 Supplement Supplement Patient Count Request to increase number of S014 Final Report PMA Application Submission for IDE Final Report Final Report PMA Application Submission Continued Access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). |
| Annual Report Annual Report First Annual Report submitted. Supplement Studies Submitted regarding FDA's conditional approval letter dated 12- Supplement Sol PA Response Patient Count Sol PA Response Patient Sol PA Response PA Additional Patient Sol PA Application Submission Continued Access Protocol and plan changes, including Increased tantalum in Onyx. Submission Submission Supplement for 3-5 year follow-up PAA Approval frontocol and Supplement for 3-5 year follow-up Supple | Annual Report Annual Report First Annual Report submitted. No Response Supplement DMSO Stability Studies submitted regarding FDA's conditional approval letter dated 12- 07-01. Supplement Supplement Patient Count patients. Supplement Patient Count Final Report PMA Application Submission Continued Access after pivotal study, protocol and plan changes, including increased tantalum in Omyx. Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and plan changes) and plan changes of pending PMA approval (protocol and plan changes) and plan changes of pending PMA approval (protocol and plan changes) and plan changes of pending PMA approval (protocol and plan changes) and plan changes of pending PMA approval (protocol and plan changes) and plan changes of pending PMA approval (protocol and plan changes) and plan changes of pending PMA approval (protocol and plan changes) and plan changes of pending PMA approval (protocol and plan changes) and plan changes of pending PMA approval (protocol and plan changes) and plan changes of pending PMA approval (protocol and plan changes) and plan changes of pending PMA approval (protocol and plan changes) and plan changes of pending PMA approval (protocol and plan changes) and plan changes of pending PMA approval (protocol and plan changes) and plan changes of pending PMA approval (protocol and plan changes) and plan changes of pending PMA approval (protocol and plan changes) and plan changes of pending PMA approval (protocol and plan changes) and plan changes of pending PMA approval (protocol and plan changes) and plan changes of pending PMA approval (protocol and plan changes) and plan changes of pending PMA approval (protocol and plan changes) and plan changes of pending PMA approval (protocol and plan changes) and plan changes of pending PMA approval (protocol and plan changes) and plan changes of pending PMA approval (protocol and plan changes) and plan changes of pending PMA approval (protocol and plan changes) and plan changes of pending | Annual Report Annual Report First Annual Report submitted. No Response Supplement DMSO Stability Studies Submitted regarding FDA's conditional approval letter dated 12- 07-01. Supplement Supplement Patient Count Submission Final Report PMA Application Submission Continued Access PMA Application Submission Submission Submission Submission Submission Submission Submission Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and plan changes, including informed consent) Submission Submiss | Annual Report Annual Report First Annual Report submitted. Supplement Studies Submitted regarding FDA's conditional approval letter dated 12- O7-01. Supplement Sol Patient Count Sol Patients. Supplement Patient Count Final Report PMA Application Submission for IDE Final Report PMA Application Submission Su | Annual Report Annual Report First Annual Report submitted. Supplement DMSO Stability Studies Submitted regarding FDA's conditional approval letter dated 12- DMSO Stability Studies Supplement Supplement Patient Count patients. Supplement Patient Count Patients. Supplement Patient Count Submission for IDE Final Report PMA Application Submission Final Report PMA Application Submission Submissi | Annual Report Annual Report First Annual Report submitted. No Response Supplement DMSO Stability Studies Submitted regarding FDA's conditional approval letter dated 12-07-01. Supplement Patient Count Submission Patients. Supplement Patient Count Request to increase number of patients. Supplement PMA Application Submission for IDE Final Report PMA Application Submission for IDE Final Report PMA approval and plan changes, including increase d tandalum in Omyx. Submission 3-5 year Follow-up pending PMA approval (protocol and plan changes) including pending PMA approval (protocol and plan changes) including pending PMA approval (protocol and plan changes) including increased tandalum in Omyx. Submission 3-5 year Follow-up pending PMA approval (protocol and plan changes) including increased tandalum in Omyx. Submission 3-5 year Follow-up pending PMA approval (protocol and plan changes) including increased tandalum in Omyx. | Annual Report Annual Report First Annual Report submitted. Supplement Supplement Studies Submitted regarding FDA's conditional approval letter dated 12- Sol Submission Submission Continued Access Protocol and Informed consent). Patient Count Patient Count Patients. Supplement Patient Count Submission for IDE Final Report PMA Application Submission for IDE Final Report PMA approval grotocol and Informed consent). No Response DMSO Stability Studies 3-15-02 FDA Response Studies Sol Studies Sol FDA Response PDA Response Enrollment Sol Final Report Submission Final Report Submission for IDE Final Report PMA Application Submission for IDE Final Report Submission FDA Response PDA Response PDA Response Submission Submiss | Annual Report Annual Report First Annual Report submitted. No Response Supplement DMSO Stability Studies Submitted regarding FDA's conditional approval letter dated 12- 07-01. Supplement Patient Count S014 Request to increase number of patients. Supplement PMA Application Submission for IDE Final Report PMA Application Submission Continued Access protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and plan changes) including pending PMA approval (protocol and plan changes) increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and plan changes) increased tantalum in Onyx. | Annual Report Annual Report First Annual Report submitted. Supplement DMSO Stability Studies Submitted regarding FDA's conditional approval letter dated 12-07-01. Supplement Supplement Patient Count Sold Request to increase number of PMA Application Submission Continued Access Protocol and plan changes, including increased tandalum in Omyx. Submission 3-5 year Follow-up pending PMA approval (protocol and plan changes) informed consent). Submission 3-5 year Follow-up pending PMA approval (protocol and plan changes) informed consent). Submission 3-5 year Follow-up pending PMA approval (protocol and plan changes) informed consent). | Annual Report Annual Report First Annual Report submitted. No Response Supplement DMSO Stability Studies Submitted regarding FDA's conditional approval letter dated 12- 07-01. Supplement Supplement Patient Count S014 Final Report PMA Application Submission for IDE Final Report PMA Application Submission of IDE Final Report PMA Application Submission of IDE Final Report PMA approval fortoned and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Submission Submission Submission Submission of IDE Final Report PDA Response Continued Access pending PMA approval (protocol and plan changes, including informed consent). | Annual Report Annual Report First Annual Report submitted. Supplement Supplement Studies Submitted regarding FDA's conditional approval letter dated 12- Sol Submission Submission Continued Access Protocol and Informed consent). Patient Count Patient Count Patients. Supplement Patient Count Submission for IDE Final Report PMA Application Submission for IDE Final Report PMA approval grotocol and Informed consent). No Response DMSO Stability Studies 3-15-02 FDA Response Studies Sol Studies Sol FDA Response PDA Response Enrollment Sol Final Report Submission Final Report Submission for IDE Final Report PMA Application Submission for IDE Final Report Submission FDA Response PDA Response PDA Response Submission Submiss | Annual Report Annual Report First Annual Report submitted. Supplement Supplement Studies Submitted regarding FDA's conditional approval letter dated 12- O7-01. Supplement Sol14 Patient Count Sol14 Patient Count Patients. Supplement Polication Submission for IDE Final Report PMA Application Submission Onlyx. Submission Syear Follow-up Pending PMA approval (protocol and plan changes, including increased tantalum in Onlyx. Submission Syear Follow-up Pending PMA approval (protocol and plan changes). Submission Syear Follow-up Pending PMA approval (protocol and plan changes). | Annual Report Annual Report First Annual Report submitted. Supplement DMSO Stability Studies Submitted regarding FDA's conditional approval letter dated 12-07-01. Supplement Supplement Patient Count Sold Request to increase number of PMA Application Submission Continued Access Protocol and plan changes, including increased tandalum in Omyx. Submission 3-5 year Follow-up pending PMA approval (protocol and plan changes) informed consent). Submission 3-5 year Follow-up pending PMA approval (protocol and plan changes) informed consent). Submission 3-5 year Follow-up pending PMA approval (protocol and plan changes) informed consent). | Annual Report Annual Report First Annual Report submitted. Supplement Studies Submitted regarding FDA's conditional approval letter dated 12- O7-01. Supplement Sol14 Patient Count Sol14 Patient Count Final Report PMA Application Submission for IDE Final Report Protocol and plan changes, including increased tantalum in Onlyx. Submission Syear Follow-up Pending PMA approval (protocol and informed consent). | Annual Report Annual Report First Annual Report submitted. Supplement Studies Submitted regarding FDA's conditional approval letter dated 12- O7-01. Supplement Sol4 Patient Count Sol4 Patient Sol4 Patient Sol4 Patients. Submission Continued Access Pools of the Final Report Submission for IDE Final Report PMA Application Increase after pivotal study, increase d tantalum in Onlyx. Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and plane). Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and plane). Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and plane). Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and plane). Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and plane). | Annual Report Annual Report First Annual Report submitted. Supplement Studies Submitted regarding FDA's conditional approval letter dated 12- O7-01. Supplement Sol Patient Count Sol Patients. Supplement Patient Count Final Report PMA Application Submission for IDE Final Report PMA Application Submission Su | Annual Report Annual Report First Annual Report submitted. Supplement Studies Submitted regarding FDA's conditional approval letter dated 12- O7-01. Supplement Sol14 Patient Count Sol14 Patient Count Final Report PMA Application Submission for IDE Final Report Protocol and plan changes, including increased tantalum in Onlyx. Submission Syear Follow-up Pending PMA approval (protocol and informed consent). | Annual Report Annual Report First Annual Report submitted. Supplement Studies Submitted regarding FDA's conditional approval letter dated 12- O7-01. Supplement Sol14 Patient Count Sol14 Patient Count Final Report PMA Application Submission for IDE Final Report Protocol and plan changes, including increased tantalum in Onlyx. Submission Syear Follow-up Pending PMA approval (protocol and informed consent). | Annual Report Annual Report First Annual Report submitted. Supplement Studies Submitted regarding FDA's conditional approval letter dated 12- O7-01. Supplement Sol4 Patient Count Sol4 Patient Sol4 Patient Sol4 Patients. Submission Continued Access Protocol and plan changes, including increased tantalum in Onyx. Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). | Annual Report Annual Report First Annual Report submitted. Supplement Studies Submitted regarding FDA's conditional approval letter dated 12- O7-01. Supplement Sol14 Patient Count Sol14 Patient Count Final Report PMA Application Submission for IDE Final Report Protocol and plan changes, including increased tantalum in Onlyx. Submission Syear Follow-up Pending PMA approval (protocol and informed consent). | Annual Report Annual Report Submitted. No Response Supplement Studies Sol13 DMSO aging/stability studies conditional approval letter dated 12-Supplement Submission Continued Access after pivotal study, protocol and plan changes, including informed consent). Annual Report PIST Annual Report Submission PIST Annual Report Submission Submission Submission Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). | Annual Report Annual Report First Annual Report submitted. Supplement Studies Submitted regarding FDA's conditional approval letter dated 12- O7-01. Supplement Sol Patient Count Sol Patients. Supplement Patient Count Final Report PMA Application Submission for IDE Final Report PMA Application Submission Su | Annual Report Annual Report First Annual Report submitted. Supplement Studies Sol13 Supplement Patient Count Soldients. Supplement Supplement Sol4 Final Report PMA Application Submission Continued Access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission Submission Supplement for 3-5 year Follow-up pending PMA approval (protocol and informed consent). Pirst Annual Report Submission No Response Submitted. No Response Solf Solf Stability Studies Solf Solf Solf Stability Studies Solf Solf Solf Stability Studies Solf Solf Solf Solf Stability Studies Solf Solf Solf Solf Solf Solf Solf Solf | Annual Report Annual Report First Annual Report submitted. Supplement Studies Submitted regarding FDA's conditional approval letter dated 12- O7-01. Supplement Sol Patient Count Sol Patients. Supplement Patient Count Final Report PMA Application Submission for IDE Final Report Protocol and plan changes, including Increased tantalum in Onlyx. Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). Submission Submissi | Annual Report Annual Report Submitted. No Response Supplement Studies Sol13 DMSO aging/stability studies conditional approval letter dated 12-Supplement Submission Continued Access after pivotal study, protocol and plan changes, including informed consent). Annual Report PIST Annual Report Submission PIST Annual Report Submission Submission Submission Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). | Annual Report Annual Report Submitted. No Response Supplement Studies Sol13 DMSO aging/stability studies conditional approval letter dated 12-Supplement Submission Continued Access after pivotal study, protocol and plan changes, including informed consent). Annual Report PIST Annual Report Submission PIST Annual Report Submission Submission Submission Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). | Annual Report Annual Report Submitted. Annual Report Annual Report submitted. Supplement Sudies Sol13 Supplement Patient Count Sol4 Supplement Sol4 Patient Count Patients. Supplement Patient Count Patients. Supplement Sol4 Final Report PMA Application Submission for IDE Final Report PMA Application Submission Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). Pirst Annual Report Subdies Solfs Solfs Solfs Solfs Enrollment PDA Response Continued Access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission S- year Follow-up pending PMA approval (protocol and informed consent). | Annual Report Annual Report First Annual Report submitted. Supplement Studies Sol13 Supplement Patient Count Request to increase number of Sol4 Final Report PMA Application Submission Continued Access protocol and plan changes, including increased tantalum in Onyx. Submission Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Print Annual Report First Annual Report submitted. No Response Sol13 3-15-02 FDA Response Sol13 Submission Submission for IDE Final Report Sol13 FDA Response Enrollment Sol16 Enrollment PACESS Protocol and plan changes, including increased tantalum in Onyx. Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). | Annual Report Annual Report First Annual Report submitted. Supplement Studies Sol13 Supplement Patient Count Request to increase number of Sol4 Final Report PMA Application Submission Continued Access protocol and plan changes, including increased tantalum in Onyx. Submission Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Print Annual Report First Annual Report submitted. No Response Sol13 3-15-02 FDA Response Sol13 Submission Submission for IDE Final Report Sol13 FDA Response Enrollment Sol16 Enrollment PACESS Protocol and plan changes, including increased tantalum in Onyx. Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). | Annual Report Annual Report First Annual Report submitted. Supplement Studies Sol13 Supplement Patient Count Request to increase number of Sol4 Final Report PMA Application Submission Continued Access protocol and plan changes, including increased tantalum in Onyx. Submission Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Print Annual Report First Annual Report submitted. No Response Sol13 3-15-02 FDA Response Sol13 Submission Submission for IDE Final Report Sol13 FDA Response Enrollment Sol16 Enrollment PACESS Protocol and plan changes, including increased tantalum in Onyx. Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). |
| Annual Report Annual Report First Annual Report submitted. Supplement Studies S013 Supplement Supplement Studies Submitted regarding FDA's submitted regarding FDA's Supplement Patient Count Patients. Supplement Supplement Prinal Report Phatents. Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up Supplement for 3-5 year follow-up Continued Access Submission Submission Submission Submission Submission Submission Submission Supplement for 3-5 year follow-up Continued Access Submission Sub | Annual Report Annual Report First Annual Report submitted. Supplement Sudies Submitted regarding FDA's submitted regarding FDA's submitted regarding FDA's conditional approval letter dated 12- Supplement Sol14 Final Report PMA Application Submission for IDE Final Report PMA approval functional and plan changes, including increased tantalum in Onyx. Submission Submission 3-5 year Follow-up pending PMA approval (protocol and plan dapproval (protocol and pending PMA approval pending PMA approval pending PMA approval pending PMA approval pending pending PMA approval pending PMA approval pending pending PMA approval pending PMA approval pending pend | Annual Report Annual Report First Annual Report submitted. Supplement Sudies Submitted regarding FDA's Sol13 Supplement Sudies Submitted regarding FDA's conditional approval letter dated 12-07-01. Supplement Patient Count Sol14 Final Report PMA Application Submission for IDE Final Report Final Report PMA Application Submission Continued Access Protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and plan changes) protocol and plan changes, including pMA approval (protocol and plan changes) PAResponse PAResponse Pending PMA approval (protocol and PDA Response) Supplement for 3-5 year follow-up pending PMA approval (protocol and PDA Response) 3-5 year Follow-up pending PMA approval (protocol and PDA Response) 3-5 year Follow-up | Annual Report Annual Report First Annual Report submitted. Supplement Supplement Studies Sol13 Supplement Patient Count Sol4 Final Report PMA Application Submission Continued Access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). Final Report PDA Response Additional Patient Sol6 Submission Submission Submission for IDE Final Report Submission Onlyx. Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). | Annual Report Annual Report First Annual Report submitted. Supplement Sudies Submited regarding FDA's Submited regarding FDA's Conditional approval letter dated 12-Supplement Submission Continued Access Enrollow-up pending PMA approval (protocol and plan changes, including protocol and pending PMA approval (protocol approval pending PMA approval pending PMA approval pending PMA approval pending PM | Annual Report Annual Report First Annual Report submitted. Supplement Sudies Sol13 Supplement Patient Count Studies Supplement Supplement Patient Count Request to increase number of Supplement Sol4 Final Report PMA Application Submission Continued Access protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and plan changes) informed consent). Submission 3-5 year Follow-up pending PMA approval (protocol and plan changes) informed consent). | Annual Report Annual Report First Annual Report submitted. Supplement Supplement Studies Sol13 Supplement Patient Count Submitted regarding FDA's conditional approval letter dated 12- 97-91. Supplement Patient Count Request to increase number of patients. Supplement Sol4 Final Report PMA Application Submission for IDE Final Report Final Report PMA Application Submission Continued access after pivotal study, increased tantalum in Conyx. Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and plan changes, including informed consent). Submission S-5 year Follow-up pending PMA approval (protocol and plan changes). Final Report PDA Response Continued Access FDA Response S-5 year Follow-up pending PMA approval (protocol and plan changes). | Annual Report Annual Report First Annual Report submitted. Supplement Sudies Submitted regarding FDA's Sol13 Supplement Sudies Submitted regarding FDA's conditional approval letter dated 12- Sol4 Supplement Sol4 Final Report PMA Application Submission for IDE Final Report PMA Application Submission Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission Supplement for 3-5 year Follow-up pending PMA approval (protocol and plan changes) increased tantalum in Onyx. Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and plan changes) increased tantalum in Onyx. Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and plan changes) increased tantalum in Onyx. Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and plan changes) increased tantalum in Onyx. | Annual Report Annual Report First Annual Report submitted. Supplement Supplement Studies Sol13 Supplement Patient Count Submitted regarding FDA's conditional approval letter dated 12- 97-91. Supplement Patient Count Request to increase number of patients. Supplement Sol14 Supplement Patient Count Request to increase number of patients. Supplement Sol14 Submission Continued Access Protocol and plan changes, including increased tantalum in Onlyx. Submission S-5 year Follow-up pending PMA approval (protocol and plan changes). Submission S-5 year Follow-up pending PMA approval (protocol and plan changes). Submission S-5 year Follow-up pending PMA approval (protocol and plan changes). Submission S-5 year Follow-up pending PMA approval (protocol and plan changes). | Annual Report Annual Report First Annual Report submitted. Supplement Sudies Submitted regarding FDA's Sol13 Supplement Sudies Submitted regarding FDA's conditional approval letter dated 12-07-01. Supplement Patient Count Sol14 Final Report PMA Application Submission for IDE Final Report Submission Continued Access Protocol and plan changes, including increased tantalum in Onyx. Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and proval (protocol and proval (protocol and plan changes) an | Annual Report Annual Report First Annual Report submitted. Supplement Supplement Studies Sol13 Supplement Patient Count Submitted regarding FDA's conditional approval letter dated 12- 97-91. Supplement Patient Count Request to increase number of patients. Supplement Sol4 Final Report PMA Application Submission for IDE Final Report Final Report PMA Application Submission Continued access after pivotal study, increased tantalum in Conyx. Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and plan changes, including informed consent). Submission S-5 year Follow-up pending PMA approval (protocol and plan changes). Final Report PDA Response Continued Access FDA Response S-5 year Follow-up pending PMA approval (protocol and plan changes). | Annual Report Annual Report First Annual Report submitted. Supplement Supplement Studies Sol13 Supplement Patient Count Submitted regarding FDA's conditional approval letter dated 12- 97-01. Supplement Patient Count Request to increase number of Supplement Sol4 Final Report PMA Application Submission for IDE Final Report. Submission Continued Access Protocol and plan changes, including increased tantalum in Onlyx. Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and plan changes, including informed consent). No Response FDA Response Additional Patient Sol13 Submission Submission Submission for IDE Final Report. Submission Submission Submission for IDE Final | Annual Report Annual Report First Annual Report submitted. Supplement Supplement Studies Sol13 Supplement Patient Count Submitted regarding FDA's conditional approval letter dated 12- 97-91. Supplement Patient Count Request to increase number of patients. Supplement Sol14 Supplement Patient Count Request to increase number of patients. Supplement Sol14 Submission Continued Access Protocol and plan changes, including increased tantalum in Onlyx. Submission S-5 year Follow-up pending PMA approval (protocol and plan changes). Submission S-5 year Follow-up pending PMA approval (protocol and plan changes). Submission S-5 year Follow-up pending PMA approval (protocol and plan changes). Submission S-5 year Follow-up pending PMA approval (protocol and plan changes). | Annual Report Annual Report First Annual Report submitted. Supplement Supplement Studies Sol13 Supplement Patient Count Sol4 Final Report PMA Application Submission Continued Access after pivotal study, pending PMA approval (protocol and plan changes, including informed consent). Submission Submission S-5 year Follow-up pending PMA approval (protocol and plan changes) informed consent). No Response FDA Response DMSO Stability Studies 3-15-02 FDA Response Studies Sol13 S-15-02 FDA Response Additional Patient Sol16 Final Report PMA Application Submission for IDE Final Report Sol16 Submission S-5 year Follow-up Pending PMA approval (protocol and plan changes, including informed consent). | Annual Report Annual Report First Annual Report submitted. Supplement Supplement Studies Sol13 Supplement Patient Count Submitted regarding FDA's conditional approval letter dated 12- 27-01. Supplement Patient Count Request to increase number of patients. Supplement Sol4 Final Report PMA Application Submission for IDE Final Report Submission Continued Access protocol and plan changes, including increased tantalum in Onlyx. Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and plan changes, including informed consent). Submission S-5 year Follow-up pending PMA approval (protocol and plan changes). | Annual Report Annual Report First Annual Report submitted. Supplement Supplement Studies Sol13 Supplement Patient Count Sol4 Final Report PMA Application Submission Continued Access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). Final Report PDA Response Additional Patient Sol6 Submission Submission Submission for IDE Final Report Submission Onlyx. Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). | Annual Report Annual Report First Annual Report submitted. Supplement Supplement Studies Sol13 Supplement Patient Count Sol4 Final Report PMA Application Submission Continued Access after pivotal study, pending PMA approval (protocol and plan changes, including informed consent). Submission Submission S-5 year Follow-up pending PMA approval (protocol and plan changes) informed consent). No Response FDA Response DMSO Stability Studies 3-15-02 FDA Response Studies Sol13 S-15-02 FDA Response Additional Patient Sol16 Final Report PMA Application Submission for IDE Final Report Sol16 Submission S-5 year Follow-up Pending PMA approval (protocol and plan changes, including informed consent). | Annual Report Annual Report First Annual Report submitted. Supplement Supplement Studies Sol13 Supplement Patient Count Sol4 Final Report PMA Application Submission Continued Access after pivotal study, pending PMA approval (protocol and plan changes, including informed consent). Submission Submission S-5 year Follow-up pending PMA approval (protocol and plan changes) informed consent). No Response FDA Response DMSO Stability Studies 3-15-02 FDA Response Studies Sol13 S-15-02 FDA Response Additional Patient Sol16 Final Report PMA Application Submission for IDE Final Report Sol16 Submission S-5 year Follow-up Pending PMA approval (protocol and plan changes, including informed consent). | Annual Report Annual Report First Annual Report submitted. Supplement Supplement Studies Sol13 Supplement Patient Count Sol4 Final Report PMA Application Submission Continued Access Eprotocol and plan changes, including informed consent). Submission Submission 3-5 year Follow-up pending PMA approval (protocol and plan changes). Annual Report PMA Response DMSO Stability studies submitted regarding FDA's Sol13 Submission Submission Submission for IDE Final Report Submission for IDE Final Report Submission on Supplement for 3-5 year follow-up pending PMA approval (protocol and plan changes, including informed consent). Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and plan changes, including informed consent). | Annual Report Annual Report First Annual Report submitted. Supplement Supplement Studies Sol13 Supplement Patient Count Sol4 Final Report PMA Application Submission Continued Access after pivotal study, pending PMA approval (protocol and plan changes, including informed consent). Submission Submission S-5 year Follow-up pending PMA approval (protocol and plan changes) informed consent). No Response FDA Response DMSO Stability Studies 3-15-02 FDA Response Studies Sol13 S-15-02 FDA Response Additional Patient Sol16 Final Report PMA Application Submission for IDE Final Report Sol16 Submission S-5 year Follow-up Pending PMA approval (protocol and plan changes, including informed consent). | Annual Report Annual Report First Annual Report submitted. Supplement Supplement Studies Sol13 Supplement Patient Count Sol14 Patient Count Sol14 Final Report PMA Application Submission for IDE Final Report PMA Application Increase d tantalum in Onlyx. Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and pin consent). Submission Submission Solphement for 3-5 year follow-up informed consent). | Annual Report Annual Report First Annual Report submitted. Supplement Supplement Studies Sol13 Supplement Patient Count Sol4 Final Report PMA Application Submission Continued Access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). Final Report PDA Response Additional Patient Sol6 Submission Submission Submission for IDE Final Report Submission Onlyx. Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). | Annual Report Annual Report First Annual Report submitted. Supplement Supplement Studies Sol13 Supplement Patient Count Sol4 Final Report PMA Application Submission Continued Access after pivotal study, protocol and plan changes, including informed consent). Submission Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and pinformed consent). No Response FDA Response DMSO Stability Studies 3-15-02 FDA Response PDA Response Additional Patient Sol13 Submission Submission Continued Access after pivotal study, protocol and plan changes, including informed consent). Final Report PDA Response Continued Access after pivotal study, protocol and plan changes, including informed consent). | Annual Report Annual Report First Annual Report submitted. Supplement Supplement Studies Sol13 Supplement Patient Count Sol4 Final Report PMA Application Submission Continued Access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). Final Report PDA Response Additional Patient Sol6 Submission Submission Submission for IDE Final Report Submission Onlyx. Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). | Annual Report Annual Report First Annual Report submitted. Supplement Supplement Studies Sol13 Supplement Patient Count Sol14 Patient Count Sol14 Final Report PMA Application Submission for IDE Final Report PMA Application Increase d tantalum in Onlyx. Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and pin consent). Submission Submission Solphement for 3-5 year follow-up informed consent). | Annual Report Annual Report First Annual Report submitted. Supplement Supplement Studies Sol13 Supplement Patient Count Sol14 Patient Count Sol14 Final Report PMA Application Submission for IDE Final Report PMA Application Increase d tantalum in Onlyx. Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and pin consent). Submission Submission Solphement for 3-5 year follow-up informed consent). | Annual Report Annual Report First Annual Report submitted. Supplement Supplement Studies Sol13 Supplement Patient Count Sol14 Patient Count Sol14 Final Report PMA Application Submission for IDE Final Report PMA Application Protocol and plan changes, including proval (protocol and pending PMA approval (protocol and informed consent). Submission Submission Solphement for 3-5 year follow-up pending PMA approval (protocol and informed consent). | Annual Report Annual Report First Annual Report submitted. Supplement Supplement Studies Sol13 Supplement Patient Count Sol14 Patient Count Patients. Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Omyx. Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). No Response FDA Response DMSO Stability Studies 3-15-02 FDA Response Additional Patient Sol16 FDA Response Enrollment PMA Application Submission for IDE Final Report Submission Office IDE Final Report PMA approval (protocol and informed consent). | Annual Report Annual Report First Annual Report submitted. Supplement Supplement Studies Sol13 Supplement Patient Count Sol14 Patient Count Patients. Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Omyx. Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). No Response FDA Response DMSO Stability Studies 3-15-02 FDA Response Additional Patient Sol16 FDA Response Enrollment PMA Application Submission for IDE Final Report Submission Office IDE Final Report PMA approval (protocol and informed consent). | Annual Report Annual Report First Annual Report submitted. Supplement Supplement Studies Sol13 Supplement Patient Count Sol14 Patient Count Patients. Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Omyx. Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). No Response FDA Response DMSO Stability Studies 3-15-02 FDA Response Additional Patient Sol16 FDA Response Enrollment PMA Application Submission for IDE Final Report Submission Office IDE Final Report PMA approval (protocol and informed consent). |
| Annual Report Annual Report First Annual Report submitted. Supplement Studies S013 Supplement Sounditional approval letter dated 12- Supplement S014 Supplement Patient Count Patients. Supplement S014 Final Report PMA Application Submission for IDE Final Report PMA Application Increase after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up Supplement for 2-5 year follow-up Continued Access Protocol and Dance of Supplement Count PMA Approval (reported access after pivotal study, protocol and Dance of Submission Continued Access Protocol and Patient Count PMA Approval (reported access after pivotal study, protocol and Dance of Supplement Count PMA Approval (reported access after pivotal study, protocol and Dance of Supplement Count PMA Approval (reported access after pivotal study, protocol and Dance of Supplement Count PMA Approval (reported access after pivotal study, protocol and Dance of Supplement Count PMA Approval (reported access after pivotal study, protocol and Dance of Supplement Count PMA Approval (reported access after pivotal study, protocol and Dance of Supplement Count PMA Approval (reported access after pivotal study, protocol and Dance of Supplement Count PMA Approval (reported access after pivotal study, protocol and Dance of Supplement Count PMA Approval (reported access after pivotal study, protocol and Dance of Supplement Count PMA Approval (reported access after pivotal study, protocol and Dance of Supplement Count PMA Approval (reported access after pivotal study, protocol and Dance of Supplement Count PMA Approval (reported access after pivotal study, protocol and Dance of Supplement Count PMA Approval (reported access after pivotal study, protocol and Dance of Supplement Count PMA Approval (reported access after pivotal study, protocol and Dance of Supplement Count PMA Approval (reported access after pivotal study, protocol and Dance of Supplement Count PMA Approval (reported access after pivotal study, protocol and Dance | Annual Report Annual Report First Annual Report submitted. Supplement Studies Sol13 Supplement Patient Count Solutional approval letter dated 12- Sol14 Supplement Sol4 Submission Continued Access Protocol and plan changes, including increased tantalum in Onyx. Submission Submission 3-5 year Follow-up pending PMA approval (protocol and plan changes) including PMA approval (protocol and pending PMA approval) Annual Report No Response Submission Submission for IDE Final Report Sol13 Submission Submission Submission of IDE Final Report Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and plan changes) including increased tantalum in Onyx. Submission Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and plan changes) including Submission Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and submission Submiss | Annual Report Annual Report First Annual Report submitted. Supplement Studies Submitted regarding FDA's submitted regarding FDA's sonditional approval letter dated 12- O7-01. Supplement Studies Submitted regarding FDA's submitted regarding FDA's sonditional approval letter dated 12- Supplement Patient Count patients. Supplement Patient Count Patient Count patients. Submission Continued Access Continued access after pivotal study, increased tantalum in Onyx. Submission Supplement for 3-5 year follow-up pending Podding Poddin | Annual Report Annual Report Pirst Annual Report submitted. Supplement Studies Sol13 Supplement Sudies Sol13 Supplement Patient Count Patients. Supplement Sudies Submission Continued Access after pivotal study, protocol and plan changes, including PMA approval (protocol and pending PMA approval (protocol and pinformed consent). No Response DMSO Stability studies 3-15-02 FDA Response Studies Submission Studies Submission for IDE Final Report Patient Sol13 FDA Response Additional Patient Sol16 FDA Response Continued Access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and plan changes). | Annual Report Annual Report First Annual Report submitted. Supplement Studies Sol13 Supplement Patient Count Solditional approval letter dated 12- Sol14 Supplement Patient Count Sol15 Supplement Patient Count Sol16 Submission Continued Access Protocol and plan changes, including increased tantalum in Onyx. Submission Supplement Supplement for 3-5 year follow-up pending PMA approval (protocol and protocol and pending PMA approval (protocol and pending PMA approv | Annual Report Annual Report Pirst Annual Report submitted. Supplement Studies Sol13 Supplement Studies Sol13 Supplement Patient Count Studies Sol14 Final Report PMA Application Submission Continued Access Protocol and plan changes, including Increase at Bubmission Supplement for 3-5 year follow-up pending PMA approval protocol and proval protocol and protocol and proval protocol and p | Annual Report Annual Report Pirst Annual Report submitted. Supplement Studies Sol13 Supplement Studies Sol13 Supplement Patient Count Studies Sol14 Final Report PMA Application Submission Continued Access Protocol and plan changes, including Increase and pending PMA approval (protocol and pending PMA approval pe | Annual Report Annual Report First Annual Report submitted. Supplement Studies Submitted regarding FDA's submitted regarding FDA's sonditional approval letter dated 12- S013 Supplement Solid Patient Count Solid Request to increase number of Solid Patients. Supplement Polication Submission for IDE Final Report Solid Submission Continued Access Protocol and plan changes, including increased tantalum in Onyx. Submission Solid Patient Solid Supplement for 3-5 year follow-up pending PMA approval (protocol and protocol and pending PMA approval (protocol and pending PMA approval (pending PMA approval pending PMA approval pending PMA approval pending PMA approval (pending PMA a | Annual Report Annual Report Pirst Annual Report submitted. Supplement Studies Sol13 Supplement Studies Sol13 Supplement Patient Count Studies Sol14 Final Report PMA Application Submission Continued Access Protocol and plan changes, including Increase at Bubmission Supplement for 3-5 year Follow-up pending PMA approval (protocol and proval protocol and pending PMA approval (protocol and proval protocol and pending PMA approval (protocol and proval protocol and pending PMA approval (protocol and pending PMA approval pen | Annual Report Annual Report Pirst Annual Report submitted. Supplement Studies Submitted regarding FDA's submitted regarding FDA's Soli3 Supplement Sudies Soli3 Supplement Patient Count Patient Count Soliditional approval letter dated 12-Solid Patients. Supplement Polication Submission Final Report PMA Application Submission Continued Access Protocol and plan changes, including increased tantalum in Onyx. Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and protocol and product) FDA Response Supplement for 3-5 year follow-up pending PMA approval (protocol and protocol and product) FDA Response Supplement for 3-5 year follow-up pending PMA approval (protocol and product) FDA Response Supplement for 3-5 year follow-up pending PMA approval (protocol and product) FDA Response Supplement for 3-5 year follow-up pending PMA approval (protocol and product) FDA Response Supplement for 3-5 year follow-up pending PMA approval (protocol and product) FDA Response Supplement for 3-5 year follow-up pending PMA approval (protocol and product) FDA Response Supplement for 3-5 year follow-up pending PMA approval (protocol and product) FDA Response Supplement for 3-5 year follow-up pending PMA approval (protocol and product) FDA Response Supplement for 3-5 year follow-up pending PMA approval (protocol and product) FDA Response Supplement for 3-5 year follow-up pending PMA approval (protocol and product) FDA Response Supplement for 3-5 year follow-up pending PMA approval (protocol and product) FDA Response Supplement FDA Response | Annual Report Annual Report Pirst Annual Report submitted. Supplement Studies Sol13 Supplement Studies Sol13 Supplement Patient Count Studies Sol14 Final Report PMA Application Submission Continued Access Protocol and plan changes, including Increase and pending PMA approval (protocol and pending PMA approval pe | Annual Report Annual Report Pirst Annual Report submitted. Supplement Studies Sol13 Supplement Sudies Sol13 Supplement Patient Count Studies Submitted regarding FDA's Sol13 Supplement Sudies Sol13 Supplement Patient Count Patient Sol14 Final Report PMA Application Submission for IDE Final Report Sol16 Submission Continued Access Continued access after pivotal study, increased tantalum in Onyx. Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and plan consent). No Response DMSO Stability studies 3-15-02 FDA Response PA Additional Patient Sol13 FDA Response Continued Access Protocol and plan changes, including increased tantalum in Onyx. Supplement for 3-5 year follow-up pending PMA approval (protocol and plan consent). | Annual Report Annual Report Pirst Annual Report submitted. Supplement Studies Sol13 Supplement Studies Sol13 Supplement Patient Count Studies Sol14 Final Report PMA Application Submission Continued Access Protocol and plan changes, including Increase at Bubmission Supplement for 3-5 year Follow-up pending PMA approval (protocol and proval protocol and pending PMA approval (protocol and proval protocol and pending PMA approval (protocol and proval protocol and pending PMA approval (protocol and pending PMA approval pen | Annual Report Annual Report Pirst Annual Report submitted. Supplement Studies Sol13 Supplement Sudies Sol13 Supplement Patient Count Studies Submitted regarding FDA's Sol13 Supplement Sudies Sol13 Supplement Patient Count Patients. Supplement Poticiation Submission for IDE Final Report Sol14 Final Report PMA Application Submission for IDE Final Report Submission Submission Submission Submission Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and plan changes, including informed consent). No Response DMSO Stability studies Submise Submise Submise Submise Submise Sol13 FDA Response Enrollment Sol16 FDA Response Continued Access Protocol and plan changes, including increased tantalum in Onyx. Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). | Annual Report Annual Report Pirst Annual Report submitted. Supplement Studies Sol13 Supplement Sudies Sol13 Supplement Patient Count Studies Submitted regarding FDA's Sol13 Supplement Sudies Sol13 Supplement Patient Count Patients. Supplement Patient Count Sol14 Final Report PMA Application Submission for IDE Final Report PMA Application Submission Submission Submission Submission Submission Submission Submission Submission Supplement for 3-5 year follow-up Pending PMA approval (protocol and plan changes, including Informed consent). No Response DMSO Stability Sudies Sol13 FDA Response PA Additional Patient Sol16 FDA Response Continued Access PA Response Portional Sudy, Including Increased tantalum in Onyx. Submission Supplement for 3-5 year follow-up Pending PMA approval (protocol and plan changes, including Informed consent). | Annual Report Annual Report Pirst Annual Report submitted. Supplement Studies Sol13 Supplement Sudies Sol13 Supplement Patient Count Patients. Supplement Sudies Submission Continued Access after pivotal study, protocol and plan changes, including PMA approval (protocol and pending PMA approval (protocol and pinformed consent). No Response DMSO Stability studies 3-15-02 FDA Response Studies Submission Studies Submission for IDE Final Report Patient Sol13 FDA Response Additional Patient Sol16 FDA Response Continued Access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and plan changes). | Annual Report Annual Report Pirst Annual Report submitted. Supplement Studies Sol13 Supplement Sudies Sol13 Supplement Patient Count Studies Submitted regarding FDA's Sol13 Supplement Sudies Sol13 Supplement Patient Count Patients. Supplement Poticiation Submission for IDE Final Report Sol14 Final Report PMA Application Submission for IDE Final Report Submission Submission Submission Submission Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and plan changes, including informed consent). No Response DMSO Stability studies Submise Submise Submise Submise Submise Sol13 FDA Response Enrollment Sol16 FDA Response Continued Access Protocol and plan changes, including increased tantalum in Onyx. Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). | Annual Report Annual Report Pirst Annual Report submitted. Supplement Studies Sol13 Supplement Sudies Sol13 Supplement Patient Count Studies Submitted regarding FDA's Sol13 Supplement Sudies Sol13 Supplement Patient Count Patients. Supplement Poticiation Submission for IDE Final Report Sol14 Final Report PMA Application Submission for IDE Final Report Submission Submission Submission Submission Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and plan changes, including informed consent). No Response DMSO Stability studies Submise Submise Submise Submise Submise Sol13 FDA Response Enrollment Sol16 FDA Response Continued Access Protocol and plan changes, including increased tantalum in Onyx. Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). | Annual Report Annual Report Pirst Annual Report submitted. Supplement Studies Sol13 Supplement Sudies Sol13 Supplement Patient Count Studies Submitted regarding FDA's Sol13 Supplement Sudies Sol13 Supplement Patient Count Patient Sol14 Final Report PMA Application Submission for IDE Final Report Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). No Response DMSO Stability Subdies Sol13 FDA Response Additional Patient Sol16 FDA Response Continued Access PAR Response Protocol and plan changes, including increased tantalum in Onyx. Supplement of 3-5 year follow-up pending PMA approval (protocol and informed consent). | Annual Report Annual Report Pirst Annual Report submitted. Supplement Studies Sol13 Supplement Studies Sol13 Supplement Patient Count Studies Submitted regarding FDA's Sol13 Supplement Patient Count Patients. Supplement Patient Count Patients. Supplement Sol4 Final Report PMA Application Submission for IDE Final Report Submission Continued Access Protocol and plan changes, including Increased tantalum in Onyx. Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and plan changes, including Informed consent). No Response DMSO Stability Studies Sol13 FDA Response Additional Patient Sol6 FDA Response Continued Access Protocol and plan changes, including Increased tantalum in Onyx. Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). | Annual Report Annual Report Pirst Annual Report submitted. Supplement Studies Sol13 Supplement Soldes Sol13 Supplement Patient Count Patients. Supplement Sol4 Supplement Sol4 Submission Continued Access after pivotal study, protocol and plan changes, including pmending PMA approval (protocol and pending PMA approval pending | Annual Report Annual Report Pirst Annual Report submitted. Supplement Studies Sol13 Supplement Sudies Sol13 Supplement Patient Count Patients. Supplement Sudies Submission Continued Access after pivotal study, protocol and plan changes, including PMA approval (protocol and pending PMA approval (protocol and pinformed consent). No Response DMSO Stability studies 3-15-02 FDA Response Studies Submission Studies Submission for IDE Final Report Patient Sol13 FDA Response Additional Patient Sol16 FDA Response Continued Access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and plan changes). | Annual Report Annual Report Pirst Annual Report submitted. Supplement Studies Sol13 Supplement Soldes Submitted regarding FDA's submitted regarding FDA's Sol13 Supplement Patient Count Patients. Supplement Patient Count Patients. Supplement Portional approval letter dated 12-Sol14 Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission Supplement for 3-5 year Follow-up pending PMA approval (protocol and informed consent). No Response DMSO Stability studies 3-15-02 FDA Response Sol13 FDA Response Continued Access Additional Patient Sol16 FDA Response Continued Access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Annual Report Annual Report Pirst Annual Report submitted. Supplement Studies Sol13 Supplement Sudies Sol13 Supplement Patient Count Patients. Supplement Sudies Submission Continued Access after pivotal study, protocol and plan changes, including PMA approval (protocol and pending PMA approval (protocol and pinformed consent). No Response DMSO Stability studies 3-15-02 FDA Response Studies Submission Studies Submission for IDE Final Report Patient Sol13 FDA Response Additional Patient Sol16 FDA Response Continued Access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and plan changes). | Annual Report Annual Report Pirst Annual Report submitted. Supplement Studies Sol13 Supplement Soldes Sol13 Supplement Patient Count Patients. Supplement Sol4 Supplement Sol4 Submission Continued Access after pivotal study, protocol and plan changes, including pmending PMA approval (protocol and pending PMA approval pending | Annual Report Annual Report Pirst Annual Report submitted. Supplement Studies Sol13 Supplement Soldes Sol13 Supplement Patient Count Patients. Supplement Sol4 Supplement Sol4 Submission Continued Access after pivotal study, protocol and plan changes, including pmending PMA approval (protocol and pending PMA approval pending | Annual Report Annual Report Pirst Annual Report submitted. Supplement Studies Sol13 Supplement Patient Count Studies Sol14 Supplement Patient Count Patients. Supplement Sol4 Submission Continued Access Protocol and plan changes, including Protocol and perioding PMA approval (protocol and and perioding PMA approval | Annual Report Annual Report Pirst Annual Report submitted. Supplement Studies Sol13 Supplement Patient Count Studies Submitted regarding FDA's continued approval letter dated 12- Supplement Sol14 Supplement Patient Count Patients. Supplement Polication Submission for IDE Final Report Pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). No Response PDA Response Suditive Submission for IDE Final Report Plan Report PAA Response Polication PMA approval (protocol and plan changes, including informed consent). | Annual Report Annual Report Pirst Annual Report submitted. Supplement Studies Sol13 Supplement Patient Count Studies Submitted regarding FDA's continued approval letter dated 12- Supplement Sol14 Supplement Patient Count Patients. Supplement Polication Submission for IDE Final Report Pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). No Response PDA Response Suditive Submission for IDE Final Report Plan Report PAA Response Polication PMA approval (protocol and plan changes, including informed consent). | Annual Report Annual Report Pirst Annual Report submitted. Supplement Studies Sol13 Supplement Patient Count Studies Submitted regarding FDA's continued approval letter dated 12- Supplement Sol14 Supplement Patient Count Patients. Supplement Polication Submission for IDE Final Report Pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). No Response PDA Response Suditive Submission for IDE Final Report Plan Report PAA Response Polication PMA approval (protocol and plan changes, including informed consent). |
| Supplement Studies Supplement Studies Supplement Studies Supplement Studies Sol13 Supplement Sudies Submitted regarding FDA's conditional approval letter dated 12- Supplement Sol14 Supplement Sudies Submission Frinal Report Patient Count Final Report Sol15 Submission Submission Submission Submission for IDE Final Report Submission Submission Supplement for 3-5 year follow-up Pending PMA approval forefolded and plan changes, including increased tandalum in Onyx. Submission Submission Submission Supplement for 3-5 year follow-up Pending PMA approval forefolded and plan changes, including increased tandalum in Onyx. Submission Submission Submission Supplement for 3-5 year follow-up PAA approval forefolded and plan changes, including increased tandalum in Onyx. Submission Submiss | Supplement Studies Supplement Studies Supplement Studies Sol 3-15-02 FDA Response PDA Response POLOcol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up Ponding PMA approval (protocol and PDA Response PDA Response PDA Response Ponding PMA approval (protocol and PDA Response PDA Response PDA Response PDA Response Ponding PMA approval (protocol and PDA Response PDA PDA Response PDA PDA Response PDA PDA Response PDA | Supplement Studies Supplement Patient Count Sold Application Submission Continued Access Enaction Submission S | Supplement Studies Supplement Patient Count Sol Stability Patients. Supplement Sudies Submitted regarding FDA's Submitted | Supplement Studies Supplement Studies Supplement Studies Sol Supplement Studies Sol Sol Studies Sol Studies Sol Sol Sol Studies Sol Sol Sol Studies Sol | Supplement Studies Supplement Patient Count Submission Continued Access Esubmission Submission Subm | Supplement Studies Supplement Patient Count Submission Continued Access Esubmission Submission Subm | Supplement Studies Supplement Studies Supplement Studies Supplement Studies Sol 3-15-02 FDA Response PDA Response PMA Application Submission Final Report PMA Application Submission Final Report PMA Application For IDE Final Report PMA Application Submission Submission Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and plan changes, including increased tantalum in Onlyx. Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and plan changes, including increased tantalum in Onlyx. Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and plan changes, including informed consent) | Supplement Studies Supplement Patient Count Submission Continued Access Submission Submi | Supplement Studies Supplement Patient Count Submitted regarding FDA's Supplement Supplement Supplement Submission Submiss | Supplement Studies Supplement Patient Count Submission Continued Access Esubmission Submission Subm | Annual Report Annual Report Stability Supplement Supplement Sudies Sol 3 - 15-02 FDA Response Studies Sol 3 - 15-02 FDA Response Studies Submitted regarding FDA's Conditional approval letter dated 12- Supplement Patient Count Patients. Supplement Supplement Patient Count Submission for IDE Final Report PMA Application Submission | Supplement Studies Supplement Patient Count Submission Continued Access Submission Submi | Supplement Studies Supplement Patient Count Sold Patients. Supplement Sudies Submitted regarding FDA's Submitted regardin | Annual Report Annual Report Stability Sudies Supplement Studies SO13 DMSO Stability Studies SO13 DMSO Stability Studies SO13 DMSO Stability Studies Submitted regarding FDA's Conditional approval letter dated 12-SO14 Patient Count Sold Patients. Supplement Patient Count Patients. Supplement Patient Count Submission for IDE Final Report Patients. Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission Submission Submission Subplement for 3-5 year follow-up pending PMA approval (protocol and plan changes), informed consent). | Supplement Studies Supplement Patient Count Sol Stability Patients. Supplement Sudies Submitted regarding FDA's Submitted | Supplement Studies Supplement Patient Count Sold Patients. Supplement Sudies Submitted regarding FDA's Submitted regardin | Supplement Studies Supplement Patient Count Sold Patients. Supplement Sudies Submitted regarding FDA's Submitted regardin | Annual Report Annual Report Stability Sudies Supplement Studies SO13 Supplement Sudies Submitted regarding FDA's Submitte | Supplement Studies Supplement Patient Count Sold Patients. Supplement Sudies Submitted regarding FDA's Submitted regardin | Supplement Studies Supplement Supplement Solutional Report Submitted Request to increase number of Solutients. Supplement Submission Continued Access Submission Sub | Supplement Studies Supplement Patient Count Sol Stability Patients. Supplement Sudies Submitted regarding FDA's Submitted | Supplement Studies Supplement Supplement Sol Stability Studies Sol Supplement Sudies Submitted regarding FDA's Sudies Submitted regarding FDA's Subm | Supplement Studies Supplement Patient Count Sol Stability Patients. Supplement Sudies Submitted regarding FDA's Submitted | Supplement Studies Supplement Supplement Solutional Report Submitted Request to increase number of Solutients. Supplement Submission Continued Access Submission Sub | Supplement Studies Supplement Supplement Solutional Report Submitted Request to increase number of Solutients. Supplement Submission Continued Access Submission Sub | Supplement Supplement Supplement Submitted. Supplement Supplement Soludies Sol Studies Sol Sol Studies Sol Studies Sol Studies Sol Studies Sol Studies Sol Sol Studies Sol Studies Sol Studies Sol Studies Sol Studies Sol Sol Studies Sol Studies Sol Studies Sol Studies Sol Sol Studies Sol Studies Sol Sol Sol Studies Sol Sol Sol Studies Sol Sol Sol Sol Studies Sol Sol Sol Sol Sol Studies Sol | Supplement Studies Supplement Patient Count Submitted Request to increase number of Studies Submission Continued Access Entral Report Submission Submissio | Supplement Studies Supplement Patient Count Submitted Request to increase number of Studies Submission Continued Access Entral Report Submission Submissio | Supplement Studies Supplement Patient Count Submitted Request to increase number of Studies Submission Continued Access Entral Report Submission Submissio |
| Supplement Studies Submitted regarding FDA's Submitted regarding FDA's Supplement Sol13 Supplement Patient Count Sol14 Final Report PMA Application Submission Continued Access protocol and plan changes, including increased tantalum in Onyx. Submission Submission 3-5 year Follow-up Supplement for 3-5 year follow-up one-direct and sold and plan changes and sold and sold and plan changes and sold and plan changes and sold and sold and sold and sold and sol | Supplement DMSO Stability studies submitted regarding FDA's Soli3 Supplement Patient Count Solidies Submission Continued Access after pivotal study, pending PMA approval (protocol and plan changes, including pending PMA approval (protocol and pending PMA approval pending PMA approval (protocol and pending PMA approval pending PMA approval pending PMA approval (protocol and pending PMA approval pending pending pending pending pendin | Supplement DMSO Stability budies submitted regarding FDA's conditional approval letter dated 12- Supplement Sol Patient Count Sol Patients. Supplement Patient Count Sol PMA Application Submission Continued Access protocol and plan changes, including increase tantalum in Onlyx. Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and plan changes) informed consent) No Response DMSO Stability studies 3-15-02 FDA Response Studies Sol PDA Response PDA Additional Patient Sol PDA Response Enrollment Sol PDA Response PDA Respons | Supplement DMSO Stability but sudies submitted regarding FDA's sonditional approval letter dated 12- Supplement Sold Patient Count sold approval letter dated 12- Supplement Sold Patients. Supplement Patient Count Request to increase number of sold Patients. Supplement PMA Application Submission for IDE Final Report Final Report PMA Application Submission for IDE Final Report PMA Application Submission for IDE Final Report PMA Approval (protocol and plan changes, including increased tantalum in Onlyx. Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). | Supplement DMSO Stability Studies S013 Supplement Patient Count S014 Supplement Patient Count S014 Supplement Sold Supplement Sold Supplement Sold Submission Continued Access protocol and plan changes, including increased tantalum in Onyx. Submission Supplement Supplement for 3-5 year Follow-up pending PMA approval (protocol and plan changes, including pending PMA approval (protocol and plan changes). Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and plan changes). Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and plan changes). Submission Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and plan changes). Submission Sub | Supplement DMSO Stability budies submitted regarding FDA's conditional approval letter dated 12- Supplement Sol Patient Count Sol Patient Count Sol Patients. Supplement Patient Count Patient Count Sol Patients. Supplement Patient Count Patients. Supplement Patient Count Patients. Supplement Patient Count Patients. Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and plan changes) informed consent). | Supplement DMSO Stability butters submitted regarding FDA's Solia Studies Submitted regarding FDA's Solia Submitted regarding FDA's Solia Submitted regarding FDA's Solia Solia Studies Solia Solia Studies Solia Solia Studies Solia Soli | Supplement DMSO Stability budies submitted regarding FDA's conditional approval letter dated 12- studies Supplement Sol Patient Count Sol Patient Count Sol Patients. Supplement Patient Count Sol PMA Application Submission Continued Access Protocol and plan changes, including increase tantalum in Onlyx. Submission Submission Spear Follow-up pending PMA approval (protocol and plan changes) informed Consent) Submission Spear Follow-up Supplement for 3-5 year follow-up pending PMA approval (protocol and plan changes) informed Consent) | Supplement DMSO Stability but its studies Submitted regarding FDA's Sol13 Studies Sol14 Patient Count Patients. Supplement Patient Count Patients. Supplement Pontinued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and pinformed consent). | Supplement DMSO Stability budies submitted regarding FDA's conditional approval letter dated 12- Supplement Sol Patient Count Sol Patient Count Sol Patient Count Sol Patients. Supplement Patient Count PMA Application Submission of IDE Final Report PMA Application Submission Continued Access Protocol and plan changes, including increased tantalum in Onlyx. Submission Submission Submission Submission of IDE Final Report Supplement for 3-5 year follow-up pending PMA approval (protocol and plan changes, including informed consent). | Supplement DMSO Stability butters submitted regarding FDA's Solia Studies Submitted regarding FDA's Solia Submitted regarding FDA's Solia Submitted regarding FDA's Solia Solia Studies Solia Solia Studies Solia Solia Studies Solia Soli | Supplement DMSO Stability butters submitted regarding FDA's Sol13 Supplement Patient Count Sol4 Final Report PMA Application Submission Continued Access protocol and plan changes, including informed consent). | Supplement DMSO Stability but its studies Submitted regarding FDA's Sol13 Studies Sol14 Patient Count Patients. Supplement Patient Count Patients. Supplement Pontinued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and pinformed consent). | Supplement DMSO Stability butters submitted regarding FDA's Sol13 Supplement Patient Count Soludies Sol14 Supplement Patient Count Patients. Supplement Sol14 Submission Continued Access protocol and plan changes, including informed consent). Submission Submission Submission Submission of 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Supplement DMSO Stability butters submitted regarding FDA's Sol13 Supplement Patient Count Sol4 Final Report PMA Application Submission Continued Access protocol and plan changes, including informed consent). | Supplement DMSO Stability but sudies submitted regarding FDA's sonditional approval letter dated 12- Supplement Sold Patient Count sold approval letter dated 12- Supplement Sold Patients. Supplement Patient Count Request to increase number of sold Patients. Supplement PMA Application Submission for IDE Final Report Final Report PMA Application Submission for IDE Final Report PMA Application Submission for IDE Final Report PMA Approval (protocol and plan changes, including increased tantalum in Onlyx. Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). | Supplement DMSO Stability butters submitted regarding FDA's Sol13 Supplement Patient Count Soludies Sol14 Supplement Patient Count Patients. Supplement Sol14 Submission Continued Access protocol and plan changes, including informed consent). Submission Submission Submission Submission of 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Supplement DMSO Stability butters submitted regarding FDA's Sol13 Supplement Patient Count Soludies Sol14 Supplement Patient Count Patients. Supplement Sol14 Submission Continued Access protocol and plan changes, including informed consent). Submission Submission Submission Submission of 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Supplement DMSO Stability butters submitted regarding FDA's Sol13 Supplement Patient Count Soludies Sol14 Supplement Patient Count Patients. Supplement Sol14 Submission Continued Access protocol and plan changes, including informed consent). Submission Submission Submission of 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Supplement DMSO Stability butters submitted regarding FDA's Sol13 Supplement Patient Count Soludies Sol14 Supplement Patient Count Patients. Supplement Sol14 Submission Continued Access protocol and plan changes, including informed consent). Submission Submission Submission Submission of 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Supplement DMSO Stability but its submitted regarding FDA's sonditional approval letter dated 12- Supplement Sol PMA Application Submission Continued Access Protocol and plan changes, including informed consent). Submission Submission Submission Submission of Supplement for 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Supplement DMSO Stability but sudies submitted regarding FDA's sonditional approval letter dated 12- Supplement Sold Patient Count sold approval letter dated 12- Supplement Sold Patients. Supplement Patient Count Request to increase number of sold Patients. Supplement PMA Application Submission for IDE Final Report Final Report PMA Application Submission for IDE Final Report PMA Application Submission for IDE Final Report PMA Approval (protocol and plan changes, including increased tantalum in Onlyx. Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). | Supplement DMSO Stability but its submitted regarding FDA's sonditional approval letter dated 12- Supplement Sold Stability studies submitted regarding FDA's sonditional approval letter dated 12- Supplement Sold Patient Count Patients. Supplement Patient Count Request to increase number of patients. Supplement Sold PMA Application Submission for IDE Final Report Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). | Supplement DMSO Stability but sudies submitted regarding FDA's sonditional approval letter dated 12- Supplement Sold Patient Count sold approval letter dated 12- Supplement Sold Patients. Supplement Patient Count Request to increase number of sold Patients. Supplement PMA Application Submission for IDE Final Report Final Report PMA Application Submission for IDE Final Report PMA Application Submission for IDE Final Report PMA Approval (protocol and plan changes, including increased tantalum in Onlyx. Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). | Supplement DMSO Stability but its submitted regarding FDA's sonditional approval letter dated 12- Supplement Sol PMA Application Submission Continued Access Protocol and plan changes, including informed consent). Submission Submission Submission Submission of Supplement for 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Supplement DMSO Stability but its submitted regarding FDA's sonditional approval letter dated 12- Supplement Sol PMA Application Submission Continued Access Protocol and plan changes, including informed consent). Submission Submission Submission Submission of Supplement for 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Supplement Studies Submitted regarding FDA's conditional approval letter dated 12- Supplement Sol PMA Application Submission Continued Access Protocol and plan changes, including informed consent). Submission Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Supplement DMSO Stability but its submitted regarding FDA's sonditional approval letter dated 12- Sol Sol Stability studies submitted regarding FDA's sonditional approval letter dated 12- Sol Sol Sol Sol Stability studies submitted regarding FDA's sonditional approval letter dated 12- Sol | Supplement DMSO Stability but its submitted regarding FDA's sonditional approval letter dated 12- Sol Sol Stability studies submitted regarding FDA's sonditional approval letter dated 12- Sol Sol Sol Sol Stability studies submitted regarding FDA's sonditional approval letter dated 12- Sol | Supplement DMSO Stability but its submitted regarding FDA's sonditional approval letter dated 12- Sol Sol Stability studies submitted regarding FDA's sonditional approval letter dated 12- Sol Sol Sol Sol Stability studies submitted regarding FDA's sonditional approval letter dated 12- Sol |
| Supplement DMSO Stability DMSO aging/stability studies submitted regarding FDA's submitted regarding FDA's submitted regarding FDA's submission Studies S013 Supplement Patient Count Patient Count Patients. Supplement Patient Count Patient Count Patients. Supplement Pontinued Access Continued access after pivotal study, protocol and plan changes, including increased tandalum in Onyx. Submission Submission Supplement for 3-5 year follow-up Continued access after pivotal and plan changes, including increased tandalum in Onyx. Submission Submission Supplement for 3-5 year follow-up Co-20-04 FDA Response Supplement for 3-5 year follow-up | Supplement DMSO Stability DMSO aging/stability studies submitted regarding FDA's submitted regarding FDA's conditional approval letter dated 12- Supplement Patient Count Supplement Patient Count Patients. Supplement Patient Count Patient Count Patients. Supplement Polication Submission for IDE Final Report Final Report PMA Application Submission for IDE Final Report PMA Application Submission for IDE Final Report PMA Application Patient Submission Ocntinued Access protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and Patient PDA Response PMA Response PAMA approval (protocol and PAMA approval (protocol and Patient PAMA approval (protocol and PA | Supplement DMSO Stability studies submitted regarding FDA's Sol13 Supplement Studies Sol13 Supplement Patient Count Former Count Sol14 Supplement Patient Count Patients. Supplement Positional approval letter dated 12- Sol13 Supplement Positional Request to increase number of patients. Supplement Positional Request to increase number of patients. Submission Continued Access Protocol and plan changes, including increased tantalum in Onyx. Submission Submission Supplement for 3-5 year follow-up pending PMA pendi | Supplement DMSO Stability studies Sol13 Studies Submitted regarding FDA's conditional approval letter dated 12- Supplement Sol14 Supplement Patient Count Patients. Supplement Sol14 Final Report PMA Application Submission for IDE Final Report PMA approval access after pivotal study, pending PMA approval (protocol and plan changes, including pending PMA approval (protocol and plan changes, informed consent). Submission Submission 3-5 year Follow-up pending PMA approval (protocol and plan changes). DMSO stability studies submissed Submise Studies Sol13 FDA Response Additional Patient Sol16 Enrollment Sol16 FDA Response Continued Access protocol and plan changes, including increased tantalum in Onyx. Submission Submission Submission Submission Onyx. Submission Submission Submission Onyx. Submission Submission Submission FDA Response Submission Onyx. | Supplement DMSO Stability studies submitted regarding FDA's sonditional approval letter dated 12- Supplement Supplement Patient Count Submission Final Report PMA Application Submission Continued Access after pivotal study, pending PMA approval (protocol and plan changes, including increased tantalum in Onyx. DMSO Stability studies submission 3-15-02 FDA Response Submission Studies Sol13 FDA Response Additional Patient Sol16 FDA Response Enrollment Enrollment Submission Submission Onyx. Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and plan changes, including increased tantalum in Onyx. Submission Submission Submission Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and plan changes, including increased tantalum in Onyx. Submission Submissi | Supplement DMSO Stability studies submitted regarding FDA's Sol13 Supplement Studies Sol13 Supplement Patient Count Fequest to increase number of Supplement Sol14 Final Report PMA Application Submission for IDE Final Report Final Report PMA application Submission Submission Submission Submission Submission Submission Occurrence dated access after pivotal study, pending PMA approval (protocol and plan changes, including informed access pending PMA approval (protocol and plan changes, including informed consent). Submission Submission Submission Occurrence dated I2- Submission Submission Occurrence of Enal Report Supplement for 3-5 year follow-up pending PMA approval (protocol and plan changes). Submission Submission Occurrence of Enal Report Supplement for 3-5 year follow-up pending PMA approval (protocol and plan changes). | Supplement DMSO Stability studies submitted regarding FDA's Sol13 Supplement Studies Sol13 Supplement Patient Count Final Report PMA Application Submission Continued Access protocol and plan changes, including informed consent). Submission Submission PMA approval (protocol and plan changes, informed consent). DMSO stability studies submise 3-15-02 FDA Response Additional Patient Sol13 FDA Response Enrollment Studies Sol13 Submission Continued Access Protocol and plan changes, including informed consent). | Supplement DMSO Stability studies submitted regarding FDA's Sol13 Supplement Studies Sol13 Supplement Patient Count Patients. Supplement Patient Count Patients. Supplement Poticiation Submission for IDE Final Report Final Report PMA Application Submission of PMA Application Submission Final Report PMA Application Submission Final Report PMA Application Submission Onlyx. Submission Submission Submission Submission of IDE Final Report Protocol and plan changes, including increased tantalum in Onlyx. Submission Submission Submission Subplement for 3-5 year follow-up pending PMA approval (protocol and plan changes). Submission Submission Submission Subplement for 3-5 year follow-up pending PMA approval (protocol and plan changes). | Supplement DMSO Stability studies submitted regarding FDA's Sol13 Supplement Studies Sol13 Supplement Patient Count Final Report PMA Application Submission Continued Access protocol and plan changes, including informed consent). Submission Submission S-5 year Follow-up pending PMA approval (protocol and plan changes). DMSO stability studies submise 3-15-02 FDA Response Additional Patient Enrollment Sol13 Submission Submission for IDE Final Report Sol16 FDA Response Enrollment Final Report Sol16 Enrollment PDA Response Continued Access after pivotal study, pending PMA approval (protocol and plan changes, including informed consent). | Supplement DMSO Stability studies submitted regarding FDA's Sol13 Supplement Studies Sol13 Supplement Patient Count Formula Request to increase number of Supplement Sol14 Final Report PMA Application Submission for IDE Final Report Final Report PMA application Submission Submission Submission Submission Submission PMA Applement for 3-5 year follow-up pending PMA approval (protocol and plan changes, including increased tantalum in Onyx. Submission Submission S-5 year Follow-up pending PMA approval (protocol and plan changes, including informed consent). Submission S-5 year Follow-up pending PMA approval (protocol and plan changes). | Supplement DMSO Stability studies submitted regarding FDA's Sol13 Supplement Studies Sol13 Supplement Patient Count Final Report PMA Application Submission Continued Access protocol and plan changes, including informed consent). Submission Submission PMA approval (protocol and plan changes, informed consent). DMSO stability studies submise 3-15-02 FDA Response Additional Patient Sol13 FDA Response Enrollment Studies Sol13 Submission Continued Access Protocol and plan changes, including informed consent). | Supplement DMSO Stability studies submitted regarding FDA's Studies Sol13 Supplement Studies Sol13 Supplement Patient Count Patients. Supplement Supplement Submission Continued Access protocol and plan changes, including informed consent). Submission Submission Submission Submission PMA approval (protocol and plan changes, informed consent). DMSO stability studies submise 3-15-02 FDA Response Studies Sol13 FDA Response Enrollment Patient Sol16 FDA Response Continued Access protocol and plan changes, including informed consent). Submission Submission Submission Submission of 1DE Final Report PA Response Continued Access protocol and plan changes, including informed consent). | Supplement DMSO Stability studies submitted regarding FDA's Sol13 Supplement Studies Sol13 Supplement Patient Count Final Report PMA Application Submission Continued Access protocol and plan changes, including informed consent). Submission Submission S-5 year Follow-up pending PMA approval (protocol and plan changes). DMSO stability studies submise 3-15-02 FDA Response Additional Patient Enrollment Sol13 Submission Submission for IDE Final Report Sol16 FDA Response Enrollment Final Report Sol16 Enrollment PDA Response Continued Access after pivotal study, pending PMA approval (protocol and plan changes, including informed consent). | Supplement DMSO Stability studies Sol13 Studies Submitted regarding FDA's conditional approval letter dated 12- Supplement Sol14 Final Report PMA Application Submission Continued Access protocol and plan changes, including increased tantalum in Onyx. Submission Submission 3-5 year Follow-up pending PMA approval (protocol and blan changes, informed consent). DMSO stability studies submise 3-15-02 FDA Response Studies Sol13 FDA Response Enrollment Sol16 FDA Response Continued Access protocol and plan changes, including increased tantalum in Onyx. Submission Submission 3-5 year Follow-up pending PMA approval (protocol and blan changes). | Supplement DMSO Stability studies submitted regarding FDA's submitted regarding FDA's Sol13 Supplement Sudies Sol13 Supplement Patient Count Patients. Supplement Submission Continued Access protocol and plan changes, including increased tantalum in Onyx. Submission Submission 3-5 year Follow-up pending PMA approval (protocol and plan changes), informed consent). DMSO stability studies submise 3-15-02 FDA Response Additional Patient Sol16 FDA Response Enrollment Submise Continued Access after pivotal study, increased tantalum in Onyx. Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and plan changes), informed consent). | Supplement DMSO Stability studies Sol13 Studies Submitted regarding FDA's conditional approval letter dated 12- Supplement Sol14 Supplement Patient Count Patients. Supplement Sol14 Final Report PMA Application Submission for IDE Final Report PMA approval access after pivotal study, pending PMA approval (protocol and plan changes, including pending PMA approval (protocol and plan changes, informed consent). Submission Submission 3-5 year Follow-up pending PMA approval (protocol and plan changes). DMSO stability studies submissed Submise Studies Sol13 FDA Response Additional Patient Sol16 Enrollment Sol16 FDA Response Continued Access protocol and plan changes, including increased tantalum in Onyx. Submission Submission Submission Submission Onyx. Submission Submission Submission Onyx. Submission Submission Submission FDA Response Submission Onyx. | Supplement DMSO Stability studies Sol13 Studies Submitted regarding FDA's conditional approval letter dated 12- Supplement Sol14 Final Report PMA Application Submission Continued Access protocol and plan changes, including increased tantalum in Onyx. Submission Submission 3-5 year Follow-up pending PMA approval (protocol and blan changes, informed consent). DMSO stability studies submise 3-15-02 FDA Response Studies Sol13 FDA Response Enrollment Sol16 FDA Response Continued Access protocol and plan changes, including increased tantalum in Onyx. Submission Submission 3-5 year Follow-up pending PMA approval (protocol and blan changes). | Supplement DMSO Stability studies Sol13 Studies Submitted regarding FDA's conditional approval letter dated 12- Supplement Sol14 Final Report PMA Application Submission Continued Access protocol and plan changes, including increased tantalum in Onyx. Submission Submission 3-5 year Follow-up pending PMA approval (protocol and blan changes, informed consent). DMSO stability studies submise 3-15-02 FDA Response Studies Sol13 FDA Response Enrollment Sol16 FDA Response Continued Access protocol and plan changes, including increased tantalum in Onyx. Submission Submission 3-5 year Follow-up pending PMA approval (protocol and blan changes). | Supplement DMSO Stability studies submitted regarding FDA's submitted regarding FDA's Sol13 Supplement Sudies Sol13 Supplement Patient Count Patients. Supplement Sol14 Final Report PMA Application Submission for IDE Final Report Submission Continued Access protocol and plan changes, including increased tantalum in Onyx. Submission Submission 3-5 year Follow-up pending PMA approval (protocol and plan changes, informed consent). DMSO Stability studies submise Su | Supplement DMSO Stability studies Sol13 Studies Submitted regarding FDA's conditional approval letter dated 12- Supplement Sol14 Final Report PMA Application Submission Continued Access protocol and plan changes, including increased tantalum in Onyx. Submission Submission 3-5 year Follow-up pending PMA approval (protocol and blan changes, informed consent). DMSO stability studies submise 3-15-02 FDA Response Studies Sol13 FDA Response Enrollment Sol16 FDA Response Continued Access protocol and plan changes, including increased tantalum in Onyx. Submission Submission 3-5 year Follow-up pending PMA approval (protocol and blan changes). | Supplement DMSO Stability studies submitted regarding FDA's submitted regarding FDA's soliditional approval letter dated 12- Supplement Supplement Patient Count patients. Supplement PMA Application Submission for IDE Final Report PMA Application Submission of TDE Final Report PMA Application Submission of TDE Final Report PMA Application Submission of TDE Final Report PMA Approval (protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and plan changes). Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and plan changes). | Supplement DMSO Stability studies Sol13 Studies Submitted regarding FDA's conditional approval letter dated 12- Supplement Sol14 Supplement Patient Count Patients. Supplement Sol14 Final Report PMA Application Submission for IDE Final Report PMA approval access after pivotal study, pending PMA approval (protocol and plan changes, including pending PMA approval (protocol and plan changes, informed consent). Submission Submission 3-5 year Follow-up pending PMA approval (protocol and plan changes). DMSO stability studies submissed Submise Studies Sol13 FDA Response Additional Patient Sol16 Enrollment Sol16 FDA Response Continued Access protocol and plan changes, including increased tantalum in Onyx. Submission Submission Submission Submission Onyx. Submission Submission Submission Onyx. Submission Submission Submission FDA Response Submission Onyx. | Supplement DMSO Stability studies submitted regarding FDA's submitted regarding FDA's soliditional approval letter dated 12- of 7-01. Supplement Supplement Patient Count solid Access Final Report PMA Application Submission Continued Access protocol and plan changes, including increased tantalum in Onyx. Submission Submission 3-5 year Follow-up pending PMA approval (protocol and protocol and pending PMA approval (protocol and pending pending PMA approval (protocol and pending p | Supplement DMSO Stability studies Sol13 Studies Submitted regarding FDA's conditional approval letter dated 12- Supplement Sol14 Supplement Patient Count Patients. Supplement Sol14 Final Report PMA Application Submission for IDE Final Report PMA approval access after pivotal study, pending PMA approval (protocol and plan changes, including pending PMA approval (protocol and plan changes, informed consent). Submission Submission 3-5 year Follow-up pending PMA approval (protocol and plan changes). DMSO stability studies submissed Submise Studies Sol13 FDA Response Additional Patient Sol16 Enrollment Sol16 FDA Response Continued Access protocol and plan changes, including increased tantalum in Onyx. Submission Submission Submission Submission Onyx. Submission Submission Submission Onyx. Submission Submission Submission FDA Response Submission Onyx. | Supplement DMSO Stability studies submitted regarding FDA's submitted regarding FDA's soliditional approval letter dated 12- Supplement Supplement Patient Count patients. Supplement PMA Application Submission for IDE Final Report PMA Application Submission of TDE Final Report PMA Application Submission of TDE Final Report PMA Application Submission of TDE Final Report PMA Approval (protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and plan changes). Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and plan changes). | Supplement DMSO Stability studies submitted regarding FDA's submitted regarding FDA's soliditional approval letter dated 12- Supplement Supplement Patient Count patients. Supplement PMA Application Submission for IDE Final Report PMA Application Submission of TDE Final Report PMA Application Submission of TDE Final Report PMA Application Submission of TDE Final Report PMA Approval (protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and plan changes). Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and plan changes). | Supplement DMSO Stability studies submitted regarding FDA's submitted regarding FDA's SO13 Supplement Patient Count SO14 Final Report PMA Application Submission for IDE Final Report Submission Submission Continued Access protocol and plan changes, including increased tantalum in Onyx. Submission Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Supplement DMSO Stability bDMSO aging/stability studies submitted regarding FDA's submitted regarding FDA's SO13 Supplement Patient Count Patients. Supplement Sol4 Final Report PMA Application Submission for IDE Final Report PMA Application Increase after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Supplement DMSO Stability bDMSO aging/stability studies submitted regarding FDA's submitted regarding FDA's SO13 Supplement Patient Count Patients. Supplement Sol4 Final Report PMA Application Submission for IDE Final Report PMA Application Increase after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Supplement DMSO Stability bDMSO aging/stability studies submitted regarding FDA's submitted regarding FDA's SO13 Supplement Patient Count Patients. Supplement Sol4 Final Report PMA Application Submission for IDE Final Report PMA Application Increase after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). |
| Supplement DMSO Stability Studies submitted regarding FDA's Sol13 Supplement Studies Submitted regarding FDA's Sol13 Supplement Patient Count Request to increase number of Sol14 Final Report PMA Application Submission for IDE Final Report PMA Application Submission Submission Submission Submission Submission Submission Supplement for 3-5 year follow-up Rending DMA approval foretocol and Patient Submission Supplement for 3-5 year follow-up Rending DMA approval foretocol and Submission Submission Submission Submission Supplement for 3-5 year follow-up Rending DMA approval foretocol and Submission | Supplement DMSO Stability Studies submitted regarding FDA s Submitted regarding FDA s Supplement Patient Count Submission Submission Continued Access Protocol and plan changes, including increased tantalum in Onyx. Submission Submission 3-5 year Follow-up pending PMA approval (protocol and plan changes) and pending PMA approval (protocol and pending PMA approval (protocol and pending PMA approval) PDA Response Supplement for 3-5 year follow-up pending PMA approval (protocol and pending PMA approval) PDA Response Supplement for 3-5 year follow-up pending PMA approval (protocol and pending PMA approval) PDA Response Supplement for 3-5 year follow-up pending PMA approval (protocol and pending PMA approval) PDA Response Supplement for 3-5 year follow-up pending PMA approval (protocol and pending PMA approval) PDA Response Supplement for 3-5 year follow-up pending PMA approval (protocol and pending PMA approval) PDA Response Supplement for 3-5 year follow-up pending PMA approval (protocol and pending PMA approval) PDA Response Supplement for 3-5 year follow-up pending PMA approval (protocol and pending PMA approval) PDA Response Supplement for 3-5 year follow-up pending PMA approval (protocol and pending PMA approval) PDA Response Supplement for 3-5 year follow-up pending PMA approval (protocol and pending PMA approval) | Supplement DMSO Stability bMSO aging/stability studies submitted regarding FDA's sonditional approval letter dated 12- Supplement Patient Count patients. Supplement Patient Count Request to increase number of 12-06-02 FDA Response Submission Submission for IDE Final Report. Final Report PMA Application Submission for IDE Final Report. Submission Continued Access Continued access after pivotal study, increased tantalum in Onyx. Submission 3-5 year Follow-up Supplement for 3-5 year follow-up informed consent) Submission Submission Supplement for 3-5 year follow-up informed consent) | Supplement DMSO Stability studies submitted regarding FDA's S013 Supplement Studies Submitted regarding FDA's conditional approval letter dated 12- S013 Supplement Patient Count S014 Final Report PMA Application Submission for IDE Final Report Submission Continued Access after pivotal study, protocol and plan changes, including increased tantalum in Omyx. Submission Submission 3-5 year Follow-up pending PMA approval (protocol and plan changes, informed consent). Submission S | Supplement DMSO Stability Studies submitted regarding FDA's Submitted regarding FDA's Supplement Patient Count patients. Supplement Patient Count Submission for IDE Final Report Final Report PMA Application Submission Continued Access Protocol and plan changes, including increased tantalum in Onyx. Submission Submission 3-5 year Follow-up pending PMA approval (protocol and part of protocol and pending PMA approval (protocol and part of 100-up pending PMA approval (protocol and part of 100- | Supplement DMSO Stability studies submitted regarding FDA's Soli3 Supplement Studies Submitted regarding FDA's Soli3 Supplement Patient Count Soli4 Final Report PMA Application Submission Continued Access protocol and plan changes, including increased tanalum in Onlyx. Submission Submission 3-5 year Follow-up pending PMA approval (protocol and plan changes). Submission Submission Submission Office PMA approval (protocol and plan changes). Submission Submission Submission Office PMA approval (protocol and plan changes). | Supplement DMSO Stability studies submitted regarding FDA's Soli3 Supplement Studies Submitted regarding FDA's Soli3 Supplement Patient Count Solid Request to increase number of Solid PMA Application Submission Continued Access Protocol and plan changes, including increased tantalum in Onyx. Submission Submission 3-5 year Follow-up pending PMA approval (protocol and plan changes, informed consent). Submission Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and plan changes, including informed consent). | Supplement DMSO Stability bMSO aging/stability studies submitted regarding FDA's Sol13 Studies Submitted regarding FDA's Sol13 Studies Submitted regarding FDA's Sol13 Studies Supplement Patient Count Patient Sol14 Patient Sol14 Patient Sol14 Patient Sol15 Sol15 Sol16 FDA Response Final Report PMA Application Submission Final Report Submission Continued Access Protocol and plan changes, including increased tantalum in Onyx. Submission Submission Solphement for 3-5 year follow-up pending PMA approval (protocol and plan changes) increased tantalum in Converting PMA Response Solphement Solp | Supplement DMSO Stability studies submitted regarding FDA's S013 Studies Supplement Patient Count S014 Final Report PMA Application Submission Continued Access protocol and plan changes, including increased tanalum in Onyx. Submission Submission 3-5 year Follow-up pending PMA approval (protocol and plan changes). Submission Submission OMSO aging/stability studies submited segunding PDA's submited aging/stability studies submited Studies S013 Submission Continued Access Continued access after pivotal study, pending PMA approval (protocol and plan changes, including increased tanalum in Onyx. Submission Submission OMSO aging/stability studies S1-5-02 FDA Response Additional Patient S016 Enrollment S016 Continued Access Protocol and plan changes, including increased tanalum in Onyx. Submission Submission OMSO stability studies S1-5-02 FDA Response Enrollment OMSO Stability Studies S013 FDA Response Continued Access Ominued Acces | Supplement DMSO Stability bMSO aging/stability studies submitted regarding FDA's sonditional approval letter dated 12- Supplement Patient Count Request to increase number of 12-06-02 FDA Response Submission PMA Application Submission for IDE Final Report PMA Application Submission Continued Access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up Supplement for 3-5 year follow-up informed consent). | Supplement DMSO Stability studies submitted regarding FDA's Soli3 Supplement Studies Submitted regarding FDA's Soli3 Supplement Patient Count Solid Request to increase number of Solid PMA Application Submission Continued Access Protocol and plan changes, including increased tantalum in Onyx. Submission Submission 3-5 year Follow-up pending PMA approval (protocol and plan changes, informed consent). Submission Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and plan changes, including informed consent). | Supplement DMSO Stability studies submitted regarding FDA's S013 Supplement Patient Count S014 Supplement Supplement Supplement Sold Submission Continued Access protocol and plan changes, including increased tantalum in Onyx. Submission Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). DMSO stability studies submised S1-15-02 FDA Response S013 FDA Response PDA Response Enrollment S1-15-02 FDA Response PDA Response S1-15-02 FDA Response PDA Response PDA Response POA P | Supplement DMSO Stability studies submitted regarding FDA's S013 Studies Supplement Patient Count S014 Final Report PMA Application Submission Continued Access protocol and plan changes, including increased tanalum in Onyx. Submission Submission 3-5 year Follow-up pending PMA approval (protocol and plan changes). Submission Submission OMSO aging/stability studies submited segunding PDA's submited aging/stability studies submited Studies S013 Submission Continued Access Continued access after pivotal study, pending PMA approval (protocol and plan changes, including increased tanalum in Onyx. Submission Submission OMSO aging/stability studies S1-5-02 FDA Response Additional Patient S016 Enrollment S016 Continued Access Protocol and plan changes, including increased tanalum in Onyx. Submission Submission OMSO stability studies S1-5-02 FDA Response Enrollment OMSO Stability Studies S013 FDA Response Continued Access Ominued Acces | Supplement DMSO Stability studies submitted regarding FDA's S013 Supplement Studies Submitted regarding FDA's conditional approval letter dated 12- S013 Supplement Patient Count S014 Final Report PMA Application Submission for IDE Final Report Submission Continued Access Protocol and plan changes, including increased tantalum in Onyx. Submission Submission 3-5 year Follow-up pending PMA approval (protocol and plan changes, informed consent). Submission | Supplement DMSO Stability studies submitted regarding FDA's S013 Supplement Patient Count S014 Supplement Patient Count PMA Application Submission Continued Access protocol and plan changes, including increased tantalum in Onyx. Submission Submission 3-5 year Follow-up pending PMA approval (protocol and blan changes, informed consent). | Supplement DMSO Stability studies submitted regarding FDA's S013 Supplement Studies Submitted regarding FDA's conditional approval letter dated 12- S013 Supplement Patient Count S014 Final Report PMA Application Submission for IDE Final Report Submission Continued Access after pivotal study, protocol and plan changes, including increased tantalum in Omyx. Submission Submission 3-5 year Follow-up pending PMA approval (protocol and plan changes, informed consent). Submission S | Supplement DMSO Stability studies submitted regarding FDA's S013 Supplement Studies Submitted regarding FDA's conditional approval letter dated 12- S013 Supplement Patient Count S014 Final Report PMA Application Submission for IDE Final Report Submission Continued Access Protocol and plan changes, including increased tantalum in Onyx. Submission Submission 3-5 year Follow-up pending PMA approval (protocol and plan changes, informed consent). Submission | Supplement DMSO Stability studies submitted regarding FDA's S013 Supplement Studies Submitted regarding FDA's conditional approval letter dated 12- S013 Supplement Patient Count S014 Final Report PMA Application Submission for IDE Final Report Submission Continued Access Protocol and plan changes, including increased tantalum in Onyx. Submission Submission 3-5 year Follow-up pending PMA approval (protocol and plan changes, informed consent). Submission | Supplement DMSO Stability studies submitted regarding FDA's S013 Supplement Patient Count S014 Supplement Patient Count S014 Final Report PMA Application Submission Continued Access protocol and plan changes, including increased tantalum in Onyx. Submission Submission 3-5 year Follow-up pending PMA approval (protocol and plan changes, informed consent). | Supplement DMSO Stability studies submitted regarding FDA's S013 Supplement Studies Submitted regarding FDA's conditional approval letter dated 12- S013 Supplement Patient Count S014 Final Report PMA Application Submission for IDE Final Report Submission Continued Access Protocol and plan changes, including increased tantalum in Onyx. Submission Submission 3-5 year Follow-up pending PMA approval (protocol and plan changes, informed consent). Submission | Supplement DMSO Stability studies submitted regarding FDA's Sol13 Supplement Patient Count Sol4 Supplement Patient Count Sol4 Final Report PMA Application Submission for IDE Final Report Submission Submission Continued Access Protocol and plan changes, including protocol and plan changes, including pending PMA approval (protocol and plan changes, informed consent). Submission Submission Supplement for 3-5 year Follow-up pending PMA approval (protocol and plan changes). | Supplement DMSO Stability studies submitted regarding FDA's S013 Supplement Studies Submitted regarding FDA's conditional approval letter dated 12- S013 Supplement Patient Count S014 Final Report PMA Application Submission for IDE Final Report Submission Continued Access after pivotal study, protocol and plan changes, including increased tantalum in Omyx. Submission Submission 3-5 year Follow-up pending PMA approval (protocol and plan changes, informed consent). Submission S | Supplement DMSO Stability studies submitted regarding FDA's Sol13 Supplement Patient Count Sol4 Supplement Sol4 Final Report PMA Application Submission Continued Access protocol and plan changes, including increased tantalum in Onyx. Submission Submission 3-5 year Follow-up pending PMA approval (protocol and plan changes, informed consent). | Supplement DMSO Stability studies submitted regarding FDA's S013 Supplement Studies Submitted regarding FDA's conditional approval letter dated 12- S013 Supplement Patient Count S014 Final Report PMA Application Submission for IDE Final Report Submission Continued Access after pivotal study, protocol and plan changes, including increased tantalum in Omyx. Submission Submission 3-5 year Follow-up pending PMA approval (protocol and plan changes, informed consent). Submission S | Supplement DMSO Stability studies submitted regarding FDA's Sol13 Supplement Patient Count Sol4 Supplement Patient Count Sol4 Final Report PMA Application Submission for IDE Final Report Submission Submission Continued Access Protocol and plan changes, including protocol and plan changes, including pending PMA approval (protocol and plan changes, informed consent). Submission Submission Supplement for 3-5 year Follow-up pending PMA approval (protocol and plan changes). | Supplement DMSO Stability studies submitted regarding FDA's Sol13 Supplement Patient Count Sol4 Supplement Patient Count Sol4 Final Report PMA Application Submission for IDE Final Report Submission Submission Continued Access Protocol and plan changes, including protocol and plan changes, including pending PMA approval (protocol and plan changes, informed consent). Submission Submission Supplement for 3-5 year Follow-up pending PMA approval (protocol and plan changes). | Supplement DMSO Stability studies submitted regarding FDA's Sol13 Supplement Studies Submitted regarding FDA's conditional approval letter dated 12- Supplement Supplement Patient Count Sol14 Supplement Patient Count PMA Application Submission for IDE Final Report PMA Application Submission for IDE Final Report PMA Application Submission for IDE Final Report PMA approval (protocol and plan changes, including increased tantalum in Onyx. Submission Supplement for 3-5 year Follow-up pending PMA approval (protocol and plan changes, including informed consent). | Supplement DMSO Stability studies submitted regarding FDA's Sol13 Supplement Patient Count Sol4 Supplement Sol4 Supplement Patient Count Sol4 Sol4 Final Report PMA Application Submission for IDE Final Report Sol5 Submission Continued Access protocol and plan changes, including increased tantalum in Onyx. Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and plan changes, informed consent). Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and plan changes) informed consent). | Supplement DMSO Stability studies submitted regarding FDA's Sol13 Supplement Patient Count Sol4 Supplement Sol4 Supplement Patient Count Sol4 Sol4 Final Report PMA Application Submission for IDE Final Report Sol5 Submission Continued Access protocol and plan changes, including increased tantalum in Onyx. Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and plan changes, informed consent). Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and plan changes) informed consent). | Supplement DMSO Stability studies submitted regarding FDA's Sol13 Supplement Patient Count Sol4 Supplement Sol4 Supplement Patient Count Sol4 Sol4 Final Report PMA Application Submission for IDE Final Report Sol5 Submission Continued Access protocol and plan changes, including increased tantalum in Onyx. Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and plan changes, informed consent). Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and plan changes) informed consent). |
| Supplement DMSO Stability but Studies submitted regarding FDA's submitted regarding FDA's sonditional approval letter dated 12- Supplement Supplement Patient Count Submission for IDE Final Report Final Report PMA Application Submission Continued Access Protocol and plan changes, including increased tantalum in Onyx. Submission Submission 3-5 year Follow-up Supplement for 3-5 year follow-up PMA approval (protocol and plan changes) and plan changes and plan cha | Supplement Studies submitted regarding FDA's submitted regarding FDA's submitted regarding FDA's sonditional approval letter dated 12- Supplement Supplement Patient Count Submission for IDE Final Report PMA Application Submission Continued Access protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and plan changes) and Submission One of the pending PMA approval (protocol and plan changes) and Submission One of the pending PMA approval (protocol and plan changes) one of the pending PMA approval (protocol approval plan changes | Supplement DMSO Stability studies submitted regarding FDA's submitted regarding FDA's Sol13 Supplement Patient Count Request to increase number of Supplement Patients. Supplement Patient Count Request to increase number of patients. Supplement Polication Submission for IDE Final Report Final Report Submission Continued Access protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and protocol and plan changes) informed consent) DMSO Stability studies 3-15-02 FDA Response Additional Patient Sol14 Enrollment PDA Response Continued Access protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and PDA Response 3-5 year Follow-up pending PMA approval (protocol and PDA Response 3-5 year Follow-up pending PMA approval (protocol and PDA Response 3-5 year Follow-up pending PMA approval (protocol and PDA Response 3-5 year Follow-up pending PMA approval (protocol and PDA Response 3-5 year Follow-up pending PMA approval (protocol and PDA Response 3-5 year Follow-up pending PMA approval (protocol and PDA Response 3-5 year Follow-up pending PMA approval (protocol and PDA Response 3-5 year Follow-up pending PMA approval (protocol and PDA Response 3-5 year Follow-up pending PMA approval (protocol and PDA Response 3-5 year Follow-up pending PMA approval (protocol and PDA Response 3-5 year Follow-up pending PMA approval (protocol and PDA Response 3-5 year Follow-up 1-5 year Follo | Supplement DMSO Stability studies submitted regarding FDA's submitted regarding FDA's soliditive studies soliditive studies soliditive studies soliditive submitted regarding FDA's soliditive submitted regarding FDA's submitted regarding FDA's submitted regarding FDA's soliditive submitted regarding FDA's sub | Supplement Studies submitted regarding FDA's submitted regarding FDA's submitted regarding FDA's sonditional approval letter dated 12- Supplement Patient Count Patients. Supplement Patient Count Submission for IDE Final Report Final Report PMA Application Submission for IDE Final Report PMA Application PMA Application Submission for IDE Final Report PMA approval protocol and plan changes, including increased tantalum in Onyx. Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and plan changes) and plan changes protocol and plan ch | Supplement DMSO Stability Studies submitted regarding FDA's Sol13 Supplement Studies Sol13 Supplement Patient Count Sol14 Supplement Patient Count Patients. Supplement Patient Count Sol14 Final Report PMA Application Submission for IDE Final Report Submission Submission Continued Access Protocol and plan changes, including PMA approval (protocol and pending PMA approval (pending PMA approval (pe | Supplement DMSO Stability Studies submitted regarding FDA's Sol13 Supplement Studies Sol13 Supplement Patient Count Supplement Patient Count Sol14 Final Report PMA Application Submission for IDE Final Report Submission Continued Access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and protocol and pending PMA approval (protocol and pending PMA approval (pending PMA approva | Supplement DMSO Stability studies submitted regarding FDA's Sol13 Supplement Studies Sol13 Supplement Patient Count Request to increase number of Sol14 Final Report PMA Application Submission for IDE Final Report Final Report Potocol and plan changes, including increased tantalum in Onyx. Submission Submission 3-5 year Follow-up Supplement for 3-5 year follow-up informed consent) DMSO Stability studies Sol13 Studies Sol13 FDA Response Additional Patient Sol16 Enrollment PAT Response Continued Access after pivotal study, informed consent Sol16 Submission Submission Submission Submission for IDE Final Report Follow-up Supplement for 3-5 year follow-up Potocol and Submission Submissi | Supplement DMSO Stability Studies submitted regarding FDA's Sol13 Supplement Studies Sol13 Supplement Patient Count Supplement Patient Count Sol14 Supplement Patient Count Patients. Supplement Polication Submission for IDE Final Report Submission Continued Access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and plan changes) informed consent). Supplement PDA Response Additional Patient Sol16 Enrollment Sol16 Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and plan changes) informed consent). | Supplement DMSO Stability studies submitted regarding FDA's submitted regarding FDA's Sol13 Supplement Patient Count Submission Final Report PMA Application Submission Submiss | Supplement DMSO Stability Studies submitted regarding FDA's Sol13 Supplement Studies Sol13 Supplement Patient Count Supplement Patient Count Sol14 Final Report PMA Application Submission for IDE Final Report Submission Continued Access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and protocol and pending PMA approval (protocol and pending PMA approval (pending PMA approva | Supplement DMSO Stability Studies submitted regarding FDA's Sol13 Supplement Studies Sol13 Supplement Patient Count Patients. Supplement Patient Count Patients. Supplement Patient Count Patients. Submission Continued Access Protocol and plan changes, including PmA approval (protocol and plan pending PmA approval (protocol and pending PmA approval pending PmA approval (protocol and pending PmA approval pending pending PmA approval pending pending PmA approval pending | Supplement DMSO Stability Studies submitted regarding FDA's Sol13 Supplement Studies Sol13 Supplement Patient Count Supplement Patient Count Sol14 Supplement Patient Count Patients. Supplement Polication Submission for IDE Final Report Submission Continued Access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and plan changes) informed consent). Supplement PDA Response Additional Patient Sol16 Enrollment Sol16 Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and plan changes) informed consent). | Supplement DMSO Stability Studies submitted regarding FDA's Sol13 Supplement Studies Sol13 Supplement Patient Count Patients. Supplement Patient Count Patients. Supplement Pontinued Access Continued access after pivotal study, increased tantalum in Onyx. Submission Submission 3-5 year Follow-up pending PMA approval (protocol and pinformed consent). DMSO Stability studies Sol13 3-15-02 FDA Response Sol13 PDA Response Enrollment Patient Sol16 Sol13 Submission Submission for IDE Final Report. Submission Submission Onlyx. Supplement for 3-5 year follow-up pending PMA approval (protocol and pinformed consent). | Supplement DMSO Stability Studies submitted regarding FDA's Sol13 Supplement Studies Sol13 Supplement Patient Count Patients. Supplement Patient Count Patients. Supplement Patient Count Patients. Submission Continued Access Protocol and plan changes, including PmA approval (protocol and plan changes, informed consent). Submission Submission 3-5 year Follow-up pending PMA approval (protocol and plan changes) informed consent). | Supplement DMSO Stability studies submitted regarding FDA's submitted regarding FDA's soliditive studies soliditive studies soliditive studies soliditive submitted regarding FDA's soliditive submitted regarding FDA's submitted regarding FDA's submitted regarding FDA's soliditive submitted regarding FDA's sub | Supplement DMSO Stability Studies submitted regarding FDA's Sol13 Supplement Studies Sol13 Supplement Patient Count Patients. Supplement Patient Count Patients. Supplement Pontinued Access Continued access after pivotal study, increased tantalum in Onyx. Submission Submission 3-5 year Follow-up pending PMA approval (protocol and pinformed consent). DMSO Stability studies Sol13 3-15-02 FDA Response Sol13 PDA Response Enrollment Patient Sol16 Sol13 Submission Submission for IDE Final Report. Submission Submission Onlyx. Supplement for 3-5 year follow-up pending PMA approval (protocol and pinformed consent). | Supplement DMSO Stability Studies submitted regarding FDA's Sol13 Supplement Studies Sol13 Supplement Patient Count Patients. Supplement Patient Count Patients. Supplement Pontinued Access Continued access after pivotal study, increased tantalum in Onyx. Submission Submission 3-5 year Follow-up pending PMA approval (protocol and pinformed consent). DMSO Stability studies Sol13 3-15-02 FDA Response Sol13 PDA Response Enrollment Patient Sol16 Sol13 Submission Submission for IDE Final Report. Submission Submission Onlyx. Supplement for 3-5 year follow-up pending PMA approval (protocol and pinformed consent). | Supplement DMSO Stability Studies submitted regarding FDA's Sol13 Supplement Studies Sol13 Supplement Patient Count Patients. Supplement Patient Count Patients. Supplement Pontinued Access Continued access after pivotal study, increase d tantalum in Onyx. Submission Submission 3-5 year Follow-up pending PMA approval (protocol and plan changes, including pending PMA approval (protocol and plan changes), informed consent). Supplement Patient Count Patient Count Patient Report I2-06-02 FDA Response Studies Sol13 FDA Response PDA Response Enrollment PDA Response Protocol and Patient PDA Response Protocol and PDA Response PODA Response PODA Response PODA Response PDA Res | Supplement DMSO Stability Studies submitted regarding FDA's Sol13 Supplement Studies Sol13 Supplement Patient Count Patients. Supplement Patient Count Patients. Supplement Pontinued Access Continued access after pivotal study, increased tantalum in Onyx. Submission Submission 3-5 year Follow-up pending PMA approval (protocol and pinformed consent). DMSO Stability studies Sol13 3-15-02 FDA Response Sol13 PDA Response Enrollment Patient Sol16 Sol13 Submission Submission for IDE Final Report. Submission Submission Onlyx. Supplement for 3-5 year follow-up pending PMA approval (protocol and pinformed consent). | Supplement DMSO Stability studies submitted regarding FDA's S013 S013 Supplement Patient Count Request to increase number of patients. Supplement Patient Count patients. Submission PMA Application Submission for IDE Final Report Submission for IDE Final Report PMA approval (protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and plan changes) informed consent). | Supplement DMSO Stability studies submitted regarding FDA's submitted regarding FDA's soliditive studies soliditive studies soliditive studies soliditive submitted regarding FDA's soliditive submitted regarding FDA's submitted regarding FDA's submitted regarding FDA's soliditive submitted regarding FDA's sub | Supplement DMSO Stability Studies submitted regarding FDA's Sol13 Supplement Studies Sol13 Supplement Patient Count Patients. Supplement Patient Count Patients. Supplement Pontinued Access Continued access after pivotal study, protocol and plan changes, including pending PMA approval (protocol and pending PMA approval (protocol and pinformed consent). Supplement Patient Count Patient Count Patient Sol13 Submission Continued Access Continued access after pivotal study, protocol and plan changes, including informed consent). DMSO stability studies Sol13 Sol13 Sol13 FDA Response Additional Patient Sol16 Enrollment Patient Count Patient Sol16 Enrollment Patient Count Pontinued Access after pivotal study, protocol and plan changes, including informed consent). | Supplement DMSO Stability studies submitted regarding FDA's submitted regarding FDA's soliditive studies soliditive studies soliditive studies soliditive submitted regarding FDA's soliditive submitted regarding FDA's submitted regarding FDA's submitted regarding FDA's soliditive submitted regarding FDA's sub | Supplement DMSO Stability studies submitted regarding FDA's S013 S013 Supplement Patient Count Request to increase number of patients. Supplement Patient Count patients. Submission PMA Application Submission for IDE Final Report Submission for IDE Final Report PMA approval (protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and plan changes) informed consent). | Supplement DMSO Stability studies submitted regarding FDA's S013 S013 Supplement Patient Count Request to increase number of patients. Supplement Patient Count patients. Submission PMA Application Submission for IDE Final Report Submission for IDE Final Report PMA approval (protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and plan changes) informed consent). | Supplement Studies submitted regarding FDA's | Supplement DMSO Stability studies submitted regarding FDA's submitted | Supplement DMSO Stability studies submitted regarding FDA's submitted | Supplement DMSO Stability studies submitted regarding FDA's submitted |
| Supplement DMSO Stability Studies S013 Supplement Studies Submitted regarding FDA's submitted regarding FDA's conditional approval letter dated 12-Supplement Patient Count S014 Final Report PMA Application Submission for IDE Final Report Submission Continued Access protocol and plan changes, including increased tantalum in Onyx. Submission Supplement for 3-5 year follow-up Conditional PMA approval forefood and plan changes, including ponding PMA approval forefood and plan changes, including conditions conditions and conditions conditions conditions approval forefood and plan changes, including conditions cond | Supplement Studies submitted regarding FDA's sonditional approval letter dated 12- Supplement Supplement Patient Count Request to increase number of Supplement Submission Continued Access Potocol and plan changes, including pending PMA approval (protocol and Submission Final Report Submission Final Report Submission | Supplement Studies submitted regarding FDA's submitted regarding FDA's submitted regarding FDA's conditional approval letter dated 12- S013 Supplement Patient Count patients. Supplement Patient Count Submission for IDE Final Report PMA Application Submission Frotocol and plan changes, including increased tantalum in Onyx Submission 3-5 year Follow-up pending PMA approval (protocol and plan changes) informed consent) DMSO Stability studies submited Submission Submission submitted regarding FDA's soubmited I2- S013 12-06-02 FDA Response Additional Patient Enrollment Enrollment 90-19-03 FDA Response Continued Access protocol and plan changes, including increased tantalum in Onyx Submission 3-5 year Follow-up pending PMA approval (protocol and protocol and proto | Supplement Studies submitted regarding FDA's sonditional approval letter dated 12- Supplement Supplement Patient Count patients. Supplement Patient Count Submission for IDE Final Report Final Report PMA Application Submission Continued Access Protocol and plan changes, including increased tantalum in Onyx. Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and plan changes). Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and plan changes). | Supplement Studies submitted regarding FDA's sonditional approval letter dated 12- Supplement Supplement Patient Count Sol Patients. Supplement Supplement Patient Count Sol Patients. Supplement Patient Count Patients. Submission Submission Continued Access Protocol and plan changes, including increased tantalum in Onyx. Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and plan changes, including plan changes, includ | Supplement Studies submitted regarding FDA's submitted regarding FDA's submitted regarding FDA's sonditional approval letter dated 12- Supplement Patient Count Supplement Patient Count Patients. Supplement PMA Application Submission for IDE Final Report Final Report Submission Continued Access Protocol and plan changes, including increased tantalum in Onyx. Submission Submission 3-5 year Follow-up pending PMA approval (protocol and pinformed consent). | Supplement Studies submitted regarding FDA's submitted regarding FDA's submitted regarding FDA's conditional approval letter dated 12- Supplement Supplement Patient Count Supplement Patient Count Submission for IDE Final Report PMA Application Submission for IDE Final Report Submission Continued Access Protocol and plan changes, including increased tantalum in Onyx. Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and plan changes). | Supplement Studies submitted regarding FDA's submitted regarding FDA's submitted regarding FDA's sonditional approval letter dated 12- Supplement Patient Count Supplement Patient Count Patients. Supplement PMA Application Submission for IDE Final Report Final Report PMA Application Submission Continued Access Protocol and plan changes, including increased tantalum in Onyx Submission 3-5 year Follow-up Supplement for 3-5 year follow-up informed consent) DMSO Stability studies submits and 3-15-02 FDA Response Studies Sol13 Submission Patient PA Additional Patient Enrollment PA Response Continued Access Protocol and Patient PA Response Protocol and Patient PA Response Protocol and Patient PA Response PA | Supplement Studies submitted regarding FDA's submitted regarding FDA's submitted regarding FDA's sonditional approval letter dated 12- Supplement Patient Count Supplement Patient Count Patients. Supplement PMA Application Submission for IDE Final Report Final Report Submission Continued Access Protocol and plan changes, including increased tantalum in Onyx. Submission Submission 3-5 year Follow-up pending PMA approval (protocol and plan changes). Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and plan changes). | Supplement Studies submitted regarding FDA's submitted regarding FDA's submitted regarding FDA's conditional approval letter dated 12- Supplement Patient Count Supplement Patient Count Patients. Supplement PMA Application Submission for IDE Final Report Final Report Submission Continued Access Protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and protocol and protoco | Supplement Studies submitted regarding FDA's submitted regarding FDA's submitted regarding FDA's conditional approval letter dated 12- Supplement Supplement Patient Count Supplement Patient Count Submission for IDE Final Report PMA Application Submission for IDE Final Report Submission Continued Access Protocol and plan changes, including increased tantalum in Onyx. Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and plan changes). | Supplement Studies submitted regarding FDA's sonditional approval letter dated 12- Supplement Supplement Patient Count Sol Application Submission Final Report PMA Application Submission Continued Access Protocol and plan changes, including informed consent). Submission Submission Submission Submission of 3-5 year Follow-up pending PMA approval (protocol and plan changes). | Supplement Studies submitted regarding FDA's submitted regarding FDA's submitted regarding FDA's sonditional approval letter dated 12- Supplement Patient Count Supplement Patient Count Patients. Supplement PMA Application Submission for IDE Final Report Final Report Submission Continued Access Protocol and plan changes, including increased tantalum in Onyx. Submission Submission 3-5 year Follow-up pending PMA approval (protocol and plan changes). Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and plan changes). | Supplement Studies submitted regarding FDA's sonditional approval letter dated 12- Supplement Supplement Patient Count patients. Supplement Patient Count patients. Submission Continued Access Continued access after pivotal study, protocol and plan changes, including informed consent). Submission 3-5 year Follow-up pending PMA approval (protocol and plan changes). | Supplement Studies submitted regarding FDA's sonditional approval letter dated 12- Supplement Supplement Supplement Supplement Sol Studies Submission Continued Access Protocol and plan changes, including informed consent). Supplement Submission Submission Submission Submission Submission Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and plan changes, informed consent). | Supplement Studies submitted regarding FDA's sonditional approval letter dated 12- Supplement Supplement Patient Count patients. Supplement Patient Count Submission for IDE Final Report Final Report PMA Application Submission Continued Access Protocol and plan changes, including increased tantalum in Onyx. Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and plan changes). Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and plan changes). | Supplement Studies submitted regarding FDA's sonditional approval letter dated 12- Supplement Supplement Patient Count patients. Supplement Patient Count patients. Submission Continued Access Continued access after pivotal study, protocol and plan changes, including informed consent). Submission 3-5 year Follow-up pending PMA approval (protocol and plan changes). | Supplement Studies submitted regarding FDA's sonditional approval letter dated 12- Supplement Supplement Patient Count patients. Supplement Patient Count patients. Submission Continued Access Continued access after pivotal study, protocol and plan changes, including informed consent). Submission 3-5 year Follow-up pending PMA approval (protocol and plan changes). | Supplement Studies Submitted regarding FDA's conditional approval letter dated 12- Supplement Supplement Patient Count Sol14 Final Report PMA Application Submission Continued Access Protocol and plan changes, including increased tantalum in Onyx. Submission Submission 3-5 year Follow-up pending PMA approval (protocol and plan changes). Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and plan changes). | Supplement Studies submitted regarding FDA's sonditional approval letter dated 12- Supplement Supplement Patient Count patients. Supplement Patient Count patients. Submission Continued Access Continued access after pivotal study, protocol and plan changes, including informed consent). Submission 3-5 year Follow-up pending PMA approval (protocol and plan changes). | Supplement Studies submitted regarding FDA's conditional approval letter dated 12- Supplement Supplement Patient Count Sol14 Final Report PMA Application Submission Continued Access protocol and plan changes, including increased tantalum in Onyx. Submission Submission 3-5 year Follow-up pending PMA approval (protocol and plan changes). Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and plan changes). | Supplement Studies submitted regarding FDA's sonditional approval letter dated 12- Supplement Supplement Patient Count patients. Supplement Patient Count Submission for IDE Final Report Final Report PMA Application Submission Continued Access Protocol and plan changes, including increased tantalum in Onyx. Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and plan changes). Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and plan changes). | Supplement Studies submitted regarding FDA's sonditional approval letter dated 12- Supplement Supplement Patient Count Sol14 Final Report PMA Application Submission Continued Access protocol and plan changes, including increased tantalum in Onyx. Submission Supplement for 3-5 year Follow-up pending PMA approval (protocol and plan changes). | Supplement Studies submitted regarding FDA's sonditional approval letter dated 12- Supplement Supplement Patient Count patients. Supplement Patient Count Submission for IDE Final Report Final Report PMA Application Submission Continued Access Protocol and plan changes, including increased tantalum in Onyx. Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and plan changes). Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and plan changes). | Supplement Studies submitted regarding FDA's conditional approval letter dated 12- Supplement Supplement Patient Count Sol14 Final Report PMA Application Submission Continued Access protocol and plan changes, including increased tantalum in Onyx. Submission Submission 3-5 year Follow-up pending PMA approval (protocol and plan changes). Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and plan changes). | Supplement Studies submitted regarding FDA's conditional approval letter dated 12- Supplement Supplement Patient Count Sol14 Final Report PMA Application Submission Continued Access protocol and plan changes, including increased tantalum in Onyx. Submission Submission 3-5 year Follow-up pending PMA approval (protocol and plan changes). Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and plan changes). | Supplement Studies submitted regarding FDA's conditional approval letter dated 12- Supplement Supplement Patient Count SO14 Final Report PMA Application Submission Continued Access after pivotal study, increase d tantalum in Omyx. Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and plan changes, including informed consent). | Supplement Studies submitted regarding FDA's submitted regarding FDA's sonditional approval letter dated 12- Supplement Supplement Patient Count Submission Final Report PMA Application Submission Continued Access Protocol and plan changes, including increased tantalum in Omyx. Submission Submission Supplement for 3-5 year Follow-up pending PMA approval (protocol and plan changes, including informed consent). | Supplement Studies submitted regarding FDA's submitted regarding FDA's sonditional approval letter dated 12- Supplement Supplement Patient Count Submission Final Report PMA Application Submission Continued Access Protocol and plan changes, including increased tantalum in Omyx. Submission Submission Supplement for 3-5 year Follow-up pending PMA approval (protocol and plan changes, including informed consent). | Supplement Studies submitted regarding FDA's submitted regarding FDA's sonditional approval letter dated 12- Supplement Supplement Patient Count Submission Final Report PMA Application Submission Continued Access Protocol and plan changes, including increased tantalum in Omyx. Submission Submission Supplement for 3-5 year Follow-up pending PMA approval (protocol and plan changes, including informed consent). |
| Supplement Studies Submitted regarding FDA's submitted regarding FDA's Sol13 Studies Sol14 Patient Count Patient Count Patient Count Patient Count Patients. Sol14 Patient Sol14 Patients. Submission Submission for IDE Final Report Submission for IDE Final Report Submission Continued Access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission Submission Submission Submission Supplement for 3-5 year follow-up Patient Submission Su | Supplement Studies Submitted regarding FDA's submitted regarding FDA's sonditional approval letter dated 12- Supplement Patient Count Supplement Patient Count Solf Potential Request to increase number of Solf Potential Report Potential Report Potential Report Potential Report Submission Continued Access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and protocol and pending PMA approval (protocol and pending PMA approval (pending PMA approval (| Supplement Studies Submitted regarding FDA's submitted regarding FDA's submitted regarding FDA's sonditional approval letter dated 12- Supplement Patient Count Request to increase number of Submission Submission for IDE Final Report PMA Application Submission for IDE Final Report PMA Application Submission Continued Access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent) Submission Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and plan changes). | Supplement Studies Submitted regarding FDA's submitted regarding FDA's sonditional approval letter dated 12- Supplement Patient Count Request to increase number of S014 PMA Application Submission for IDE Final Report PMA Application Submission for IDE Final Report PMA Application Submission for IDE Final Report PMA Application Submission Continued Access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). | Supplement Patient Count Studies Submitted regarding FDA's conditional approval letter dated 12- Supplement Patient Count Supplement Patient Count Submission Final Report PMA Application Submission Continued Access Protocol and plan changes, including increased tantalum in Onyx. Submission Submission 3-5 year Follow-up pending PMA approval (protocol and protocol and pending PMA approval (protocol and pending PMA approval (pending PMA approval (pe | Supplement Studies Submitted regarding FDA's submitted regarding FDA's submitted regarding FDA's sonditional approval letter dated 12- Supplement Patient Count Request to increase number of Submission Submission for IDE Final Report PMA Application Submission of IDE Final Report PMA Application Submission of IDE Final Report PMA Application Submission Submission Submission Submission Submission Submission Submission Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). Submission Submiss | Supplement Studies Submitted regarding FDA's submitted regarding FDA's submitted regarding FDA's sonditional approval letter dated 12- Supplement Patient Count Request to increase number of S014 PMA Application Submission for IDE Final Report PMA Application Submission of IDE Final Report PMA Application Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). | Supplement Studies Submitted regarding FDA's submitted regarding FDA's submitted regarding FDA's sonditional approval letter dated 12- Supplement Patient Count Request to increase number of Supplement S014 PMA Application Submission for IDE Final Report PMA Application Submission for IDE Final Report PMA Application Submission Continued Access Protocol and plan changes, including increased tantalum in Onyx. Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent) Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and plan changes) informed consent) | Supplement Studies Submitted regarding FDA's submitted regarding FDA's submitted regarding FDA's sonditional approval letter dated 12- Supplement Patient Count Request to increase number of Submission Final Report PMA Application Submission for IDE Final Report PMA Application Submission Continued Access Protocol and plan changes, including increased tantalum in Onyx. Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). | Supplement Studies Submitted regarding FDA's submitted regarding FDA's submitted regarding FDA's sonditional approval letter dated 12- Supplement Patient Count Request to increase number of S014 PAA Application Submission for IDE Final Report PMA Application Submission of IDE Final Report PMA Application Submission Continued Access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). | Supplement Studies Submitted regarding FDA's submitted regarding FDA's submitted regarding FDA's sonditional approval letter dated 12- Supplement Patient Count Request to increase number of S014 PMA Application Submission for IDE Final Report PMA Application Submission of IDE Final Report PMA Application Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). | Supplement Studies Submitted regarding FDA's submitted regarding FDA's submitted regarding FDA's sonditional approval letter dated 12- Supplement Patient Count Patients. Supplement Patient Count Patients. Supplement PMA Application Submission for IDE Final Report PMA Application Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). | Supplement Studies Submitted regarding FDA's submitted regarding FDA's submitted regarding FDA's sonditional approval letter dated 12- Supplement Patient Count Request to increase number of Submission Final Report PMA Application Submission for IDE Final Report PMA Application Submission Continued Access Protocol and plan changes, including increased tantalum in Onyx. Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). | Supplement Studies Submitted regarding FDA's submitted regarding FDA's submitted regarding FDA's sonditional approval letter dated 12- Supplement Patient Count Patients. Supplement Patient Count Patients. Supplement PMA Application Submission for IDE Final Report PMA Application Submission for IDE Final Report PMA Application Submission for IDE Final Report PMA Application Submission Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). | Supplement Studies Submitted regarding FDA's submitted regarding FDA's submitted regarding FDA's sonditional approval letter dated 12- Supplement Patient Count Patients. Supplement Patient Count Patients. Supplement PMA Application Submission for IDE Final Report PMA Application Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). | Supplement Studies Submitted regarding FDA's submitted regarding FDA's sonditional approval letter dated 12- Supplement Patient Count Request to increase number of S014 PMA Application Submission for IDE Final Report PMA Application Submission for IDE Final Report PMA Application Submission for IDE Final Report PMA Application Submission Continued Access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). | Supplement Studies Submitted regarding FDA's submitted regarding FDA's submitted regarding FDA's sonditional approval letter dated 12- Supplement Patient Count Patients. Supplement Patient Count Patients. Supplement PMA Application Submission for IDE Final Report PMA Application Submission for IDE Final Report PMA Application Submission for IDE Final Report PMA Application Submission Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). | Supplement Studies Submitted regarding FDA's submitted regarding FDA's submitted regarding FDA's sonditional approval letter dated 12- Supplement Patient Count Patients. Supplement Patient Count Patients. Supplement PMA Application Submission for IDE Final Report PMA Application Submission for IDE Final Report PMA Application Submission for IDE Final Report PMA Application Submission Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). | Supplement Studies Submitted regarding FDA's submitted regarding FDA's sonditional approval letter dated 12- Supplement Patient Count Request to increase number of S014 PMA Application Submission for IDE Final Report PMA Application Submission for IDE Final Report PMA Application Submission of IDE Final Report PMA Application Submission Frotocol and plan changes, including increased tantalum in Onyx. Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). | Supplement Studies Submitted regarding FDA's submitted regarding FDA's submitted regarding FDA's sonditional approval letter dated 12- Supplement Patient Count Patients. Supplement Patient Count Patients. Supplement PMA Application Submission for IDE Final Report PMA Application Submission for IDE Final Report PMA Application Submission for IDE Final Report PMA Application Submission Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). | Supplement Studies Submitted regarding FDA's submitted regarding FDA's sonditional approval letter dated 12- Supplement Patient Count Request to increase number of S014 PAMA Application Submission for IDE Final Report PMA Application Submission for IDE Final Report PMA Application Submission of IDE Final Report PMA Application Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). | Supplement Studies Submitted regarding FDA's submitted regarding FDA's sonditional approval letter dated 12- Supplement Patient Count Request to increase number of S014 PMA Application Submission for IDE Final Report PMA Application Submission for IDE Final Report PMA Application Submission for IDE Final Report PMA Application Submission Continued Access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). | Supplement Studies Submitted regarding FDA's submitted regarding FDA's submitted regarding FDA's sonditional approval letter dated 12- Supplement Patient Count Patients. Supplement Patient Count Request to increase number of S014 PAMA Application Submission for IDE Final Report PMA Application Submission for IDE Final Report PMA Application Submission for IDE Final Report PMA approval (protocol and plan changes, including increased tantalum in Onyx. Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). | Supplement Studies Submitted regarding FDA's submitted regarding FDA's sonditional approval letter dated 12- Supplement Patient Count Request to increase number of S014 PMA Application Submission for IDE Final Report PMA Application Submission for IDE Final Report PMA Application Submission for IDE Final Report PMA Application Submission Continued Access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). | Supplement Studies Submitted regarding FDA's submitted regarding FDA's sonditional approval letter dated 12- Supplement Patient Count Request to increase number of S014 PAMA Application Submission for IDE Final Report PMA Application Submission for IDE Final Report PMA Application Submission of IDE Final Report PMA Application Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). | Supplement Studies Submitted regarding FDA's submitted regarding FDA's sonditional approval letter dated 12- Supplement Patient Count Request to increase number of S014 PAMA Application Submission for IDE Final Report PMA Application Submission for IDE Final Report PMA Application Submission of IDE Final Report PMA Application Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). | Supplement Studies Studies Sol13 Studies Sol14 Patient Count Patient Sol14 Patient Sol14 Patient Sol16 PMA Application Submission for IDE Final Report Submission Continued Access Protocol and plan changes, including increased tantalum in Onyx. Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and plan changes). Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and plan changes). | Supplement Studies Studies Sol13 Studies Sol14 Patient Count Patient Sol14 Patient Count Patients. Final Report PMA Application Submission for IDE Final Report Sol16 Final Report Sol16 Enrollment Sol16 Submission Continued Access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and plan changes) informed consent). | Supplement Studies Studies Sol13 Studies Sol14 Patient Count Patient Sol14 Patient Count Patients. Final Report PMA Application Submission for IDE Final Report Sol16 Final Report Sol16 Enrollment Sol16 Submission Continued Access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and plan changes) informed consent). | Supplement Studies Studies Sol13 Studies Sol14 Patient Count Patient Sol14 Patient Count Patients. Final Report PMA Application Submission for IDE Final Report Sol16 Final Report Sol16 Enrollment Sol16 Submission Continued Access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and plan changes) informed consent). |
| Supplement Patient Count Submission Final Report PMA Application Continued Access Protocol and plan changes, increase follow-up Patient for 3-5 year Follow-up Submission Submission Submission Submission Submission Submission Order of Supplement for 3-5 year follow-up Supplement for 3-5 year follow-up Supplement for 3-5 year follow-up Submission Submission Studies Submission Studies Continued Access Final Report Submission Sub | Supplement Patient Count Submission Continued Access Protocol and Plan changes, including increased tantalum in Onyx. Submission Submission Submission 3-5 year Follow-up pending PMA approval (protocol and plan changes, including pending PMA approval (protocol and plan changes). | Supplement Patient Count Submitted regarding FDA's conditional approval letter dated 12- 07-01. Supplement Patient Count Submission Final Report PMA Application Submission Continued Access Protocol and plan changes, including increased tantalum in Onyx. Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent) Submission Submission Submission Submission Onyx. Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent) Submission Submission Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and plan changes, including informed consent) | Supplement Patient Count Submission Final Report PMA Application Continued Access after pivotal study, pending PMA approval (protocol and pending PMA approval (protocol and pinformed consent). Submission Submission Submission Submission PMA approval (protocol and pinformed consent). | Supplement Patient Count Potients. Supplement Patient Count Sold Submission Continued Access protocol and plan changes, including pending PMA approval (protocol and pending PMA approval (protocol approval (protocol approval pending PMA approval (protocol approval pending PMA approval (protocol approval pending PMA | Supplement Patient Count Submitted regarding FDA's conditional approval letter dated 12- 07-01. Supplement Patient Count Submission Final Report PMA Application Submission Continued Access Protocol and plan changes, including increased tantalum in Onyx. Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). | Supplement Patient Count Submitted regarding FDA's conditional approval letter dated 12- 07-01. Supplement Patient Count Submission Final Report PMA Application Submission Continued Access Protocol and plan changes, including increased tantalum in Onyx. Submission Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and protocol an | Supplement Patient Count Submitted regarding FDA's conditional approval letter dated 12- 07-01. Supplement Patient Count Submission Final Report PMA Application Submission Continued Access Protocol and plan changes, including increased tantalum in Onyx. Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and protocol | Supplement Patient Count Submitted regarding FDA's conditional approval letter dated 12- 07-01. Supplement Patient Count Submission Final Report PMA Application Submission Continued Access Protocol and plan changes, including informed consent). Submission Submission Submission PMA approval (protocol and protocol a | Supplement Patient Count Submitted regarding FDA's conditional approval letter dated 12- 07-01. Supplement Patient Count Submission Final Report PMA Application Submission Final Report Continued Access Protocol and plan changes, including PMA approval (protocol and pending PMA approval (protocol and protocol and pending PMA approval (protocol and protocol and pending PMA approval (protocol and protocol and pending PMA approval (protocol and pending PMA approval (pending PMA | Supplement Patient Count Submitted regarding FDA's conditional approval letter dated 12- 07-01. Supplement Patient Count Submission Final Report PMA Application Submission Continued Access Protocol and plan changes, including increased tantalum in Onyx. Submission Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and protocol an | Supplement Patient Count Submitted regarding FDA's conditional approval letter dated 12- 07-01. Supplement Patient Count Submission Final Report PMA Application Submission Continued Access Protocol and plan changes, including informed consent). Submission Submission Submission Submission Onyx. Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and plan changes). | Supplement Patient Count Submitted regarding FDA's conditional approval letter dated 12- 07-01. Supplement Patient Count Submission Final Report PMA Application Submission Continued Access Protocol and plan changes, including informed consent). Submission Submission Submission PMA approval (protocol and protocol a | Supplement Patient Count Submitted regarding FDA's conditional approval letter dated 12- 07-01. Supplement Patient Count Submission Final Report PMA Application Submission Final Report Continued Access Protocol and plan changes, including increased tantalum in Onyx. Submission Submission Submission Supplement for 3-5 year Follow-up pending PMA approval (protocol and protocol an | Supplement Patient Count Submitted regarding FDA's conditional approval letter dated 12- 07-01. Supplement Patient Count Request to increase number of Submission Final Report PMA Application Submission Final Report Continued Access Protocol and plan changes, including increased tantalum in Onyx. Submission Submission 3-5 year Follow-up pending PMA approval (protocol and protocol and plan changes). | Supplement Patient Count Submission Final Report PMA Application Continued Access after pivotal study, pending PMA approval (protocol and pending PMA approval (protocol and pinformed consent). Submission Submission Submission Submission PMA approval (protocol and pinformed consent). | Supplement Patient Count Submitted regarding FDA's conditional approval letter dated 12- 07-01. Supplement Patient Count Submission Final Report PMA Application Submission Final Report Continued Access Protocol and plan changes, including increased tantalum in Onyx. Submission Submission Submission Supplement for 3-5 year Follow-up pending PMA approval (protocol and protocol an | Supplement Patient Count Submitted regarding FDA's conditional approval letter dated 12- 07-01. Supplement Patient Count Submission Final Report PMA Application Submission Final Report Continued Access Protocol and plan changes, including increased tantalum in Onyx. Submission Submission Submission Supplement for 3-5 year Follow-up pending PMA approval (protocol and protocol an | Supplement Patient Count Submitted regarding FDA's conditional approval letter dated 12- 07-01. Supplement Patient Count Submission for IDE Final Report PMA Application Submission Continued Access Protocol and plan changes, including increased tantalum in Onyx. Submission Submission 3-5 year Follow-up pending PMA approval (protocol and protocol and pro | Supplement Patient Count Submitted regarding FDA's conditional approval letter dated 12- 07-01. Supplement Patient Count Submission Final Report PMA Application Submission Continued Access Protocol and plan changes, including increased tantalum in Onyx. Submission Submission Submission Submission Onyx. | Supplement Patient Count Supplication Patient Count Supplication Patient Supplement Patient Count Submission Submi | Supplement Patient Count Submission Final Report PMA Application Continued Access after pivotal study, pending PMA approval (protocol and pending PMA approval (protocol and pinformed consent). Submission Submission Submission Submission PMA approval (protocol and pinformed consent). | Supplement Patient Count Supplication Patient Count Supplication Patient Supplement Patient Count Submission Submi | Supplement Patient Count Submission Final Report PMA Application Continued Access after pivotal study, pending PMA approval (protocol and pending PMA approval (protocol and pinformed consent). Submission Submission Submission Submission PMA approval (protocol and pinformed consent). | Supplement Patient Count Supplication Patient Count Supplication Patient Supplement Patient Count Submission Submi | Supplement Patient Count Supplication Patient Count Supplication Patient Supplement Patient Count Submission Submi | Supplement Supplement Patient Count Supplication PMA Application Continued access after pivotal study, pending PMA approval for 3-5 year Follow-up pending PMA approval (protocol and pinformed consent). | Supplement Patient Count Submission Final Report PMA Application Submission or IDE Final Report Submission Continued Access Protocol and plan changes, including increased tantalum in Onyx. Submission Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and plan changes). | Supplement Patient Count Submission Final Report PMA Application Submission or IDE Final Report Submission Continued Access Protocol and plan changes, including increased tantalum in Onyx. Submission Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and plan changes). | Supplement Patient Count Submission Final Report PMA Application Submission or IDE Final Report Submission Continued Access Protocol and plan changes, including increased tantalum in Onyx. Submission Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and plan changes). |
| Supplement Patient Count Patients. Supplement Patient Count Patients. Supplement Phinal Report PMA Application Submission Continued Access Protocol and plan changes, including increased tantalum in Onyx. Submission Submission Supplement for 3-5 year follow-up Pending PMA approval foresteed and O2-20-04 FDA Response Supra Follow-up Parallel PMA approval foresteed and O2-20-04 FDA Response Supra Follow-up | Supplement Patient Count Submission Final Report PMA Application Submission Continued Access Protocol and Plan changes, including increased tantalum in Onyx. Submission Submission 3-5 year Follow-up pending PMA approval (protocol and plan changes) and Supplement for 3-5 year follow-up pending PMA approval (protocol and plan changes) and Submission S | Supplement Patient Count Request to increase number of S014 Final Report PMA Application Submission for IDE Final Report Submission Continued Access Protocol and plan changes, including increased tantalum in Onyx. Submission Submission 3-5 year Follow-up pending PMA approval (protocol and plan changes) informed consent) Submission Submission Submission Oracles | Supplement Patient Count Submission Final Report PMA Application Submission S | Supplement Supplement Patient Count Solia Conditional approval letter dated 12-Supplement Solia Patient Count Solia Patient Count Solia Patients. Supplement Patient Count Request to increase number of Solia Patient Solia Patient Solia Solia Patient Solia Solia Patient Solia Solia Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission Solia S | Supplement Patient Count Request to increase number of S014 Supplement Patient Count Patients. Supplement Patient Count Request to increase number of S014 Final Report PMA Application Submission for IDE Final Report Submission Continued Access Protocol and plan changes, including increased tantalum in Onyx. Submission Submission 3-5 year Follow-up pending PMA approval (protocol and plan changes). Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and plan changes). | Supplement Patient Count Request to increase number of S014 Supplement Patient Count Request to increase number of S014 Final Report PMA Application Submission for IDE Final Report Submission Continued Access Protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Supplement Patient Count Request to increase number of S014 Final Report PMA Application Submission for IDE Final Report Submission Continued Access Protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and plan changes) informed consent) Submission 3-5 year Follow-up pending PMA approval (protocol and plan changes) informed consent) | Supplement Patient Count Request to increase number of S014 Supplement Patient Count Request to increase number of S014 Final Report PMA Application Submission for IDE Final Report Submission Submission Continued Access Protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Supplement Patient Count Submission Final Report PMA Application Submission Continued Access Protocol and plan changes, including Informed Consent). Submission Submission Submission Submission O2-20-04 FDA Response Submission PMA approval (protocol and plan changes, including Informed Consent). | Supplement Patient Count Request to increase number of S014 Supplement Patient Count Request to increase number of S014 Final Report PMA Application Submission for IDE Final Report Submission Continued Access Protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Supplement Patient Count Submission Final Report PMA Application Submission Continued Access Protocol and plan changes, including informed consent). Submission Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Supplement Patient Count Request to increase number of S014 Supplement Patient Count Request to increase number of S014 Final Report PMA Application Submission for IDE Final Report Submission Submission Continued Access Protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Supplement Patient Count Submission Final Report PMA Application Submission S | Supplement Patient Count Submission Final Report PMA Application Submission Continued Access after pivotal study, Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and plan changes, including informed consent). | Supplement Patient Count Submission Final Report PMA Application Submission S | Supplement Patient Count Submission Final Report PMA Application Submission S | Supplement Patient Count Submission Final Report PMA Application Submission S | Supplement Patient Count Submission Final Report PMA Application Submission Continued Access after pivotal study, Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and plan changes, including pending PMA approval (protocol and plan changes) Supplement for 3-5 year follow-up pending PMA approval (protocol and plan changes) Supplement Supplement for 3-5 year follow-up pending PMA approval (protocol and plan changes) Supplement Supplem | Supplement Patient Count Submission Final Report PMA Application Submission S | Supplement Patient Count Supplement Patient Count Sol Patients. Supplement Patient Count Sol Patients. Supplement Patient Count Sol Patients. Final Report PMA Application Submission for IDE Final Report Submission Continued access after pivotal study, increased tantalum in Onyx. Submission Submission Supplement for 3-5 year Follow-up pending PMA approval (protocol and pinformed consent). Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and pinformed consent). | Supplement Patient Count Submission Final Report PMA Application Submission S | Supplement Patient Count Supplement Patient Count Sol Patients. Supplement Patient Count Sol Patients. Supplement Patient Count Sol Patients. Final Report PMA Application Submission for IDE Final Report Submission Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Supplement Patient Count Submission Final Report PMA Application Submission S | Supplement Patient Count Supplement Patient Count Sol Patients. Supplement Patient Count Sol Patients. Supplement Patient Count Sol Patients. Final Report PMA Application Submission for IDE Final Report Submission Continued access after pivotal study, increased tantalum in Onyx. Submission Submission Supplement for 3-5 year Follow-up pending PMA approval (protocol and pinformed consent). Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and pinformed consent). | Supplement Patient Count Supplement Patient Count Sol Patients. Supplement Patient Count Sol Patients. Supplement Patient Count Sol Patients. Final Report PMA Application Submission for IDE Final Report Submission Continued access after pivotal study, increased tantalum in Onyx. Submission Submission Supplement for 3-5 year Follow-up pending PMA approval (protocol and pinformed consent). Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and pinformed consent). | Supplement Patient Count Supplement Patient Count Sol Patients. Supplement Patient Count Sol Patients. Supplement Patient Count Sol Patients. Final Report PMA Application Submission for IDE Final Report Submission Continued Access after pivotal study, increased tantalum in Onyx. Submission Submission Supplement for 3-5 year Follow-up pending PMA approval (protocol and pinformed consent). Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and pinformed consent). | Supplement Patient Count Supplement Patient Count Sol Patients. Supplement Patient Count Sol Patients. Supplement Patient Count Sol Patients. Final Report PMA Application Submission for IDE Final Report Submission Continued Access Protocol and plan changes, including increased tantalum in Onyx. Submission Submission PMA approval (protocol and plan changes, including pending PMA approval (protocol and plan changes). Submission Submission PMA approval (protocol and plan changes). Submission PMA approval (protocol and plan changes). | Supplement Patient Count Supplement Patient Count Sol Patients. Supplement Patient Count Sol Patients. Supplement Patient Count Sol Patients. Final Report PMA Application Submission for IDE Final Report Submission Continued Access Protocol and plan changes, including increased tantalum in Onyx. Submission Submission PMA approval (protocol and plan changes, including pending PMA approval (protocol and plan changes). Submission Submission PMA approval (protocol and plan changes). Submission PMA approval (protocol and plan changes). | Supplement Patient Count Supplement Patient Count Sol Patients. Supplement Patient Count Sol Patients. Supplement Patient Count Sol Patients. Final Report PMA Application Submission for IDE Final Report Submission Continued Access Protocol and plan changes, including increased tantalum in Onyx. Submission Submission PMA approval (protocol and plan changes, including pending PMA approval (protocol and plan changes). Submission Submission PMA approval (protocol and plan changes). Submission PMA approval (protocol and plan changes). |
| Supplement Patient Count Request to increase number of Supplement Patient Count Sold Patients. Supplement Patient Count Request to increase number of Supplement Submission for IDE Final Report PMA Application Submission for IDE Final Report Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up Supplement for 3-5 year follow-up prending DMA approval forestood and plan changes increased tantalum of Onyx. Submission 3-5 year Follow-up Supplement for 3-5 year follow-up O2-20-04 FDA Response 3-5 year Follow-up | Supplement Patient Count Supplement Supplement Patient Count Patients. Supplement Patient Count Submission for IDE Final Report Final Report PMA Application Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and plan changes) Supplement for 3-5 year follow-up pending PMA approval (protocol and plan changes) Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and plan changes) Supplement for 3-5 year follow-up pending PMA approval (protocol and plan changes) Supplement for 3-5 year follow-up pending PMA approval (protocol and plan changes) Supplement for 3-5 year follow-up pending PMA approval (protocol and plan changes) Supplement for 3-5 year follow-up pending PMA approval (protocol and plan changes) Supplement for 3-5 year follow-up pending PMA approval (protocol and plan changes) Supplement for 3-5 year follow-up pending PMA approval (protocol and plan changes) Supplement for 3-5 year follow-up pending PMA approval (protocol and plan changes) Supplement for 3-5 year follow-up pending PMA approval (protocol and plan changes) Supplement for 3-5 year follow-up pending PMA approval (protocol and plan changes) Supplement for 3-5 year follow-up pending PMA approval (protocol and plan changes) Supplement for 3-5 year follow-up pending PMA approval (protocol and plan changes) Supplement for 3-5 year follow-up pending PMA approval (protocol and plan changes) Supplement for 3-5 year follow-up pending PMA approval (protocol and plan changes) Supplement for 3-5 year follow-up pending PMA approval (protocol and plan changes) Supplement for 3-5 year follow-up pending PMA approval (protocol and plan changes) Supplement for 3-5 year follow-up pending PMA approval (protocol and plan changes) Supplement for 3-5 year follow-up pending PMA approval (protocol and plan changes) Supplement for 3-5 year follow-up pending PMA approval (protoco | Supplement Patient Count Request to increase number of Supplement Patient Count Patients. Supplement Patient Count Submission for IDE Final Report Final Report PMA Application Submission for IDE Final Report Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent) Submission Submission Submission Onyx. Submission Submission Onyx. Submission Submission Onyx. Submission Submission Onyx. Submission Onyx. Submission One of the first dated 12- Submission Ontinued Access Additional Patient Solid Submission Onlyx. Submission Ontinued Access Ontinued Access Ontinued Access Ontinued Access Ontinued Access Ontinued One-up Pending PMA approval (protocol and One-up On | Supplement Supplement Patient Count Submission Final Report PMA Application Submission Continued Access Protocol and Plan changes, including informed consent). Submission Submission Submission Operated tantalum in Onyx. Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). | Supplement Patient Count Patients. Supplement Patient Count Patients. Supplement Patient Count Sold Patients. Final Report PMA Application Submission for IDE Final Report Submission Continued Access Protocol and plan changes, including increased tantalum in Onyx. Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and plan changes) and plan changes protocol and plan changes, including increased tantalum in Onyx. Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and plan changes) and plan changes, including increased tantalum in Onyx. Submission Submissio | Supplement Patient Count Request to increase number of Supplement Patient Count Solid Patients. Supplement PMA Application Submission for IDE Final Report Final Report PMA Application Submission Continued Access Protocol and plan changes, including increased tantalum in Onyx. Submission Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Supplement Patient Count Submission Continued Access Protocol and plan changes, including informed consent). Submission Submission 3-5 year Follow-up pending PMA approval (protocol and plan changes, informed consent). | Supplement Patient Count Request to increase number of Supplement Patient Count Patients. Supplement Phatient Count Phatients. Supplement Phatient Count Phatients. Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and plan changes) and pending PMA approval (protocol and plan changes) are pending PMA approval (protocol and plan changes) and pending PMA approval (protocol and plan changes) are pending PMA approval (protocol and plan changes) | Supplement Patient Count Patients. Supplement Patient Count Request to increase number of Submission Final Report PMA Application Submission for IDE Final Report PMA Application Submission Continued Access Protocol and plan changes, including increased tantalum in Onyx. Submission Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Supplement Patient Count Request to increase number of Supplement Patient Count Solid Patients. Supplement PMA Application Submission for IDE Final Report Final Report PMA Application Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission Submission 3-5 year Follow-up pending PMA approval (protocol and plan changes) informed consent). | Supplement Patient Count Submission Continued Access Protocol and plan changes, including informed consent). Submission Submission 3-5 year Follow-up pending PMA approval (protocol and plan changes, informed consent). | Supplement Patient Count Submission Continued Access Protocol and plan changes, including informed consent). Submission Submission 3-5 year Follow-up pending PMA approval (protocol and letter dated 12- O7-01. Request to increase number of 12-06-02 FDA Response Additional Patient Sol14 Submission Submission for IDE Final Report Final Report PMA approval study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and letter dated 12- O7-01. Submission PAR Response Continued Access protocol and plan changes, including informed consent). | Supplement Patient Count Patients. Supplement Patient Count Request to increase number of Submission Final Report PMA Application Submission for IDE Final Report PMA Application Submission Continued Access Protocol and plan changes, including increased tantalum in Onyx. Submission Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Supplement Supplement Patient Count Submission Final Report PMA Application Submission Continued Access Protocol and Plan changes, including informed consent). Submission Submission Submission Operated Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). | Supplement Patient Count Submission Continued Access Enrollow-up pending PMA approval (protocol and informed consent). | Supplement Supplement Patient Count Submission Final Report PMA Application Submission Continued Access Protocol and Plan changes, including informed consent). Submission Submission Submission Operated tantalum in Onyx. Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). | Supplement Supplement Patient Count Submission Final Report PMA Application Submission Continued Access Protocol and Plan changes, including informed consent). Submission Submission Submission Operated Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). | Supplement Supplement Patient Count Submission Final Report PMA Application Submission Continued Access Protocol and Plan changes, including informed consent). Submission Submission Submission Operated Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). | Supplement Patient Count Submission Continued Access Entrollow-up pending PMA approval (protocol and informed consent). | Supplement Supplement Patient Count Submission Final Report PMA Application Submission Continued Access Protocol and Plan changes, including informed consent). Submission Submission Submission Operated Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). | Supplement Patient Count Patients. Supplement Patient Count Patients. Supplement Patient Count Submission for IDE Final Report PMA Application Submission Continued Access Protocol and Patient Pmanued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). | Supplement Supplement Patient Count Submission Final Report PMA Application Submission Continued Access Protocol and Plan changes, including informed consent). Submission Submission Submission Operated tantalum in Onyx. Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). | Supplement Patient Count Submission Final Report PMA Application Submission Continued Access Protocol and Plan changes, including informed consent). Submission Submission Submission Onyx. Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). | Supplement Supplement Patient Count Submission Final Report PMA Application Submission Continued Access Protocol and Plan changes, including informed consent). Submission Submission Submission Operated tantalum in Onyx. Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). | Supplement Patient Count Patients. Supplement Patient Count Patients. Supplement Patient Count Submission for IDE Final Report PMA Application Submission Continued Access Protocol and Patient Pmanued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). | Supplement Patient Count Patients. Supplement Patient Count Patients. Supplement Patient Count Submission for IDE Final Report PMA Application Submission Continued Access Protocol and Patient Pmanued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). | Supplement Supplement Patient Count Patients. Supplement Patient Count Submission for IDE Final Report PMA Application Submission Continued Access Protocol and Patient increase number of Submission Submission Submission Submission PMA approval (protocol and plan changes, including pending PMA approval (protocol and informed consent). | Supplement Patient Count Patients. Supplement Patient Count Patients. Supplement Patient Count Sold Patients. Final Report PMA Application Submission for IDE Final Report PMA Application Continued Access Protocol and Protocol and Patient PMA approval (protocol and plan changes, including increased tantalum in Onyx. Submission Submission S-5 year Follow-up Pending PMA approval (protocol and informed consent). | Supplement Patient Count Patients. Supplement Patient Count Patients. Supplement Patient Count Sold Patients. Final Report PMA Application Submission for IDE Final Report PMA Application Continued Access Protocol and Protocol and Patient PMA approval (protocol and plan changes, including increased tantalum in Onyx. Submission Submission S-5 year Follow-up Pending PMA approval (protocol and informed consent). | Supplement Patient Count Patients. Supplement Patient Count Patients. Supplement Patient Count Sold Patients. Final Report PMA Application Submission for IDE Final Report PMA Application Continued Access Protocol and Protocol and Patient PMA approval (protocol and plan changes, including increased tantalum in Onyx. Submission Submission S-5 year Follow-up Pending PMA approval (protocol and informed consent). |
| Supplement Patient Count Supplement Patient Count Policiation Submission Continued Access Protocol and Plan changes, including Increased tantalum in Onyx. Submission Submission 3-5 year Follow-up Pending PMA approval (protocol and plan changes) and plan changes are plan changes and plan changes and plan changes are plan changes and plan changes and plan changes are plan changes are plan changes and plan changes are plan changes and plan changes are plan change | Supplement Patient Count Sol Patient Count Sol Patient Count Patients. Final Report PMA Application Submission for IDE Final Report Submission Continued Access Protocol and plan changes, including increased tantalum in Onyx. Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and plan changes) protocol and plan changes, including increased tantalum in Onyx. Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and plan changes) protocol and plan changes, including increased tantalum in Onyx. Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and plan changes) protocol and plan changes, including pending PMA approval (protocol and plan changes) protocol and plan changes, including pending PMA approval (protocol and plan changes) protocol and plan changes, including pending PMA approval (protocol and plan changes) protocol and plan changes, including pending PMA approval (protocol and plan changes) protocol and plan changes, including pending PMA approval (protocol and plan changes) protocol and plan changes, including pending PMA approval (protocol and plan changes) protocol and plan changes, including pending PMA approval (protocol and plan changes) protocol and plan changes protocol and plan chang | Supplement Patient Count Request to increase number of S014 Patient Count Patients. Request to increase number of S014 Patients. Request to increase number of S014 Patients. PDA Response Additional Patient S014 S016 Enrollment S014 S016 Enrollment S016 Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent) 02-20-04 FDA Response S-5 year follow-up | Supplement Patient Count Sol Patient | Supplement Patient Count Supplement Patient Count Patients. Supplement Supplement Patient Count Submission for IDE Final Report Final Report PMA Application Submission Continued Access Protocol and Plan changes, including Increased tantalum in Onyx. Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and PDA Response Supplement for 3-5 year follow-up pending PMA approval (protocol and PDA Response Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and PDA Response Supplement for 3-5 year follow-up pending PMA approval (protocol and PDA Response Supplement for 3-5 year follow-up pending PMA approval (protocol and PDA Response Supplement for 3-5 year follow-up pending PMA approval (protocol and PDA Response Supplement for 3-5 year follow-up pending PMA approval (protocol and PDA Response Supplement for 3-5 year follow-up pending PMA approval (protocol and PDA Response Supplement for 3-5 year follow-up pending PMA approval (protocol and PDA Response Supplement for 3-5 year follow-up pending PMA approval (protocol and PDA Response Supplement for 3-5 year follow-up pending PMA approval (protocol and PDA Response Supplement for 3-5 year follow-up pending PMA approval (protocol and PDA Response Supplement for 3-5 year follow-up pending PMA approval (protocol and PDA Response Supplement for 3-5 year follow-up pending PMA approval (protocol and PDA Response Supplement for 3-5 year follow-up pending PMA approval (protocol and PDA Response Supplement for 3-5 year follow-up pending PMA approval (protocol and PDA Response Supplement for 3-5 year follow-up pending PMA approval (protocol and PDA Response Supplement for 3-5 year follow-up pending PMA approval (protocol and PDA Response Supplement for 3-5 year follow-up pending PMA approval (protocol and PDA Response Supplement for 3-5 year follow-up pending PMA approval (protocol and PDA Response Supplement for 3-5 year follow-up pending PMA approval (protocol and PDA Response Supplement for 3-5 year follow-up pendi | Supplement Patient Count Request to increase number of S014 Final Report PMA Application Submission for IDE Final Report Continued Access Protocol and plan changes, including increased tantalum in Onyx. Submission Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Supplement Patient Count Request to increase number of S014 Final Report PMA Application Submission for IDE Final Report Submission Continued Access Protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Supplement Patient Count Submission of I2-06-02 FDA Response Additional Patient Enrollment Final Report PMA Application Submission for IDE Final Report Submission Continued Access Protocol and plan changes, including increased tantalum in Onyx. Submission Submission 3-5 year Follow-up pending PMA approval (protocol and plan changes) informed consent) Submission Submission 3-5 year Follow-up pending PMA approval (protocol and plan changes) informed consent) | Supplement Patient Count Request to increase number of S014 Final Report PMA Application Submission for IDE Final Report Submission Continued Access Protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Supplement Patient Count Request to increase number of S014 Patient Count Patients. Request to increase number of S014 Patients. PA Response Additional Patient Enrollment Final Report PMA Application Submission for IDE Final Report. Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and plan changes). Submission 3-5 year Follow-up pending PMA approval (protocol and plan changes). | Supplement Patient Count Request to increase number of S014 Final Report PMA Application Submission for IDE Final Report Submission Continued Access Protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Supplement Patient Count Supplement Patient Count Politication Submission Final Report PMA Application Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Supplement Patient Count Request to increase number of S014 Final Report PMA Application Submission for IDE Final Report Submission Continued Access Protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Supplement Patient Count Sol Patient | Supplement Patient Count Supplement Patient Count Politication Submission Final Report PMA Application Submission Continued Access Protocol and plan changes, including increased tantalum in Onyx. Submission Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Supplement Patient Count Sol Patient | Supplement Patient Count Sol Patient | Supplement Patient Count Sol Patient | Supplement Patient Count Sold Patient Count Patients. Final Report PMA Application Submission for IDE Final Report Submission Continued Access Protocol and plan changes, including increased tantalum in Onyx. Submission Supplement for 3-5 year Follow-up pending PMA approval (protocol and plan changes). | Supplement Patient Count Sol Patient | Supplement Patient Count Squest to increase number of Sol4 Patient Count Patients. Final Report PMA Application Submission for IDE Final Report Submission Continued Access Protocol and plan changes, including increased tantalum in Onyx. Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). | Supplement Patient Count Sol Patient | Supplement Patient Count Sol Patient Sol P | Supplement Patient Count Sol Patient | Supplement Patient Count Squest to increase number of Sol4 Patient Count Patients. Final Report PMA Application Submission for IDE Final Report Submission Continued Access Protocol and plan changes, including increased tantalum in Onyx. Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). | Supplement Patient Count Squest to increase number of Sol4 Patient Count Patients. Final Report PMA Application Submission for IDE Final Report Submission Continued Access Protocol and plan changes, including increased tantalum in Onyx. Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). | Supplement Supplement Patient Count Sol Patient Count Sol Patient Count Sol Patient Count Sol Patients. Final Report PMA Application Submission for IDE Final Report Submission Continued Access Protocol and plan changes, including increased tantalum in Onyx. Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). | Supplement Patient Count Supplement Patient Count Submission Final Report PMA Application Submission Continued Access Protocol and Plan changes, including increased tantalum in Onyx. Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). | Supplement Patient Count Supplement Patient Count Submission Final Report PMA Application Submission Continued Access Protocol and Plan changes, including increased tantalum in Onyx. Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). | Supplement Patient Count Supplement Patient Count Submission Final Report PMA Application Submission Continued Access Protocol and Plan changes, including increased tantalum in Onyx. Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). |
| Supplement Patient Count Request to increase number of Supplement Patient Count Patients. Supplement Patient Count Request to increase number of Supplement Submission for IDE Final Report PMA Application Submission for IDE Final Report Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up Supplement for 3-5 year follow-up prending DMA approval forestood and plan changes increased tantalum of the patient Supplement for 3-5 year follow-up on the patient Supplement | Supplement Patient Count Request to increase number of Supplement Patient Count Patients. Final Report PMA Application Submission for IDE Final Report Submission Continued Access Protocol and Plan changes, including increased tantalum in Onyx. Submission Submission 3-5 year Follow-up pending PMA approval (protocol and plan changes, including pending PMA approval (protocol and plan changes, including pending PMA approval (protocol and plan changes, including pending PMA approval (protocol and pending PMA approval (pending PMA approval pending PMA approval pending PMA a | Supplement Patient Count Request to increase number of Supplement Patient Count Patients. Final Report PMA Application Submission for IDE Final Report Submission Continued Access Protocol and plan changes, including increased tantalum in Onyx. Submission Submission 3-5 year Follow-up Pending PMA approval (protocol and plan changes) informed consent) Supplement for 3-5 year follow-up pending PMA approval (protocol and plan changes) informed consent) | Supplement Patient Count Submission Final Report PMA Application Submission Continued Access Protocol and Plan changes, including informed consent). Submission Submission Submission Operated tantalum in Onyx. Submission Submission Operated tantalum in Onyx. | Supplement Patient Count Request to increase number of Supplement Patient Count Patients. Final Report PMA Application Submission for IDE Final Report Final Report PMA Application Submission Continued Access Protocol and plan changes, including increased tantalum in Onyx. Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and Patient 12-06-02 FDA Response Continued Access Protocol and Patients Submission Submission Submission Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and Submission Su | Supplement Patient Count Request to increase number of Supplement Patient Count Patients. Final Report PMA Application Submission for IDE Final Report Submission Continued Access Protocol and plan changes, including increased tantalum in Onyx. Submission Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Supplement Patient Count Request to increase number of Supplement Patient Count Patients. Final Report PMA Application Submission for IDE Final Report Final Report PMA Application Submission Continued Access Protocol and plan changes, including increased tantalum in Onyx. Submission Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Supplement Patient Count Request to increase number of Supplement Patient Count Patients. Final Report PMA Application Submission for IDE Final Report Submission Continued Access Protocol and plan changes, including increased tantalum in Onyx. Submission Submission 3-5 year Follow-up pending PMA approval (protocol and plan changes) PMA approval (protocol and pl | Supplement Patient Count Request to increase number of Supplement Patient Count Patients. Final Report PMA Application Submission for IDE Final Report Final Report PMA Application Submission Continued Access Protocol and plan changes, including increased tantalum in Onyx. Submission Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Supplement Patient Count Request to increase number of Supplement Patient Count Patients. Final Report PMA Application Submission for IDE Final Report Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission Submission 3-5 year Follow-up pending PMA approval (protocol and plan changes) informed consent). Submission Submission Submission Onyx. Submission Submission Submission Onyx. Submission Submission Onyx. Submission Submission Onyx. Submission One of the Equest to increase number of Submission for IDE Final Report Submission of IDE Final Report Submission On IDE Final Report Submi | Supplement Patient Count Request to increase number of Supplement Patient Count Patients. Final Report PMA Application Submission for IDE Final Report Final Report PMA Application Submission Continued Access Protocol and plan changes, including increased tantalum in Onyx. Submission Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Supplement Patient Count Request to increase number of Supplement Patient Count Patients. Final Report PMA Application Submission for IDE Final Report Submission Continued Access Continued access after pivotal study, increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Supplement Patient Count Request to increase number of Supplement Patient Count Patients. Final Report PMA Application Submission for IDE Final Report Final Report PMA Application Submission Continued Access Protocol and plan changes, including increased tantalum in Onyx. Submission Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Supplement Patient Count Submission Final Report PMA Application Submission Continued Access Protocol and Plan changes, including informed consent). Submission Submission Submission Operated tantalum in Onyx. Submission Submission Operated tantalum in Onyx. Operated tantalum in Onyx. Submission Operated tantalum in Onyx. | Supplement Patient Count Supplement Patient Count Patients. Supplement Patient Count Patients. Final Report PMA Application Submission for IDE Final Report Submission Continued Access Continued access after pivotal study, increased tantalum in Onyx. Submission Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Supplement Patient Count Submission Final Report PMA Application Submission Continued Access Protocol and Plan changes, including informed consent). Submission Submission Submission Operated tantalum in Onyx. Submission Submission Operated tantalum in Onyx. | Supplement Patient Count Submission Final Report PMA Application Submission Continued Access Protocol and Plan changes, including informed consent). Submission Submission Submission Operated tantalum in Onyx. Submission Submission Operated tantalum in Onyx. Operated tantalum in Onyx. Submission Operated tantalum in Onyx. | Supplement Patient Count Submission Final Report PMA Application Submission Continued Access Protocol and Plan changes, including informed consent). Submission Submission Submission Operated tantalum in Onyx. Submission Submission Operated tantalum in Onyx. | Supplement Patient Count Submission Final Report PMA Application Submission Continued Access Protocol and plan changes, including informed consent). Submission Submission Submission Operated tantalum in Onyx. Submission Submission Operated tantalum in Onyx. | Supplement Patient Count Submission Final Report PMA Application Submission Continued Access Protocol and Plan changes, including informed consent). Submission Submission Submission Operated tantalum in Onyx. Submission Submission Operated tantalum in Onyx. | Supplement Patient Count Request to increase number of Supplement Patient Count Patients. Final Report PMA Application Submission for IDE Final Report Submission Continued Access Protocol and Protocol and Protocol and Patient Submission Submission Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). | Supplement Patient Count Submission Final Report PMA Application Submission Continued Access Protocol and Plan changes, including informed consent). Submission Submission Submission Operated tantalum in Onyx. Submission Submission Operated tantalum in Onyx. | Supplement Patient Count Submission Final Report PMA Application Submission Continued Access Protocol and Patient for 3-5 year Follow-up pending PMA approval (protocol and informed consent). Supplement Patient Count Request to increase number of 12-06-02 FDA Response Additional Patient Solf PA Response Continued Access Final Report PMA approval (protocol and Submission Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). | Supplement Patient Count Submission Final Report PMA Application Submission Continued Access Protocol and Plan changes, including informed consent). Submission Submission Submission Operated tantalum in Onyx. Submission Submission Operated tantalum in Onyx. | Supplement Patient Count Request to increase number of Supplement Patient Count Patients. Final Report PMA Application Submission for IDE Final Report Submission Continued Access Protocol and Protocol and Protocol and Patient Submission Submission Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). | Supplement Patient Count Request to increase number of Supplement Patient Count Patients. Final Report PMA Application Submission for IDE Final Report Submission Continued Access Protocol and Protocol and Protocol and Patient Submission Submission Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). | Supplement Supplement Patient Count Submission for IDE Final Report PMA Application Submission Continued Access Protocol and Plan changes, including increased tantalum in Onyx. Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). | Supplement Patient Count Request to increase number of S014 Final Report PMA Application Submission for IDE Final Report Final Report Continued Access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission Submission S-5 year Follow-up pending PMA approval (protocol and informed consent). | Supplement Patient Count Request to increase number of S014 Final Report PMA Application Submission for IDE Final Report Final Report Continued Access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission Submission S-5 year Follow-up pending PMA approval (protocol and informed consent). | Supplement Patient Count Request to increase number of S014 Final Report PMA Application Submission for IDE Final Report Final Report Continued Access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission Submission S-5 year Follow-up pending PMA approval (protocol and informed consent). |
| Supplement Patient Count Request to increase number of S014 Patient Count Patients. Request to increase number of S014 Patients. PDA Response Additional Patient Enrollment Final Report PMA Application Submission for IDE Final Report Submission Continued Access Protocol and plan changes, including increased tantalum in Onyx. Submission Submission Submission Submission Submission Subplement for 3-5 year follow-up Pending PMA approval forefood and Submission S | Supplement Patient Count Request to increase number of S014 Patient Count Patients. Request to increase number of S014 Patient | Supplement Patient Count Request to increase number of S014 Patient Count Patients. Request to increase number of S014 Patient Physical Report PMA Application Submission Final Report Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission Submi | Supplement Patient Count Sol Patient Count Patient Count Sol Patients. Final Report PMA Application Submission for IDE Final Report Submission Continued Access Protocol and plan changes, including increased tantalum in Onyx. Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and protocol and protocol and protocol and protocol and protocol and pending PMA approval (protocol and protocol and protocol and pending PMA approval (protocol and protocol and protocol and protocol and protocol and pending PMA approval (protocol and protocol and protocol and protocol and protocol and pending PMA approval (protocol and protocol and protocol and pending PMA approval (protocol and protocol and protoc | Supplement Patient Count Sol Patient Count Sol Patient Count Patient Count Sol Patient Submission Continued Access Protocol and Plan changes, including Patient Patient Patient Patient Sol Patient Patien | Supplement Patient Count Request to increase number of S014 Patient Count Patients. Request to increase number of S014 Patient Count Patients. Submission PMA Application Submission for IDE Final Report Submission Continued Access Protocol and Plan changes, including increased tantalum in Onyx. Supplement for 3-5 year follow-up pending PMA approval (protocol and plan changes). Submission S-5 year Follow-up pending PMA approval (protocol and plan changes). Submission PMA approval (protocol and plan changes). | Supplement Patient Count Request to increase number of S014 Patient Count Patients. Request to increase number of S014 Patient Physical Patients. Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). Submission Submissio | Supplement Patient Count Request to increase number of Solf PDA Response PDA Response PDA Response PDA Response PDA Response PDA Response Enrollment Solf PDA Response PDA PDA Response PDA PDA Response PDA | Supplement Patient Count Request to increase number of S014 Patient Count Patients. Request to increase number of S014 Patient Count Patients. Submission PMA Application Submission for IDE Final Report Submission Continued Access Protocol and Plan changes, including increased tantalum in Onyx. Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). Submission Submission Submission PMA approval (protocol and plan changes, including pending PMA approval (protocol and plan changes, including pending PMA approval (protocol and pending PMA approval (pending PMA approval pending PMA approval | Supplement Patient Count Request to increase number of S014 Patient Count Patients. Request to increase number of S014 Patient S014 Patients. Submission Final Report PMA Application Submission Final Report Continued Access Protocol and plan changes, including increased tantalum in Onyx. Submission Submissio | Supplement Patient Count Request to increase number of S014 Patient Count Patients. Request to increase number of S014 Patient Physical Patients. Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). Submission Submissio | Supplement Patient Count Request to increase number of S014 Final Report PMA Application Submission for IDE Final Report Submission Continued Access Protocol and plan changes, including increased tantalum in Onyx. Submission Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Supplement Patient Count Request to increase number of S014 Patient Count Patients. Request to increase number of S014 Patient Count Patients. Submission PMA Application Submission for IDE Final Report Submission Continued Access Protocol and Plan changes, including increased tantalum in Onyx. Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). Submission Submission Submission PMA approval (protocol and plan changes, including pending PMA approval (protocol and plan changes, including pending PMA approval (protocol and pending PMA approval (pending PMA approval pending PMA approval | Supplement Patient Count Sol Patient Count Patient Count Sol Patients. Final Report PMA Application Submission for IDE Final Report Submission Continued Access Protocol and plan changes, including increased tantalum in Onyx. Submission Submission Supplement for 3-5 year Follow-up pending PMA approval (protocol and plan changes). | Supplement Patient Count Request to increase number of S014 Final Report PMA Application Submission for IDE Final Report Submission Continued Access Protocol and plan changes, including increased tantalum in Onyx. Submission Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Supplement Patient Count Sol Patient Count Patient Count Sol Patients. Final Report PMA Application Submission for IDE Final Report Submission Continued Access Protocol and plan changes, including increased tantalum in Onyx. Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and protocol and protocol and protocol and protocol and protocol and pending PMA approval (protocol and protocol and protocol and pending PMA approval (protocol and protocol and protocol and protocol and protocol and pending PMA approval (protocol and protocol and protocol and protocol and protocol and pending PMA approval (protocol and protocol and protocol and pending PMA approval (protocol and protocol and protoc | Supplement Patient Count Sol Patient Count Patient Count Sol Patients. Final Report PMA Application Submission for IDE Final Report Submission Continued Access Protocol and plan changes, including increased tantalum in Onyx. Submission Submission Supplement for 3-5 year Follow-up pending PMA approval (protocol and plan changes). | Supplement Patient Count Sol Patient Count Sol Patient Count Patient Sol Patients. Final Report PMA Application Submission for IDE Final Report Submission Continued Access Protocol and plan changes, including increased tantalum in Onyx. Submission Submission PMA approval (protocol and plan changes, including pending PMA approval (protocol and protocol and protocol and protocol and protocol and pending PMA approval (protocol and protocol and protocol and pending PMA approval (protocol and protocol and pending PMA approval (protocol and protocol and pending PMA approval (protocol and pending PMA approval (pending PMA ap | Supplement Patient Count Sol Patient Count Sol Patient Count Patient Sol Patients. Final Report PMA Application Submission for IDE Final Report Submission Continued Access Protocol and plan changes, including increased tantalum in Onyx. Submission Submission 3-5 year Follow-up pending PMA approval (protocol and plan changes). | Supplement Patient Count Sol Patient Count Sol Patient Count Patient Sol Patients. Final Report PMA Application Submission for IDE Final Report Submission Continued Access Protocol and plan changes, including increased tantalum in Onyx. Submission Submission PMA approval (protocol and plan changes, including pending PMA approval (protocol and protocol and protocol and protocol and protocol and pending PMA approval (protocol and protocol and protocol and pending PMA approval (protocol and protocol and pending PMA approval (protocol and protocol and pending PMA approval (protocol and pending PMA approval (pending PMA ap | Supplement Patient Count Sol Patient Count Sol Patient Count Patient Count Sol Patient Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission Submission Sol Pear Follow-up pending PMA approval (protocol and informed consent). | Supplement Patient Count Sol Patient Count Patient Count Sol Patients. Final Report PMA Application Submission for IDE Final Report Submission Continued Access Protocol and plan changes, including increased tantalum in Onyx. Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and protocol and protocol and protocol and protocol and protocol and pending PMA approval (protocol and protocol and protocol and pending PMA approval (protocol and protocol and protocol and protocol and protocol and pending PMA approval (protocol and protocol and protocol and protocol and protocol and pending PMA approval (protocol and protocol and protocol and pending PMA approval (protocol and protocol and protoc | Supplement Patient Count Sol Patient Count Patient Count Sol Patients. Final Report PMA Application Submission for IDE Final Report Submission Continued Access Protocol and plan changes, including increased tantalum in Onyx. Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). | Supplement Patient Count Sol Patient Count Patient Count Sol Patients. Final Report PMA Application Submission for IDE Final Report Submission Continued Access Protocol and plan changes, including increased tantalum in Onyx. Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and protocol and protocol and protocol and protocol and protocol and pending PMA approval (protocol and protocol and protocol and pending PMA approval (protocol and protocol and protocol and protocol and protocol and pending PMA approval (protocol and protocol and protocol and protocol and protocol and pending PMA approval (protocol and protocol and protocol and pending PMA approval (protocol and protocol and protoc | Supplement Patient Count Sol Patient Count Sol Patient Count Patient Count Sol Patient Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission Submission Sol Pear Follow-up pending PMA approval (protocol and informed consent). | Supplement Patient Count Sol Patient Count Sol Patient Count Patient Count Sol Patient Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission Submission Sol Pear Follow-up pending PMA approval (protocol and informed consent). | Supplement Supplement Patient Count Sol Patient Count Sol Patient Count Sol Patient Count Sol Patient | Supplement Patient Count Supplement Patient Count Patients. Patient Count Patient Count Patients. Patient Count Patient Count Patient Count Submission For IDE Final Report Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission Submission Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). | Supplement Patient Count Supplement Patient Count Patients. Patient Count Patient Count Patients. Patient Count Patient Count Patient Count Submission For IDE Final Report Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission Submission Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). | Supplement Patient Count Supplement Patient Count Patients. Patient Count Patient Count Patients. Patient Count Patient Count Patient Count Submission For IDE Final Report Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission Submission Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). |
| Supplement Supplement Patient Count Patient Count Sol14 Final Report PMA Application Submission for IDE Final Report Final Report Submission Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up Supplement for 3-5 year follow-up predice DMA approval forefood and Submission S | Supplement Supplement Patient Count Submission Continued Access Protocol and Plan Changes, including Submission Submission Submission Supplement for 3-5 year Follow-up pending PMA approval (protocol and plan changes) Supplement for 3-5 year follow-up pending PMA approval (protocol and plan changes) Supplement for 3-5 year follow-up pending PMA approval (protocol and plan changes) Supplement for 3-5 year follow-up pending PMA approval (protocol and plan changes) Supplement for 3-5 year follow-up pending PMA approval (protocol and plan changes) Supplement for 3-5 year follow-up pending PMA approval (protocol and plan changes) Supplement for 3-5 year follow-up pending PMA approval (protocol and plan changes) Supplement for 3-5 year follow-up pending PMA approval (protocol and plan changes) Supplement for 3-5 year follow-up pending PMA approval (protocol and plan changes) Supplement for 3-5 year follow-up pending PMA approval (protocol and plan changes) Supplement for 3-5 year follow-up pending PMA approval (protocol and plan changes) Supplement for 3-5 year follow-up pending PMA approval (protocol and plan changes) Supplement for 3-5 year follow-up pending PMA approval (protocol and plan changes) Supplement for 3-5 year follow-up pending PMA approval (protocol and plan changes) Supplement for 3-5 year follow-up pending PMA approval (protocol and plan changes) Supplement for 3-5 year follow-up pending PMA approval (protocol and plan changes) Supplement for 3-5 year follow-up pending PMA approval (protocol and plan changes) Supplement for 3-5 year follow-up pending PMA approval (protocol and plan changes) Supplement for 3-5 year follow-up pending PMA approval (protocol and plan changes) Supplement for 3-5 year follow-up pending PMA approval (protocol and plan changes) Supplement for 3-5 year follow-up pending PMA approval (protocol and plan changes) Supplement for 3-5 year follow-up pending PMA approval (protocol and plan changes) Supplement for 3-5 year follow-up pending PMA approval (protocol and plan changes) Sup | Supplement Supplement Patient Count Patient Count Sol14 Final Report PMA Application Submission for IDE Final Report Final Report PMA Application Submission Continued Access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission Submission Submission Submission Opending PMA approval (protocol and plan changes) informed consent) Submission Submission Submission Subplement for 3-5 year follow-up pending PMA approval (protocol and plan changes) informed consent) PAR Response Additional Patient Sol16 Enrollment Open Continued Access Protocol and Plan changes, including increased tantalum in Onyx. Submission Submission Submission Open Open Open Open Open Open Open Ope | Supplement Supplement Patient Count Submission Frinal Report PMA Application Submission Continued Access Protocol and Plan changes, including PMA approval (protocol and informed consent). Supplement Patient Count Request to increase number of 12-06-02 FDA Response Enrollment Submission Submission PMA approval (protocol and plan changes, including informed consent). | Supplement Supplement Patient Count Request to increase number of S014 Patient Count Potients. Final Report PMA Application Submission for IDE Final Report Submission Continued Access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and plan changes) and Supplement for 3-5 year follow-up pending PMA approval (protocol and supplement for 3-5 year follow-up pending PMA approval (protocol and supplement for 3-5 year follow-up pending PMA approval (protocol and supplement for 3-5 year follow-up pending PMA approval (protocol and supplement for 3-5 year follow-up pending PMA approval (protocol and supplement for 3-5 year follow-up pending PMA approval (protocol and supplement for 3-5 year follow-up pending PMA approval (protocol and supplement for 3-5 year follow-up pending PMA approval (protocol and supplement for 3-5 year follow-up pending PMA approval (protocol and supplement for 3-5 year follow-up pending PMA approval (protocol and supplement for 3-5 year follow-up pending PMA approval (protocol and supplement for 3-5 year follow-up pending PMA approval (protocol and supplement for 3-5 year follow-up pending PMA approval (protocol and supplement for 3-5 year follow-up pending PMA approval (protocol and supplement for 3-5 year follow-up pending PMA approval (protocol and supplement for 3-5 year follow-up pending PMA approval (protocol and supplement for 3-5 year follow-up pending PMA approval (protocol and supplement for 3-5 year follow-up pending PMA approval (protocol and supplement for 3-5 year follow-up pending PMA approval (protocol and supplement for 3-5 year follow-up pending PMA approval (protocol and supplement for 3-5 year follow-up pending PMA approval (protocol and supplement for 3-5 year follow-up pending PMA approval (protocol and supplement for 3-5 year follow-up pending PMA approval (protocol and supplement for 3-5 year follow-up pending PMA approval (protocol and supplemen | Supplement Supplement Patient Count Patient Count Sol 12-06-02 FDA Response Additional Patient Sol 14 PMA Application Submission for IDE Final Report PMA Application Submission for IDE Final Report Submission Continued Access Protocol and plan changes, including increased tantalum in Onyx. Submission Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Supplement Supplement Patient Count Sol Patient Count Sol Patient Count Sol Patient Sol Patient Sol Patient Sol Patient Sol Patient Sol Patient Sol PMA Application Submission for IDE Final Report Submission Continued Access Protocol and plan changes, including increased tantalum in Onyx. Submission Submission 3-5 year Follow-up pending PMA approval (protocol and plan changes). | Supplement Supplement Patient Count Patient Count Solf Solf Solf Solf Solf Solf Solf Solf | Supplement Supplement Patient Count Sol Patients. Final Report PMA Application Submission for IDE Final Report Final Report PMA Application Submission Continued Access Protocol and plan changes, including increased tantalum in Onyx. Submission Submission 3-5 year Follow-up pending PMA approval (protocol and plan changes). Submission Submission 3-5 year Follow-up pending PMA approval (protocol and plan changes). | Supplement Supplement Patient Count Patient Count Sol14 Final Report PMA Application Submission for IDE Final Report PMA Application Submission for IDE Final Report Submission Continued Access Protocol and plan changes, including increased tantalum in Onyx. Submission Submission 3-5 year Follow-up pending PMA approval (protocol and plan changes) informed consent). 12-06-02 FDA Response Additional Patient Sol16 Sol16 Enrollment Enrollment Online Access Protocol and Plan Changes, including increased tantalum in Onyx. Submission Submission 3-5 year Follow-up pending PMA approval (protocol and PDA Response Solution PMA approval (protocol and PDA Response Solution PDA Respo | Supplement Supplement Patient Count Sol Patient Count Sol Patient Count Sol Patient Sol Patient Sol Patient Sol Patient Sol Patient Sol Patient Sol PMA Application Submission for IDE Final Report Submission Continued Access Protocol and plan changes, including increased tantalum in Onyx. Submission Submission 3-5 year Follow-up pending PMA approval (protocol and plan changes). | Supplement Supplement Patient Count Patient Count Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Supplement Supplement Patient Count Sol Patients. Final Report PMA Application Submission for IDE Final Report Final Report PMA Application Submission Continued Access Protocol and plan changes, including increased tantalum in Onyx. Submission Submission 3-5 year Follow-up pending PMA approval (protocol and plan changes). Submission Submission 3-5 year Follow-up pending PMA approval (protocol and plan changes). | Supplement Supplement Patient Count Submission Final Report PMA Application Submission Continued Access Protocol and Plan changes, including informed consent). Patient Count Request to increase number of 12-06-02 FDA Response Enrollment Submission of IDE Final Report PMA Application Submission Continued Access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Supplement Supplement Patient Count Submission Final Report PMA Application Submission Continued Access Protocol and Plan changes, including Informed Consent). Submission Submission Submission Submission Operated tantalum in Onyx. Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). | Supplement Supplement Patient Count Submission Frinal Report PMA Application Submission Continued Access Protocol and Plan changes, including PMA approval (protocol and informed consent). Supplement Patient Count Request to increase number of 12-06-02 FDA Response Enrollment Submission Submission PMA approval (protocol and plan changes, including informed consent). | Supplement Supplement Patient Count Submission Final Report PMA Application Submission Continued Access Protocol and Plan changes, including informed consent). Patient Count Request to increase number of 12-06-02 FDA Response Enrollment Submission of IDE Final Report PMA Application Submission Continued Access Protocol and Plan changes, including increased tantalum in Onyx. Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). | Supplement Supplement Patient Count Submission Final Report PMA Application Submission Continued Access Protocol and Plan changes, including informed consent). Patient Count Request to increase number of 12-06-02 FDA Response Enrollment Submission of IDE Final Report PMA Application Submission Continued Access Protocol and Plan changes, including increased tantalum in Onyx. Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). | Supplement Supplement Patient Count Submission Final Report PMA Application Submission Continued Access Protocol and Plan changes, including informed consent). Supplement Patient Count Request to increase number of 12-06-02 FDA Response Enrollment Submission Submission for IDE Final Report PMA Application Submission Continued Access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). | Supplement Supplement Patient Count Submission Final Report PMA Application Submission Continued Access Protocol and Plan changes, including informed consent). Patient Count Request to increase number of 12-06-02 FDA Response Enrollment Submission of IDE Final Report PMA Application Submission Continued Access Protocol and Plan changes, including increased tantalum in Onyx. Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). | Supplement Supplement Patient Count Solf Solf Solf Solf Solf Solf Solf Solf | Supplement Supplement Patient Count Submission Frinal Report PMA Application Submission Continued Access Protocol and Plan changes, including PMA approval (protocol and informed consent). Supplement Patient Count Request to increase number of 12-06-02 FDA Response Enrollment Submission Submission PMA approval (protocol and plan changes, including informed consent). | Supplement Supplement Patient Count Submission Frinal Report PMA Application Submission Continued Access Protocol and Patient for 3-5 year Follow-up pending PMA approval (protocol and informed consent). PATRESPONSE FOR Response Additional Patient Solfs Submission Submission Continued Access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). | Supplement Supplement Patient Count Submission Frinal Report PMA Application Submission Continued Access Protocol and Plan changes, including PMA approval (protocol and informed consent). Supplement Patient Count Request to increase number of 12-06-02 FDA Response Enrollment Submission Submission PMA approval (protocol and plan changes, including informed consent). | Supplement Supplement Patient Count Solf Solf Solf Solf Solf Solf Solf Solf | Supplement Supplement Patient Count Solf Solf Solf Solf Solf Solf Solf Solf | Supplement Supplement Patient Count Solf Patient Count Solf Solf Solf Solf Solf Solf Solf Solf | Supplement Supplement Patient Count Solf Patient Count Solf Solf Solf Solf Solf Solf Solf Solf | Supplement Supplement Patient Count Solf Patient Count Solf Solf Solf Solf Solf Solf Solf Solf | Supplement Supplement Patient Count Solf Patient Count Solf Solf Solf Solf Solf Solf Solf Solf |
| Supplement Patient Count Request to increase number of Solf FDA Response Additional Patient Solf Solf Solf Solf Solf Solf Solf Solf | Submission Submis | Submission Octoal and plan changes, including increased tantalum in Onyx. Submission Submission Submission Submission Submission Submission Submission Octoal and plan changes, including increased tantalum in Onyx. Submission Submission Submission Submission Submission Submission Submission Submission Submission for IDE Final Report Submission for IDE Final Report Submission Submission Octoal Access FDA Response Submission | Submission Continued Access Continued access after pivotal study, protocol and plan changes, including informed consent). Submission Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Submission Continued Access Continued access after pivotal study, protocol and Submission Submissio | Submission Continued Access Continued access after pivotal study, pending PMA application Supplement for 3-5 year Follow-up pending PMA approval (protocol and informed consent). Submission Continued Access Continued access after pivotal study, protocol and plan changes, including informed consent). Final Report PMA Application Submission for IDE Final Report Solid Submission Submission Continued Access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission Submission Solid PMA approval (protocol and plan changes) including informed consent). | Submission Submission 3-5 year Follow-up pending PMA approval (protocol and linformed consent). Final Report PMA Application Submission for IDE Final Report Submission Submiss | Supplement Patient Count Request to increase number of S014 PAResponse Patients. Final Report PMA Application Submission for IDE Final Report Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent) Supplement Request to increase number of 12-06-02 FDA Response Additional Patient S016 Enrollment S016 Enrol | Submission Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Final Report PMA Application Submission for IDE Final Report Submission Submissi | Submission Submis | Submission Submission 3-5 year Follow-up pending PMA approval (protocol and linformed consent). Final Report PMA Application Submission for IDE Final Report Submission Submiss | Submission Continued Access Continued access after pivotal study, pending PMA application Submission Only Submission Subm | Submission Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Final Report PMA Application Submission for IDE Final Report Submission Submissi | Submission Continued Access Continued access after pivotal study, protocol and plan changes, including informed consent). Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Submission Continued Access Continued access after pivotal study, protocol and plan changes, including informed consent). Submission 3-5 year Follow-up pending PMA approval (protocol and pinn formed consent). | Submission Continued Access Continued access after pivotal study, protocol and plan changes, including informed consent). Submission Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Submission Continued Access Continued access after pivotal study, protocol and plan changes, including informed consent). Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Submission Continued Access Continued access after pivotal study, protocol and plan changes, including informed consent). Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Submission Continued Access Continued access after pivotal study, protocol and plan changes, including informed consent). Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Submission Continued Access Continued access after pivotal study, protocol and plan changes, including informed consent). Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Submission Continued Access Continued access after pivotal study, protocol and plan changes, including informed consent). Submission Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Submission Continued Access Continued access after pivotal study, protocol and plan changes, including informed consent). Submission Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Submission Continued Access Continued access after pivotal study, protocol and plan changes, including informed consent). Submission Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Submission Continued Access Continued access after pivotal study, protocol and plan changes, including informed consent). Submission Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Submission Continued Access Continued access after pivotal study, protocol and plan changes, including informed consent). Submission Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Submission Continued Access Continued access after pivotal study, protocol and plan changes, including informed consent). Submission Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Submission Submission Submission 3-5 year Follow-up informed consent). Final Report PMA Application Submission for IDE Final Report Submission | Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission Submission Submission Only Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). | Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission Submission Submission Only Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). | Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission Submission Submission Only Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). |
| Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up Supplement for 3-5 year follow-up predicts. Submission Solid Enrollment Solid Enr | Submission Continued Access Protocol and Plan changes, including increased tantalum in Onyx. Submission Submission 3-5 year Follow-up pending PMA approval (protocol and plan changes) and Submission Continued Access Protocol and Plan changes, including pending PMA approval (protocol and PDA Response Submission Continued Access Protocol and Plan changes, including PMA approval (protocol and Co-20-04 PDA Response Submission Continued Access Protocol and Co-20-04 PDA Response Continued Access Continued Access Protocol and Co-20-04 PDA Response Continued Access Continued Access Protocol and Co-20-04 PDA Response Continued Access Continued Access Continued Access Protocol and Co-20-04 PDA Response Continued Access Continued Access Protocol and Co-20-04 PDA Response Continued Access Continued Access Protocol and Plan Changes, including Polyment Polymen | Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission Submission Submission Submission 3-5 year Follow-up pending PMA approval (protocol and plan changes) Submission 3-5 year Follow-up pending PMA approval (protocol and plan changes) Submission 3-5 year Follow-up pending PMA approval (protocol and plan changes) Submission 3-5 year Follow-up pending PMA approval (protocol and plan changes) Submission 3-5 year Follow-up pending PMA approval (protocol and plan changes) | Submission Continued Access Continued access after pivotal study, protocol and plan changes, including informed consent). Submission Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Enrollment Solfs Submission Submission of IDE Final Report Submission of IDE Final Report Submission Submission of IDE Final Report Submission of IDE Fin | Submission Continued Access Protocol and Plan changes, including increased tantalum in Onyx. Submission Submission 3-5 year Follow-up pending PMA approval (protocol and plan changes) and pending PMA approval (protocol and plan changes) are follow-up pending PMA approv | Submission Continued Access Protocol and plan changes, including informed consent). Submission Submission 3-5 year Follow-up pending PMA approval (protocol and plan changes). Enrollment Solid Enrollment Submission Octinued Access Protocol and plan changes, including increased tantalum in Onyx. Submission Octinued Access Protocol and PMA approval (protocol and plan changes). Enrollment Octinued Access PDA Response Continued Access Protocol and PMA approval (protocol and PDA Response Octinued Access POA Response POA Respo | Submission Continued Access Protocol and plan changes, including informed consent). Submission Submission 3-5 year Follow-up pending PMA approval (protocol and plan changes). Enrollment Solid Enrollment Submission Octinued Access Protocol and plan changes, including informed consent). Enrollment Solid Enrollment Submission Octinued Access Protocol and PMA approval (protocol and plan changes). Enrollment Octinued Access PDA Response Continued Access Protocol and PMA approval (protocol and PDA Response PDA Response Solid PDA Response PDA Response PDA Response Solid PDA Response P | Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and plan changes) of the pending PMA approval (protocol and p | Submission Continued Access Protocol and plan changes, including informed consent). Submission Submission 3-5 year Follow-up pending PMA approval (protocol and plan changes). Enrollment Solid Enrollment Solid Enrollment of 1DE Final Report Submission Submission Submission 3-5 year Follow-up pending PMA approval (protocol and plan changes, including informed consent). | Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and plan changes). Enrollment Solfa Enrollment Submission 3-5 year Follow-up pending PMA approval (protocol and plan changes). Enrollment Solfa Enrollment O6-19-03 FDA Response Continued Access protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and plan changes). | Submission Continued Access Protocol and plan changes, including informed consent). Submission Submission 3-5 year Follow-up pending PMA approval (protocol and plan changes). Enrollment Solid Enrollment Submission Octinued Access Protocol and plan changes, including informed consent). Enrollment Solid Enrollment Submission Octinued Access Protocol and PMA approval (protocol and plan changes). Enrollment Octinued Access PDA Response Continued Access Protocol and PMA approval (protocol and PDA Response PDA Response Solid PDA Response PDA Response PDA Response Solid PDA Response P | Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Enrollment Solfa Enrollment Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Submission Continued Access Protocol and plan changes, including informed consent). Submission Submission 3-5 year Follow-up pending PMA approval (protocol and plan changes). Enrollment Solid Enrollment Solid Enrollment of 1DE Final Report Submission Submission Submission 3-5 year Follow-up pending PMA approval (protocol and plan changes, including informed consent). | Submission Continued Access Continued access after pivotal study, protocol and plan changes, including informed consent). Submission Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Enrollment Solfs Solfs Enrollment Submission Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Enrollment Solfa Enrollment Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Submission Continued Access Continued access after pivotal study, protocol and plan changes, including informed consent). Submission Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Enrollment Solfs Submission Submission of IDE Final Report Submission of IDE Final Report Submission Submission of IDE Final Report Submission of IDE Fin | Submission Continued Access Continued access after pivotal study, protocol and plan changes, including informed consent). Submission Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Enrollment Solfs Solfs Enrollment Submission Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Submission Continued Access Continued access after pivotal study, protocol and plan changes, including informed consent). Submission Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Enrollment Solfs Solfs Enrollment Submission Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Submission Continued Access Continued access after pivotal study, protocol and plan changes, including informed consent). Submission Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Enrollment Solfs Solfs Enrollment Submission Office PMA approval (protocol and informed consent). | Submission Continued Access Continued access after pivotal study, protocol and plan changes, including informed consent). Submission Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Enrollment Solfs Solfs Enrollment Submission Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Submission Continued Access Protocol and Plan changes, including increased tantalum in Onyx. Submission Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Enrollment Solfs Submission Submission Submission PMA approval (protocol and informed consent). Enrollment Solfs Submission Submission Submission Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). | Submission Continued Access Continued access after pivotal study, protocol and plan changes, including informed consent). Submission Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Enrollment Solfs Submission Submission of IDE Final Report Submission of IDE Final Report Submission Submission Submission of IDE Final Report Submission | Submission Continued Access Protocol and plan changes, including increased tantalum in Onyx. Submission Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Submission Submission Submission Submission Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). Enrollment Submission Submiss | Submission Continued Access Continued access after pivotal study, protocol and plan changes, including informed consent). Submission Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Enrollment Solfs Submission Submission of IDE Final Report Submission of IDE Final Report Submission Submission Submission of IDE Final Report Submission | Submission Continued Access Protocol and Plan changes, including increased tantalum in Onyx. Submission Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Enrollment Solfs Submission Submission Submission PMA approval (protocol and informed consent). Enrollment Solfs Submission Submission Submission Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). | Submission Continued Access Protocol and Plan changes, including increased tantalum in Onyx. Submission Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Enrollment Solfs Submission Submission Submission PMA approval (protocol and informed consent). Enrollment Solfs Submission Submission Submission Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). | Submission Continued Access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission Submission 3-5 year Follow-up pending PMA approval (protocol and plan changen). Enrollment Submission Submission Onyx. Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). | Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Enrollment Solfa Enrollment Submission Ontinued Access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission Ontinued Access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission Ontinued Access ontinued Access PDA Response Ontinued Access Ontinued Access PDA Response Ontinued Access Ontinued Ontin | Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Enrollment Solfa Enrollment Submission Ontinued Access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission Ontinued Access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission Ontinued Access ontinued Access PDA Response Ontinued Access Ontinued Access PDA Response Ontinued Access Ontinued Ontin | Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Enrollment Solfa Enrollment Submission Ontinued Access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission Ontinued Access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission Ontinued Access ontinued Access PDA Response Ontinued Access Ontinued Access PDA Response Ontinued Access Ontinued Ontin |
| Final Report PMA Application Submission for IDE Final Report Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up Supplement for 3-5 year follow-up pending PMA approval (protocol and plan changes) and plan changes are pending PMA approval (protocol and plan changes) and plan changes are pending PMA approval (protocol and plan changes) and plan changes are pending PMA approval (protocol and plan changes) and plan changes are pending PMA approval (protocol and plan changes) and plan changes are pending PMA approval (protocol and plan changes) and plan changes are pending PMA approval (protocol and plan changes) and plan changes are pending PMA approval (protocol and plan changes) are pending PMA approval (prot | Final Report PMA Application Submission for IDE Final Report Submission Continued Access Protocol and plan changes, including increased tantalum in Onyx. Submission Submission 3-5 year Follow-up pending PMA approval (protocol and plan changes) and plan Continued Access Protocol and plan Continued Access Protocol and PMA approval (protocol an | Final Report PMA Application Submission for IDE Final Report Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and plan changes) informed consent) Submission 3-5 year Follow-up pending PMA approval (protocol and plan changes) informed consent) | Final Report PMA Application Submission for IDE Final Report Submission Continued Access Protocol and plan changes, including increased tantalum in Onyx. Submission Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Submission Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Final Report PMA Application Submission for IDE Final Report Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and plan changes) Supplement for 3-5 year follow-up pending PMA approval (protocol and plan changes) Supplement for 3-5 year follow-up pending PMA approval (protocol and plan changes) Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and plan changes) Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and plan changes) Submission | Final Report PMA Application Submission for IDE Final Report Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Final Report PMA Application Submission for IDE Final Report Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Final Report PMA Application Submission for IDE Final Report Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and plan changes) informed consent) Submission 3-5 year Follow-up pending PMA approval (protocol and plan changes) informed consent) | Final Report PMA Application Submission for IDE Final Report Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Final Report PMA Application Submission for IDE Final Report Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and plan changes) informed consent). | Final Report PMA Application Submission for IDE Final Report Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Final Report PMA Application Submission for IDE Final Report Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Final Report PMA Application Submission for IDE Final Report Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Final Report PMA Application Submission for IDE Final Report Submission Continued Access Protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Submission Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Final Report PMA Application Submission for IDE Final Report Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Final Report PMA Application Submission for IDE Final Report Submission Continued Access Protocol and plan changes, including increased tantalum in Onyx. Submission Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Submission Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Final Report PMA Application Submission for IDE Final Report Submission Continued Access Protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Submission Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Final Report PMA Application Submission for IDE Final Report Submission Continued Access Protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Submission Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Final Report PMA Application Submission for IDE Final Report Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Final Report PMA Application Submission for IDE Final Report Submission Continued Access Protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Submission Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Final Report PMA Application Submission for IDE Final Report Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). | Final Report PMA Application Submission for IDE Final Report Submission Continued Access Protocol and plan changes, including increased tantalum in Onyx. Submission Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Submission Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Final Report PMA Application Submission for IDE Final Report Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Submission Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Final Report PMA Application Submission for IDE Final Report Submission Continued Access Protocol and plan changes, including increased tantalum in Onyx. Submission Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Submission Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Final Report PMA Application Submission for IDE Final Report Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). | Final Report PMA Application Submission for IDE Final Report Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). | Final Report PMA Application Submission for IDE Final Report Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Final Report PMA Application Submission for IDE Final Report Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Final Report PMA Application Submission for IDE Final Report Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Final Report PMA Application Submission for IDE Final Report Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). |
| Final Report PMA Application Submission for IDE Final Report Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up Supplement for 3-5 year follow-up O2-20-04 FDA Response 3-5 year Follow-up | Final Report PMA Application Submission for IDE Final Report Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and protocol and pending PMA approval (protocol and pending PMA approval (pr | Final Report PMA Application Submission for IDE Final Report Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent) Submission 3-5 year Follow-up pending PMA approval (protocol and protocol and pending PMA approval (protocol and pending PM | Final Report PMA Application Submission for IDE Final Report Submission Continued Access Protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Final Report PMA Application Submission for IDE Final Report Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and plan changes) PDA Response 3-5 year Follow-up | Final Report PMA Application Submission for IDE Final Report Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Final Report PMA Application Submission for IDE Final Report Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Final Report PMA Application Submission for IDE Final Report Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed Consent) Supplement for 3-5 year follow-up pending PMA approval (protocol and informed Consent) Submission 3-5 year Follow-up pending PMA approval (protocol and informed Consent) | Final Report PMA Application Submission for IDE Final Report Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Final Report PMA Application Submission for IDE Final Report Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and plan changes). | Final Report PMA Application Submission for IDE Final Report Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Final Report PMA Application Submission for IDE Final Report Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Final Report PMA Application Submission for IDE Final Report Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Final Report PMA Application Submission for IDE Final Report Submission Continued Access Protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Final Report PMA Application Submission for IDE Final Report Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Final Report PMA Application Submission for IDE Final Report Submission Continued Access Protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Final Report PMA Application Submission for IDE Final Report Submission Continued Access Protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Final Report PMA Application Submission for IDE Final Report Submission Continued Access Protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Final Report PMA Application Submission for IDE Final Report Submission Continued Access Protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Final Report PMA Application Submission for IDE Final Report Submission Continued Access Protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Final Report PMA Application Submission for IDE Final Report Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Final Report PMA Application Submission for IDE Final Report Submission Continued Access Protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Final Report PMA Application Submission for IDE Final Report Submission Continued Access Protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Final Report PMA Application Submission for IDE Final Report Submission Continued Access Protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Final Report PMA Application Submission for IDE Final Report Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Final Report PMA Application Submission for IDE Final Report Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Final Report PMA Application Submission for IDE Final Report Submission Continued Access Protocol and plan changes, including increased tantalum in Onyx. Submission Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Final Report PMA Application Submission for IDE Final Report Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Final Report PMA Application Submission for IDE Final Report Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Final Report PMA Application Submission for IDE Final Report Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). |
| Final Report PMA Application Submission for IDE Final Report Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up Supplement for 3-5 year follow-up one-of-ing PMA approach for foreign and plan changes in Continued Access protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up Supplement for 3-5 year follow-up one-of-ing PMA approach foreign and plan changes in Continued Access protocol and plan changes in Continued Access protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up Supplement for 3-5 year follow-up | Final Report PMA Application Submission for IDE Final Report Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and plan changes) in Continued Access Protocol and PMA approval (protocol and PDA Response Submission Submis | Final Report PMA Application Submission for IDE Final Report Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent) Submission 3-5 year Follow-up pending PMA approval (protocol and protocol and pending PMA approval (protocol and pending PM | Final Report PMA Application Submission for IDE Final Report Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Final Report PMA Application Submission for IDE Final Report Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up Supplement for 3-5 year follow-up pending PMA approval (protocol and protocol an | Final Report PMA Application Submission for IDE Final Report Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Final Report PMA Application Submission for IDE Final Report Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Final Report PMA Application Submission for IDE Final Report Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent) Submission 3-5 year Follow-up pending PMA approval (protocol and protocol and pending PMA approval (protocol and pending PM | Final Report PMA Application Submission for IDE Final Report Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Submission 3-5 year Follow-up pending PMA approval (protocol and plan changes, including informed consent). | Final Report PMA Application Submission for IDE Final Report Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). FDA Response Continued Access Continued Access protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Final Report PMA Application Submission for IDE Final Report Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Final Report PMA Application Submission for IDE Final Report Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Final Report PMA Application Submission for IDE Final Report Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Continued Access Continued Access including protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Final Report PMA Application Submission for IDE Final Report Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Final Report PMA Application Submission for IDE Final Report Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Final Report PMA Application Submission for IDE Final Report Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Final Report PMA Application Submission for IDE Final Report Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Final Report PMA Application Submission for IDE Final Report Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Final Report PMA Application Submission for IDE Final Report Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Final Report PMA Application Submission for IDE Final Report Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Final Report PMA Application Submission for IDE Final Report Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Submission 3-5 year Follow-up Pending PMA approval (protocol and informed consent). | Final Report PMA Application Submission for IDE Final Report Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Final Report PMA Application Submission for IDE Final Report Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Final Report PMA Application Submission for IDE Final Report Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Final Report PMA Application Submission for IDE Final Report Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Submission 3-5 year Follow-up Pending PMA approval (protocol and informed consent). | Final Report PMA Application Submission for IDE Final Report Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Submission 3-5 year Follow-up Pending PMA approval (protocol and informed consent). | Final Report PMA Application Submission for IDE Final Report Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Final Report PMA Application Submission for IDE Final Report Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Final Report PMA Application Submission for IDE Final Report Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Final Report PMA Application Submission for IDE Final Report Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). |
| Final Report PMA Application Submission for IDE Final Report Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up Supplement for 3-5 year follow-up O2-20-04 FDA Response 3-5 year Follow-up | Final Report PMA Application Submission for IDE Final Report Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and protocol and pending PMA approval (protocol and pending PMA approval (pr | Final Report PMA Application Submission for IDE Final Report Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent) Submission 3-5 year Follow-up pending PMA approval (protocol and plan changes, including pending PMA approval (protocol and plan changes) pending PMA approval | Final Report PMA Application Submission for IDE Final Report Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Continued Access Continued access after pivotal study, protocol and protocol and protocol and protocol and protocol and informed consent). Continued Access Continued Access PDA Response Continued Access PDA Response 3-5 year Follow-up pending PMA approval (protocol and protocol and p | Final Report PMA Application Submission for IDE Final Report Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and plan for 3-5 year follow-up pending PMA approval (protocol and plan for 3-5 year follow-up pending PMA approval (protocol and plan for 3-5 year follow-up pending PMA approval (protocol and plan for 3-5 year follow-up pending PMA approval (protocol and plan for 10-19-03 pending PMA approval (protocol an | Final Report PMA Application Submission for IDE Final Report Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Continued Access Protocol and PDA Response Continued Access Protocol and PDA Response Submission Submission O2-20-04 FDA Response S-5 year Follow-up PDA Response S-5 year Fol | Final Report PMA Application Submission for IDE Final Report Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Continued Access Protocol and PDA Response Continued Access Protocol and PDA Response Submission Submission O2-20-04 FDA Response Sear Follow-up PDA approval (protocol and Informed consent). | Final Report PMA Application Submission for IDE Final Report Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent) Submission Only PMA application Submission Only PMA approval (protocol and informed consent) Submission Only PMA application Submission Only PMA approval (protocol and informed consent) | Final Report PMA Application Submission for IDE Final Report Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Continued Access Protocol and PDA Response Continued Access Protocol and PDA Response 3-5 year Follow-up pending PMA approval (protocol and plan changes). | Final Report PMA Application Submission for IDE Final Report Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Continued Access Continued Access Protocol and PDA Response Continued Access Protocol and PDA Response 3-5 year Follow-up Ponding PMA approval (protocol and PDA Response 3-5 year Follow-up | Final Report PMA Application Submission for IDE Final Report Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Continued Access Protocol and PDA Response Continued Access Protocol and PDA Response Submission Submission O2-20-04 FDA Response Sear Follow-up PDA approval (protocol and Informed consent). | Final Report PMA Application Submission for IDE Final Report Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Continued Access Continued access after pivotal study, protocol and increased tantalum in Onyx. Continued Access Continued Access increased tantalum in Onyx. Continued Access PDA Response Continued Access PDA Response 3-5 year Follow-up informed consent). | Final Report PMA Application Submission for IDE Final Report Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Continued Access Protocol and PDA Response Continued Access Protocol and PDA Response 3-5 year Follow-up pending PMA approval (protocol and plan changes). | Final Report PMA Application Submission for IDE Final Report Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Continued Access Continued access after pivotal study, protocol and protocol and increased tantalum in Onyx. Continued Access PDA Response Continued Access Continued Access POLOM-up Polomore Consent). | Final Report PMA Application Submission for IDE Final Report Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Continued Access Continued access after pivotal study, protocol and increased tantalum in Onyx. Continued Access Continued Access Continued Access PDA Response Continued Access PDA Response 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Final Report PMA Application Submission for IDE Final Report Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Continued Access Continued access after pivotal study, protocol and protocol and protocol and protocol and protocol and informed consent). Continued Access Continued Access PDA Response Continued Access PDA Response 3-5 year Follow-up pending PMA approval (protocol and protocol and p | Final Report PMA Application Submission for IDE Final Report Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Continued Access Continued access after pivotal study, protocol and protocol and increased tantalum in Onyx. Continued Access PDA Response Continued Access Continued Access POLOM-up Polomore Consent). | Final Report PMA Application Submission for IDE Final Report Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Continued Access Continued access after pivotal study, protocol and protocol and increased tantalum in Onyx. Continued Access PDA Response Continued Access Continued Access POLOM-up Polomore Consent). | Final Report PMA Application Submission for IDE Final Report Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Continued Access Continued access after pivotal study, protocol and increased tantalum in Onyx. Continued Access Continued Access Continued Access PDA Response Continued Access PDA Response Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Final Report PMA Application Submission for IDE Final Report Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Continued Access Continued access after pivotal study, protocol and protocol and increased tantalum in Onyx. Continued Access PDA Response Continued Access Continued Access POLOM-up Polomore Consent). | Final Report PMA Application Submission for IDE Final Report Submission Continued Access Protocol and plan changes, including increased tantalum in Onyx. Submission Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Continued Access Protocol and PDA Response Continued Access Protocol and PDA Response Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). | Final Report PMA Application Submission for IDE Final Report Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Continued Access Continued access after pivotal study, protocol and protocol and protocol and protocol and protocol and informed consent). Continued Access Continued Access PDA Response Continued Access PDA Response 3-5 year Follow-up pending PMA approval (protocol and protocol and p | Final Report PMA Application Submission for IDE Final Report Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Continued Access Continued Access fire pivotal study, protocol and pending PMA approval (protocol approval (protocol approval pending PMA approval (protocol approval pending PMA approval (protocol approval pending PMA approval pending | Final Report PMA Application Submission for IDE Final Report Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Continued Access Continued access after pivotal study, protocol and protocol and protocol and protocol and protocol and informed consent). Continued Access Continued Access PDA Response Continued Access PDA Response 3-5 year Follow-up pending PMA approval (protocol and protocol and p | Final Report PMA Application Submission for IDE Final Report Submission Continued Access Protocol and plan changes, including increased tantalum in Onyx. Submission Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Continued Access Protocol and PDA Response Continued Access Protocol and PDA Response Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). | Final Report PMA Application Submission for IDE Final Report Submission Continued Access Protocol and plan changes, including increased tantalum in Onyx. Submission Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Continued Access Protocol and PDA Response Continued Access Protocol and PDA Response Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). | Final Report PMA Application Submission for IDE Final Report Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Continued Access PDA Response Continued Access PDA Response Submission O2-20-04 FDA Response Submission PMA approval (protocol and informed consent). | Final Report PMA Application Submission for IDE Final Report Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Continued Access PDA Response Continued Access PDA Response Submission Onyx. Submission Submission Octavity Oc | Final Report PMA Application Submission for IDE Final Report Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Continued Access PDA Response Continued Access PDA Response Submission Onyx. Submission Submission Octavity Oc | Final Report PMA Application Submission for IDE Final Report Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Continued Access PDA Response Continued Access PDA Response Submission Onyx. Submission Submission Octavity Oc |
| Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up Supplement for 3-5 year follow-up prediction DMA approach for foreign and plan changes in Continued Access protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up Supplement for 3-5 year follow-up 02-20-04 FDA Response 3-5 year Follow-up | Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and plan changes) Continued Access protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and plan changes) Continued Access protocol and plan changes, including protocol and plan changes, i | Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and plan changes) and pending PMA approval (protocol and plan changes) protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and plan changes) protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and plan changes) protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and plan changes) protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and plan changes) protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and plan changes) protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and plan changes) protocol and plan changes pr | Final Report PMA Application Submission for IDE Final Report Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Submission Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and plan changes) and pending PMA approval (protocol and pending PMA | Final Report PMA Application Submission for IDE Final Report Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Continued Access Continued Access protocol and plan changes, including increased tantalum in Onyx. Continued Access PDA Response Continued Access Protocol and PDA Response Submission O2-20-04 FDA Response S-5 year Follow-up | Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA application Submission 3-5 year Follow-up pending PMA approval (protocol and plan changes) and pending PMA approval (protocol and pending PMA approval (proto | Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Final Report PMA Application Submission for IDE Final Report Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent) Continued Access PDA Response Continued Access Protocol and PDA Response Continued Access Protocol and PDA Response Submission O2-20-04 FDA Response S-5 year Follow-up | Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Final Report PMA Application Submission for IDE Final Report Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Continued Access Continued Access including increased tantalum in Onyx. Continued Access PDA Response Continued Access Protocol and PDA Response Submission O2-20-04 FDA Response S-5 year Follow-up PDA approval (protocol and PDA Response S-5 year Follow-up PDA approval (protocol and PDA Response S-5 year Follow-up PDA approval (protocol and PDA Response S-5 year Follow-up PDA approval (protocol and PDA Response S-5 year Follow-up PDA approval (protocol and PDA Response S-5 year Follow-up PDA approval (protocol and PDA Response S-5 year Follow-up PDA approval (protocol and PDA Response S-5 year Follow-up PDA approval (protocol and PDA Response S-5 year Follow-up PDA approval (protocol and PDA Response S-5 year Follow-up PDA approval (protocol and PDA Response S-5 year Follow-up PDA approval (protocol and PDA Response S-5 year Follow-up PDA approval (protocol and PDA Response S-5 year Follow-up PDA Response S-5 year Follow- | Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Final Report PMA Application Submission for IDE Final Report Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Continued Access Protocol and plan changes, including increased tantalum in Onyx. Continued Access Protocol and PDA Response Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Final Report PMA Application Submission for IDE Final Report Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Submission Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Final Report PMA Application Submission for IDE Final Report Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Continued Access Protocol and plan changes, including increased tantalum in Onyx. Continued Access Protocol and PDA Response Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Final Report PMA Application Submission for IDE Final Report Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Continued Access Protocol and plan changes, including increased tantalum in Onyx. Continued Access Protocol and PDA Response Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Final Report PMA Application Submission for IDE Final Report Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Continued Access Protocol and plan changes, including increased tantalum in Onyx. Continued Access Protocol and PDA Response Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Final Report PMA Application Submission for IDE Final Report Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Continued Access Continued Access protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Final Report PMA Application Submission for IDE Final Report Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Submission Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Final Report PMA Application Submission for IDE Final Report Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Continued Access Continued Access protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Final Report PMA Application Submission for IDE Final Report Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Submission Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Final Report PMA Application Submission for IDE Final Report Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Continued Access Continued Access protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Final Report PMA Application Submission for IDE Final Report Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Continued Access Continued Access protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Final Report PMA Application Submission for IDE Final Report Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Submission Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). |
| Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up Supplement for 3-5 year follow-up | Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and protocol and pro | Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and plan changes) and pending PMA approval (protocol and plan changes) and pending PMA approval (protocol and plan changes) are protocol and plan changes, including protocol and plan changes protocol and plan changes protocol | Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Continued Access PDA Response Continued Access protocol and informed consent). | Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and plan changes) increased tantalum of the pending PMA approval (protocol and plan changes) including plan changes, including plan changes, including protocol and plan changes, including protocol and p | Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Continued Access Continued access after pivotal study, protocol and protocol and informed access after pivotal study, protocol and informed access after pivotal study, protocol and protocol and protocol and protocol and informed consent). | Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed Consent) Submission 3-5 year Follow-up pending PMA approval (protocol and informed Consent) | Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and plan changes). Submission 3-5 year Follow-up pending PMA approval (protocol and plan changes). | Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Continued Access Continued access after pivotal study, protocol and protocol and informed access after pivotal study, protocol and informed access after pivotal study, protocol and protocol and protocol and protocol and informed consent). | Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Continued Access Continued access after pivotal study, protocol and informed access after pivotal study, protocol and protocol and informed access after pivotal study, protocol and protocol and informed access after pivotal study, protocol and protocol and protocol and protocol and pivotal study, protocol and protoco | Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Continued Access Continued Access after pivotal study, protocol and informed access after pivotal study, protocol and p | Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Continued Access Continued access after pivotal study, protocol and informed access after pivotal study, protocol and protocol and informed access after pivotal study, protocol and proto | Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Continued Access PDA Response Continued Access protocol and informed consent). | Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Continued Access Continued Access after pivotal study, protocol and informed access after pivotal study, protocol and p | Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Continued Access Continued Access after pivotal study, protocol and informed access after pivotal study, protocol and p | Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Continued Access Continued Access after pivotal study, protocol and informed access after pivotal study, protocol and p | Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Continued Access PDA Response Continued Access Protocol and PDA Response Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Continued Access PDA Response Continued Access protocol and informed access after pivotal study, 06-19-03 FDA Response Continued Access protocol and informed access after pivotal study, 06-19-03 FDA Response Continued Access protocol and informed access after pivotal study, 06-19-03 FDA Response Continued Access protocol and informed access after pivotal study, 06-19-03 FDA Response Continued Access protocol and informed access after pivotal study, 06-19-03 FDA Response Continued Access protocol and increased tantalum in Onyx. | Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Continued Access PDA Response Continued Access protocol and informed consent). | Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Continued Access PDA Response Continued Access protocol and informed access after pivotal study, 06-19-03 FDA Response Continued Access protocol and informed access after pivotal study, 06-19-03 FDA Response Continued Access protocol and informed access after pivotal study, 06-19-03 FDA Response Continued Access protocol and informed access after pivotal study, 06-19-03 FDA Response Continued Access protocol and informed access after pivotal study, 06-19-03 FDA Response Continued Access protocol and informed access after pivotal study, 06-19-03 FDA Response Continued Access protocol and informed access after pivotal study, 06-19-03 FDA Response Continued Access protocol and informed access after pivotal study, 06-19-03 FDA Response Continued Access protocol and informed access after pivotal study, 06-19-03 FDA Response Continued Access protocol and informed access after pivotal study, 06-19-03 FDA Response Continued Access protocol and informed access after pivotal study, 06-19-03 FDA Response Continued Access protocol and informed access after pivotal study, 06-19-03 FDA Response Continued Access protocol and informed access after pivotal study, 06-19-03 FDA Response Continued Access protocol and informed access after pivotal study, 06-19-03 FDA Response Continued Access protocol and informed access after pivotal study, 06-19-03 FDA Response Continued Access protocol and informed access after pivotal study, 06-19-03 FDA Response Continued Access protocol and informed access access protocol and informed access access protocol access protocol access access protocol access protoco | Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Continued Access PDA Response Continued Access protocol and informed consent). | Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Continued Access PDA Response Continued Access protocol and informed access after pivotal study, 06-19-03 FDA Response Continued Access protocol and informed access after pivotal study, 06-19-03 FDA Response Continued Access protocol and informed access after pivotal study, 06-19-03 FDA Response Continued Access protocol and informed access after pivotal study, 06-19-03 FDA Response Continued Access protocol and informed access after pivotal study, 06-19-03 FDA Response Continued Access protocol and increased tantalum in Onyx. | Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Continued Access PDA Response Continued Access protocol and informed access after pivotal study, 06-19-03 FDA Response Continued Access protocol and informed access after pivotal study, 06-19-03 FDA Response Continued Access protocol and informed access after pivotal study, 06-19-03 FDA Response Continued Access protocol and informed access after pivotal study, 06-19-03 FDA Response Continued Access protocol and informed access after pivotal study, 06-19-03 FDA Response Continued Access protocol and increased tantalum in Onyx. | Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Submission Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Submission Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Submission Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Submission Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). |
| Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up Supplement for 3-5 year follow-up pending PMA approval forestood and plan changes after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up PMA approval forestood and plan changes after pivotal study, protocol and plan changes, including protocol and plan changes | Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and protocol and pro | Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent) Continued Access PDA Response Continued Access protocol and informed consent) Continued Access After pivotal study, 06-19-03 FDA Response Continued Access protocol and informed consent) | Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Continued Access Continued Access protocol and year protocol and plan changes, including increased tantalum in Onyx. Continued Access PDA Response Continued Access protocol and informed consent). | Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and protocol and pro | Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Continued Access PDA Response Continued Access protocol and PDA Response Continued Access Protocol and Continued Access Protocol and PDA Response Continued Access Protocol and PDA Response Continued Access Protocol and PDA Response Continued Access Protocol and Continued Access Protocol and PDA Response PDA Response Continued Access Protocol and PDA Response PDA | Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Continued Access Continued Access protocol and plan changes, including increased tantalum in Onyx. Continued Access PDA Response Continued Access protocol and informed access after pivotal study, 06-19-03 FDA Response Continued Access protocol and informed access after pivotal study, 06-19-03 FDA Response Continued Access protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent) Continued Access PDA Response Continued Access protocol and informed consent) Continued Access After pivotal study, 06-19-03 FDA Response Continued Access protocol and informed consent) | Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Continued Access Continued Access protocol and plan changes, including increased tantalum in Onyx. Continued Access Continued Access PDA Response Continued Access Protocol and PDA Response Continued Access PDA Response PDA Response Continued Access PDA Response PDA PDA Response PDA PDA Response PDA PDA Response PDA PDA Response P | Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent) Continued Access PDA Response Continued Access protocol and informed access after pivotal study, 06-19-03 FDA Response Continued Access protocol and informed access after pivotal study, 06-19-03 FDA Response Continued Access protocol and informed access after pivotal study, 06-19-03 FDA Response Continued Access protocol and informed access after pivotal study, 06-19-03 FDA Response Continued Access protocol and informed access after pivotal study, 06-19-03 FDA Response Continued Access protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and plan changes) including informed access after pivotal study, 06-19-03 FDA Response Continued Access protocol and informed access protocol and informed access after pivotal study, 06-19-03 FDA Response Continued Access protocol and informed access after pivotal study, 06-19-03 FDA Response Continued Access protocol and informed access after pivotal study, 06-19-03 FDA Response Continued Access protocol and informed access after pivotal study, 06-19-03 FDA Response Continued Access protocol and informed access after pivotal study, 06-19-03 FDA Response Continued Access protocol and informed access after pivotal study, 06-19-03 FDA Response Continued Access protocol and informed access after pivotal study, 06-19-03 FDA Response Continued Access protocol and informed access after pivotal study, 06-19-03 FDA Response Continued Access protocol and informed access after pivotal study, 06-19-03 FDA Response Continued Access protocol and informed access after pivotal study, 06-19-03 FDA Response Continued Access protocol and informed Access protocol and i | Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Continued Access Continued Access protocol and plan changes, including increased tantalum in Onyx. Continued Access PDA Response Continued Access protocol and informed access after pivotal study, 06-19-03 FDA Response Continued Access protocol and informed access after pivotal study, 06-19-03 FDA Response Continued Access protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Continued Access After pivotal study, 06-19-03 FDA Response Continued Access protocols and informed access after pivotal study, 06-19-03 FDA Response Continued Access protocols and informed access after pivotal study, 06-19-03 FDA Response Continued Access protocols and informed access after pivotal study, 06-19-03 FDA Response Continued Access protocols and informed access after pivotal study, 06-19-03 FDA Response Continued Access protocols and informed access after pivotal study, 06-19-03 FDA Response Continued Access protocols and informed access after pivotal study, 06-19-03 FDA Response Continued Access protocols and informed access after pivotal study, 06-19-03 FDA Response Continued Access protocols and informed access after pivotal study, 06-19-03 FDA Response Continued Access protocols and informed access after pivotal study, 06-19-03 FDA Response Continued Access protocols and informed access after pivotal study, 06-19-03 FDA Response Continued Access protocols and informed access after pivotal study, 06-19-03 FDA Response Continued Access protocols and informed access after pivotal study, 06-19-03 FDA Response Continued Access protocols and informed access after pivotal study, 06-19-03 FDA Response Continued Access protocols and informed access after pivotal study, 06-19-03 FDA Response Continued Access protocols and informed access after pivotal study, 06-19-03 FDA Response Continued Access protocols and informed access after pivotal study, 06-19-03 FDA Response Continued Access protocols and informed access after pivotal study, 06-19-03 FDA Response Continued Access protocols and Informed Access protocols an | Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Continued Access Continued Access protocol and plan changes, including increased tantalum in Onyx. Continued Access Continued Access PDA Response Continued Access Protocol and PDA Response Continued Access PDA Response PDA Response Continued Access PDA Response PDA PDA Response PDA PDA Response PDA PDA Response PDA PDA Response P | Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Continued Access Protocol and plan changes, including increased tantalum in Onyx. Continued Access PDA Response Continued Access Protocol and informed access after pivotal study, protocol and plan changes, including protocol and plan changes protocol and plan changes protocol an | Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Continued Access PDA Response Continued Access protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Continued Access Continued Access protocol and year protocol and plan changes, including increased tantalum in Onyx. Continued Access PDA Response Continued Access protocol and informed consent). | Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Continued Access Protocol and plan changes, including increased tantalum in Onyx. Continued Access PDA Response Continued Access Protocol and informed access after pivotal study, protocol and plan changes, including protocol and plan changes protocol and plan changes protocol an | Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Continued Access Protocol and plan changes, including increased tantalum in Onyx. Continued Access PDA Response Continued Access Protocol and informed access after pivotal study, protocol and plan changes, including protocol and plan changes protocol and plan changes protocol an | Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Continued Access Protocol and plan changes, including increased tantalum in Onyx. Continued Access PDA Response Continued Access Protocol and informed access after pivotal study, protocol and plan changes, including protocol and plan changes, including protocol and pr | Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Continued Access Protocol and plan changes, including increased tantalum in Onyx. Continued Access PDA Response Continued Access Protocol and informed access after pivotal study, protocol and plan changes, including protocol and plan changes protocol and plan changes protocol an | Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Continued Access PDA Response Continued Access protocol and informed access after pivotal study, protocol and increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Continued Access PDA Response Continued Access Protocol and PDA Response Continued Access Protocol and Continued Access Protocol and PDA Response Continued Access Protocol and Continued Access Protocol and PDA Response Supplies PDA Response PDA Re | Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Continued Access PDA Response Continued Access protocol and increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Continued Access PDA Response Continued Access Protocol and PDA Response Continued Access Protocol and Continued Access Protocol and PDA Response Continued Access Protocol and Continued Access Protocol and PDA Response Supplies PDA Response PDA Re | Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Continued Access PDA Response Continued Access protocol and informed access after pivotal study, protocol and increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Continued Access PDA Response Continued Access protocol and informed access after pivotal study, protocol and increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Continued Access PDA Response Continued Access protocol and informed access after pivotal study, 06-19-03 FDA Response Continued Access protocol and informed access after pivotal study, 06-19-03 FDA Response Continued Access protocol and informed access after pivotal study, 06-19-03 FDA Response Continued Access protocol and informed access after pivotal study, 06-19-03 FDA Response Continued Access protocol and informed access after pivotal study, 06-19-03 FDA Response Continued Access protocol and informed access after pivotal study, 06-19-03 FDA Response Continued Access protocol and informed access after pivotal study, 06-19-03 FDA Response Continued Access protocol and informed access after pivotal study, 06-19-03 FDA Response Continued Access protocol and informed access after pivotal study, 06-19-03 FDA Response Continued Access protocol and informed access after pivotal study, 06-19-03 FDA Response Continued Access protocol and informed access after pivotal study, 06-19-03 FDA Response Continued Access protocol access protocol and informed access after pivotal study, 06-19-03 FDA Response Continued Access protocol access protoc | Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Continued Access PDA Response Continued Access protocol and informed access after pivotal study, 06-19-03 FDA Response Continued Access protocol and informed access after pivotal study, 06-19-03 FDA Response Continued Access protocol and informed access after pivotal study, 06-19-03 FDA Response Continued Access protocol and informed access after pivotal study, 06-19-03 FDA Response Continued Access protocol and informed access after pivotal study, 06-19-03 FDA Response Continued Access protocol and informed access after pivotal study, 06-19-03 FDA Response Continued Access protocol and informed access after pivotal study, 06-19-03 FDA Response Continued Access protocol and informed access protocol and informed access protocol and informed access protocol and informed access after pivotal study, 06-19-03 FDA Response Continued Access protocol access protocol and informed access after pivotal study, 06-19-03 FDA Response Continued Access protocol access protocol and informed access protocol access p | Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Continued Access PDA Response Continued Access protocol and informed access after pivotal study, 06-19-03 FDA Response Continued Access protocol and informed access after pivotal study, 06-19-03 FDA Response Continued Access protocol and informed access after pivotal study, 06-19-03 FDA Response Continued Access protocol and informed access after pivotal study, 06-19-03 FDA Response Continued Access protocol and informed access after pivotal study, 06-19-03 FDA Response Continued Access protocol and informed access after pivotal study, 06-19-03 FDA Response Continued Access protocol and informed access after pivotal study, 06-19-03 FDA Response Continued Access protocol and informed access protocol and informed access protocol and informed access protocol and informed access after pivotal study, 06-19-03 FDA Response Continued Access protocol access protocol and informed access after pivotal study, 06-19-03 FDA Response Continued Access protocol access protocol and informed access protocol access p | Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Continued Access PDA Response Continued Access protocol and informed access after pivotal study, 06-19-03 FDA Response Continued Access protocol and informed access after pivotal study, 06-19-03 FDA Response Continued Access protocol and informed access after pivotal study, 06-19-03 FDA Response Continued Access protocol and informed access after pivotal study, 06-19-03 FDA Response Continued Access protocol and informed access after pivotal study, 06-19-03 FDA Response Continued Access protocol and informed access after pivotal study, 06-19-03 FDA Response Continued Access protocol and informed access after pivotal study, 06-19-03 FDA Response Continued Access protocol and informed access protocol and informed access protocol and informed access protocol and informed access after pivotal study, 06-19-03 FDA Response Continued Access protocol access protocol and informed access after pivotal study, 06-19-03 FDA Response Continued Access protocol access protocol and informed access protocol access p |
| Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up Supplement for 3-5 year follow-up PAA approval (protocol and plan changes) and plan changes, including protocol and plan changes protocol and plan change | Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and plan changes) including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and protocol and pr | Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and plan changes) | Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Continued Access After pivotal study, 06-19-03 FDA Response Continued Access protocol and increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and protocol and pro | Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Continued Access After pivotal study, 06-19-03 FDA Response Continued Access protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up 02-20-04 FDA Response 3-5 year Follow-up informed consent). | Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Continued Access After pivotal study, 06-19-03 FDA Response Continued Access protocol and increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent) Continued Access Continued Access after pivotal study, protocol and plan changes, including increased continued Access Continued Access Continued Access PDA Response Continued Access Protocol and PDA Response 3-5 year Follow-up pending PMA approval (protocol and plan changes, including protocol and plan changes p | Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Continued Access After pivotal study, 06-19-03 FDA Response Continued Access protocol and increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and plan changes) informed consent). Continued Access After pivotal study, 06-19-03 FDA Response Continued Access protocol and plan changes, including protocol and informed consent). | Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Continued Access After pivotal study, 06-19-03 FDA Response Continued Access protocol and increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Continued Access Continued Access after pivotal study, protocol and increased tantalum, 06-19-03 FDA Response Continued Access Continued Access PDA Response PDA Response Continued Access PDA Response PDA R | Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Continued Access After pivotal study, 06-19-03 FDA Response Continued Access protocol and increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Continued Access Continued Access after pivotal study, protocol and increased tantalum, 06-19-03 FDA Response Continued Access protocol and increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Continued Access Continued Access after pivotal study, protocol and increased tantalum, 06-19-03 FDA Response Continued Access protocol and increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Continued Access After pivotal study, 06-19-03 FDA Response Continued Access protocol and increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Continued Access Continued Access after pivotal study, protocol and increased tantalum, 06-19-03 FDA Response Continued Access protocol and increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Continued Access Continued Access after pivotal study, protocol and increased tantalum, 06-19-03 FDA Response Continued Access protocol and increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Continued Access Continued Access after pivotal study, protocol and increased tantalum, 06-19-03 FDA Response Continued Access protocol and increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Continued Access Continued Access after pivotal study, protocol and increased tantalum, 06-19-03 FDA Response Continued Access protocol and increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Continued Access PDA Response PD | Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Continued Access After pivotal study, 06-19-03 FDA Response Continued Access protocol and increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Continued Access PDA Response PD | Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Continued Access After pivotal study, 06-19-03 FDA Response Continued Access protocol and increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Continued Access PDA Response PD | Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Continued Access PDA Response PD | Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Continued Access PDA Response Continued Access Protocol and increased tantalum in Onyx. Continued Access PDA Response Submission O2-20-04 FDA Response 3-5 year Follow-up informed consent). | Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Continued Access PDA Response Continued Access protocol and increased tantalum in Onyx. Continued Access After pivotal study, 06-19-03 FDA Response Continued Access protocol and increased tantalum in Onyx. Continued Access after pivotal study, 06-19-03 FDA Response Continued Access protocol and increased tantalum in Onyx. Continued Access after pivotal study, 06-19-03 FDA Response Continued Access protocol and increased tantalum in Onyx. | Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Continued Access PDA Response Continued Access protocol and increased tantalum in Onyx. Continued Access After pivotal study, 06-19-03 FDA Response Continued Access protocol and increased tantalum in Onyx. Continued Access after pivotal study, 06-19-03 FDA Response Continued Access protocol and increased tantalum in Onyx. Continued Access after pivotal study, 06-19-03 FDA Response Continued Access protocol and increased tantalum in Onyx. | Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Continued Access PDA Response Continued Access protocol and increased tantalum in Onyx. Continued Access After pivotal study, 06-19-03 FDA Response Continued Access protocol and increased tantalum in Onyx. Continued Access after pivotal study, 06-19-03 FDA Response Continued Access protocol and increased tantalum in Onyx. Continued Access after pivotal study, 06-19-03 FDA Response Continued Access protocol and increased tantalum in Onyx. |
| Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up Supplement for 3-5 year follow-up pending PMA approval foreigned and supplement for 3-5 year follow-up pending PMA approval foreigned and supplement for 3-5 year follow-up supplement for 3-5 year follow-up pending PMA approval foreigned and supplement for 3-5 year follow-up supplement | Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and protocol and pro | Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent) Continued Access Continued Access protocol and pr | Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Continued Access Continued Access PDA Response Continued Access Protocol and Continued Access Protocol Ac | Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and protocol and pro | Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Continued Access PDA Response Continued Access protocol and informed access after pivotal study, protocol and increased tantalum in Onyx. Continued Access PDA Response Continued Access protocol and informed access after pivotal study, protocol and increased tantalum in Onyx. Continued Access PDA Response Continued Access protocol and informed access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed access after pivotal study, protocol and protocol and informed access after pivotal study, protocol and pro | Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Continued Access PDA Response Continued Access protocol and PDA Response Continued Access PDA Response PDA | Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent) Continued Access Continued Access protocol and protocol and informed consent) Continued Access Continued Access protocol and p | Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Continued Access PDA Response Continued Access protocol and PDA Response Continued Access POLA Response Continued Access Protocol and PDA Response Continued Access Protocol and PDA Response Continued Access POLA Response Continued Access Protocol and PDA Response Continued Access POLA Response POLA Response Continued Access POLA Response POLA Resp | Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent) Continued Access Continued Access protocol and pr | Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Continued Access PDA Response Continued Access protocol and PDA Response Continued Access PDA Response PDA | Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Continued Access PDA Response Continued Access Protocol and Continued Access Protocol and Continued Access Protocol and PDA Response Submission Continued Access Protocol and PDA Response Continued Access Protocol and PDA Response Continued Access Protocol and PDA Response PDA Response Submission Continued Access Protocol and PDA Response PDA Respon | Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Continued Access PDA Response Continued Access protocol and PDA Response Continued Access POLA Response Continued Access Protocol and PDA Response Continued Access Protocol and PDA Response Continued Access POLA Response Continued Access Protocol and PDA Response Continued Access POLA Response POLA Response Continued Access POLA Response POLA Resp | Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Continued Access Continued Access PDA Response Continued Access Protocol and Plan Changes, including Continued Access Protocol and Plan Changes, including Continued Access Protocol and Continued Access Protocol Access Protoco | Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Continued Access PDA Response Continued Access Protocol and Continued Access Protocol Acc | Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Continued Access Continued Access PDA Response Continued Access Protocol and Continued Access Protocol Ac | Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Continued Access Continued Access PDA Response Continued Access Protocol and Plan Changes, including Continued Access Protocol and Plan Changes, including Continued Access Protocol and Continued Access Protocol Access Protoco | Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Continued Access Continued Access PDA Response Continued Access Protocol and Plan Changes, including Continued Access Protocol and Plan Changes, including Continued Access Protocol and Continued Access Protocol Access Protoco | Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Continued Access PDA Response Continued Access Protocol and Continued Access Protocol Acc | Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Continued Access Continued Access PDA Response Continued Access Protocol and Plan Changes, including Continued Access Protocol and Plan Changes, including Continued Access Protocol and Continued Access Protocol Access Protoco | Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Continued Access Continued Access protocol and p | Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Continued Access Continued Access PDA Response Continued Access Protocol and Continued Access Protocol Ac | Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Continued Access Continued Access protocol and year protocol and protocol and informed access after pivotal study, 06-19-03 FDA Response Continued Access protocols and informed access after pivotal study, 06-19-03 FDA Response Continued Access protocols and informed access after pivotal study, 06-19-03 FDA Response Continued Access protocols and informed access after pivotal study, 06-19-03 FDA Response Continued Access protocols and informed access after pivotal study, 06-19-03 FDA Response Continued Access protocols and informed access after pivotal study, 06-19-03 FDA Response Continued Access protocols and informed access after pivotal study, 06-19-03 FDA Response Continued Access protocols and informed access after pivotal study, 06-19-03 FDA Response Continued Access protocols and informed access after pivotal study, 06-19-03 FDA Response Continued Access protocols and informed access after pivotal study, 06-19-03 FDA Response Continued Access protocols and informed access after pivotal study, 06-19-03 FDA Response Continued Access protocols and informed access after pivotal study, 06-19-03 FDA Response Continued Access protocols and informed access after pivotal study, 06-19-03 FDA Response Continued Access protocols and 19-19-19-19-19-19-19-19-19-19-19-19-19-1 | Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Continued Access Continued Access PDA Response Continued Access Protocol and Continued Access Protocol Ac | Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Continued Access Continued Access protocol and p | Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Continued Access Continued Access protocol and p | Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Continued Access PDA Response Continued Access protocol and informed Access PDA Response Continued Access protocol and informed Access protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up Pending PMA approval (protocol and informed Access protocol and informed Access protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up Pending PMA approval (protocol and informed Access protocol and informed Access protocol and increased tantalum in Onyx. | Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Continued Access PDA Response Continued Access protocol and informed Access protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up Pending PMA approval (protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up Pending PMA approval (protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up Pending PMA approval (protocol and plan changes) increased tantalum in Onyx. | Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Continued Access PDA Response Continued Access protocol and informed Access protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up Pending PMA approval (protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up Pending PMA approval (protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up Pending PMA approval (protocol and plan changes) increased tantalum in Onyx. | Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Continued Access PDA Response Continued Access protocol and informed Access protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up Pending PMA approval (protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up Pending PMA approval (protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up Pending PMA approval (protocol and plan changes) increased tantalum in Onyx. |
| Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up Supplement for 3-5 year follow-up one-of-ing PMA approval (protocol and plan changes). Submission 3-5 year Follow-up one-of-ing PMA approval (protocol and plan changes). Submission 3-5 year Follow-up one-of-ing PMA approval (protocol and plan changes). | Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and protocol and pr | Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent) Continued Access Continued Access After pivotal study, protocol and plan changes, including increased tantalum in Onyx. Continued Access Continued Access After pivotal study, protocol and plan changes, including protocol and | Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Continued Access Continued access after pivotal study, protocol and increased tantalum, 06-19-03 FDA Response Continued Access PDA Response Continued Access PDA Response Continued Access Protocol and PDA Response 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and plan changes) including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and protocol and pr | Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Continued Access Continued Access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Continued Access Continued Access after pivotal study, protocol and plan changes, including protocol and plan changes | Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Continued Access Protocol and plan changes, including increased tantalum in Onyx. Continued Access PDA Response Continued Access protocol and informed consent). | Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent) Continued Access Continued Access including 06-19-03 FDA Response Continued Access protocol and protocol and 06-19-03 FDA Response Continued Access including PDA Response 3-5 year Follow-up | Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Continued Access Continued Access protocol and plan changes, including increased tantalum in Onyx. FDA Response Continued Access protocol and informed consent). | Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Continued Access Continued Access after pivotal study, protocol and increased tantalum, protocol and plan changes, including increased tantalum in Onyx. Continued Access Continued Access After pivotal study, protocol and plan changes, including protocol and plan changes protocol and plan c | Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Continued Access Protocol and plan changes, including increased tantalum in Onyx. Continued Access PDA Response Continued Access protocol and informed consent). | Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Continued Access Continued Access after pivotal study, 06-19-03 FDA Response Continued Access protocol and increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Continued Access Continued Access protocol and plan changes, including increased tantalum in Onyx. FDA Response Continued Access protocol and informed consent). | Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Continued Access Continued access after pivotal study, protocol and increased tantalum, 06-19-03 FDA Response Continued Access PDA Response Continued Access Protocol and informed access after pivotal study, 06-19-03 FDA Response Continued Access Protocol and Increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Continued Access Continued Access After pivotal study, protocol and increased tantalum, 06-19-03 FDA Response Continued Access POA Response Continued Access Protocol and informed access after pivotal study, 06-19-03 FDA Response Continued Access Protocol and Informed Access Protocol Informed Protocol Inform | Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Continued Access Continued access after pivotal study, protocol and increased tantalum, 06-19-03 FDA Response Continued Access PDA Response Continued Access PDA Response Continued Access Protocol and PDA Response 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Continued Access Continued access after pivotal study, protocol and increased tantalum, 06-19-03 FDA Response Continued Access PDA Response Continued Access Protocol and informed access after pivotal study, 06-19-03 FDA Response Continued Access Protocol and Increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Continued Access Continued access after pivotal study, protocol and increased tantalum, 06-19-03 FDA Response Continued Access PDA Response Continued Access Protocol and informed access after pivotal study, 06-19-03 FDA Response Continued Access Protocol and Increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Continued Access Continued access after pivotal study, protocol and increased tantalum, 06-19-03 FDA Response Continued Access POA Response Continued Access POA Response Continued Access Protocol and PDA Response 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Continued Access Continued access after pivotal study, protocol and increased tantalum, 06-19-03 FDA Response Continued Access PDA Response Continued Access Protocol and informed access after pivotal study, 06-19-03 FDA Response Continued Access Protocol and Increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Continued Access Continued access after pivotal study, protocol and increased tantalum, 06-19-03 FDA Response Continued Access protocol and increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Continued Access Continued access after pivotal study, protocol and increased tantalum, 06-19-03 FDA Response Continued Access PDA Response Continued Access PDA Response Continued Access Protocol and PDA Response 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Continued Access Continued access after pivotal study, protocol and increased tantalum, 06-19-03 FDA Response Continued Access PDA Response | Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Continued Access Continued access after pivotal study, protocol and increased tantalum, 06-19-03 FDA Response Continued Access PDA Response Continued Access PDA Response Continued Access Protocol and PDA Response 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Continued Access Continued access after pivotal study, protocol and increased tantalum, 06-19-03 FDA Response Continued Access protocol and increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Continued Access Continued access after pivotal study, protocol and increased tantalum, 06-19-03 FDA Response Continued Access protocol and increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Continued Access PDA Response Continued Access Protocol and PDA Response 3-5 year Follow-up Ponding PMA approval (protocol and informed consent). | Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Continued Access PDA Response Continued Access protocol and increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Continued Access PDA Response Continued Access protocol and increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Continued Access PDA Response Continued Access protocol and increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). |
| Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up Supplement for 3-5 year follow-up produced and plan changes after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Continued Access Continued Access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up O2-20-04 FDA Response 3-5 year Follow-up | Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and protocol and pro | Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent) Continued Access Continued Access PDA Response Continued Access Protocol and PDA Response Submission Submission Submission Submission Submission Submission Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent) | Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Continued Access Continued Access after pivotal study, protocol and continued Access protocol and protocol and protocol and continued Access protocol and protocol and continued Access protocol and protocol and continued Access protocol and protocol and protocol and continued Access protocol and continued Access after pivotal study, continued Access protocol and protocol | Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and protocol and pro | Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Continued Access PDA Response Continued Access protocol and increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Continued Access PDA Response Continued Access Protocol and Continued Access Protocol Access Pr | Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent) Continued Access Continued Access after pivotal study, protocol and increased Continued Access protocol and increased Continued Access protocol and protocol and protocol and informed Contents after pivotal study, protocol and proto | Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Continued Access PDA Response Continued Access Protocol and PDA Response Continued Access Protocol and PDA Response PDA Response Supplier PDA Response PD | Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Continued Access Continued Access protocol and plan changes, including increased tantalum in Onyx. Continued Access PDA Response Continued Access protocol and informed consent). | Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Continued Access PDA Response Continued Access Protocol and Continued Access Protocol Access Pr | Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Continued Access PDA Response Continued Access Protocol and Continued Access Protocol and Continued Access Protocol and Continued Access PDA Response Continued Access Protocol and Continued Access Protocol and Continued Access PDA Response Continued Access Protocol and Continued Access Protocol and PDA Response Continued Access Protocol and PDA Response Continued Access PDA Response PDA Response Continued Access PDA Response PD | Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Continued Access PDA Response Continued Access Protocol and PDA Response Continued Access Protocol and PDA Response PDA Response Supplier PDA Response PD | Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Continued Access Continued Access after pivotal study, protocol and increased tantalum, in Onyx. Continued Access after pivotal study, protocol and increased tantalum in Onyx. Continued Access PDA Response Continued Access after pivotal study, protocol and increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Continued Access PDA Response Continued Access Protocol and Continued Access Protocol and Continued Access Protocol and Continued Access PDA Response Continued Access Protocol and Continued Access Protocol and Continued Access PDA Response Continued Access Protocol and Continued Access Protocol and PDA Response Continued Access Protocol and PDA Response Continued Access PDA Response PDA Response Continued Access PDA Response PD | Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Continued Access Continued Access after pivotal study, protocol and continued Access protocol and protocol and protocol and continued Access protocol and protocol and continued Access protocol and protocol and continued Access protocol and protocol and protocol and continued Access protocol and continued Access after pivotal study, continued Access protocol and protocol | Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Continued Access Continued Access after pivotal study, protocol and increased tantalum, in Onyx. Continued Access after pivotal study, protocol and increased tantalum in Onyx. Continued Access PDA Response Continued Access after pivotal study, protocol and increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Continued Access Continued Access after pivotal study, protocol and increased tantalum, in Onyx. Continued Access after pivotal study, protocol and increased tantalum in Onyx. Continued Access PDA Response Continued Access after pivotal study, protocol and increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Continued Access Continued Access after pivotal study, protocol and increased tantalum, in Onyx. Continued Access After pivotal study, protocol and increased tantalum in Onyx. Continued Access After pivotal study, protocol and increased tantalum in Onyx. Continued Access After pivotal study, protocol and increased tantalum in Onyx. Continued Access After pivotal study, protocol and increased tantalum in Onyx. Continued Access After pivotal study, protocol and increased tantalum in Onyx. Continued Access After pivotal study, protocol and increased tantalum in Onyx. Continued Access After pivotal study, protocol and increased tantalum in Onyx. Continued Access After pivotal study, protocol and increased tantalum in Onyx. Continued Access After pivotal study, protocol and increased tantalum in Onyx. Continued Access After pivotal study, protocol and increased tantalum in Onyx. Continued Access After pivotal study, protocol and increased tantalum in Onyx. Continued Access After pivotal study, protocol and increased tantalum in Onyx. Continued Access After pivotal study, protocol and increased tantalum in Onyx. Continued Access After pivotal study, protocol and pro | Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Continued Access Continued Access after pivotal study, protocol and increased tantalum, in Onyx. Continued Access after pivotal study, protocol and increased tantalum in Onyx. Continued Access PDA Response Continued Access after pivotal study, protocol and increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Continued Access Continued Access PDA Response Continued Access Protocol and Plan Changes, including Continued Access Protocol and Plan Changes, including Continued Access Protocol and Continued Access Protocol Access Protoco | Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Continued Access Continued Access after pivotal study, protocol and continued Access protocol and protocol and protocol and continued Access protocol and protocol and continued Access protocol and protocol and continued Access protocol and protocol and protocol and continued Access protocol and continued Access after pivotal study, continued Access protocol and protocol | Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Continued Access Continued Access after pivotal study, protocol and continued Access protocol and protocol and protocol and protocol and protocol and protocol and consent). Continued Access Continued Access after pivotal study, protocol and p | Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Continued Access Continued Access after pivotal study, protocol and continued Access protocol and protocol and protocol and continued Access protocol and protocol and continued Access protocol and protocol and continued Access protocol and protocol and protocol and continued Access protocol and continued Access after pivotal study, continued Access protocol and protocol | Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Continued Access Continued Access PDA Response Continued Access Protocol and Plan Changes, including Continued Access Protocol and Plan Changes, including Continued Access Protocol and Continued Access Protocol Access Protoco | Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Continued Access Continued Access PDA Response Continued Access Protocol and Plan Changes, including Continued Access Protocol and Plan Changes, including Continued Access Protocol and Continued Access Protocol Access Protoco | Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Continued Access Continued Access after pivotal study, protocol and continued Access protocol and protocol and protocol and protocol and protocol and protocol and consent). Continued Access Continued Access after pivotal study, protocol and p | Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Continued Access Continued Access PDA Response Continued Access Protocol and PDA Response Continued Access Protocol and Continued Access Protocol and PDA Response PDA | Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Continued Access Continued Access PDA Response Continued Access Protocol and PDA Response Continued Access Protocol and Continued Access Protocol and PDA Response PDA | Submission Continued Access Continued access after pivotal study, protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Continued Access Continued Access PDA Response Continued Access Protocol and PDA Response Continued Access Protocol and Continued Access Protocol and PDA Response PDA |
| Submission Continued Access Continued access after pivotal study, 06-19-03 FDA Response Continued Access protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up Supplement for 3-5 year follow-up one-of-line PMA approval (protocol and plan changes). Submission 3-5 year Follow-up O2-20-04 FDA Response 3-5 year Follow-up | Submission Continued Access Continued access after pivotal study, 06-19-03 FDA Response Continued Access protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and protocol and protocol and protocol and pending PMA approval (protocol and protocol and protoco | Submission Continued Access Continued access after pivotal study, 06-19-03 FDA Response Continued Access protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up Pending PMA approval (protocol and informed consent) Submission 3-5 year Follow-up Pending PMA approval (protocol and informed consent) | Submission Continued Access Continued access after pivotal study, 06-19-03 FDA Response Continued Access protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Continued Access Continued Access PDA Response PDA Response PDA Response Submission Continued Access PDA Response Continued Access PDA Response Continued Access PDA Response PDA Response Continued Access PDA Response PDA PDA Response PDA Response PDA PDA Response PDA Response PDA | Submission Continued Access Continued access after pivotal study, 06-19-03 FDA Response Continued Access protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and plan changes) protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and plan changes) protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and plan changes) protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and plan changes) protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and plan changes) protocol and plan changes, including increased tantalum in Onyx. | Submission Continued Access Continued access after pivotal study, 06-19-03 FDA Response Continued Access protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). | Submission Continued Access Continued access after pivotal study, 06-19-03 FDA Response Continued Access protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). Continued Access Continued Access PDA Response Continued Access Protocol and Continued Access Protocol and Continued Access Protocol and Continued Access PDA Response Continued Access Protocol and PDA Response PDA Response Continued Access Protocol and PDA Response Continued Access Protocol and PDA Response PDA Response Continued Access Protocol and PDA Response PDA PDA Response PDA Response PDA | Submission Continued Access Continued access after pivotal study, 06-19-03 FDA Response Continued Access protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent) Continued Access Continued Access PDA Response Continued Access Protocol and Continued Access PDA Response Continued Access PDA Response Continued Access PDA Response Continued Access Protocol and PDA Response Continued Access Protocol and PDA Response Continued Access PDA Response Continued Access PDA Response Continued Access PDA Response PDA Response Continued Access PDA Response Continued Access PDA Response Continued Access PDA Response PDA | Submission Continued Access Continued access after pivotal study, 06-19-03 FDA Response Continued Access protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up Pending PMA approval (protocol and informed consent). Continued Access Continued Access PDA Response Continued Access Protocol and Continued Access Protocol and Continued Access PDA Response Continued Access Protocol and Continued Access Protocol and Continued Access Protocol and PDA Response PDA Response Continued Access Protocol and PDA Response Continued Access Protocol and PDA Response PDA Response Continued Access Protocol and PDA Response PDA PDA Response PDA Response PDA | Submission Continued Access Continued access after pivotal study, 06-19-03 FDA Response Continued Access protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). | Submission Continued Access Continued access after pivotal study, 06-19-03 FDA Response Continued Access protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). Continued Access Continued Access PDA Response Continued Access Protocol and Continued Access Protocol and Continued Access Protocol and Continued Access PDA Response Continued Access Protocol and PDA Response PDA Response Continued Access Protocol and PDA Response Continued Access Protocol and PDA Response PDA Response Continued Access Protocol and PDA Response PDA PDA Response PDA Response PDA | Submission Continued Access Continued access after pivotal study, 06-19-03 FDA Response Continued Access protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Continued Access Continued Access Protocol and PDA Response Continued Access Protocol and Continued Access Protocol and Continued Access Protocol and PDA Response PDA Re | Submission Continued Access Continued access after pivotal study, 06-19-03 FDA Response Continued Access protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up Pending PMA approval (protocol and informed consent). Continued Access Continued Access PDA Response Continued Access Protocol and Continued Access Protocol and Continued Access PDA Response Continued Access Protocol and Continued Access Protocol and Continued Access Protocol and PDA Response PDA Response Continued Access Protocol and PDA Response Continued Access Protocol and PDA Response PDA Response Continued Access Protocol and PDA Response PDA PDA Response PDA Response PDA | Submission Continued Access Continued access after pivotal study, 06-19-03 FDA Response Continued Access protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Continued Access Continued Access PDA Response PDA Response Continued Access PDA Response Continued Access PDA Response Continued Access PDA Response PDA Respon | Submission Continued Access Continued access after pivotal study, 06-19-03 FDA Response Continued Access protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Continued Access Continued Access PDA Response PDA Response Continued Access PDA Response Continued Access PDA Response Continued Access PDA Response Continued Access PDA Response PDA PDA Response PDA Response PDA PDA | Submission Continued Access Continued access after pivotal study, 06-19-03 FDA Response Continued Access protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Continued Access Continued Access PDA Response PDA Response PDA Response Submission Continued Access PDA Response Continued Access PDA Response Continued Access PDA Response PDA Response Continued Access PDA Response PDA PDA Response PDA Response PDA PDA Response PDA Response PDA | Submission Continued Access Continued access after pivotal study, 06-19-03 FDA Response Continued Access protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Continued Access Continued Access PDA Response PDA Response Continued Access PDA Response Continued Access PDA Response Continued Access PDA Response PDA Respon | Submission Continued Access Continued access after pivotal study, 06-19-03 FDA Response Continued Access protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Continued Access Continued Access PDA Response PDA Response Continued Access PDA Response Continued Access PDA Response Continued Access PDA Response PDA Respon | Submission Continued Access Continued access after pivotal study, 06-19-03 FDA Response Continued Access protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Continued Access Continued Access PDA Response PDA Response Continued Access PDA Response Continued Access PDA Response Continued Access PDA Response PDA | Submission Continued Access Continued access after pivotal study, 06-19-03 FDA Response Continued Access protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Continued Access Continued Access PDA Response PDA Response Continued Access PDA Response Continued Access PDA Response Continued Access PDA Response PDA Respon | Submission Continued Access Continued access after pivotal study, 06-19-03 FDA Response Continued Access protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Continued Access Continued Access PDA Response PDA PDA Response PDA PDA Response PDA Response PDA PDA Response PDA PDA Response PDA PDA | Submission Continued Access Continued access after pivotal study, 06-19-03 FDA Response Continued Access protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Continued Access Continued Access PDA Response PDA Response PDA Response Submission Continued Access PDA Response Continued Access PDA Response Continued Access PDA Response PDA Response Continued Access PDA Response PDA PDA Response PDA Response PDA PDA Response PDA Response PDA | Submission Continued Access Continued access after pivotal study, 06-19-03 FDA Response Continued Access protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Continued Access Continued Access PDA Response PDA Response Continued Access PDA Response PDA PDA Response PDA | Submission Continued Access Continued access after pivotal study, 06-19-03 FDA Response Continued Access protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Continued Access Continued Access PDA Response PDA Response PDA Response Submission Continued Access PDA Response Continued Access PDA Response Continued Access PDA Response PDA Response Continued Access PDA Response PDA PDA Response PDA Response PDA PDA Response PDA Response PDA | Submission Continued Access Continued access after pivotal study, 06-19-03 FDA Response Continued Access protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Continued Access Continued Access PDA Response PDA PDA Response PDA PDA Response PDA Response PDA PDA Response PDA PDA Response PDA PDA | Submission Continued Access Continued access after pivotal study, 06-19-03 FDA Response Continued Access protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Continued Access Continued Access PDA Response PDA PDA Response PDA PDA Response PDA Response PDA PDA Response PDA PDA Response PDA PDA | Submission Continued Access Continued access after pivotal study, 06-19-03 FDA Response Continued Access protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Submission Continued Access Continued access after pivotal study, 06-19-03 FDA Response Continued Access protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Submission Continued Access Continued access after pivotal study, 06-19-03 FDA Response Continued Access protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Submission Continued Access Continued access after pivotal study, 06-19-03 FDA Response Continued Access protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). |
| protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up Supplement for 3-5 year follow-up 02-20-04 FDA Response 3-5 year Follow-up | protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up Supplement for 3-5 year follow-up pending PMA approval (protocol and protocol | protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent) Submission 3-5 year Follow-up 02-20-04 FDA Response 3-5 year Follow-up pending PMA approval (protocol and informed consent) | Submission 3-5 year Follow-up Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). | protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up Supplement for 3-5 year follow-up pending PMA approval (protocol and protocol | Submission 3-5 year Follow-up Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). | Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). | protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent) One of the protocol and protocol and informed consent in formed consent in forme | Submission 3-5 year Follow-up Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). | protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). | Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Submission 3-5 year Follow-up Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). | Submission 3-5 year Follow-up Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). | Submission 3-5 year Follow-up Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). | Submission 3-5 year Follow-up Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). | Submission 3-5 year Follow-up Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). | Submission 3-5 year Follow-up Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). | Submission 3-5 year Follow-up Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). | Submission 3-5 year Follow-up Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). | Submission 3-5 year Follow-up Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). | Submission 3-5 year Follow-up Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). | Submission 3-5 year Follow-up Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). | Submission 3-5 year Follow-up Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). | Submission 3-5 year Follow-up Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). | Submission 3-5 year Follow-up Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). | Submission 3-5 year Follow-up Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). | Submission 3-5 year Follow-up Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). | Submission 3-5 year Follow-up Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). | Submission 3-5 year Follow-up Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). | Submission 3-5 year Follow-up Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). |
| Submission 3-5 year Follow-up Supplement for 3-5 year follow-up 02-20-04 FDA Response 3-5 year Follow-up | Submission 3-5 year Follow-up pending PMA approval (protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and plan changes, including increased tantalum in Onyx. 3-5 year Follow-up O2-20-04 FDA Response 3-5 year Follow-up | Submission 3-5 year Follow-up Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent) Protocol and plan changes, including increased tantalum in Onyx. 3-5 year Follow-up 02-20-04 FDA Response 3-5 year Follow-up informed consent) | Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Submission 3-5 year Follow-up pending PMA approval (protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and plan changes, including plan changes, i | Submission 3-5 year Follow-up Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). Protocol and plan changes, including increased tantalum in Onyx. 3-5 year Follow-up 02-20-04 FDA Response 3-5 year Follow-up informed consent). | Submission 3-5 year Follow-up Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). Protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up 02-20-04 FDA Response 3-5 year Follow-up informed consent). | Submission 3-5 year Follow-up Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent) Protocol and plan changes, including increased tantalum in Onyx. 3-5 year Follow-up 02-20-04 FDA Response 3-5 year Follow-up informed consent) | Submission 3-5 year Follow-up Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). Protocol and plan changes, including increased tantalum in Onyx. 3-5 year Follow-up 02-20-04 FDA Response 3-5 year Follow-up informed consent). | Submission 3-5 year Follow-up Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent) Protocol and plan changes, including increased tantalum in Onyx. 3-5 year Follow-up 02-20-04 FDA Response 3-5 year Follow-up informed consent) | Submission 3-5 year Follow-up Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). Protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up 02-20-04 FDA Response 3-5 year Follow-up informed consent). | Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Submission 3-5 year Follow-up Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). Protocol and plan changes, including increased tantalum in Onyx. 3-5 year Follow-up 02-20-04 FDA Response 3-5 year Follow-up informed consent). | Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Protocol and plan changes, including increased tantalum in Onyx. Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Submission 3-5 year Follow-up Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). Protocol and plan changes, including increased tantalum in Onyx. 3-5 year Follow-up 02-20-04 FDA Response 3-5 year Follow-up informed consent). | Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). |
| Submission 3-5 year Follow-up Supplement for 3-5 year follow-up 02-20-04 FDA Response 3-5 year Follow-up | Submission 3-5 year Follow-up pending PMA approval (protocol and 02-20-04 FDA Response 3-5 year Follow-up | Submission 3-5 year Follow-up Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent) Submission 3-5 year Follow-up 02-20-04 FDA Response 3-5 year Follow-up pending PMA approval (protocol and informed consent) | Submission 3-5 year Follow-up Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). | Submission 3-5 year Follow-up Supplement for 3-5 year follow-up pending PMA approval (protocol and pending PMA) | Submission 3-5 year Follow-up Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). | Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Submission 3-5 year Follow-up Supplement for 3-5 year follow-up pending PMA approval (protocol and informaci consent) Submission 3-5 year Follow-up 02-20-04 FDA Response 3-5 year Follow-up | Submission 3-5 year Follow-up Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). | Submission 3-5 year Follow-up Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent) Submission 3-5 year Follow-up 02-20-04 FDA Response 3-5 year Follow-up informed consent) | Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Submission 3-5 year Follow-up Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). | Submission 3-5 year Follow-up Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). | Submission 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Submission 3-5 year Follow-up Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). | Submission 3-5 year Follow-up Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). | Submission 3-5 year Follow-up Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). | Submission 3-5 year Follow-up Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). | Submission 3-5 year Follow-up Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). | Submission 3-5 year Follow-up Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). | Submission 3-5 year Follow-up Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). | Submission 3-5 year Follow-up Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). | Submission 3-5 year Follow-up Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). | Submission 3-5 year Follow-up Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). | Submission 3-5 year Follow-up Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). | Submission 3-5 year Follow-up Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). | Submission 3-5 year Follow-up Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). | Submission 3-5 year Follow-up Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). | Submission 3-5 year Follow-up Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). |
| Submission 3-5 year Follow-up Supplement for 3-5 year follow-up 02-20-04 FDA Response 3-5 year Follow-up | Submission 3-5 year Follow-up Supplement for 3-5 year follow-up pending PMA approval (protocol and pending PMA) | Submission 3-5 year Follow-up Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent) Submission 3-5 year Follow-up 02-20-04 FDA Response 3-5 year Follow-up informed consent) | Submission 3-5 year Follow-up Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). Submission 3-5 year Follow-up 02-20-04 FDA Response 3-5 year Follow-up informed consent). | Submission 3-5 year Follow-up Supplement for 3-5 year follow-up pending PMA approval (protocol and 5-5 year Follow-up pending PMA) | Submission 3-5 year Follow-up Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). Consent Conse | Submission 3-5 year Follow-up Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). Submission 3-5 year Follow-up 02-20-04 FDA Response 3-5 year Follow-up 10-20-04 FDA Response 10-20- | Submission 3-5 year Follow-up Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent) Submission 3-5 year Follow-up 02-20-04 FDA Response 3-5 year Follow-up | Submission 3-5 year Follow-up Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). Submission 3-5 year Follow-up 02-20-04 FDA Response 3-5 year Follow-up informed consent). | Submission 3-5 year Follow-up Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent) Consent Consen | Submission 3-5 year Follow-up Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). Submission 3-5 year Follow-up 02-20-04 FDA Response 3-5 year Follow-up 10-20-04 FDA Response 10-20- | Submission 3-5 year Follow-up Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). Submission 3-5 year Follow-up 02-20-04 FDA Response 3-5 year Follow-up informed consent). | Submission 3-5 year Follow-up Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). Submission 3-5 year Follow-up 02-20-04 FDA Response 3-5 year Follow-up informed consent). | Submission 3-5 year Follow-up Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). Submission 3-5 year Follow-up 02-20-04 FDA Response 3-5 year Follow-up informed consent). | Submission 3-5 year Follow-up Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). Submission 3-5 year Follow-up 02-20-04 FDA Response 3-5 year Follow-up 3-5 year Follow-u | Submission 3-5 year Follow-up Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). Submission 3-5 year Follow-up 02-20-04 FDA Response 3-5 year Follow-up informed consent). | Submission 3-5 year Follow-up Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). Submission 3-5 year Follow-up 02-20-04 FDA Response 3-5 year Follow-up informed consent). | Submission 3-5 year Follow-up Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). Submission 3-5 year Follow-up 02-20-04 FDA Response 3-5 year Follow-up informed consent). | Submission 3-5 year Follow-up Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). Submission 3-5 year Follow-up 02-20-04 FDA Response 3-5 year Follow-up 1-5 year Follow-up 3-5 year Follow-u | Submission 3-5 year Follow-up Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). Submission 3-5 year Follow-up 02-20-04 FDA Response 3-5 year Follow-up informed consent). | Submission 3-5 year Follow-up Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). Submission 3-5 year Follow-up 02-20-04 FDA Response 3-5 year Follow-up informed consent). | Submission 3-5 year Follow-up Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). Submission 3-5 year Follow-up 02-20-04 FDA Response 3-5 year Follow-up informed consent). | Submission 3-5 year Follow-up Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). Submission 3-5 year Follow-up 02-20-04 FDA Response 3-5 year Follow-up informed consent). | Submission 3-5 year Follow-up Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). Submission 3-5 year Follow-up 02-20-04 FDA Response 3-5 year Follow-up informed consent). | Submission 3-5 year Follow-up Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). Submission 3-5 year Follow-up 02-20-04 FDA Response 3-5 year Follow-up informed consent). | Submission 3-5 year Follow-up Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). Submission 3-5 year Follow-up 02-20-04 FDA Response 3-5 year Follow-up informed consent). | Submission 3-5 year Follow-up Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). Submission 3-5 year Follow-up 02-20-04 FDA Response 3-5 year Follow-up informed consent). | Submission 3-5 year Follow-up Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). Submission 3-5 year Follow-up 02-20-04 FDA Response 3-5 year Follow-up informed consent). | Submission 3-5 year Follow-up Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). Submission 3-5 year Follow-up 02-20-04 FDA Response 3-5 year Follow-up informed consent). | Submission 3-5 year Follow-up Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). Submission 3-5 year Follow-up 02-20-04 FDA Response 3-5 year Follow-up informed consent). |
| Submission 3-5 year Follow-up Supplement for 3-5 year follow-up 02-20-04 FDA Response 3-5 year Follow-up | Submission 3-5 year Follow-up Supplement for 3-5 year follow-up pending PMA approval (protocol and PDA Response 3-5 year Follow-up | Submission 3-5 year Follow-up Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent) Submission 3-5 year Follow-up 02-20-04 FDA Response 3-5 year Follow-up pending PMA approval (protocol and informed consent) | Submission 3-5 year Follow-up Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). | Submission 3-5 year Follow-up Supplement for 3-5 year follow-up 02-20-04 FDA Response 3-5 year Follow-up pending PMA approval (protocol and | Submission 3-5 year Follow-up Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). | Submission 3-5 year Follow-up Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). | Submission 3-5 year Follow-up Supplement for 3-5 year follow-up pending PMA approval (protocol and informaci consent) Submission 3-5 year Follow-up 02-20-04 FDA Response 3-5 year Follow-up | Submission 3-5 year Follow-up Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). | Submission 3-5 year Follow-up Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent) Submission 3-5 year Follow-up 02-20-04 FDA Response 3-5 year Follow-up informed consent) | Submission 3-5 year Follow-up Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). | Submission 3-5 year Follow-up Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). | Submission 3-5 year Follow-up Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). | Submission 3-5 year Follow-up Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). | Submission 3-5 year Follow-up Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). | Submission 3-5 year Follow-up Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). | Submission 3-5 year Follow-up Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). | Submission 3-5 year Follow-up Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). | Submission 3-5 year Follow-up Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). | Submission 3-5 year Follow-up Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). | Submission 3-5 year Follow-up Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). | Submission 3-5 year Follow-up Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). | Submission 3-5 year Follow-up Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). | Submission 3-5 year Follow-up Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). | Submission 3-5 year Follow-up Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). | Submission 3-5 year Follow-up Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). | Submission 3-5 year Follow-up Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). | Submission 3-5 year Follow-up Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). | Submission 3-5 year Follow-up Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). | Submission 3-5 year Follow-up Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). |
| Submission 3-5 year Follow-up Supplement for 3-5 year follow-up 02-20-04 FDA Response 3-5 year Follow-up | Submission 3-5 year Follow-up Supplement for 3-5 year follow-up 02-20-04 FDA Response 3-5 year Follow-up pending PMA approval (protocol and | Submission 3-5 year Follow-up Supplement for 3-5 year follow-up 02-20-04 FDA Response 3-5 year Follow-up pending PMA approval (protocol and informed consent) | Submission 3-5 year Follow-up Supplement for 3-5 year follow-up 02-20-04 FDA Response 3-5 year Follow-up informed consent). | Submission 3-5 year Follow-up Supplement for 3-5 year follow-up 02-20-04 FDA Response 3-5 year Follow-up pending PMA approval (protocol and | Submission 3-5 year Follow-up Supplement for 3-5 year follow-up 02-20-04 FDA Response 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Submission 3-5 year Follow-up Supplement for 3-5 year follow-up 02-20-04 FDA Response 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Submission 3-5 year Follow-up Supplement for 3-5 year follow-up 02-20-04 FDA Response 3-5 year Follow-up pending PMA approval (protocol and informed consent) | Submission 3-5 year Follow-up Supplement for 3-5 year follow-up 02-20-04 FDA Response 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Submission 3-5 year Follow-up Supplement for 3-5 year follow-up 02-20-04 FDA Response 3-5 year Follow-up pending PMA approval (protocol and informed consent) | Submission 3-5 year Follow-up Supplement for 3-5 year follow-up 02-20-04 FDA Response 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Submission 3-5 year Follow-up Supplement for 3-5 year follow-up 02-20-04 FDA Response 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Submission 3-5 year Follow-up Supplement for 3-5 year follow-up 02-20-04 FDA Response 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Submission 3-5 year Follow-up Supplement for 3-5 year follow-up 02-20-04 FDA Response 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Submission 3-5 year Follow-up Supplement for 3-5 year follow-up 02-20-04 FDA Response 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Submission 3-5 year Follow-up Supplement for 3-5 year follow-up 02-20-04 FDA Response 3-5 year Follow-up informed consent). | Submission 3-5 year Follow-up Supplement for 3-5 year follow-up 02-20-04 FDA Response 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Submission 3-5 year Follow-up Supplement for 3-5 year follow-up 02-20-04 FDA Response 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Submission 3-5 year Follow-up Supplement for 3-5 year follow-up 02-20-04 FDA Response 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Submission 3-5 year Follow-up Supplement for 3-5 year follow-up 02-20-04 FDA Response 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Submission 3-5 year Follow-up Supplement for 3-5 year follow-up 02-20-04 FDA Response 3-5 year Follow-up informed consent). | Submission 3-5 year Follow-up Supplement for 3-5 year follow-up 02-20-04 FDA Response 3-5 year Follow-up informed consent). | Submission 3-5 year Follow-up Supplement for 3-5 year follow-up 02-20-04 FDA Response 3-5 year Follow-up informed consent). | Submission 3-5 year Follow-up Supplement for 3-5 year follow-up 02-20-04 FDA Response 3-5 year Follow-up informed consent). | Submission 3-5 year Follow-up Supplement for 3-5 year follow-up 02-20-04 FDA Response 3-5 year Follow-up informed consent). | Submission 3-5 year Follow-up Supplement for 3-5 year follow-up 02-20-04 FDA Response 3-5 year Follow-up informed consent). | Submission 3-5 year Follow-up Supplement for 3-5 year follow-up 02-20-04 FDA Response 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Submission 3-5 year Follow-up Supplement for 3-5 year follow-up 02-20-04 FDA Response 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Submission 3-5 year Follow-up Supplement for 3-5 year follow-up 02-20-04 FDA Response 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Submission 3-5 year Follow-up Supplement for 3-5 year follow-up 02-20-04 FDA Response 3-5 year Follow-up pending PMA approval (protocol and informed consent). |
| Submission 3-5 year Follow-up Supplement for 3-5 year follow-up 02-20-04 FDA Response 3-5 year Follow-up | Submission 3-5 year Follow-up Supplement for 3-5 year follow-up 02-20-04 FDA Response 3-5 year Follow-up pending PMA approval (protocol and | Submission 3-5 year Follow-up Supplement for 3-5 year follow-up 02-20-04 FDA Response 3-5 year Follow-up pending PMA approval (protocol and informed consent) | Submission 3-5 year Follow-up Supplement for 3-5 year follow-up 02-20-04 FDA Response 3-5 year Follow-up informed consent). | Submission 3-5 year Follow-up Supplement for 3-5 year follow-up 02-20-04 FDA Response 3-5 year Follow-up pending PMA approval (protocol and | Submission 3-5 year Follow-up Supplement for 3-5 year follow-up 02-20-04 FDA Response 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Submission 3-5 year Follow-up Supplement for 3-5 year follow-up 02-20-04 FDA Response 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Submission 3-5 year Follow-up Supplement for 3-5 year follow-up 02-20-04 FDA Response 3-5 year Follow-up pending PMA approval (protocol and informed consent) | Submission 3-5 year Follow-up Supplement for 3-5 year follow-up 02-20-04 FDA Response 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Submission 3-5 year Follow-up Supplement for 3-5 year follow-up 02-20-04 FDA Response 3-5 year Follow-up pending PMA approval (protocol and informed consent) | Submission 3-5 year Follow-up Supplement for 3-5 year follow-up 02-20-04 FDA Response 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Submission 3-5 year Follow-up Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). 3-5 year Follow-up 02-20-04 FDA Response 3-5 year Follow-up informed consent). | Submission 3-5 year Follow-up Supplement for 3-5 year follow-up 02-20-04 FDA Response 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Submission 3-5 year Follow-up Supplement for 3-5 year follow-up 02-20-04 FDA Response 3-5 year Follow-up informed consent). | Submission 3-5 year Follow-up Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). 3-5 year Follow-up 02-20-04 FDA Response 3-5 year Follow-up informed consent). | Submission 3-5 year Follow-up Supplement for 3-5 year follow-up 02-20-04 FDA Response 3-5 year Follow-up informed consent). | Submission 3-5 year Follow-up Supplement for 3-5 year follow-up 02-20-04 FDA Response 3-5 year Follow-up informed consent). | Submission 3-5 year Follow-up Supplement for 3-5 year follow-up 02-20-04 FDA Response 3-5 year Follow-up informed consent). | Submission 3-5 year Follow-up Supplement for 3-5 year follow-up pending PMA approval (protocol and informed consent). 3-5 year Follow-up 02-20-04 FDA Response 3-5 year Follow-up informed consent). | Submission 3-5 year Follow-up Supplement for 3-5 year follow-up 02-20-04 FDA Response 3-5 year Follow-up informed consent). | Submission 3-5 year Follow-up Supplement for 3-5 year follow-up 02-20-04 FDA Response 3-5 year Follow-up informed consent). | Submission 3-5 year Follow-up Supplement for 3-5 year follow-up 02-20-04 FDA Response 3-5 year Follow-up informed consent). | Submission 3-5 year Follow-up Supplement for 3-5 year follow-up 02-20-04 FDA Response 3-5 year Follow-up informed consent). | Submission 3-5 year Follow-up Supplement for 3-5 year follow-up 02-20-04 FDA Response 3-5 year Follow-up informed consent). | Submission 3-5 year Follow-up Supplement for 3-5 year follow-up 02-20-04 FDA Response 3-5 year Follow-up informed consent). | Submission 3-5 year Follow-up Supplement for 3-5 year follow-up 02-20-04 FDA Response 3-5 year Follow-up informed consent). | Submission 3-5 year Follow-up Supplement for 3-5 year follow-up 02-20-04 FDA Response 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Submission 3-5 year Follow-up Supplement for 3-5 year follow-up 02-20-04 FDA Response 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Submission 3-5 year Follow-up Supplement for 3-5 year follow-up 02-20-04 FDA Response 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Submission 3-5 year Follow-up Supplement for 3-5 year follow-up 02-20-04 FDA Response 3-5 year Follow-up pending PMA approval (protocol and informed consent). |
| Submission 3-5 year Follow-up Supplement for 3-5 year follow-up 02-20-04 FDA Response 3-5 year Follow-up nending DMA approval (professor) and | Submission 3-5 year Follow-up Supplement for 3-5 year follow-up 02-20-04 FDA Response 3-5 year Follow-up pending PMA approval (protocol and | Submission 3-5 year Follow-up Supplement for 3-5 year follow-up 02-20-04 FDA Response 3-5 year Follow-up pending PMA approval (protocol and informed consent) | Submission 3-5 year Follow-up Supplement for 3-5 year follow-up 02-20-04 FDA Response 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Submission 3-5 year Follow-up Supplement for 3-5 year follow-up 02-20-04 FDA Response 3-5 year Follow-up pending PMA approval (protocol and | Submission 3-5 year Follow-up Supplement for 3-5 year follow-up 02-20-04 FDA Response 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Submission 3-5 year Follow-up Supplement for 3-5 year follow-up 02-20-04 FDA Response 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Submission 3-5 year Follow-up Supplement for 3-5 year follow-up 02-20-04 FDA Response 3-5 year Follow-up pending PMA approval (protocol and informed consent) | Submission 3-5 year Follow-up Supplement for 3-5 year follow-up 02-20-04 FDA Response 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Submission 3-5 year Follow-up Supplement for 3-5 year follow-up 02-20-04 FDA Response 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Submission 3-5 year Follow-up Supplement for 3-5 year follow-up 02-20-04 FDA Response 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Submission 3-5 year Follow-up Supplement for 3-5 year follow-up 02-20-04 FDA Response 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Submission 3-5 year Follow-up Supplement for 3-5 year follow-up 02-20-04 FDA Response 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Submission 3-5 year Follow-up Supplement for 3-5 year follow-up 02-20-04 FDA Response 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Submission 3-5 year Follow-up Supplement for 3-5 year follow-up 02-20-04 FDA Response 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Submission 3-5 year Follow-up Supplement for 3-5 year follow-up 02-20-04 FDA Response 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Submission 3-5 year Follow-up Supplement for 3-5 year follow-up 02-20-04 FDA Response 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Submission 3-5 year Follow-up Supplement for 3-5 year follow-up 02-20-04 FDA Response 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Submission 3-5 year Follow-up Supplement for 3-5 year follow-up 02-20-04 FDA Response 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Submission 3-5 year Follow-up Supplement for 3-5 year follow-up 02-20-04 FDA Response 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Submission 3-5 year Follow-up Supplement for 3-5 year follow-up 02-20-04 FDA Response 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Submission 3-5 year Follow-up Supplement for 3-5 year follow-up 02-20-04 FDA Response 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Submission 3-5 year Follow-up Supplement for 3-5 year follow-up 02-20-04 FDA Response 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Submission 3-5 year Follow-up Supplement for 3-5 year follow-up 02-20-04 FDA Response 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Submission 3-5 year Follow-up Supplement for 3-5 year follow-up 02-20-04 FDA Response 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Submission 3-5 year Follow-up Supplement for 3-5 year follow-up 02-20-04 FDA Response 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Submission 3-5 year Follow-up Supplement for 3-5 year follow-up 02-20-04 FDA Response 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Submission 3-5 year Follow-up Supplement for 3-5 year follow-up 02-20-04 FDA Response 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Submission 3-5 year Follow-up Supplement for 3-5 year follow-up 02-20-04 FDA Response 3-5 year Follow-up pending PMA approval (protocol and informed consent). | Submission 3-5 year Follow-up Supplement for 3-5 year follow-up 02-20-04 FDA Response 3-5 year Follow-up pending PMA approval (protocol and informed consent). |
| nending DMA anneaval (protocol and | pending PMA approval (protocol and | pending PMA approval (protocol and | pending PMA approval (protocol and informed consent). | pending PMA approval (protocol and | pending PMA approval (protocol and informed consent). | pending PMA approval (protocol and informed consent). | pending PMA approval (protocol and | pending PMA approval (protocol and informed consent). | pending PMA approval (protocol and informed consent) | pending PMA approval (protocol and informed consent). |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | _ | | _ | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |

APPENDIX E

Onyx® Liquid Embolic System (LES)

Chronology for Premarket Approval (PMA) P030004

| | Pre-clinical data | | | | Pre-cinical data | | |
|------------------------------------|----------------------------------|--------------------------------------|-----------------|--|----------------------------------|--------------------------------------|-----------------|
| Acknowledgement of receipt. | PMA Amendment: | A005 | 07-23-03 | MTI submits hard copy of the original IR absorption results. | PMA Amendment: | A005 | 07-18-03 |
| Acknowledgement of receipt. | PMA Amendment: Pre-clinical data | A003 | 07-11-03 | MTI submits the following: Infrared (IR) absorption results Gel permeation chromatography Compliance with 0.5 endotoxin (EU)/mL specification Mfg. procedure for 1 mL syringe Syringe drawings High Performance Liquid Chromatography (HPLC) results from Onyx® in vitro coil compatibility study Onyx® 8% solidification time test | PMA Amendment: Pre-clinical data | A003 | 07-9-03 |
| Acknowledgement of receipt. | PMA Amendment | A002 | 06-19-03 | In response to 05-09-03 facsimile from Peter Hudson (of FDA), MTI submits answers to initial review questions regarding the following: clinical, statistics, labeling, manufacturing (Mfg.), bioresearch monitoring (BIMO) and preclinical | PMA Amendment | A002 | 06-17-03 |
| Acknowledgement of receipt. | PMA Amendment: Pre-clinical data | A001 | 05-20-03 | MTI submits the following: Component material specifications and test parameters Sterilization validation summary and references Onyx® and dimethyl sulfoxide (DMSO) stability test summary and references | PMA Amendment: Pre-clinical data | A001 | 05-16-03 |
| PMA P030004 - suitable for filing. | PMA Application | Hardcopy, FDA to MTI | 05-02-03 | MTI submits original PMA Application for Onyx® Liquid Embolic System (LES). | PMA Application | Hardcopy Submission | 03-12-03 |
| Summary Description | Purpose/ Subject | Contact Type/ Reference Number | Contact Date | Summary Description | Purpose/ Subject | Contact Type/ Reference Number | Contact Date |
| ferences | FDA Response References | | | Submissions to FDA by Micro Therapeutics, Inc. (MTI) | o FDA by Micro Th | Submissions t | |

Onyx® Liquid Embolic System (LES)

Chronology for PMA P030004

| Mail date of Approval of PMA under Section 515 | PMA Approval | | 07-21-05 | | | | |
|--|----------------------------------|--------------------------------------|--|---|----------------------------------|--------------------------------------|-----------------|
| | | | | Independent data system review provided by Dr. Murphy 08-24-04 - Corrective Action Plan from MTI submitted 02-01-05 - BIMO Inspection for corrective action completed | | | |
| Acknowledgement of receipt. | PMA Amendment: Integrity hold | A008 | 03-28-05 | Integrity Hold release: O9-12-03 - Letter placing integrity hold Independent data audit report provided by Dr. Weiner | PMA Amendment: Integrity hold | A008 | 03-25-05 |
| Acknowledgement of receipt. | PMA Amendment: Clinical data | A007 | 08-18-03 | MTI submits clinical data amendment and statistics with the following: • Frequency of complications • New events since PMA first submitted • Patient cohort tables • Cranial and non cranial tables | PMA Amendment: Clinical data | A007 | 08-15-03 |
| Acknowledgement of receipt. | PMA Amendment: Pre-clinical data | A006 | 08-15-03 | MTI submits information regarding Onyx® Material Change • Request for increased tantalum concentration formulation change • Slides submitted regarding in-service training for the increased tantalum arteriovenous malformation (AVM) formulations | PMA Amendment: Pre-clinical data | A006 | 08-12-03 |
| Acknowledgement of receipt. | PMA Amendment: Pre-clinical data | A004 | 07-22-03 | In response to FDA e-mail request of 07-09-03, MTI submits the following: Copy of the results of the Onyx® solidification test Copy of HPLC results | PMA Amendment: Pre-clinical data | A004 | 07-21-03 |
| Summary Description | Purpose/ Subject | Contact Type/ Reference Number | Contact Date | Summary Description | Purpose/ Subject | Contact Type/ Reference Number | Contact Date |
| eferences | FDA Response References | | The second secon | Submissions to FDA by Micro Therapeutics, Inc. (MTI) | o FDA by Micro T | Submissions t | |